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ABSTRACT OF DISSERTATION

FACTORS AFFECTING SKELETAL MUSCLE PROTEIN SYNTHESIS IN THE
HORSE
Skeletal muscle protein synthesis is regulated by the mammalian target of
rapamycin (mTOR) signaling pathway. The first objective was to optimize the
methodological procedures for assessing mTOR signaling in horses. The response of
mTOR signaling (P-Akt Ser473, P-S6K1 Thr389, P-rpS6 Ser235/26 & 240/244, and P-4EBP1
Thr37/46 by Western blotting techniques) to meal consumption was determined at three
gluteal muscle biopsy depths (6, 8, and 10 cm), and the repeatability of the contralateral
side at 8 cm during 5 days of repeated biopsies. There was no effect (P > 0.05) of
sampling side or biopsy depth on mTOR signaling in mature horses. During repeated
biopsies there was an increase (P < 0.05) in downstream (P-S6K1 Thr389, P-rpS6 Ser235/236
& 240/244
and P-4EBP1 Thr389) mTOR signaling in response to feeding. The second
objective was to characterize alterations in mTOR signaling throughout the equid
lifespan. Adolescent horses (yearlings and two year olds) studied in the postprandial had
a lowered (P < 0.05) activation of downstream mTOR signaling with aging. There was a
lower (P < 0.05) abundance of P-S6K1 Thr389 in aged horses (23.5 years old) than in
mature horses (11 years old) during the post-absorptive state. The final objective was to
assess mTOR signaling during acute and chronic inflammation. Acute inflammation
occurred during 5 days of repeated biopsies, and chronic inflammation is characteristic of
the aged. During acute inflammation, characterized by increased muscle mRNA
expression of inflammatory cytokines, there was an increase (P < 0.05) in downstream
mTOR signaling. Chronic inflammation resulted in a decrease (P < 0.05) in the
abundance of P-S6K1 Thr389. Phenylbutazone was administered to reduce (P < 0.05)
acute and chronic inflammation in muscle. Phenylbutazone administration during acute
inflammation reduced (P < 0.05) the activation of downstream mTOR signaling and
trended to increase (P = 0.09) P-S6K1 Thr389 abundance during chronic inflammation.
Whole-body protein synthesis determined using isotope infusion techniques increased (P
< 0.05) when chronic inflammation was reduced due to phenylbutazone administration.
This research provides new standards for muscle biopsy collection when examining

mTOR signaling, and insight into management and feeding practices for adolescent and
aging horses.
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CHAPTER I.
The literature review
1.1. INTRODUCTION
The horse is a highly athletic animal that excels in a wide variety of sports that
require targeted training of specific muscle groups with the intent of muscle accretion.
Skeletal muscle is a unique tissue with a high degree of plasticity in its ability to increase
and decrease in size, which is dictated by protein content, and in the horse comprises
50% of body mass (1). However, the horse has received little research attention with
regards to protein metabolism and accretion. Rather, the research in the horse has
focused on N balance studies, and assessment of ADG during development in order to
determine protein and lysine requirements, and characterization of skeletal muscle
physiology, specifically fiber types, during exercise and development.
The molecular signaling pathway that regulates protein synthesis has been
extensively studied in cell culture, rodents, neonatal piglets, and humans. The
mammalian target of rapamycin signaling (mTOR) pathway regulates protein synthesis
and has been examined in a single study in the mature horse, where it was demonstrated
that the anabolic stimulus of meal consumption increases mTOR signaling (2). These
results were in agreement with the numerous studies examining mTOR signaling in
response to meal consumption in other mammalian species. The end point of the mTOR
signaling pathway is protein synthesis and has been examined in the mature horse
following the anabolic stimuli of exercise using isotope techniques, where it was
demonstrated that muscle protein synthesis increased to the greatest extent when an
1

amino acid-glucose mixture was infused in the jugular vein during the recovery period
(3). Although the studies examining mTOR signaling and muscle protein fractional
synthesis rates have examined the response to anabolic stimuli in various ages of animals,
including neonates, adults, and the aged, there has not been a single study in any
mammalian species to examine mTOR signaling in response to anabolic stimuli during
adolescent development.
The focus of this review is to examine the literature pertaining to the current
knowledge of the mTOR signaling pathway, the pathways involved in protein
breakdown, whole-body and muscle protein synthesis, acute and chronic inflammation,
and to provide a review of the relevant equine literature. Specifically, the upstream and
downstream factors involved in the mTOR signaling pathway, and a review of the
literature examining the effects of anabolic stimuli throughout the lifespan will be
discussed. The methodologies used to examine whole-body and muscle protein synthesis
and the literature regarding whole-body and muscle protein synthesis in response to
anabolic stimuli throughout the lifespan will also be discussed. Next, there will be a brief
discussion of inflammatory signaling, followed by a description of the inflammatory
response to both acute and chronic stimuli. The literature review will end with an
overview of the equine literature, including an overview of the research pertaining to
protein nutrition (digestion and absorption, digestibility, and requirements),
characterization of how muscle physiology, specifically fiber typing, changes with
development and exercise, and the inflammatory response to acute and chronic
inflammation.
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1.2. THE MAMMALIAN TARGET OF RAPAMYCIN SIGNALING PATHWAY
The mTOR signaling pathway was initially discovered in yeast in 1991 by
Heitman and colleagues (4). In yeast, mTOR is referred to simply as TOR and received
its name because it was demonstrated that the protein was inhibited by rapamycin (4). In
mammals the mTOR signaling pathway proteins are ubiquitous (5), but the focus of this
literature review will focus on mTOR signaling in skeletal muscle (Figure 1.1).
Protein synthesis is limited by both the abundance and efficiency of ribosomes to
translate mRNA into protein and the availability of amino acids to form a protein. The
efficiency of ribosomes to translate mRNA into a protein is modulated by a series of
intracellular signaling cascades that are associated with the mTOR pathway.
1.2.1. The mammalian target of rapamycin complexes
mTOR and the complexes it forms are predominately localized to the cytoplasm
during inactivated states, but shuttling to the nucleus and lysosomes occurs during
various activated states (6), which will be discussed further below. mTOR behaves as the
catalytic subunit in 2 complexes: the mTOR complex 1 and 2 (mTORC1 and mTORC2).
mTORC1 (Figure 1.2A) consists of 5 proteins: mTOR, mammalian lethal with SEC13
protein 8 (mLST8; also known as GβL), DEP domain-containing mTOR-interacting
protein (DEPTOR), regulatory-associated protein of mTOR (RAPTOR), and 40 kDa prorich Akt substrate (PRAS40; also known as AKT1S1). GβL acts as a stabilizer for the
mTOR-RAPTOR association, and RAPTOR serves to recruit mTOR substrates (7). GβL
is also thought to act as a positive regulator for mTORC1 function (8), whereas DEPTOR
(9) and PRAS40 (10) may have an inhibitory role; all of which will be further described
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below (Section 1.2.2). mTORC2 (Figure 1.2B) is comprised of six proteins, three of
which are also found in mTORC1: mTOR, GβL, and DEPTOR. The three remaining
proteins that are unique to mTORC2 are rapamycin-insensitive companion of mTOR
(RICTOR), mammalian stress-activated map kinase-interacting protein 1 (mSIN1; also
known as MAPKAP1), and protein observed with RICTOR (PROTOR). RICTOR and
PROTOR aid in the assembly of the mTORC2 complex (11). mSIN1 appears to function
in the relocalization of the mTORC2 complex towards the cell membrane where it can
interact with Akt, a signaling factor within the mTOR signaling pathway (12, 13). The
two complexes of mTOR have varied functions and contributions to the mTOR signaling
pathway which will be discussed further below (Section 1.2.2). Regardless of complex,
the activated form of mTOR is phosphorylated at sites Ser2448 and Ser2481 (14, 15). From
this point on mTOR signaling will refer to mTORC1 signaling.
1.2.2.

Upstream inputs of the mTOR signaling pathway
Upstream input into the mTOR signaling pathway comes from a variety of

sources including: metabolites, hormones, mechanical stimulation, and physiological
states. This section of the literature review will be subdivided by these inputs.
1.2.2.1. Insulin and Insulin like growth factor
The insulin and mTOR signaling pathways are joined through protein kinase B
(PKB; also known as Akt). Insulin and insulin like growth factor (IGF) bind with their
respective receptors, resulting in the autophosphorylation of tyrosine residues. The
activation of this insulin receptor tyrosine kinase complex results in the phosphorylation
of the insulin receptor substrates (IRS-1, IRS-2, and IRS-3) (16). The IRS act as docking
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units for the regulatory subunit of phosphoinositide 3-kinase (PI3K) (16, 17), and
together the activated subunit phosphorylates PtdIns(3,4)P2 / PtdIns(3,4,5)P3-dependent
kinase 1 (PDK1) on the serine residues. PDK1 then phosphorylates Akt at Thr308 (18).
An additional phosphorylation site (Ser473) must also be phosphorylated for Akt to be
activated (18). Akt is phosphorylated at Ser473 by the mTORC2 (19, 20). Although the
upstream substrates resulting in mTORC2 activation have not been fully elucidated, Akt
is phosphorylated at Ser473 in response to insulin and IGF-1(18). Researchers currently
theorize that phosphorylation of Ser473 primes Akt for further phosphorylation at Thr308
(21); however, additional research is necessary to confirm this. In summary, insulin and
IGF act through the insulin signaling pathway to activate Akt, linking the insulin and
mTOR signaling pathways.
There are also several negative effectors that can inhibit activation in the insulin
signaling pathway which include protein tyrosine phosphatase-1β (PTP1β), phosphatase
and tensin homolog deleted on chromosome 10 (PTEN), and protein phosphatase
2A(PP2A) (22-24). PTP1β dephosphorylates both the insulin receptor and IRS, and thus,
deactivating the insulin receptor and IRS, which inhibits signaling through the pathway
(22, 24). PTEN prevents PI3K from phosphorylating PDK1, inhibiting further signaling
in the insulin pathway (22, 24). PP2A dephosphorylates the upstream effector Akt, and
the downstream effector, 70 kDa S6 Kinase 1 (S6K1) (22, 24), which will be discussed in
detail below (Section 1.2.3.1). Ultimately, for Akt activation to occur through the insulin
signaling pathway the activity of these negative effectors must be suppressed.
Akt activation leads to mTOR activation through the inhibition of PRAS40 and
tuberous sclerosis 2 (TSC2). PRAS40 interacts with RAPTOR as a component of
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mTORC1 and behaves as a negative regulator, inhibiting mTORC1 activity (25). Akt
phoshphorylation of PRAS40 at Thr246 inhibits PRAS40 activity (10), allowing mTORC1
activation which results in the activation of PRAS40 at Ser183 and Ser221 and subsequent
disassociation from mTOR (26, 27). Disassociated PRAS40 then binds to the scaffolding
protein 14-3-3 (27). Activated Akt phosphorylates TSC2 at four residues (Ser939,
Ser1086/1088, Thr1462, and Thr1422) (28, 29). TSC2 is a component of the TSC1/2 complex,
which acts as a GTPase activating protein (GAP) for the G protein, Ras homologue
enriched in brain (RHEB) (30, 31). Because GDP loaded RHEB cannot activate mTOR,
the TSC1/2 complex acts as an upstream inhibitor of mTOR. Akt inhibition of TSC2
inhibits the TSC1/2 complex resulting in the inhibition of GAP activity. This keeps
RHEB bound to GTP, allowing for the activation of mTOR. PRAS40 and TSC1/2
complex are inactivated by Akt through phosphorylation and mediate the activity of the
mTORC1 complex.
Akt influences other cell mediators not involved in the mTOR signaling pathway.
Although a detailed description of this is beyond the scope of this literature review, a
discussion of Akt would not be complete without it. Activation of Akt results in the
translocation of glucose transporter 4 (GLUT4) to the cell membrane (16), and
phosphorylates the transcription factors, forkhead box protein O1 (FoxO1) and O3
(FoxO3) (32). The translocation of the 12-transmembrane domain protein, GLUT4,
results in the transport of glucose into the cell (33, 34). Alternatively, the FoxO proteins
are involved in the molecular signaling pathway regulating protein breakdown (Section
1.3) (35), and in activating the expression of genes regulating apoptosis (36). Thus, Akt
influences protein synthesis, protein breakdown, glucose metabolism, and the cell cycle.
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1.2.2.2. Glucose
Although glucose does not directly influence mTOR signaling, cellular energy,
which is partly derived from glucose, mediates mTOR signaling. Glucose is transported
into the cell by GLUT4, which is translocated to the cell membrane by Akt (16). Briefly,
ATP is produced from glucose through glycolysis in the cytoplasm, and the Krebs cycle
and electron chain transport in the mitochondria. The ratio of AMP to ATP, an indicator
of cellular energy status, is allosterically monitored by AMPK. AMPK activity is
inhibited when there are elevated levels of ATP because the AMP/ATP ratio is reduced.
During times of low energy status, AMP/ATP ratio is increased, activating AMPK.
Therefore, any physiological state altering ATP status can affect mTOR signaling,
because activated AMPK phosphorylates TSC2 at Thr1227 and Ser1345, causing activation
of TSC2 and forms the TSC1/2 complex (37). As previously mentioned, the TSC1/2
complex acts as a GAP for RHEB (30, 31). Activation of the TSC1/2 complex stimulates
GAP activity toward RHEB inhibiting mTOR. AMPK can also inhibit mTORC1 through
phosphorylating RAPTOR at Ser722 and Ser792 inducing the association of RAPTOR and
scaffold protein 14-3-3 (38). Any physiological state affecting AMPK status, such as
stress and DNA damage, will alter mTOR signaling. DNA damage upregulates AMPK
in a p53 dependent manner (39), resulting in inhibition of mTOR signaling. Because
AMPK can directly and indirectly inhibit mTORC1, any physiological state affecting
ATP status can alter mTOR signaling; therefore, in a glucose rich environment, for
example following a meal, AMPK is reduced allowing mTOR signaling.

7

1.2.2.3 Amino Acids
Intracellular amino acids stimulate mTOR signaling (40), and this stimulation
requires a system of amino acid transporters in order to transport extracellular amino
acids from blood into the muscle. Although there is not a full understanding of how
amino acids stimulate mTORC1 activation, potential mediators have been recognized
including mitogen-activated protein 4 kinase kinase kinase kinase (MAP4K3) (41, 42)
and PI3K catalytic subunit type 3 (VPS34) (43). MAP4K3 is stimulated by amino acids
independent of insulin and is not suppressed by rapamycin, and results in the activation
of S6K1, a downstream signaling factor in the mTOR signaling pathway, which will be
discussed in detail below (Section 1.2.3.1) (42). Therefore, it is thought that amino acid
stimulation of MAP4K3 activates S6K1 independent of mTOR, but this requires further
elucidation. Although the mechanistic action of VPS34 on downstream mTOR signaling
factors is not fully understood, VPS34 may be the primary modulator of mTOR signaling
in response to amino acids (44), and it has been suggested that VPS34 is required for
leucine stimulation of S6K1 (45). Another potential mediator is the Rag family of
GTPases (46). In the absence of amino acids, the Rag GTPases maintain an inactive
conformation, but in the presence of amino acids the Rag GTPases become activated and
interact with RAPTOR resulting in mTORC1 relocalization onto the surface of
endosomes and lysosomes. This may enable mTORC1 interaction with RHEB and
mTORC1 activation (46); however, this requires further elucidation. Even though a
mixture of amino acids stimulate mTOR signaling, arginine and leucine have been shown
to directly stimulate mTOR signaling. Although the mechanism requires further
elucidation, arginine stimulated mTOR signaling in a nitric oxide independent manner
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(47). Leucine has been identified as a key amino acid in mTORC1 activation (48-50).
The stimulation of the mTOR signaling pathway by amino acids is pivitol area of
research and may provide insight to more effective diet formulation.
1.2.2.4. Growth factors
Growth factors, such as IGF, epidermal growth factor (EGF), platelet derived
growth factor (PDGF), and vascular endothelial growth factor (VEGF) can also stimulate
mTOR through Akt-independent mechanism (51-53). Stimulation of the extracellular
regulated kinase (MEK/ERK) axis through growth factor activation of a small GTPase in
the RAt Sarcoma protein subfamily (Ras) and subsequently mitogen activated protein
kinase kinase kinase (MAP3K) stimulates MEK and then ERK1/2 to inactivate TSC2
through phosphoryaltion at Ser664 (52). Additionally, Wingless-Type MMTV Integration
site family (Wnt) inhibits glycogen synthase kinase 3β (GSK3β) through the β-catenin
pathway, allowing mTOR activation; however, β-catenin, itself, does not affect mTOR
activation (51). The activated form of GSK3β phosphorylates TSC2 at Thr1329, Ser1333,
Ser1337, and Ser1341 resulting in mTOR inhibition (51). Growth factors, specifically IGF,
can also stimulate mTOR signaling in an Akt-dependent manner, which was previously
discussed above (Section 1.2.2.1).
1.2.2.5. Other physiological states
Regulated in development and DNA damage response 1 (REDD1; also known as
RTP801/DDIT4) is a hypoxia induced gene, and can alter mTOR signaling through
several mechanisms including stress (54-56), glucocorticoid treatment (57), and exercise
(58). Hypoxia induces REDD1 expression causing TSC2 to dissociate from scaffolding
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protein 14-3-3, and allowing TSC1/2 complex activation (55, 56). Energy stress can also
act through AMPK dependent and independent mechanisms similar to what is seen
during hypoxia, with induced expression REDD1 and subsequent TSC1/2 complex
activation (54). Additionally, REDD1 expression is induced following glucocorticoid
treatment with dexamethasone leading to mTOR inhibition through TSC1/2 complex
activation (59). Immediately following endurance exercise REDD1 expression is
elevated (58) and may be responsible for the inhibition of mTOR during exercise;
however, these mechanisms have not been fully elucidated.
Another hypoxia induced gene, REDD2 (also known as RTP801L/DDIT4L), also
acts as an mTOR signaling inhibitor; however, much less is known about REDD2.
Similar to REDD1, REDD2 does not inhibit mTOR signaling through TSC2 activation
directly, but through interactions with the scaffolding protein 14-3-3, which results in
activation of the TSC1/2 complex. REDD2 expression is stimulated by leucine and
mechanical stretch (60), demonstrating that positive and negative signaling components
influence the activation of mTOR simultaneously. As a result, in order for mTOR
activation to occur, the positive signaling must be greater than the negative signaling.
1.2.2.6. Summary of the upstream activators of mTOR
In conclusion, physiological states such as stress, hypoxia, and exercise, growth
factors, and metabolites are all upstream effectors of the mTOR signaling pathway. With
the exception of amino acids, all other effectors work through either activating (negative
effectors: low energy status, DNA damage, hypoxia) or inhibiting (positive effectors:
high energy status, insulin, amino acids, and growth factors) the TSC1/2 complex which
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allows for the inhibition or activation of the mTORC1, respectively. Upstream of
mTORC1 the insulin and mTOR signaling pathways converge at Akt (Figure 1.3).
Additionally, the MEK/ERK axis feeds into the mTOR signaling pathway through the
TSC1/2 complex. This series of events leads to the activation of mTORC1.
1.2.3. Downstream effectors of the mTOR signaling pathway
Following mTORC1 activation by RHEB, a series of cell signaling events occurs
leading to the formation of the ribosome and the initiation of the translation of mRNA
into a protein. Activated mTORC1 causes the phosphorylation of S6K1 at Thr389, Thr229,
Ser404, and Thr412 and eukaryotic initiation factor (eIF) 4E-binding protein 1 (4EBP1) at
Thr 36/47 Ser65, and Thr70 through RAPTOR recruitment (61). The function of RAPTOR
in mTORC1 is to recruit substrates in order for these substrates to be in close enough
proximity for the catalytic activity of mTOR to phosphorylate the substrates (7). This
section of the literature review will be subdivided by the downstream effectors.
1.2.3.1. S6K1
The activation of S6K1 through phosphorylation is required for RNA processing
and mRNA translation initiation. S6K1 mediates several downstream proteins including:
the transcription factor CREMτ (62), the 80 kDa RNA splicing export factor nuclear capbinding protein (CBP80; also known as NCBP1) (63), Aly/REF-like target (SKAR; also
known as POLDIP3) (64), ribosomal protein S6 (rpS6) (65, 66), and eIF4B (67, 68). Of
the targets of S6K1, only SKAR, rpS6, and eIF4B have been extensively studied. SKAR
is a scaffolding protein that recruits S6K1 to newly synthesized mRNAs and interacts
with the exon junction complex that is involved in splicing pre-mRNA (64). S6K1
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influence on both CBP80 and SKAR demonstrates the contribution of S6K1 in enhancing
translational efficiency gained from splicing of pre-mRNA (63, 64). Translation
efficiency is the effectiveness of the ribosome to form a protein from the mRNA and
depends on the availability of amino acids. rpS6 is activated through phosphorylation at
Ser235, Ser236, Ser240, Ser244, and Ser247 by S6K1, and was once suggested to increase
translational efficiency of 5’terminal oligopyrimidine (TOP) mRNAs, which encode
components of the translation machinery, through ribosomal recruitment (65, 66);
however, this theory has been disproven (69). rpS6 activation is necessary for increased
protein synthesis, but the mechanism is still unclear (69). rpS6 is also involved in cell
proliferation (70) and determining cell growth (69). rpS6 knockout mouse embryo
fibroblasts have accelerated cell division due to a shortened G1 phase (70). rpS6 aids in
the determination of cell growth through controlling protein synthesis and cell division
(69). S6K1 activates the RNA-binding protein, eIF4B, through phosphorylation at Ser422,
and is required for ribosomal recruitment to mRNA (68). Activated eIF4B stimulates the
ATPase and helicase activities of eIF4A (67), which enhances the translation of mRNAs
with some secondary structure because the helicase function can unwind the mRNA
secondary structure (71). Overall, S6K1 is thought to increase translational capacity of
the cell through translation component enhancement (also known as ribosome biogenesis)
(72), and through ribosomal recruitment to mRNA.
1.2.3.2. 4EBP1
mTORC1 activation leads to the phosphorylation of 4EBP1at Thr37and Thr46,
which is thought to prime 4EBP1 for the subsequent phosphorylation at Ser65 and Thr70
(73). 4EBP1 acts as a regulator for the formation of the eIF4F complex that is required in
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the initiation of cap-dependent mRNA translation. The phosphorylation of 4EBP1 causes
its dissociation from eIF4E, which allows eIF4E and eIF4G to associate. eIF4E is the
rate-limiting translation initiation factor that initiates cap-dependent translation through
binding to the Cap structure (m7GpppN) at the 5’ end of mRNA transcripts (74);
therefore, the phosphorylation of 4EBP1 and subsequent dissociation from eIF4E is a key
step in translation initiation. The eIF4E/G complex behaves as a scaffolding protein and
recruits eIF4A and eIF3; together forming the eIF4F complex (75) that is bound to
m7GpppN. This complex acts as a mediator of mRNA binding to the 40S ribosomal
subunit. Next, eIF4B associates with the eIF4F complex, facilitating mRNA and
ribosome association (76). Prior to mRNA recruitment to the 40S subunit, GTP loaded
eIF2 bound to Met-tRNAi is recruited to the 40S subunit (77). This entire complex is
referred to as the 43S pre-initiation complex. At this point, the 43S complex scans the
mRNA, once the AUG start codon is reached, the GTPase, eIF5, binds to the complex
and hydrolyzes eIF2 loaded with GTP to GDP allowing eIF5B to bind to the complex.
This series of events causes displacement of the eIF2 and recruitment of the 60S
ribosomal subunit, and relocalizes the 60S ribosomal subunit to the 43S complex (77,
78).
1.2.3.3. Elongation of the polypeptide chain
The initiation complex then begins elongating the peptide chain with the
association of eukaryotic elongation factor (eEF) 2 (79). eEF2 mediates the translocation
step from the “P” to the “A” site of the peptidyl-tRNA, facilitating ribosome movement
along the mRNA (53). The “P” and “A” sites are named because they are the sites where
the peptidyl-tRNA and the aminoacyl-tRNA bind, respectively. eEF1A bound to GTP
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delivers the next aminoacyl-tRNA to the ribosome at the “A” site (80). A second GTP is
then needed to remove eEF1A following correct codon, anti-codon recognition (80).
Finally, eEF1B assists in the regeneration of eEF1A to its active form, where it can
collect another aminoacyl-tRNA (80). This process requires metabolic energy in the
form of GTP, where two molecules of GTP are cleaved for every amino acid added to the
polypeptide chain.
1.2.3.4. Termination of the elongation of the polypeptide chain
The last step in translation is termination which occurs when the ribosome reaches
the stop codon. The eukaryotic releasing factor 1 (eRF1) is activated by eRF3 in a GTPdependent manner, which results in eRF1 binding to the ribosome and cleaving the bond
between the peptide chain and the tRNA (80). This also requires the hydrolysis of GTP
(80). The net result is an increase in protein synthesis.
1.2.3.5. Summary of the downstream effectors of mTOR
In conclusion, the activation of mTORC1 results in the downstream activation of
S6K1 and 4EBP1 (Figure 1.3). Each of these proteins are key players in forming the
initiation complex. S6K1 activates rpS6 and eIF4B. The phosphorylation of 4EBP1
causes it to dissociate from eIF4E, allowing for the association of eIF4E and eIF4G. This
series of events initiates the formation of the initiation complex along the mRNA.
Initiation is followed by elongation and, once the polypeptide chain is formed,
termination. The net result is protein synthesis.
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1.2.4.

Feedback mechanisms within the mTOR signaling pathway
The interaction of the insulin and mTOR signaling pathways has been previously

discussed in regards to activation through these pathways toward translation initiation.
These pathways also interact in a negative feedback manner. Hyperactivation of
mTORC1 triggers activated S6K1 to inhibit IRS1, resulting in decreased Akt activation
and subsequently mTORC1 (81). This negative feedback loop also has consequences for
insulin signaling, such as reduced insulin sensitivity and glucose uptake, which may have
implications for horses with metabolic syndrome.
1.2.5. Effects of anabolic stimuli on mTOR signaling in mature mammals
Anabolic stimuli such as meal consumption (82-84), amino acid administration
(85, 86), insulin (85, 86), or exercise (87-91) increases the activation of translation
initiation factors in the mTOR signaling pathway and increases muscle protein fractional
synthesis rates. In mature sedentary animals, skeletal muscle protein turnover occurs at a
fairly slow rate with slight variations occurring during fasting and feeding, where the net
breakdown and synthesis are greater at these times, respectively (92). Fasting has a
greater effect of reducing mTOR signaling in muscles primarily composed of fast twitch
fibers compared to slow twitch fibers (93). Specifically, during times of short term
fasting (18-24 hours) and long term (2-3 days), phosphorylation of Akt and mTOR,
respectively, are greater in muscle primarily composed of slow twitch fibers than fast
twitch fibers (93). The absence of insulin, glucose, and amino acids during fasting
activates AMPK which subsequently activates the TSC1/2 complex which inhibits
mTOR activation (Section 1.2.2.2), ultimately suppressing protein synthesis (37, 56, 94).
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The difference in mTOR signaling during short and long term fasting where there is an
increase in the phosphorylation of Akt and mTOR, respectively, is due to the pro-survival
role of autophagy. Upregulation of autophagy in liver, white adipose tissue, and muscle
recycles protein, glycogen and lipid stores and releases them as amino acids, glucose, and
free fatty acids into the blood stream. These metabolites can then be used by skeletal
muscle to cause partial reactivation of mTOR signaling (95), which suppresses autophagy
during long term fasting (96). A recent study showed that Gadd34, a protein that is
traditionally upregulated during growth arrest and DNA damage, binds to and
dephosphorylates TSC2 at Thr1462 during fasting, leading to mTOR suppression (97).
Meal consumption results in the stimulation of the mTOR signaling pathway (8284). Following meal consumption, there is an elevation in amino acids, free fatty acids,
glucose, and insulin concentrations in the blood stream. As mentioned above (Section
1.2.2), amino acids and insulin stimulate mTOR signaling. Therefore, many studies have
been performed using clamps to stimulate a fed state (98) which have demonstrated
increased mTOR signaling. Intravenous clamps maintain circulating levels of a desired
metabolite or hormone at a set state. Regardless of nutrient content, ingestion of any type
of meal will increase circulating insulin. Therefore, in order to determine if both amino
acids and insulin are required to stimulate mTOR leading to protein synthesis, reduced
amino acid hyperglycemic hyperinsulinemic hyperlipidemic clamp studies were
performed, which demonstrated that insulin alone does not sufficiently stimulate mTOR
to lead to increased protein synthesis (85, 86), but Akt is activated (86). This
phenomenon may be explained due to a lack of available amino acids to form a protein or
due to insufficient translation initiation. Additionally, insulin stimulates vasodilation
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which promotes protein synthesis through increasing the flow of available nutrients, such
as amino acids, to the muscle (99). This mechanism has not been fully elucidated, but
does not appear to require Akt activation (99).
Amino acids alone can stimulate the mTOR signaling pathway and subsequently
protein synthesis. The increase in protein synthesis due to amino acids is not affected by
the method of delivery of amino acids (oral or infusion) (100). Because leucine has been
demonstrated as the key amino acid in regulating mTOR signaling, many studies have
focused on supplementing leucine. Even though elevating leucine ingestion past
0.14g/kg in mature rodents resulted in a near maximal stimulation of protein synthesis,
the activation of mTOR signaling factors appears to be dose dependent (101).
Additionally, the ingestion of carbohydrate and amino acid mixture enriched in leucine
seems to stimulate mTOR signaling through AMPK-TSC1/2 complex axis, likely from
the carbohydrate portion of the mixture (102), and S6K1 and 4EBP1 due to the amino
acid and leucine component in resting humans (103). This study also demonstrated that
this leucine enriched mixture decreased the phosphorylation of eEF2 which promotes
elongation and stimulated muscle protein fractional synthesis rates (103). Regardless of
delivery method, amino acids stimulate protein synthesis at the molecular points of
translation and elongation.
During exercise, skeletal muscle contractile activity, which can also be thought of
as mechanical stimulation, increases. Mechanical stimulation of skeletal muscle fiber
(104) can occur through the stimulation of muscle fibers in the laboratory, or subjects
performing aerobic or resistance exercise, the result is still some form of mechanical
stimulation. Mechanical stimulation increases the activity of the mTOR signaling
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pathway. Elevated protein synthesis through activation of the mTOR signaling pathway
can lead to an enlargement in muscle fibers (105). Following acute resistance exercise in
rodents, there is almost an immediate (5-10 min post exercise bout) increase in mTOR
signaling factors: phosphorylation of Akt, 4EBP1, and rpS6 and the association of eIF4E
to eIF4G (87). The activation of mTOR itself has had mixed reports in response to
mechanical stimulation, where there are reports of no affect on the phosphorylation of
mTOR at Ser2481 (88, 89), an increase in the phosphorylation of mTOR at Ser2448 (91), or
no affect on the phosphorylation of mTOR at Ser2448 (87). However, the downstream
effectors have been shown to increase in phosphorylation (61, 65, 67), and these proteins
are associated with an increase in the rate of muscle protein synthesis (81). Although the
mechanism still requires elucidation, it is currently accepted that there is an increase in
the downstream effectors (90, 106, 107) and subsequent protein synthesis (108) following
the mechanical stimulation of skeletal muscle. It has been demonstrated that activation of
the downstream effectors due to mechanical stimulation is independent of PI3K/Akt
signaling (90). However, it appears that mechanical stimulation activates the
downstream effector, rpS6 through an mTORC1 independent mechanism. Following
mechanical stimulation there is an increase in MEK/ERK signaling (90), which activates
p 90 ribosomal S6 kinases (RSK). RSK activate rpS6 through phosphorylation of Ser235
and Ser236 (90, 107). Because mTORC1 inhibitor rapamycin can inhibit S6K1
phosphorylation following mechanical stimulation, and not rpS6 phosphorylation, it
appears that protein synthesis due to mechanical stimulation is regulated by both the
MEK/ERK signaling pathway and the mTOR signaling pathway (90).
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The adaptation of skeletal muscle to hypertrophy following exercise has been
shown to be fiber type dependent, where fast twitch fibers (Type II) are more susceptible
to adaptation than slow twitch fibers (Type I) (109). This can be partly explained by the
fact that muscle groups containing greater proportion of Type II compared to Type I
fibers have a greater phosphorylation of S6K1 in response to resistance exercise (110).
Additionally, maximal lengthening contraction stimulates S6K1, rpS6, and MAP3K
greater in Type II fibers compared to Type I, which not only further demonstrates fiber
type differences, but also indicates the role of MEK/ERK in contraction driven protein
synthesis (111). Another explanation may be that the majority of muscle groups that are
predominately slow twitch fibers are mainly used in posture and this continuous
mechanical stimulation is less effective than intermittent mechanical stimulation at
activating the mTOR pathway (112, 113).
Both aerobic (endurance) and resistance exercise increase mTOR pathway
signaling and subsequent protein synthesis (106, 108). However, following resistance
exercise the phosphorylation of S6K1, rpS6, and myofibrillar muscle fraction synthesis
rates were higher than following endurance exercise in untrained humans (108). Humans
who have been trained for resistance exercise have elevated phosphorylation of Akt and
eIF4E, and increased myofibrillar protein fractional synthesis rates following a bout of
resistance exercise compared to following a bout of endurance exercise in endurancetrained individuals (108). Additionally, mitochondrial protein fractional synthesis rates
in the muscle are elevated to the same extent following a bout of endurance or resistance
exercise in untrained individuals; however, in trained individuals muscle mitochondrial
protein fractional synthesis rates are greater following endurance exercise (108). The
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mechanistic differences in which endurance and resistance exercise stimulate the mTOR
signaling pathway may explain the differences demonstrated by Wilkinson and
colleagues (108). Endurance exercise results in AMPK inhibition of TSC2, while
resistance exercise elevates phosphorylation of Akt and subsequent TSC2
phosphorylation (114). A recent study in untrained subjects, following a bout of aerobic
exercise the phosphorylated forms of Akt, TSC2, and 4EBP1 were greater in the skeletal
muscle of these subjects than in those subjects performing the resistance exercise (106).
However, a few studies (115, 116) in humans have indicated an additional upstream
mechanism (MEK/ERK) that results in the stimulation of mTOR during resistance
exercise, but this has yet to be demonstrated under endurance exercise conditions.
The combination of consuming a high protein meal either before (117) or after
(118) an endurance exercise bout has been demonstrated to have greater activation of
mTOR signaling than either stimulus alone. However, the effect of resistance exercise on
the activation of mTOR signaling appears to be benefitted from the ingestion of a high
protein meal following exercise, but not prior to exercise (82, 119, 120). In addition to
activating mTOR signaling, elevated MAPK signaling occurs when a high protein meal is
consumed following resistance exercise (82). Thus, combining anabolic stimuli (exercise
and feeding) results in a further increase in mTOR signaling.
Both amino acid supplementation and exercise have been demonstrated to
increase the mRNA expression of several amino acid transporters in skeletal muscle
(121-123). One hour following ingestion of essential amino acids, mRNA expressions of
the amino acid transporters LAT1/SLC7A5, CD98/SLC3A2, SNAT2/SLC38A2, and
PAT1/SLC36A1 were elevated (121). This led to increased protein abundance of
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LAT1/SLC7A5 and SNAT2/SLC38A2 3 hours following the ingestion of essential amino
acids (121). Resistance exercise had similar effects on amino acid transporters, but the
time course was delayed. The mRNA expression of the amino acid transporters
CD98/SLC3A2, PAT1/SLC36A1, and CAT1/SLC7A1 increased 6 hours following
resistance exercise (122), and the mRNA expression of LAT1/SLC7A5 increased 3 hours
following resistance exercise (122). This led to increased protein abundance of
LAT1/SLC7A5 and CD98/SLC3A2 at 6 and 24 hours post-resistance exercise,
respectively (122). These studies (121-123) also examined VPS34, mTOR, S6K1, rpS6,
and eIF4G markers of mTOR signaling, which were elevated following the respective
anabolic stimulus used in each study indicating that the elevated expression of amino acid
transporters may be dependent on mTOR signaling; however, this requires further
elucidation.
1.2.6.

mTOR signaling response to anabolic stimuli throughout the life span
As previously mentioned (Section 1.2.2.4), growth factors affect the activation of

translation initiation, and thus, during the life stage where there are increased (neonatal
and development) or decreased (aging) circulating growth factors (124), there are
alterations in the response of mTOR signaling and subsequently protein synthesis to
anabolic stimuli. The neonatal period is characterized by the highest growth rate during
the lifespan with skeletal muscle showing the largest increase in mass (125). Elevated
growth rate in the neonate is a result of protein synthesis rates being higher than protein
degradation rates. However, with post-natal maturation, protein synthesis rates gradually
decrease (125-127) until both synthesis and degradation are equal in non-growing adult
muscle (128).
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The activation of translation initiation factors (129-131) and protein synthesis
(132, 133) in skeletal muscle are more responsive to feeding during early postnatal life
and declines with development. Insulin infusion can stimulate muscle protein synthesis
and whole-body protein synthesis during a period of fasting in weaned rats (134) and
fetal sheep (135), respectively. However, insulin alone does not stimulate protein
synthesis in adult animals or humans (85, 86, 136), which indicates that muscle protein
synthesis response may be developmentally regulated. This was further demonstrated by
examining the insulin signaling pathway activation in response to feeding where the
activation of insulin receptor, IRS-1, IRS-2, PI3K (137) and Akt (23) are greater in the 7
day old neonatal pig compared to the 26 day old. Additionally, increasing insulin
elevates protein synthesis and the activation of insulin and mTOR signaling factors in a
dose-dependent manner, even when amino acid concentrations are low (138-140).
Elevated rates of protein synthesis during the neonatal period are a result of an
increased efficiency of dietary amino acids used for protein accretion (141). Activated
mTOR signaling and protein synthesis due to amino acid supplementation decreases with
development, similar to the response of insulin and feeding (138, 142). Of all of the
essential amino acids, leucine, has received the most attention, because leucine alone has
been shown to stimulate mTOR signaling (143), while the other branched chain amino
acids cannot stimulate mTOR signaling alone (49). Leucine, individually, does not elicit
the same increase in mTOR signaling activation as when it is given with a balanced
amino acid mixture (48), which may be partly attributed to the fact that the ability of
leucine or any other anabolic stimuli to stimulate protein synthesis is dependent on the
availability of amino acids needed for synthesis of a protein (50).
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The negative regulators of insulin and mTOR signaling, PTP1B, PTEN, PP2A,
and TSC2, are less active in the skeletal muscle of neonates, but the activity of these
negative regulators increases with age (23, 144). However, the inhibition of mTOR
signaling due to AMPK did not appear to be developmentally regulated when the
stimulation was feeding (23). Feeding also inhibits TSC2 activation in the skeletal
muscle of neonates, and this is attenuated with age (23).
Not only are the positive factors of the insulin and mTOR signaling pathways
more active during neonatal development, but there is also a greater total abundance of
these factors in skeletal muscle. The abundance of the insulin receptor, PDK-1, and Akt
in skeletal muscle decreases with development (131, 137). The abundance of mTOR and
RAPTOR also decreases with postnatal development, which results in a decreased
association of the two proteins (23, 129, 145) However, the abundance of downstream
signaling factors such as S6K1, rpS6, and 4EBP1 do not change with development (146).
In addition to the highly responsive mTOR signaling pathway, skeletal muscle of
neonates has been reported to have a higher concentration of ribosomes which decreases
with age (127, 147), and may also contribute to the elevated protein synthetic rates
because of a higher efficiency to synthesize proteins. Overall, the skeletal muscle of the
rapidly growing neonate is physiologically adept to synthesize protein efficiently and
thus accrete muscle mass.
Aging is characterized by the involuntary loss of muscle mass and strength which
is referred to as sarcopenia. Sarcopenia has been partially attributed to a multitude of
factors which include a decline in physical activity and a less than optimal diet in the
aging human population (148-150). Sarcopenia is a result of an imbalance of protein
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synthesis and breakdown. The increase in muscle protein fractional synthesis rates in
response to anabolic stimuli such as exercise (149, 151, 152), amino acids (149, 153),
insulin (154), or meal consumption (152, 153) is decreased in the aged compared to the
younger adult, and may be due to dysregulation of signaling factors in the insulin and
mTOR signaling pathways (155, 156). Meal consumption in the aged does not increase
protein synthesis or activate the mTOR signaling pathway to the same magnitude as in
the young adult (155-157); however, when the meal is supplemented with leucine there is
a restoration in the anabolic effect of feeding (158). This may indicate that amino acid
supplementation, specifically leucine, plays a larger role in stimulating protein synthesis
than insulin in the aged. Physiological hyperinsulinemia does not stimulate mTOR
signaling in aging skeletal muscle as it does in young adult skeletal muscle (159, 160);
however, at supraphysiological levels of hyperinsulinemia mTOR signaling in the aging
skeletal muscle is restored (159). This may indicate that insulin resistance with aging
may at least partially be responsible for sarcopenia (161). Additionally, aerobic exercise
(162, 163), amino acid supplementation (164), and vaso-dilation (165) can improve the
anabolic response of mTOR signaling to hyperinsulinemia. Thus, activation of the
mTOR signaling pathway in aging skeletal muscle appears to behave similar to young
adult skeletal muscle when stimulated by multiple anabolic stimuli rather than just one.
This also holds true for resistance exercise, which more effectively stimulates mTOR
signaling in the elderly if amino acids are supplemented following the exercise bout
(166). However, amino acid supplementation prior to a bout of resistance exercise does
not enhance muscle protein synthesis relative to resistance exercise alone (120). Similar
to the young adult, aging skeletal muscle has increased mRNA expression of several
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amino acid transporters (LAT1/SLC7A5, CD98/SLC3A2, PAT1/SLC36A1,
CAT1/SLC7A1) following resistance exercise; however, the expression of these amino
acid transporters remain elevated for a longer period of time in the aged skeletal muscle
(122). This may mechanistically explain how adding amino acid supplementation to
resistance exercise stimulates the activation of mTOR signaling pathway to the same
extent as in the young adult skeletal muscle.
It has been stated that mTOR signaling and protein synthesis decrease with aging;
however, the signaling factor that appears to be the most influenced by aging is S6K1.
The activation of S6K1 in response to various anabolic stimuli such as meal consumption
(129, 145, 156), amino acids (142, 155-157), insulin (142, 156, 162), and exercise (157,
162) consistently decreases throughout development and into aging. Additionally, the
activation of S6K1 in the post-absorptive state declines during development (142, 145)
and from mature to aging adults (155). The influence on aging is also demonstrated in
the time course response of S6K1 compared to the other mTOR signaling factors. With
aging, the activation of the mTOR signaling factors to exercise and amino acids is
delayed except for the activation of S6K1, even though the abundance is still lowered in
the aged (157). It has also been demonstrated that the total abundance of S6K1 declines
during aging (155). The response of S6K1 to various anabolic stimuli during aging
indicates that it may be the most influenced by aging.
Even though it is currently accepted that there is an overall decline with aging in
the activation of mTOR signaling and protein synthesis in response to anabolic stimuli,
the research that supports this only examines the neonatal phase and post-adulthood
aging. This leaves a hole in the literature for the peri-pubertal, and post-pubertal slow
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growth phase occasionally referred to as adolescence. In order to be sure that mTOR
signaling and protein synthesis decline throughout the lifespan this life phase must not be
ignored. Unfortunately, due to the restrictions of common research models, this phase
has been overlooked. In the humans there are regulations making it difficult to collect
muscle tissue from healthy children under the age of 18 years; whereas, the time of the
adolescent phase is extremely brief in both rodents and pigs, making it difficult to
implement experimental conditions. As a result, this phase has received little to no
research attention.
1.3. THE MOLECULAR MARKERS OF PROTEIN BREAKDOWN AND THE
INTERACTION WITH mTOR SIGNALING
A review of the literature pertaining to muscle mass accretion would not be
complete without mentioning protein breakdown. Although the focus of this dissertation
has been on protein synthesis, muscle mass cannot be accreted without the rates of
muscle protein synthesis being greater than the rates of muscle protein breakdown.
Protein breakdown, similar to protein synthesis, has associated pathways that can be
studied to improve our understanding of the process. The main pathways involved in
protein breakdown are the lysosome, ubiquitin-proteasome, and calcium dependent
pathways, and apoptosis (167); however, skeletal muscle contains a limited number of
lysosomes, and the contribution of lysosomal proteases and cathepsins to proteolysis or
myofibrillar protein degradation is limited (168). The lysosomal system is mainly
responsible for the degradation of organelles and membrane proteins. The ubiquitinproteasome pathway is responsible for the degradation of most of the skeletal muscle
proteins (169), and requires muscle specific ubiquitin ligases, such as muscle-RING26

finger protein 1(MuRF1) and atrogin-1/MAFbx (169-171). There are three ubiquitin
ligases involved in the addition of ubiquitin to a protein substrate: E1 ubiquitin-activating
enzyme, E2 ubiquitin-conjugating enzyme and E3 ubiquitin –ligating enzyme (172). The
E3 ubiquitin ligases confer substrate specificity (172), and muscle has the specific
ubiquitin ligases (169-171), mentioned earlier. Many sarcomeric proteins are degraded
through the calcium dependent pathway due to ubiquitous calpains 1 and 2, and muscle
specific calpain 3 (168, 173). Within skeletal muscle, satellite cells, which are muscle
stem cells, are the most susceptible to apoptosis, which activates the caspases (174) and is
regulated by the transcription factor, forkead box proteins (FoxO) (175). Caspase-3 may
be involved in the initiation of the degradation of actin (176). FoxO also regulates the
expression of atrogin-1 (177), which is a muscle specific E3 ubiquitin ligase (171). The
molecular components of these pathways such as MuRF1, atrogin-1, calpain 3, and FoxO
can be studied as indicators of protein degradation.
Many of the mTOR signaling proteins interact with the main molecular
components of protein degradation. The active form of Akt inhibits FoxO through
phosphorylation, which recruits 14-3-3 proteins preventing relocalization to the nucleus
(175). Additionally, FoxO is inhibited by the phosphorylation of serum- and
glucocorticoid regulated kinase by mTORC2 and PDK1 (21). Caspase 3 may also be
inhibited by the activated form of Akt (177), but further elucidation is required. Nuclear
factor κ B (NF-κB) is stimulated by inflammatory cytokines, and may play a role in
inactivating Akt and increasing the expression of MuRF-1 (177); however further
research is warranted. Additionally, activation of mTOR inhibits atrogin-1,
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independently of FoxO (178); however this mechanism requires further elucidation.
Therefore, Akt and mTOR play a pivotal role in both protein synthesis and degradation.
Similar to protein synthesis, protein breakdown is altered during various
physiological states such as aging (35, 179), and during postprandial and post-absorptive
states (180). During development, muscle protein metabolism is elevated, and rates of
both muscle protein synthesis and breakdown are increased, with a net result of protein
synthesis (181). Research examining the molecular markers of protein degradation is
limited; however, it has been determined that caspase-3 and caspase-9 are downregulated
during development in the skeletal muscle of rodents (182). This is an area that requires
further elucidation during development; however, aging rodents have elevated
proteasome content and activity and free ubiquitin and ubiquitylated protein
concentrations in skeletal muscle compared to younger mature rodents (179). The aged
also have higher abundance of FoxO than the mature counterparts (35). Additionally,
ubiquitination rate is greater in the post-absorptive state than the postprandial state in the
aged rodent whereas the mature rodents are not affected by physiological state (180).
Overall, it appears that there is an increase in the molecular markers of protein
degradation throughout the lifespan.
Although there is much work still to be done examining these interactions
between the molecular markers of protein synthesis and breakdown, it appears that
protein breakdown and protein synthesis are both regulated by the activation of Akt (175,
177) and mTOR (178). Additionally, with aging there is an elevation in the molecular
markers of protein degradation (179-181), which is pronounced during the post-
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absorptive state (180). Ultimately, in order to study protein accretion effectively, both
protein synthesis and degradation need to be examined.
1.4. WHOLE-BODY AND MUSCLE PROTEIN SYNTHESIS:
METHODOLOGIES AND THE EFFECT OF ANABOLIC STIMULI
1.4.1.

Isotope methodologies
Up to this point the literature review has focused on the mTOR signaling pathway

and how it results in protein synthesis. Studying the mTOR signaling pathway provides
insight to researchers as to whether or not a potential exists for an increase in the rate of
muscle protein synthesis. Isotopic measurements are used to quantify rates of protein
synthesis. Both whole-body and muscle protein synthesis rates are typically measured
using the infusion of a stable amino acid isotope, for example [1-13C]phenylalanine. By
measuring phenylalanine flux and rates of phenylalanine oxidation to carbon dioxide
(CO2) during [1-13C]phenylalanine infusion, researchers can estimate the rate of wholebody protein synthesis using a stochastic approach (Figure 1.4). This estimate of wholebody protein synthesis is based on the principle that phenylalanine flux is equal to the
rate that phenylalanine enters (from the diet and protein breakdown) and exits (through
oxidation to CO2, use in protein synthesis and conversion to tyrosine) the free amino acid
pool, and is calculated from the dilution of the isotope by unlabeled phenylalanine in the
plasma (183). The calculated difference of measured phenylalanine converted to CO2
and flux results in non-oxidative disposal, which is an indirect measure of whole-body
protein synthesis, because non-oxidative disposal includes the rate of phenylalanine used
for protein synthesis and phenylalanine conversion to tyrosine. If researchers supply both
phenylalanine and tyrosine at equal levels to the different treatment groups, then it is
29

generally assumed that the phenylalanine conversion to tyrosine should also be equal
among treatment groups; therefore, an increase in phenylalanine oxidation indicates a
decrease in whole-body protein synthesis. During these infusion procedures, the rate of
muscle protein synthesis can also be measured, through the collection of muscle biopsies,
during and at the end of the isotope infusion and measuring the rate of [113

C]phenylalanine incorporation into muscle protein (184). Although phenylalanine was

used during this explanation of isotope methodologies, researchers can use any stable
indispensable amino acid isotope, as long as the carboxyl group is released as 13CO2 in
the breath as the amino acids are catabolized.
1.4.2. Alterations in whole-body protein metabolism in response to anabolic stimuli
Whole-body protein synthesis is the sum of all of the individual tissue rates of
protein synthesis and reflects the overall change in protein synthesis occurring during the
physiological state that is being studied. This makes it a useful tool to understand what is
occurring on a large scale basis.
Whole-body protein metabolism is affected by anabolic stimuli such as meal
consumption (185, 186) and exercise (187). During the post-absorptive state, isotope
tracer oxidation is less than following the consumption of a high protein meal (186),
indicating that feeding increases the amino acid flux. The additional amino acids that
enter the free amino acid pool following meal consumption (dietary intake) that are not
utilized for protein synthesis or conversion to other metabolites are oxidized; therefore,
during the postprandial state amino acid isotope tracer oxidation is elevated because there
is an excess of free amino acids in the plasma pool. However, during the post-absorptive
state the opposite is true, there is a reduction in free amino acids in the plasma pool
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because amino acid entry is coming entirely from protein degradation rather than dietary
intake, as is the case of the postprandial state. Because there is a reduction in the free
amino acid pool, there is not an excess of free amino acids, which results in a decrease in
amino acid oxidation. If flux is unchanged then, the increase in amino acid oxidation
typically results in a decrease in protein synthesis; however, during the post-absorptive
and postprandial periods, flux is not equal. Non oxidative disposal can then be derived
from the difference in flux and oxidation (Section 1.4.1). In addition to a reduction in
amino acid oxidation during the post-absorptive state, there is a reduction in protein
synthesis in comparison to protein breakdown (186, 188, 189). As a result, protein
balance is in a negative state, where protein degradation is occurring at a higher rate than
protein synthesis. However, the opposite is true during the postprandial state, where nonoxidative disposal is greater than release from protein breakdown (186, 188, 189), which
results in a positive protein balance, because there is a greater rate of protein synthesis
than protein degradation. Overall, during the postprandial state there is a net increase in
whole-body protein synthesis leading to protein accretion, and a net loss of whole-body
protein during the post-absorptive period. In a mature, sedentary, individual this cyclical
balance of protein gain and loss during the postprandial and post-absorptive states
throughout the day is equal, resulting in no accretion of protein.
Whole-body protein metabolism is altered both during and following an exercise
bout. Because most exercise bouts last only a short period of time (minutes to hours),
many researchers hypothesize that post-exercise changes in whole-body protein
metabolism are of greater physiological relevance than changes occurring during the
exercise state. As a result, there is an abundance of literature examining the post-exercise
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effects on whole-body protein metabolism, whereas studies of whole-body protein
metabolism during exercise are limited and typically examine endurance or aerobic type
exercise. There are conflicting reports regarding changes in whole-body protein
breakdown during aerobic exercise, where it has been demonstrated to be elevated (190192) or remain unchanged (193, 194). However, all of these reports are in agreement that
there is an increase in amino acid tracer oxidation (190, 192, 194), which may be derived
from an increase in protein degradation. The majority of these studies used leucine as the
amino acid tracer, which is extensively catabolized in skeletal muscle. Additionally,
whole-body protein synthesis has been demonstrated to both decrease (190, 192) and
remain unchanged (193) during aerobic exercise. This provides supporting evidence for
a negative protein balance during exercise, where there is an overall loss in whole-body
protein. The authors of these reports attribute two possible tissue systems for the increase
in whole-body protein breakdown during aerobic exercise: the gastrointestinal tract (191),
and skeletal muscle (190). Reports on post-exercise alterations in whole-body protein
metabolism are also conflicting; however, this may be primarily due to differences in the
types of exercise. Whole-body protein synthesis is elevated and unchanged following
aerobic (190, 195) and resistance (196) type exercise, respectively. Whole-body protein
breakdown has been demonstrated to decrease (190) or remain unchanged (195) from
pre-exercise resting rates following aerobic exercise. Additionally, whole-body protein
breakdown is unchanged from resting rates following resistance type exercise (196, 197).
Thus, it appears that following resistance exercise there is no change in whole-body
protein metabolism, whereas, following endurance exercise there appears to be an
increase in protein accretion. The majority of these studies, regardless of exercise type,
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examine individuals exercising during the post-absorptive period, which may attribute to
a negative protein balance and may not be physiologically relevant to the common
practices of athletic humans or horses. Therefore, additional research is warranted
examining the effects of exercise on whole-body protein metabolism during the
postprandial state.
Skeletal muscle is responsible for 25% of whole-body protein synthesis (198,
199), and fat free mass plays a key role in whole-body protein synthesis (187, 200, 201).
Specifically, differences in the fat free mass of human subjects accounts for up to 87% of
the variation seen in whole-body protein kinetics (187). For this reason, some
researchers theorize that the reduction in whole-body protein synthesis during the
postprandial state seen in the aged may not be due to aging specifically, but rather due to
a reduction in the fat free mass in this population (185). Regardless of whether the
reduction in whole-body protein synthesis in the aged population in response to the
anabolic stimuli of meal consumption is actually due to aging or a product of the increase
in fat mass, it is certain that there are differences in whole-body protein metabolism in the
frail aged population and younger mature adults, which may suggest a higher protein
requirement (202). However, there is no effect of age on whole-body protein synthesis
during the post-absorptive state (186). Unfortunately, studies examining whole-body
protein metabolism in children and adolescents are limited, due to the ethical constraints
in studying this population (203), compared to healthy children of the same age. It has
been determined that children with diabetes have elevated whole-body protein
degradation and amino acid oxidation (203). Further research is warranted to examine
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whole-body protein metabolism in a research model for healthy human children and
adolescents.
1.4.3. Alterations in muscle protein fractional synthesis rates in response to anabolic
stimuli
Skeletal muscle comprises approximately 50% of body weight, but only
contributes to 25% of whole-body protein synthesis (198, 199). As a result, changes in
muscle protein synthesis may only be detected at the whole-body level if they are
dramatic. Furthermore, if another tissue decreases its rate of protein synthesis and the
muscle increases its rate of protein synthesis, then there would be no net effect measured
at the whole-body level. Because of this, it is useful to measure skeletal muscle protein
synthesis directly. In Section 1.2, the anabolic stimuli that increase muscle protein
fractional synthesis rates were discussed. There have been numerous studies (103, 204206) examining feeding-induced changes in muscle protein synthesis and breakdown,
which highlight the more dramatic elevation in muscle protein synthesis compared to
muscle protein breakdown (Section 1.3). Because of the alterations in protein synthesis
and breakdown in response to anabolic stimuli, it can be stated that within protein
metabolism the overall limitation is within the regulation of protein synthesis. Muscle
protein synthesis increases following meal consumption in adult humans (103, 204-206)
and neonatal pigs (133, 207), but eventually slows and returns to basal levels
approximately 240 min post meal consumption, as demonstrated in the neonatal piglet
(207). Muscle protein synthesis is greatly affected by extracellular levels of amino acids
following meal consumption; however, the effects of amino acids on muscle protein
synthesis is graded until saturation (208). Regardless of age, the muscle protein synthesis
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response to graded intakes of amino acids has been demonstrated to be curvilinear, with a
plateau at 0.13 g/kg body weight of indispensable amino acids in humans (155).
However, it is important to note that the postprandial rates of muscle protein synthesis at
any given concentration of amino acids for younger adults (~28 years old) was greater
than for older humans (~70 years old) (155). There are no age related differences
between adults and aged humans in muscle protein synthesis during the post-absorptive
state (155-157). It was previously mentioned that whole-body protein synthesis is
affected by fat free mass and this also holds true for muscle protein synthesis, where
muscle protein fractional synthesis rates in lean young adult (20 years old) and aged lean
men (75 years old) following the co-ingestion of a protein and leucine supplement are not
different (209).
Exercise may influence protein metabolism to a greater extent in muscle than in
any other tissue in the body. However, similar to whole-body protein metabolism,
different types of exercise affect muscle protein fractional synthesis rates differently.
Myofibrillar protein fractional synthesis rates are elevated and remain unchanged from
pre-exercise resting rates following a bout of resistance and aerobic type exercise,
respectively, in previously untrained muscle (108). However, mitochondrial protein
fractional synthesis rates were elevated from pre-exercise resting rates following a bout
of exercise, regardless of exercise type, in previously untrained muscle (108). Other
reports (210, 211) examining mixed muscle protein fractional synthesis rates immediately
following aerobic type exercise are conflicting with reports of no change (210) and
increases (211) compared to pre-exercise rates. Wilkinson and colleagues (108) suggest
that these conflicts are due to differences in exercise intensity, increased AMPK (Section
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1.2.2), time of sampling, and only examining mixed muscle rather than mitochondrial and
myofibrillar fractional synthesis rates, which may have concealed the changes in
mitochondrial fractional synthesis rates. Additionally, the increased mitochondrial
fractional synthesis rates following aerobic exercise (108) correspond to increased
mitochondrial content with aerobic training (212, 213).
In addition to the bout of exercise, the training status of an individual can alter
both resting and post-exercise muscle protein fractional synthesis rates. Resting
myofibrillar fractional synthesis rates were elevated following 10 weeks of resistance
training (108). However, a single bout of resistance exercise increased myofibrillar
fractional synthesis rates to the same extent in trained and untrained individuals (108).
Resistance training did alter resting mitochondrial fractional synthesis rates, and the
increase in mitochondrial fractional synthesis rates seen with a single bout of resistance
exercise in untrained individuals was not present when trained individuals performed a
single bout of resistance exercise (108). Ten weeks of aerobic exercise training did not
alter myofibrillar or mitochondrial fractional synthesis rates at rest or following a bout of
aerobic exercise, compared to pre-training rates (108). The authors hypothesized that the
untrained individual may be in a heightened state of responsiveness to the anabolic
stimuli of exercise (108).
As with other anabolic stimuli, such as feeding, the response of muscle protein
fractional synthesis rates to an exercise bout is altered with aging. Reports have indicated
a delayed response of mixed muscle protein fractional synthesis rates in aged subjects (36 hours following an exercise bout) compared to adults (1-3 hours following an exercise
bout) (157). However, the use of resistance exercise to increase muscle mass and
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strength is recommended in older individuals for the prevention or delay of sarcopenia
(214-216). Furthermore, combining anabolic stimuli, specifically consuming amino acids
following a bout of resistance exercise increases mixed muscle protein fractional
synthesis rates beyond the effects of amino acid supplementation or exercise alone (119,
217, 218), and may prove to be useful in reducing sarcopenia in the aging population;
however, further research is warranted.
1.4.4.

Summary of the alterations in whole-body and muscle protein metabolism in
response to anabolic stimuli
The use of isotope infusion protocols is a useful and commonly practiced

technique in human research examining both whole-body and muscle protein synthesis.
Both whole-body and muscle protein synthesis in response to anabolic stimuli such as
meal consumption (103, 157, 202) and exercise (157, 211), declines with age. However,
aging does not alter whole-body and muscle protein synthesis during the post-absorptive
state (122, 155, 186). Additionally, at least a portion of the variation in both whole-body
and muscle protein synthesis are attributed to differences in fat free mass of the subjects
(187). Overall, using isotope infusion protocols to study whole-body and muscle protein
synthesis allows researchers to examine protein metabolism of the entire subject and at
the tissue level. When these techniques are used in addition to molecular tools to
determine mTOR signaling, then information about the whole system can be studied from
the cellular to the whole-body level.
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1.5. AN OVERVIEW OF THE LITERATURE ON INFLAMMATION
RELATING TO THE RESEARCH IN THIS DISSERTATION:
MECHANISMS OF INFLAMMATORY SIGNALING, THE EFFECTS OF
ACUTE AND CHRONIC INFLAMMATION IN CIRCULATION AND
SKELETAL MUSCLE, AND THE REDUCTION OF ACUTE AND CHRONIC
INFLAMMATION THROUGH NON-STEROIDAL ANTI-INFLAMMATORY
DRUGS
1.5.1.

Inflammatory signaling
Inflammation is a physiological response to a variety of stimuli such as infection,

tissue damage, exercise, and aging. Inflammation can occur as an acute or chronic
process depending on the stimulation. For example, the inflammatory response to a
disease or aging can be chronic, whereas the response to infection, exercise and tissue
damage from a muscle biopsy is typically acute. Both acute and chronic inflammation
will be discussed below (Section1.5.3-1.5.4), but first, this review of inflammation will
examine inflammatory cytokine production (Figure 1.5).
There are a number of inflammatory cytokines that play a pivotal role in the
development of both chronic and acute inflammation. A cytokine is a small (molecular
weights range from 8 to 40,000 d) nonstructural signaling protein, and an inflammatory
cytokine is a cytokine that mediates inflammation. Examples of cytokines include the
interleukins (-1,-6,-8, -10, -12,-18), tumor necrosis factor−α (TNF−α), and interferon γ
(IFN−γ). When tissue damage (which we will define as anything that elicits an
inflammatory response such as exercise, infection or a muscle biopsy) occurs, mast cells
that are located in the damaged tissue degranulate, resulting in the release of pro38

inflammatory cytokines, histamine, and eicosanoids (219). Histamine, eicosanoids, and
the initial pro-inflammatory cytokines move from the damaged tissue into circulation,
resulting in neutrophil migration from bone marrow to circulation. Full infiltration of
neutrophils into the damaged tissue occurs within 6 hours (219). Neutrophil migration to
the damaged tissue occurs as a result of mediators of acute inflammation from the
vascular endothelial cell release of E- and P-selectin which are endothelial adhesion
molecules (219, 220). Once at the site of damage, neutrophils begin to tether to the
vascular endothelium and release macrophage inflammatory proteins. These macrophage
inflammatory proteins attract and activate macrophages to the site of damage (219, 220).
Macrophages arrive at the site of tissue damage 5-6 hours later. Activated macrophages
secrete IL-1, IL-6, and TNF−α (221, 222). The effects of these inflammatory cytokines
are similar: induction of localized fever, synthesis of acute phase inflammatory proteins
in the liver, increased vascular permeability, and T and B cell activation (219, 221, 222).
Both IL-1 and TNF−α also increase adhesion molecules on vascular epithelium,
fibroblast proliferation, and induce IL-6 and IL-8 secretion, which are potent
chemoattractors of neutrophils and can be produced by almost all cell types (219, 221,
222). The stimulation of platelet production and immunoglobin synthesis are unique
effects of the interleukins and IL-6, respectively (219, 221, 222). IFN−γ also activates
macrophage and monocyte secretion of inflammatory cytokines, and is produced by
activated CD4+, CD8+, and natural killer cells (223). The overall response of
inflammatory cytokines to tissue damage in circulation is to draw attention to the site of
tissue damage, and stimulate macrophage migration into the damaged tissue.
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Inflammatory cytokines and macrophages migrate into the damaged tissue, where
activated macrophages secrete IL-1, IL-6 and TNF−α. These inflammatory cytokines
then activate IκB kinase complex (IκKB), which phosphorylates NF−κB (224). Even
though IL-1, IL-6, and TNF−α are secreted together in the body, cell culture work with
C2C12 myocytes treated with TNF−α indicates that IκKB activation is very susceptible
to TNF−α alone (225). Although NF−κB is phosphorylated, activation does not occur
until IκB is ubiquitinated and targeted to the proteasome for degradation (224).
Activated NF−κB interferes with mTOR signaling and stimulates further production of
inflammatory cytokines, as described in Section 1.3. Overall this entire inflammatory
response typically results in the involvement of the components of the adaptive immune
response (T and B cells), although it can occur without it (as described above). For the
purposes of this literature review, where the focus of inflammation is due to exercise and
aging, the involvement of the adaptive immune response is limited and therefore will not
be discussed.
Until this point, the focus has been on the pro-inflammatory response; however,
some of the pro-inflammatory cytokines also have anti-inflammatory properties.
Additionally, there are many cytokines that function in suppressing the inflammatory
response, and are appropriately referred to as anti-inflammatory cytokines. The role of
anti-inflammatory cytokines is to regulate the pro-inflammatory response so that healing
can occur without resulting in further tissue damage. The role of IFN−γ as a proinflammatory cytokine was discussed above; however, IFN−γ suppresses the production
of IL-1 in macrophages (226), and inhibits IL-1 activity through stimulating the
production of IL-1 receptor antagonist (227) and type II IL-1 receptors (222, 228), which
40

binds the receptors of IL-1, inhibiting interaction of IL-1 and its receptor. IFN−γ also
inhibits IL-18 function through the stimulation of IL-18 binding protein gene induction
(229, 230). This may serve as a negative feedback loop because IL-18 induces IFN−γ
production (231). Additionally, IFN−γ disrupts the stimulation of IL-8 production by
TNF−α (232) and IL-1 (233), and reduced IL-8 expression has been associated with
impaired TNF−α induced NF−κB activation (234). Because of the involvement of
NF−κB in potentially reducing protein synthesis through interactions with mTOR
signaling (Section 1.3), this may be a regulatory mechanism in the protection of protein
loss; however, further research is necessary. Other major anti-inflammatory cytokines
include transforming growth factor−β (TGF−β) and IL-10. TGF−β inhibits NF−κB
activation through the decreased production of IL-8, IL-1 and TNF−α. Additionally,
TGF−β blocks differentiation of naive CD4+and CD8+ cells (235), which when activated
secrete IFN−γ, a pro-inflammatory cytokine that stimulates the macrophage secretion of
IL-1 and TNF−α. IL-10 is secreted by anti-inflammatory macrophages, T, B, dendritic,
and mast cells, and neutrophils and eosinophils (236) in response to IL-12 (237), IL-6
(238), Il-27 (239), and TGF−β (240). IL-10 acts in a negative feedback loop inhibiting
the secretion of IFN−γ, TNF−α, IL-1 and IL-2 (241-243). Therefore, following a proinflammatory response, IL-10 secretion is induced and serves to mitigate inflammation,
possibly inhibiting potentially harmful effects of inflammation (protein loss) on tissue.
1.5.2.

Summary of inflammatory signaling
There are two types of inflammatory cytokines, pro-and anti-inflammatory

cytokines, which stimulate and suppress inflammation, respectively. Some of the main
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pro-inflammatory cytokines include: IL-1, IL-2, IL-6, IL-8, IL-12, IL-18, TNF−α, and
IFN−γ. The major anti-inflammatory cytokines include: IL-10, TGF−β, and IFN−γ.
IFN−γ is a unique cytokine with both pro- and anti-inflammatory properties. When tissue
is damaged, there is a rise in circulating pro-inflammatory cytokines which results in the
migration of macrophages into the damaged tissue, resulting in the production of more
pro-inflammatory cytokines. In relation to protein metabolism, the increase in proinflammatory cytokines in the damaged tissue activates NF−κB, which interacts with
mTOR signaling and may reduce protein synthesis in the damaged tissue. Antiinflammatory cytokines regulate this process and are secreted in response to elevated
circulating pro-inflammatory cytokines. The purpose of anti-inflammatory cytokines is
to protect the tissue from potentially harmful effects that may be induced by prolonged
inflammation.
1.5.3.

Factors affecting acute inflammation
In addition to acute illness, acute inflammation can occur following muscle

biopsy collection or a bout of exercise. Acute inflammation is characterized by a local
increase in inflammatory cytokines that persists for no longer than 24 hours (244, 245).
There may also be an increase in systemic inflammatory cytokines which does persist
longer than 24 hours (244, 245).
The effect of percutaneous muscle biopsy collection on muscle and circulating
inflammatory cytokines has been examined. From a methodological standpoint, the use
of a single incision for the collection of repeated biopsies separated by 30 min is not
advised because of alterations in the stress related ERK1/2 signaling pathway (246),
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which is affected by inflammatory cytokines (247). Unfortunately, research examining
the effects of using of a single incision site for the collection of repeated biopsies on
muscle inflammatory cytokines is limited, but previous work (246) demonstrating an
increase in the activation of the ERK1/2 pathway, suggests that there may be an increase
in muscle inflammatory cytokines, even though muscle inflammatory cytokines were not
examined. Thus, there is a need to study the effects of the collection of repeated biopsies
from a single incision site on muscle inflammatory cytokines. Further research is also
necessary to determine if the use of single incision site for multiple biopsies induces a
greater inflammatory response than the use of multiple incision sites for additional
biopsies. In humans, the collection of two percutaneous muscle biopsies from separate
incision sites on the right leg immediately and 30 minutes following the collection of the
first biopsy did not result in differences in IL-6 mRNA expression (248). An additional
biopsy was collected from the left leg 31 minutes following the incision on the right leg
of the subjects in this study and again no differences in IL-6 mRNA expression were
reported (248). However, in a biopsy collected from the right leg 123 minutes after the
initial biopsy, from a new incision site, there was a 1.8 fold increase in IL-6 mRNA
expression (248). The results from this study indicate that the collection of multiple
biopsies from the separate incision sites can be performed within a 30 minute period
without altering IL-6 expression. Additionally, the collection of repeated biopsies using a
new incision site for each consecutive biopsy in humans has demonstrated an increase in
the percentage of neutrophils in circulation at 30 minutes and up to 24 hours following
the initial biopsy from the percentage of circulating neutrophils at the time of the initial
biopsy (245). It was also determined that the expression of IL−1β was elevated in the
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muscle 30 minutes after the collection of the initial muscle biopsy, and IL−1α expression
in skeletal muscle was elevated at 30 minutes and up 6 hours following the initial biopsy
(245). However, in horses there was no change in muscle or circulating inflammatory
cytokine mRNA expression (IFN−γ, IL-1, IL-6, and TNF−α) for 24 hours following the
initial biopsy when a separate incision site was used for each biopsy (244). This apparent
disconnect between human and equine skeletal muscle requires further investigation to
determine whether it is a result of different research protocols or due to different
physiological mechanisms in the two species.
The vast research examining the effects of aerobic exercise on inflammation
varies in both tissue collection methods and in the inflammatory markers studied;
however, it is clear that a bout of aerobic exercise elicits an acute inflammatory response.
The percentage of neutrophils and monocytes in circulation were elevated at 6 hours and
on the fourth day following a bout of aerobic exercise (245). Circulating levels of IL-6
are elevated for 24 hours following a plyometric exercise (249), which is aerobic exercise
that involves rapid deceleration followed by rapid acceleration in the opposite direction,
and for at least 4 hours (last sampling point) following an incremental aerobic exercise
test (250). Other pro-inflammatory cytokines, TNF−α and IL−1β, were also elevated in
circulation for 3 hours and 30 minutes, respectively, following aerobic exercise (250). In
addition, the anti-inflammatory cytokine, IL-10, and the functional blocker of IL-1, IL-1
receptor antagonist, are elevated in circulation following aerobic exercise for at least 4
hours, which was the last sampling point in that study (250). Unfortunately, the literature
examining exercise induced skeletal muscle inflammation is limited; however, IL−1β has
been demonstrated to increase in skeletal muscle 30 minutes following an aerobic
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exercise bout (245). Although the majority of this work has been performed in humans,
performance of an incremental exercise test in horses increased IFN−γ, IL-6, and TNF−α
in skeletal muscle 1 hour, 30 minutes, and immediately following exercise, respectively,
whereas skeletal muscle IL-1 mRNA expression remained unchanged from pre-exercise
values (244). The authors of this study also examined circulating inflammatory cytokines
and demonstrated an increase in IL-1, TNF−α, and IFN−γ from 2 to 6 hours, at 6 hours,
and immediately following exercise, respectively; however, there was no change in the
mRNA expression of circulating IL-6 following exercise (244). Although species may
play a role in the time course elevations of the respective inflammatory cytokines, which
needs further investigation, it is certain that a bout of aerobic exercise induces an acute
inflammatory response.
The role of exercise induced inflammation is currently thought to be a result of
muscle damage in the form of disrupted contractile structures (251, 252) and
permeabilization of the sarcolemma (253, 254). Thus, the body of literature has been
focused on bouts of strenuous aerobic exercise with limited investigation of resistance
exercise, which has been the focus of the majority of exercise studies on mTOR signaling
and protein synthesis. As a result of the interaction of downstream inflammatory
signaling components (Section 1.5.1) and mTOR signaling factors (Section 1.2) needs to
be studied in response to resistance exercise. However, it has been determined that 3
hours after a bout of resistance exercise, circulating mRNA expression of TNF−α, IL−1β,
IL-6, and IL-8 were elevated from pre-exercise levels, despite no change in the mRNA
expression in skeletal muscle of these inflammatory cytokines (255).
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1.5.4. Factors affecting low grade chronic inflammation
Aging is characterized by chronic low grade inflammation which has been coined
“inflamm-aging” (256). Low grade chronic inflammation results from increased
concentrations of circulating inflammatory cytokines (257-259) and a prolonged acute
inflammatory response to infections and tissue damage in the aged, compared to their
younger counterparts (260-262). Compared to the healthy, mature population, there is an
elevated expression of pro-inflammatory cytokines, such as TNF−α (263−265) and IL-6
(263, 266, 267), increased concentration of acute phase proteins, for example, C-reactive
protein, which is associated with the acute inflammatory response (268), and high
neutrophil count (269) in the circulation of the human aging population. Additionally,
there is an increase in anti-inflammatory cytokine, IL-10, and anti-inflammatory
mediator, IL-1 receptor antagonist, in human aging circulation (270). There is an overall
increase in circulating inflammatory cytokines with aging.
Low grade chronic inflammation has been associated with the loss of skeletal
muscle mass, referred to as sarcopenia, in the aging population (271-273). The mRNA
expression of circulating TNF−α and the concentration of circulating soluble TNF−α
receptor have been inversely correlated with hand grip (274) and muscular strength (275),
respectively, in aged humans (older than 85 years of age). Elevated serum IL-6
concentrations have been correlated with decreased muscle strength in the aged (271).
Additionally, reduced muscle strength that has been attributed to increased circulating IL6 and TNF−α has also been correlated with decreased muscle mass in the aged (273). As
a result, low grade chronic inflammation is thought to be a partial cause of reduced
skeletal muscle mass in the elderly.
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The alterations in skeletal muscle inflammatory cytokines and their relationship to
sarcopenia have not been as well characterized as the elevations in the circulating
inflammatory cytokines in the aged population. Current research on the role of IL−1β
and TNF−α mRNA expression in skeletal muscle in the aged is inconclusive (276-278),
and there is no difference in skeletal muscle mRNA expression of IL-6 and TGF−β
between young and aging humans (276, 278, 279). However, the skeletal muscle mRNA
expression of IL-6 receptor has been demonstrated to increase with aging (280), which
may indicate that cells are more sensitive to IL-6. TNF−α has been demonstrated to be a
greater stimulus of satellite cell apoptosis in aged compared to young rodents (174, 281).
Although the expression of muscle inflammatory cytokines in the aged varies, it appears
that there may be an increased sensitivity to muscle inflammatory cytokines in aged
skeletal muscle fibers and satellite cells.
The association of skeletal muscle inflammatory cytokines with sarcopenia has
primarily been studied using cell culture techniques. C2C12 myotube cell culture studies
have shown that IL−1β stimulates IL-6 mRNA expression, resulting in the activation of
p38 MAPK, NF−κB, atrogen-1 and MuRF-1, leading to proteolysis (282, 283). TNF−α
reduces mTOR signaling in human myoblast (284) and C2C12 myoblasts (285-287).
Although human studies in this area are limited, it has been demonstrated that increased
TNF−α mRNA expression in the skeletal muscle is inversely correlated with muscle
protein synthesis following resistance exercise in the aged (288). These studies indicate
that sarcopenia may be a result of increased inflammatory cytokines interfering with the
signaling pathways for muscle protein synthesis, while stimulating the pathways of
muscle protein degradation.
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In addition to the increase in pro-inflammatory cytokines with aging, there is also
an increase in anti-inflammatory cytokines. The skeletal muscle of aged men shows
increased mRNA expression of both IL-10 and IL-1 receptor antagonist, compared to
younger men. These anti-inflammatory cytokines may be produced in the circulation and
then migrate to skeletal muscle, because the number of anti-inflammatory macrophages
in skeletal muscle is less in the aged compared to younger adult humans; however,
further research is needed to determine this. Alternatively, it is possible that the
increased skeletal muscle anti-inflammatory cytokines in the aged are due to elevations in
the activity of anti-inflammatory macrophages in skeletal muscle. The elevated
expression of anti-inflammatory cytokines in skeletal muscle is thought to be a
physiological attempt to reduce pro-inflammatory cytokines in the aged.
Low grade chronic inflammation in the aged is thought to contribute to delayed
skeletal muscle regeneration following injury (289-291). Skeletal muscle damage can
occur after a bout of exercise (Section 1.5.3), and because the aged are in a state of
chronic inflammation, it is possible that the capacity of the immune cells to respond to
additional inflammatory stimuli is limited. The reported changes in inflammation that
occur following a bout of exercise in the aged are conflicting due to differences in the age
and physical condition of the elderly subjects studied. This results in differences in the
extent of chronic inflammation, and differences in the mode and intensity of the aerobic
exercise bout, which may lead to differences in the acute inflammatory response. It has
been demonstrated that 4-6 hours following a bout of aerobic exercise, there is a decrease
in circulating neutrophils (292, 293) and IL-6 (294) concentration in aged humans
compared to their mature counterparts. In contrast, no difference in the post-aerobic
48

exercise (6 hour) circulating neutrophil count and an increase in IL-6 concentration were
found when comparing aged and mature humans (295). The conflicting results of these
studies may be a result of the intensity of aerobic exercise. Additionally, circulating IL-1
receptor antagonist and TGF−β protein concentrations increased similarly in both age
groups following a bout of aerobic exercise (294, 295), indicating that the antiinflammatory response to acute inflammatory stimuli is not altered with low grade
chronic inflammation in the aged.
Another characteristic of low grade chronic inflammation in the aged is an
increase in the time it takes for skeletal muscle regeneration to occur following tissue
damage. This prolongs the muscle damage associated with exercise in the aged
compared to their younger counterparts. Reduced macrophage infiltration of skeletal
muscle in aged compared to younger mature men following exercise (276, 278) may play
a pivitol role in inhibiting muscle regeneration. Reports of the effects of aging on the
muscle inflammatory cytokine response to acute inflammatory stimuli of exercise vary.
Skeletal muscle TNF−α mRNA expression increases similarly in both mature and aged
humans (276) or remains unchanged (296). mRNA expression of IL-6 in aged skeletal
muscle is increased (297), decreased (276), or is similar to mature counterparts (278),
following exercise. There is either a decrease (278, 298) or similar increase as seen in
mature adult skeletal muscle (276) in the mRNA expression of IL−1β in aged skeletal
muscle following exercise. There has been less examination of aged skeletal muscle antiinflammatory cytokine response to exercise, but it has been determined that IL-1 receptor
antagonist mRNA is unchanged following exercise regardless of age, and IL-10 is lower
in skeletal muscle of aged compared to mature men following exercise (278). In order to
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improve our understanding of the response of aged skeletal muscle to acute inflammation
cause by exercise, additional research is necessary which should attempt to standardize
for the degree of pre-study low grade chronic inflammation in the aged subjects and
standardize the experimental exercise tests.
1.5.5.

Summary of acute and chronic Inflammation
Acute inflammation is a response to inflammatory stimuli such as an infection,

tissue damage, or exercise and typically persists for a 24 hour period. Chronic
inflammation can be a result of a disease state or aging. Following exercise, there is an
increase in circulating and skeletal muscle inflammatory cytokines which is thought as a
necessary step for satellite cell proliferation and regeneration of damaged skeletal muscle,
and will be discussed in detail below (Section 1.5.6). Inflamm-aging occurs in the
elderly, where there are persisting increased levels of both circulating and skeletal muscle
inflammatory cytokines. This is thought to be at least partially responsible for
sarcopenia, through the increased activation of NF−κΒ and the signaling pathways of
protein degradation (Section 1.3) and reduction in the activation of the protein synthesis
pathways. Additionally, chronic inflammation alters the acute inflammatory response
and affects the muscle’s ability to recover from acute tissue damage, such as exercise.
This is thought to be a result of a decreased capacity of immune cells to increase
inflammatory cytokines in both circulation and skeletal muscle in response to exercise;
however, the results from these studies are extremely variable and require further
research. Ultimately, the interaction of inflammation and protein synthesis is
complicated, where the effects of acute and chronic inflammation on protein synthesis
appear beneficial and deleterious, respectively, and require further elucidation.
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1.5.6.

Effect of acute and chronic inflammation on satellite cells
Satellite cells have been mentioned throughout this dissertation, but to this point

have not been fully explained. Satellite cells are undifferentiated myogenic stem cells
that have the ability to re-enter the cell cycle, generating new muscle fibers or providing
new myonuclei during postnatal growth (299, 300). Additionally, satellite cells have the
ability to generate daughter cells that can become new satellite cells (301). Satellite cells
are located outside of the sarcolemma, under the basal lamina of the muscle, laying
parallel or obliquely to the long axis of the fiber (302). A number of molecular markers
have been proposed to identify satellite cells have been the topic of recent review (303),
and are an alternate method to the more classical method of using toluidine blue staining
and a light microscope to examine the high heterochromatin myonuclei (304). Some of
these molecular markers include: the membrane-bound neural cell adhesion molecule (NCAM/CD56/Leu-19), which is a cell-surface glycoprotein localized to satellite cells, the
Ca++-dependent muscle specific cadherin (M-cadherin), the myocyte nuclear factor
(MNF), the receptor for the hepatocyte growth factor (HGF), and the paired box protein 7
(PAX7), a transcription factor that plays a role in embryonic patterning and
organogenesis (303). However, many of these molecular markers are expressed during
both the quiescent and activated state and there is currently no consensus on the best
marker to label activated versus quiescent satellite cells.
Satellite cell content in humans varies between muscle groups (305-308), the
amount of physical activity (305-307) and the age (307, 308) of the individual. Satellite
cells are activated (proliferated) following a single bout of exercise, regardless of
exercise type, for up to 8 days (309). Typically activated satellite cells will proliferate
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following exercise, but terminal differentiation does not always occur (309). Satellite
cells are also altered following exercise training where, regardless of exercise type,
training enhances the satellite cell content in the skeletal muscle of human athletes (306,
307, 310, 311). However, the satellite cell response to low intensity aerobic exercise
training is greater than for high intensity resistance training (307). Overall, a single bout
of exercise increases satellite cell proliferation and exercise training increases satellite
cell content in skeletal muscle.
The alterations in satellite cell activity following exercise are thought to be a
result of tissue damage, and the release of inflammatory cytokines and growth factors
following exercise. Section 1.5.3 discussed the changes in inflammatory cytokines
following exercise as a result of exercise induced tissue damage. It has been
demonstrated that IL-6 and TNF−α are involved in the regulation of satellite cell
proliferation in rodent skeletal muscle (312, 313). Additionally, the administration of
non-steroidal anti-inflammatory drugs (NSAID) to humans and animal models negatively
affects satellite cell proliferation, differentiation and fusion (314-318). Thus, the increase
in inflammatory cytokines during acute inflammation is a beneficial process enhancing
skeletal muscle repair, and in the case of exercise this process coincides with elevated
mTOR signaling and subsequent protein synthesis.
The alterations in circulating and muscle inflammatory cytokines during low
grade chronic inflammation that is associated with aging have been discussed in detail in
Section 1.5.4. In that section, it was briefly mentioned that in aging rodents, the increase
in TNF−α stimulates satellite cell apoptosis (174, 281). As a result, the number of
satellite cells is lowered in the elderly compared to the younger mature rodents (307,
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319). Additionally, in humans the proliferative capacity of the satellite cells of the aged
is decreased compared to the mature counterparts (320). Together these studies indicate
that low grade chronic inflammation reduces the number and activity of satellite cells in
the aging population. Non-damaging exercise (aerobic and resistance) has been shown to
increase satellite cell proliferation in the aged (305, 309, 311), and if a training regimen is
implemented, the satellite cell pool can be replenished in this population (310).
1.5.7.

Summary of the effects of acute and chronic inflammation on satellite cells
Satellite cells are myogenic stem cells that are activated by inflammatory

cytokines. During an acute inflammatory response, there is an increase in satellite cell
proliferation indicating a beneficial effect of inflammation. However, during low grade
chronic inflammation there is a reduction in both satellite cell content and activity, which
can be combated by non-damaging exercise training.
1.5.8.

Reducing inflammation with non-steroidal anti-inflammatory drugs

1.5.8.1. Mechanism of action of non-steroidal anti-inflammatory drugs
NSAID include a range of drugs that inhibit prostaglandin formation, for example
aspirin, ibuprofen, mefenamic acid, and phenylbutazone (321). Although the entire
mechanism in which NSAID reduce inflammatory cytokines has not been elucidated, it
has been the topic of several reviews (321-323). Briefly, NSAID reduce inflammation by
blocking cyclo-oxygenase (COX) enzymatic activity. As a result, the production of
prostaglandin E2 (PGE2) from arachadonic acid is nearly ceased (321, 323). Both COX-2
and PGE2 regulate the activation of NF−κB (322, 323); however this mechanism is still
unclear. Because NF−κB is also a regulator of inflammatory cytokine release (Section
53

1.5.1) (322, 323), the reduction in COX activity is believed to be the mechanism whereby
NSAID reduce inflammatory cytokines. There are two different isoforms of the COX:
COX-1 and COX-2. Both forms of COX are expressed in the majority of tissues in the
body, including skeletal and cardiac muscle, gastrointestinal tissue, kidney, brain and
epithelial cells. COX-2 expression in these tissues is minimal unless activated by
inflammatory cytokines (324), whereas, COX-1 is highly expressed in gastrointestinal
tissue. As previously mentioned, both COX-1 and -2 are involved in the formation of
PGE2 from arachadonic acid. PGE2 has a physiological protective role in gastrointestinal
tissue, behaves as a vaso-dilator, and contributes to erythema, and hyperalgesia (321,
323). Because of the role of PGE2 in gastrointestinal tissue, when PGE2 production is
ceased in the presence of NSAID, gastric ulcer formation may occur.
Prolonged NSAID administration has been implicated in the development of
gastric ulcers in several species (323, 325), including horses (326). In the stomach, the
COX-1 enzyme is generally expressed at a higher level than the COX-2 enzyme, and the
resulting PGE2 plays an important protective role. PGE2 in the stomach suppresses
TNF−α expression, neutrophil adherence, and epithelial cell apoptosis (323). As a result
the overall function of PGE2 in the stomach is to prevent the formation of gastric ulcers.
However, when COX-1 is inhibited or in the presence of gastric ulcers, COX-2 becomes
upregulated (327), due to an increase in inflammatory cytokines to the tissue. The
increase in COX-2 activity results in an increase in PGE2 formation, which is an attempt
to suppress further tissue damage. Unfortunately, most NSAID do not selectively inhibit
the activity of COX-2 and as a result, both COX-1 and COX-2 in the stomach are
inhibited (323), reducing PGE2 production. The COX enzymes also regulate the
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formation of other prostaglandins from arachadonic acid. These prostaglandin are
involved in the regulation of bicarbonate, mucous, and acid secretion, and accelerate
ulcer healing (323). As a result, extended NSAID administration can result in gastric
ulcers in many mammalian species.
1.5.8.2. Reducing acute inflammation with NSAID
NSAID are commonly used to reduce the discomfort associated with muscle
damage caused by strenuous exercise. NSAID administration post-exercise has been
extensively studied to characterize post-exercise physiology and as a mechanism to
eliminate inflammatory effects on physiological responses to exercise. Following any
type of exercise, skeletal muscle COX-2 mRNA expression and protein content are
elevated (255, 328, 329) compared to at rest, and post-exercise NSAID administration
reduced the elevated levels of COX-2 mRNA expression and protein content (329, 330).
Oral administration of a NSAID during 12 weeks of resistance exercise training resulted
in skeletal muscle COX-1 protein abundance that was lower than in an exercised group
that received a placebo in place of NSAID (331). Furthermore, oral administration of a
herbal supplement (curcumin), with properties functionally similar to a NSAID, reduced
muscle IL-1β, IL-6, and TNF-α mRNA expression in rodents following exercise (332).
The local infusion of a NSAID post-exercise in humans reduced the skeletal muscle
mRNA expression of TNF-α, but did not alter the skeletal muscle mRNA expression of
TGF−β and IL−1β (333), nor was there an increase in macrophage or neutrophil
infiltration (316). Because the increase in inflammatory cytokines following exercise
may be necessary for muscle repair post-exercise (334), and inflammatory cytokines play
a regulatory role in satellite cell proliferation (312, 313), the administration of NSAID
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with the goal of reducing inflammation may be preventing muscle recovery by reducing
satellite cell proliferation (316). Further research is required in this area to determine if
the benefits of NSAID during an acute inflammatory response outweigh the possible
consequences.
1.5.8.3. Reducing chronic inflammation with NSAID
The study of the use of NSAID to reduce circulating and skeletal muscle
inflammatory cytokines in the aged has been limited because of the long term harmful
effects of NSAID use, such as gastric ulcers (323). However, the use of NSAID
administration as a tool to study the association behind aging related inflammatory
cytokines and the development of sarcopenia has been investigated. In aged rodents, 5
months of oral NSAID administration (ibuprofen) reduced circulating levels of IL-6 and
IL−1β, while increasing skeletal muscle mass and muscle protein fractional synthesis
rates (335). Therefore, future research is needed to fully elucidate these mechanisms and
then develop strategies to reduce both circulating and skeletal muscle inflammatory
cytokines in order to promote the maintenance of muscle mass with old age.
1.5.8.4. Summary of reducing inflammation with NSAID
NSAID reduce inflammatory cytokines through the inhibition of the enzymatic
activity of COX, which suppresses the activation of NF−κB and inhibits the release of
inflammatory cytokines. Although the prostaglandins produced by COX mediate
inflammatory cytokines through NF−κB, there are also many beneficial physiological
effects of these prostaglandins throughout the body. In the stomach, the prostaglandins
produced by COX-1 play an important role in protecting the stomach from the
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development of gastric ulcers. However, because most NSAID do not inhibit a specific
COX isoform, the beneficial effects of prostaglandins are also affected by NSAID
administration and prolonged NSAID administration has been associated with the
development of gastric ulcers (323). The administration of NSAID during acute
inflammation reduces circulating and muscle inflammatory cytokines, which coincides
with a reduction in satellite cell proliferation. The latter may impair the recovery of
skeletal muscle during acute inflammation (Section 1.5.6). The literature examining
NSAID reduction of inflammatory cytokines during chronic inflammation is limited due
to the side effects of extended NSAID use; however, NSAID administration has been
demonstrated to reduce circulating inflammatory cytokines in the aged. Ultimately,
further research is warranted to determine whether there are other methods that can be
used over a longer period to reduce chronic inflammation without causing side effects
such as gastric ulcers.
1.6. AN OVERVIEW OF THE EQUINE LITERATURE RELATING TO THE
RESEARCH IN THIS DISSERTATION: PROTEIN NUTRITION AND
METABOLISM, AND MUSCLE PHYSIOLOGY THAT MAY ALTER
PROTEIN METABOLISM
In comparison to cell culture models, rodents, neonatal piglets, and humans, there
is only limited data regarding muscle protein metabolism in the horse. However, there is
considerable research in horses concerning protein digestibility and utilization, crude
protein requirements, muscle biology and development, and inflammation and the review
of the literature in horses will focus on these areas.
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1.6.1.

Protein nutrition in the horse

1.6.1.1. Dietary indispensable and dispensable amino acids in the horse
Although the protein requirement as reported by the NRC (336) is written for
crude protein (CP), the horse actually has requirements for individual amino acids, the
building blocks of protein. CP is a calculation of total nitrogen (N) in the feed, where CP
is equal to N times 6.25 (336). This calculation is derived from the fact that, by weight,
protein is 16% N. Horses, like other mammals, are believed to require 9 dietary
indispensable amino acids (histidine, isoleucine, leucine, lysine, methionine,
phenylalanine, threonine, tryptophan, and valine) and, under certain physiological states,
an additional 6 conditionally indispensable amino acids (arginine, cysteine, glutamine,
glycine, proline, and tyrosine) may be required. Arginine is a conditionally indispensable
amino acid because the rate of arginine synthesis in many growing mammals is
insufficient to meet its needs, and is indispensable during illness or injury due to the role
of arginine in immune function as a precursor to nitric oxide. Cysteine and tyrosine can
be synthesized from dietary methionine and phenylalanine, respectively, if supplied in
sufficient quantities. During times of illness or physiological stress, glutamine becomes
indispensable, and glycine and proline are also indispensable during the growth period.
The remaining amino acids are considered dietary dispensable amino acids because of
their ability to be synthesized in sufficient enough quantities to meet the body’s needs
(alanine, asparagine, aspartate, glutamate, and serine).
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1.6.1.2. Protein digestion in the horse
For the most part, amino acids are consumed in the equine diet as part of whole
proteins, which must be broken down to individual amino acids or small peptides for
absorption. In the horse, dietary protein is digested in the foregut, similar to other
nonruminant species, and this process has been the topic of several chapters and entire
books (337-339). In short, prior to consumption of a meal, the vagal release of
acetylcholine stimulates the upper gastro-intestinal tract, initiating saliva secretion in the
mouth, and hydrochloric acid, pepsinogen, and sodium bicarbonate secretion from the
stomach. The equine stomach is unique in that it has a section referred to as the margo
plicatus where the squamous epithelial mucosa lacks the mucous-sodium bicarbonate
barrier to buffer the high acidity. This is the area where gastric ulcers and erosion tends
to occur (340), and gastric ulcers do occur at a higher rate in horses compared to other
nonruminants. The stomach has four main secretions, hydrochloric acid, pepsinogen,
sodium bicarbonate, and mucus, which begin enzymatic digestion of proteins.
Hydrochloric acid is secreted from the parietal cells resulting in an increase in the acidity
of the stomach. The reduced pH denatures dietary protein, unfolding it to a linear
polypeptide chain, and at pH 4 causes pepsinogen, the zymogen (inactive enzyme) of
pepsin, to become pepsin. This mechanism protects the cells of the stomach from pepsin
trying to break the peptide bonds involving aromatic amino acids (phenylalanine,
tryptophan, and tyrosine) of proteins bound to cell membranes: pepsin is only in its active
form when there is protein from feedstuffs available for enzymatic digestion. Pepsinogen
is secreted from chief cells, and once it is in the active form it begins cleaving the peptide
bonds involving aromatic amino acids, resulting in some oligopeptides and short
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polypeptide chains which will be further enzymatically digested in the small intestine.
As previously mentioned, sodium bicarbonate is also secreted in the stomach from
epithelial mucous cells and acts to buffer the stomach from the acidic pH.
During the initial digestion of dietary proteins in the stomach, the vagal release of
cholecystokinin in the exocrine pancreas stimulates release of other zymogens. Although
this causes the release of a number of enzymes from the pancreas, the ones involved in
protein digestion (trypsinogen, chymotrypsinogen, and procarboxypeptidase A and B) are
secreted from the acinar cells. These zymogens and sodium bicarbonate, produced by the
duct cells, enter the duodenum, the first section of the small intestine, where
enteropeptidase, secreted from the duodenal crypts of Lieberkühn, converts trypsinogen
into the active form, trypsin. Together enteropeptidase and trypsin convert
chymotrypsinogen, and procarboxypeptidase A and B to chymotrypsin and
carboxypeptidase A and B, respectively. Trypsin is a serine protease that cleaves at the
carboxyl side of lysine and arginine, except when followed by proline. Chymotrypsin is
an endopeptidase that cleaves peptide amide bonds where the carboxyl side of the bond is
an aromatic amino acid. Carboxypeptidase A and B are exopeptidases, cleaving peptide
bonds at either the C- or N-terminus of the oligopeptides and short polypeptide chains
that have entered the duodenum from the stomach. As a result, oligopeptides, di- and tripeptides, and free amino acids enter the jejunum, the second section of the small
intestine.
The di-, tri-peptides are absorbed via peptide transporter 1 (PepT1) located on the
apical side of the enterocytes in the jejunum (341). It is important to note that PepT1
transporters are also located in the enterocytes of the ileum, resulting in some di-, tri60

peptide absorption; however, the majority of PepT1 transporter expression is in the
jejunum, and therefore, most di-, tri-peptide absorption occurs in the jejunum (341).
Some of these di-, tri-peptides are broken down to free amino acids in the cytosol of the
enterocyte cells, while others remain intact. For the oligopeptides and di-, tri-peptides
that do not get transported into the enterocytes by PepT1, further digestion occurs at the
enterocytes brush border membrane, by aminopeptidases and endopeptidases. Although
these peptidases are located throughout the entire length of the small intestine, the
jejunum and ileum posses the highest activities (342). PepT1 has not yet been
characterized in the equine gastrointestinal tract, but the mRNA expression of PepT1 was
high in the small intestine, decreased in the colon, and not detectable in the cecum of
another hind-gut fermenter, the rabbit (343). Additionally, PepT1 activity has been
suggested in equine jejunum through increased current flow through equine jejunal
membrane when incubated with a dipeptide (344).
For the di-, tri-peptides not transported into the enterocytes by PepT1 and
oligopeptides, further digestion occurs at the brush border membrane, resulting in free
amino acids. Free amino acids are transported into the enterocytes by a variety of apical
transporters, specific for certain types of AA. The free amino acids transported into the
cytosol of the enterocyte cells can be further metabolized by the enterocytes, used for
enterocyte protein synthesis, or transported across the basolateral membrane and into
portal vein. Both apical and basolateral membrane amino acid transporters are specific to
the amino acids transported, based on the amino acid properties such as size, polarity, and
charge (345). The majority of amino acid transporters do not require energy; however,
sodium dependent transporters require ATP because the co-transport of sodium and
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amino acid requires the removal of sodium out of the enterocyte via a sodium/potassiumATPase (345). Some amino acid transporters are unique to the apical (system names:
ASC, B0, B0,+, b0,+, IMINO, X-AG) or basolateral membrane (system names: A, L, y+, y+L)
while others can be found on both membranes of the enterocyte (system name: T) (345,
346). The study of amino acid transporters in the equine gastrointestinal tract has been
limited. However, glutamine transport has been demonstrated across the basolateral
membrane from the bloodstream to the enterocytes where it is proposed to be used as a
key energy substrate in the equine enterocyte (347). This study was useful in that it
examined the amino acid flow, so although Duckworth and colleagues (347) did not
determine the amino acid transport system, their study indicated that there is a glutamine
transporter on the basolateral membrane of the enterocyte transporting from the
bloodstream into the enterocyte. More recently, Woodward and colleagues (348) have
examined the distribution of the mRNA of specific amino acid transporters along the
intestinal tract of mature horses, where the mRNA expression of the apical b0,+ system
was expressed similarly throughout the jejunum, ileum, cecum and colon. The mRNA
expressions of the basolateral y+ and basolateral medium affinity L transport systems
were higher in the small intestine than in the large intestine, while the low affinity L
transport system mRNA expression was greater in the cecum than the jejunum (348).
These results indicate that, at least for the b0,+ system, there may be similar absorption
throughout the jejunum, ileum, cecum and colon; however, because the basolateral y+ and
basolateral medium affinity L transport were greater in the small intestine, this indicates
that the greatest absorption of amino acids that contributes to whole-body protein
metabolism occurs in the small intestine due to the greater mRNA expression of
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basolateral amino acid transporters and therefore, a greater ability to transport the
absorbed amino acids from the enterocytes into circulation. Because there was
expression of some transport systems in the cecum and colon, this study (348) also
indicates that there may be some amino acid absorption in the large intestine; providing a
mechanism for the absorption of microbial amino acids. However, additional research is
needed to characterize the presence and function of amino acid transport systems in the
cecum and colon.
Not all of the dietary protein that is consumed is completely digested and then
absorbed in the small intestine. The dietary protein that bypasses digestion and/or
absorption in the small intestine and reaches the cecum and large intestine can be
metabolized by the residing microbial population. Although little is known of the
microbial protein metabolism in the equine hindgut, it has been demonstrated that the
microbial population of the equine hindgut can degrade and utilize dietary protein,
partially degraded protein and ammonia and urea that have bypassed small intestine
absorption (349). Once absorbed by the microbe, peptides are cleaved into free amino
acids for microbial protein synthesis or degraded to the carbon skeleton and ammonia.
The carbon skeleton can be utilized for energy while the ammonia can be used to
synthesize amino acids or secreted by the microbe (350). Because microbial digestion
occurs proximal to digestion and absorption in the ruminant, microbial protein can be
digested and absorbed similar to dietary protein in nonruminants. However, microbial
digestion occurs distal to digestion and absorption in the horse, and therefore microbial
proteins cannot be absorbed similarly to dietary proteins due to anatomical constraints.
As a result, researchers have attempted to increase the understanding of the physiological
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mechanisms contributing to possible amino acid absorption and quantify the microbial
amino acid contribution to whole-body amino acid metabolism in the horse.
The use of isotope tracers has led researchers to believe that some microbially
synthesized amino acids may end up in circulation. Infusing 15N labeled cecal bacterial
protein into the cecum of an anaesthetized pony, resulted in 15N labeled amino acids in
circulation (351). There was less than 10% labeled amino acid recovery in the tissues of
ponies fed 15N urea (352). However, the infusion of 14C labeled bacteria or protein into
the cecum of ponies showed no 14C labeled amino acids in the circulation (353). These
studies show that a small amount of N is being absorbed in the large intestine; however,
the fact that the carbon backbone of these amino acids was not absorbed may indicate
that microbial amino acids are not being absorbed, but rather a N compound such as
ammonia is (352, 354, 355). Once ammonia is absorbed, it can be used to form
dispensable amino acids. However, urea supplementation to horses has not been found to
be beneficial if the indispensable amino acid requirements are not met (355).
Even though amino acid transport systems have been found on the apical
membrane of the large intestine of horses (348), the isotope tracer work (mentioned
above) and ex vivo studies do not currently support the idea of large amounts of
indispensable dietary amino acids being absorbed in the large intestine and contributing
to whole-body protein metabolism. Minimal amounts of alanine (356), arginine (357),
histadine (357), leucine (358), and lysine (357) have been demonstrated to cross the
equine colonic mucosa in ex vivo experiments. However, a great deal of ammonia is
transported across the mucosal membrane of the equine colon (357). As a result, it is
generally accepted that ammonia that is transported across the apical membrane of the
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equine large intestine contributes to protein metabolism; however, this is an area where
additional research is needed.
1.6.1.3. Protein digestibility in the horse
It was mentioned above (Section 1.6.1.1) that horses actually require amino acids,
but the current requirements according the NRC (336) are for crude protein and lysine.
Unfortunately, not all protein is created equal with regards to digestibility and quality.
Quality refers to the amino acid composition of the protein in relation to the animal’s
amino acid requirements, whereas digestibility refers to the amount of dietary protein that
disappears, and is presumably absorbed, along the gastrointestinal tract.
Studies in horses examining protein digestibility vary extensively in the method
of measuring digestibility, age of horse, and feedstuffs examined. The method of
measuring digestibility is crucial when comparing these studies, because it accounts for
how much protein has been digested at which point along the gastrointestinal tract (337).
The simplest measurement is apparent total tract digestibility and is determined by the
difference of the N intake (feed) and N output (feces) divided by the N intake (337). This
does not correct for endogenous losses such as sloughed cells, microbes and microbial
protein, and typically underestimates protein absorption. Correction factors that have
been determined for endogenous losses range from 0.72 - 0.91 mg endogenous
nitrogen/kg dry matter consumed, due to differences in total intake and diet composition
(359-362). When endogenous losses are accounted for in the calculation of protein
digestibility, it is no longer coined apparent digestibility, but rather true digestibility
(337). Because it is believed that the majority of protein is digested and amino acids are
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absorbed proximal to the cecum, pre-cecal digestibility has been a tool used by
researchers in an attempt to more accurately determine protein absorbed as amino acids
(337). Again, the endogenous losses must be accounted for, and the correction factors for
pre-cecal endogenous N losses that have been reported to range from 1.8 - 5.8 mg
endogenous nitrogen/kg dry matter consumed (359-362).
Diet composition and intake affect endogenous losses and protein digestibility.
The NRC (336) has reported estimates of total tract apparent nitrogen digestibility and
pre-cecal apparent nitrogen digestibilities of 79 and 51%, respectively. Concentrates tend
to have higher pre-cecal digestibility than forages (360-365). The differences in protein
digestibility and endogenous losses between diets high in forage or concentrate are
thought to be a factor of the bulkiness and slow rate of movement through the
gastrointestinal tract of diets primarily composed of forage, where there are higher
endogenous losses than diets that have a greater proportion of concentrate. Specifically,
pre-cecal apparent digestibilities of concentrates range from 48 - 72% depending on the
type of concentrate (360, 362) and pre-cecal apparent digestibilities of forages range from
1.3 - 21% (361). The pre-cecal true digestibilities of concentrates and forages range 59 62% (364) and 27 - 42% (361), respectively. Additionally, protein intake also affects
digestibility and endogenous losses. As CP intake increases, there is a reduction in
endogenous N losses relative to intake, resulting in greater apparent nitrogen digestibility
(365). However, increasing CP intake from low to moderate does not alter true CP
digestibility, but increasing CP intake to high levels reduces true and apparent pre-cecal
digestibility (360). Others claim that regardless of dietary N concentration, true total
tract digestibility ranges between 0.7 - 0.9 (337). Overall, compared to forage-based
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diets, endogenous losses and protein digestibility, regardless of type (true or apparent),
appear to be reduced and elevated, respectively, in diets that are primarily composed of
concentrates in mature horses.
The discussion of protein digestibility has focused on CP digestibility; however, it
was previously mentioned that horses actually have requirements for amino acids. It has
been determined that the majority of amino acids have pre-cecal apparent digestibilities
that range from 0.3 - 0.6 (366). Similar to what was seen with increasing CP intake,
apparent amino acid digestibility is increased with increasing amino acid intake (367).
True and apparent amino acid digestibilities range for the individual amino acids from
52.8 - 86.3% for glycine and leucine, respectively (367). Additionally, physiological
state may alter amino acid digestibilities, gestating mares were reported to have higher
amino acid digestibilities (368) than those reported in foals (367). This is an area where
additional research is warranted.
The growing horse has received less attention in the area of protein digestibility
than the mature horse, and it appears that the growing (~6 months old) horse may have a
decreased capacity to digest and absorb protein than their mature counterparts. Weaned
foals (3 - 7 months old) and yearlings consuming a primarily concentrate diet (<60%)
had apparent total tract N digestibilities of 35 - 45% (369) and 80% (370), respectively.
The apparent total tract N digestibility reported in the weaned foals is lower than the
estimate for mature horses by the NRC (336); however, the apparent total tract N
digestibility reported in the yearlings was comparable to that of mature horse. This may
indicate that there are developmental limitations in protein digestibility; however, it is
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necessary to elucidate the time course changes in protein digestibility that occur during
development.
1.6.1.4. Protein and amino acid requirements in the horse
There are several methods for expressing protein requirements of horses, which
are used in various locations across the world. In the United States, protein requirements
are expressed as amounts of CP and lysine required, and have been detailed in the recent
NRC (336). CP and digestible CP are used to express the protein requirements of horses
in Japan and Germany, respectively. In France, protein requirements of horses are
expressed in “horse digestible crude protein” or “Matieres Azotees Digestibles Cheval”
(MADC). A detailed examination of all of these systems is beyond the scope of this
dissertation. However, this section will provide a brief overview of the US system,
including a discussion of the research that was used to determine the requirements, and a
short comparison of the US to the French system.
1.6.1.4.1. Protein and amino acid requirements based on physiological status in the
horse
Nutrient requirements are specific to the physiological state of the animal. The
NRC (336) separates these physiological states into: Maintenance, Growth, Pregnancy,
Lactation, and Exercise. Examples of the protein and lysine requirements of a 600 kg
mare at various physiological states according to the NRC (336) are provided in Table
1.1. The focus of this section will be to discuss the factors affecting protein requirements
in the various physiological states and some of the research that led to the development of
those requirements.
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Maintenance requirements for protein are generally the amount of protein
consumption needed by the animal in order to support the daily processes of life.
Although animals at maintenance are making and degrading protein at the same rate and
for this reason should be able to “recycle” amino acids released from protein degradation
for use in protein synthesis, this system is not perfectly matched and even at maintenance
dietary amino acids are needed. “Losses” of amino acids in animals in the maintenance
state include endogenous losses in the gastrointestinal tract, cutaneous losses, and amino
acids from proteins that have been post translationally modified (for example: amino
acids that are methylated) and can no longer interact with their respective tRNA to be
used for protein synthesis. The maintenance requirements have been calculated from
linear regression and broken line analysis of means from the numerous N balance studies
that have been conducted in mature horses, receiving a variety of feedstuffs. The CP
requirement has been identified based on the N intake where N retention is zero.
However, the minimum CP requirement was actually set slightly higher than zero
because the majority of N balance studies do not account for endogenous losses of hair,
skin and sweat; thus overestimating N retention (336). As a result, the CP of average
maintenance has been derived as: BW × 1.26g CP/kg BW/d (336). The requirements of
amino acids during maintenance have not been determined due to lack of data; however,
based on the amino acid content of common feedstuffs fed to horses and the limiting
amino acids of other nonruminants, mainly swine (371), it is thought that the first three
limiting amino acids may be lysine, threonine, and methionine. The lysine requirement
during maintenance has been calculated as 4.3% of CP requirement (336). Linear
regression of N balance studies that reported the diet composition were used to determine
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the lysine intake required to obtain zero N retention. Then, broken-line analysis was used
to determine the lysine intake at which N retention plateaued (336). Additionally, in
horses receiving diets supplemented with lysine and threonine, the amino acid
supplementation resulted in lower plasma urea N concentrations in mature and aged
horses, compared to horses receiving the unsupplemented diet (372), providing additional
support that lysine and/or threonine are likely candidates for limiting amino acids in the
mature horse.
During growth, the maintenance requirements must initially be met in order to
sustain the physiological processes and maintain the current weight. Then, the growing
horse requires additional amino acids (protein) to support the tissue (for example,
muscle) accretion that occurs when an animal is growing. The protein requirements of
growing horses have been derived from N balance studies (369, 373) and the use of ADG
measurements (369, 374, 375) with varying protein or amino acids intakes provided by
the diet. The latter has been a classical tool to study protein requirements extensively
used in growing horse. When the protein or amino acid intake provided by the diet is
below requirements, increases in intake will result in an increased ADG. Once the
required level has been met, ADG will not increase with increasing intake of the amino
acid or protein. The means of data collected in these studies were fitted to broken-line
analysis and then extrapolated to a mature body weight to incorporate the changes in
body weight with age (336). This provided a total CP requirement for a certain aged
horse at a specific weight. In order to determine the separate requirements of
maintenance and growth, the maintenance requirements must be subtracted from the total
requirements (336). The CP requirement of growing horses has been determined using a
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factorial approach and based on the assumption that gain is 20% protein: (BW × 1.44 g
CP/kg BW) + ((ADG × 0.20)/Efficiency of use of dietary protein)/0.79 (336). The
efficiency of use of DP is estimated from 50% in 4-6 month old horses to 30% in
yearlings and older growing horses (336).
There have also been some studies examining the effects of amino acid
supplementation, mainly lysine, on ADG in growing horses (369, 375-378), where it has
been concluded that lysine is vital for growth. When lysine is supplemented to poor
quality protein diets of linseed meal (369) and brewer’s dried grains (376), the ADG was
equivalent to high protein quality diets of milk and soy bean meal, respectively.
Additionally, ADG was not altered in horses fed low CP diets that were supplemented
with lysine compared to higher CP diets (375). Using linear regression and broken-line
analysis from the means of the previously mentioned studies, the NRC determined that
the lysine requirement of growing horses was 4.3% of CP requirements (336).
Additionally, supplementing low protein diets with lysine and threonine resulted in lower
plasma urea N concentrations, indicating threonine may be the second limiting amino
acid in growing horse diets (374).
There is minimal research regarding protein requirements during gestation in
horses due to the possible unwanted effects, such as fetal loss or stunted growth of the
foal, of consuming a protein (or amino acid) deficient diet during pregnancy. From the
minimal research in this field, there have been more studies examining protein
requirements during mid to late compared to early gestation. Similar to the growing
animal, the maintenance requirements must be met and there are additional protein
requirements for increased protein synthesis to support fetal and placental growth, as well
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as for the production and secretion of placental fluids. However, because there is not a
large ADG during early pregnancy, the NRC (336) has concluded that protein
requirements are only slightly higher than maintenance: BW × 1.26 g CP/kg BW/d.
Linear regression of fetal weight gain was performed in horses (379) and ponies (380),
which in addition to cow data, were used in non-linear regression analysis to determine
fetal growth rates. The NRC (336) then assumed that fetal composition is equivalent to
neonatal composition. From this, the NRC (336), could calculate the amount of CP
deposited per day in horses and ponies. Using a factorial approach of protein efficiency
the CP requirements were determined for gestating mares from 5 months through
parturition: (BW × 1.26 g CP/kg BW/d) + (fetal gain in kg/0.5)/0.79 (336). The 0.5
comes from the estimation of 50% efficiency of use of dietary protein in pregnancy, and
0.79 is representative of the 79% digestibility of the protein (336). It is also important to
note that the calculated CP of fetal gain does not account for protein needs of the uterus
(336). Additionally, due to the lack of data on amino acid requirements, the NRC
suggests that the same estimation of lysine requirements during pregnancy as
maintenance (336).
Rather than the ADG studies that were used to estimate protein requirements in
the growing horse, milk production was used for the determination of protein
requirements beyond maintenance during lactation. In addition to the maintenance
protein requirements, lactating mares require additional dietary protein to support the
synthesis of milk protein. Broken-line analysis of the CP content of milk produced
throughout gestation found that milk protein concentration plateaus at day 22 of gestation
(336). This led the NRC (336) to determine the CP requirement during the first month of
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lactation to be greater than the rest of lactation. Again, the NRC (336) used a factorial
approach incorporating 50% efficiency of utilization and 79% protein digestibility to
determine the lactating mare CP requirement: (BW × 1.44 g CP/kg BW/d) + (milk
production kg/d ×50 g CP/kg milk). The amino acid requirements during lactation have
been suggested by Wickens and colleagues (381) and are based on the amino acid to
lysine ratio in milk. The NRC (336) accepts this suggestion (kg milk/d multiplied by
3.3.g lysine per kg milk), but adds the maintenance requirement for lysine.
Additionally, if any of these physiological classes (adult maintenance, gestating,
lactating, or growing) of horses undergo exercise, there will be an additional requirement
above what has already been discussed. The NRC (336) has classified exercise
requirements by intensity (light, moderate, heavy, and very heavy), which have been
classified based on heart rate and oxygen utilization above rest. Correction factors have
been developed from the literature to account for protein synthesis for muscle growth and
to repair damaged muscle following exercise (336). Additional correction factors have
also been determined based on the percentage of body weight lost in sweat at each
intensity of exercise (336). Again, the NRC (336) used a factorial approach to determine
the CP requirement of exercising horses based on the 50% efficiency of utilization and
79% protein digestibility: (BW × muscle gain) + (((BW × sweat loss × 7.8
g/kg)/0.50)/0.79) + the maintenance requirement for protein (336). It is also important to
note that at very high intensities of exercise, a substantial increase in lean gain may also
increase the maintenance protein requirements. The lysine requirement of exercising
horses has been determined using broken-line analysis of the means of data from N
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retention studies that reported diet composition and intake and lysine intake and was
determined as 4.3% CP requirement (336).
1.6.1.4.2.

Protein requirement systems

The French system expresses protein requirements in MADC, which has some
similarities to digestible CP, the method used by the Germans. MADC is based on the
assumptions that protein quality in terms of amino acid composition and site of digestion
(pre- versus post- cecal) affect the availability of the amino acids to the animal. The
advantage of this system compared to the US and German systems is that differences in
small intestinal availability of amino acids in various feeds are accounted for.
Additionally, this system more accurately estimates forage amino acid availability than
digestible CP because the physical bulkiness of forages result in a decrease in the amino
acids available for small intestinal absorption from the forage (382, 383). From a
scientific perspective, this system has many advantages to the US system because it more
accurately assesses the availability of amino acids for absorption; however, the lack of
knowledge of digestible CP and amino acid availability in many of the common
feedstuffs fed to horses make it difficult to use this system.
1.6.1.5. Summary of protein nutrition in the horse
Although there is still a vast amount of research to be performed in the horse,
regarding protein nutrition (digestion, digestibility, and requirements), the scientific
knowledge base has improved substantially from the previous (384) to the current (336)
NRC which were published 18 years apart. The majority of protein digestion and
absorption occurs in the small intestine of horses. The primary contribution of the
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hindgut to protein metabolism is through the absorption of ammonia produced by the
hindgut microbes. The NRC (336) provides both CP and lysine requirements for horses
at the various physiological states, which have been derived using linear regression and
broken-line analysis from the means of the available studies, followed by a factorial
approach considering efficiency of utilization and protein digestibility. Ultimately, there
is still a lot left to elucidate and further research is necessary in all of these areas of
protein nutrition in order to better feed and manage these animals.
1.6.2. Muscle biology and development in the horse
The horse is an athletic animal with nearly 50% of body mass composed of
skeletal muscle (1). Thus, there is a considerable amount of research over the past
century that has focused on equine skeletal muscle. The majority of equine skeletal
muscle research has focused around the characterization and possible treatments of
disease related states, such as metabolic syndrome (385-387), pituitary pars intermedia
dysfunction also referred to as Cushing’s disease (388, 388, 389, 389), exertional
rhabdomyolysis also referred to as tying-up (390-394), hyperkalaemic periodic paralysis
also referred to as HYPP (395-398), neuromuscular disorders (399-402), polysaccharide
storage myopathy also referred to as PSM (403-405) and the combination of these
disorders (406-408). However, a detailed examination of the alterations of skeletal
muscle physiology and metabolism during these disease states is beyond the scope of this
literature review. Rather, this section will focus on the sizeable body of literature
examining the characterization of skeletal muscle fiber type, the alterations of skeletal
muscle physiology and metabolism during development, exercise (409-414), and exercise
during development (411, 415-419).
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1.6.2.1. Characterization of skeletal muscle fiber types
1.6.2.1.1.

A historical introduction

Researchers have been examining skeletal muscle fiber types for well over a
century. The characterization of fiber types began in 1865 with the correlation of a
greater blood supply to red muscle compared to white muscle, and was followed by the
demonstration that contraction velocity was faster in the white muscle compared to the
red muscle (420). With advances in technology in the mid 1880s to the late 1910s,
researchers began histological studies of skeletal muscle demonstrating a greater number
of mitochondria in red compared to white muscle fibers (420).
The development of a correlation between velocity of muscle shortening to
ATPase activity when the muscle was with or without load in both vertebrates and
invertebrates (421) led to the discovery of a link between morphological and
histochemical characteristics to physiological properties of the fiber. This link was
displayed in the motor units of the cat gastrocnemius (422). Burke and colleagues (422)
categorized fibers as fast twitch fatigue sensitive (FF), fast twitch fatigue resistant (FR),
and slow twitch fatigue resistant (S). Higher glycogen concentrations, lactate
dehydrogenase activity, and myofibrillar ATPase activity were seen in FF and FR
compared to S fibers. This connection opened the door to the current thought of fiber
types characterized as slow twitch being primarily oxidative, and fast twitch fibers being
primarily glycolytic.
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1.6.2.1.2.

Description of the fiber types

Most mammalian twitch muscles can be divided into two categories: slow (Type
I) and fast (Type II) twitch. Fast twitch fibers can be further subdivided into three
subcategories: fast oxidative-glycolytic (FOG; Type IIA), fast-glycolytic (FG; Type IIB),
and an intermediate fiber (Type IIX, Type IIC, or Type IID).
Slow twitch fibers are characterized with a red color, slow contraction speed and
duration of contraction, and a high oxidative capacity. Type I fibers are well vascularized
providing increased blood flow for the delivery of O2 which increases the oxidative
capacity. To further aid in their oxidative capacity, slow twitch fibers contain high
concentrations of mitochondria and myoglobin. An increased number of mitochondria
are present to allow for higher capacity to efficiently operate the Krebs cycle and electron
chain transport to produce ATP for work. The high concentration of myoglobin provides
O2 storage for increased production of ATP. Slow twitch fibers also have a decreased
glycolytic capacity and glycogen content.
Fast twitch Type IIA fibers are also described as red in color, but are faster in
contraction speed and duration of contraction than slow twitch fibers. Type IIA fibers
have both oxidative and glycolytic capacities. As a result, these fibers have many of the
same properties as both slow twitch Type I and fast twitch Type IIB fibers.
Fast twitch Type IIB fibers are characterized as a white colored muscle fiber with
the fastest contraction speed. These fibers utilize glycolytic metabolism for the
production of energy for work. As a result, they are poorly vascularized with a decreased
need for O2 because of their reliance on anaerobic metabolism. In addition, Type IIB
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fibers have low concentrations of myoglobin and mitochondria. Glycolytic metabolism,
unlike oxidative phosphorylation, takes place in the sarcoplasm not the mitochondria;
hence a decreased need for mitochondria in Type IIB fibers.
Fast twitch Type IIX, or occasionally referred to as IIC or IID, fibers are
considered an intermediate fiber between the fast twitch types IIA and IIB. Type IIX
fibers have both glycolytic and oxidative capabilities, but are faster in speed of
contraction than Type IIA fibers. As a result, this fiber type has been poorly
distinguished until the use of myosin heavy chain isoforms as a tool to differentiate
between the various fiber types.
1.6.2.1.3.

Fiber Type Differentiation as a Result of Myosin Heavy Chain Isoforms

Myosin is one of the most prominent proteins in the muscle and comprises the
majority of the thick filament. The myosin molecule is composed of six different
proteins: two heavy chains (myosin heavy chains; MHC) and four light chains (myosin
light chains; MLC; (423). Both MHC and MLC components of myosin occur as several
uniquely distinct isoforms; all of which are coded by different genes (424). In fact, there
are eight different MHC isoforms found in skeletal and cardiac mammalian muscle (425).
It has been shown that slow and fast twitch fibers contain different isoforms of MHC
(426). The MHC-I isoform is expressed in slow fibers, and hydrolyzes ATP slowly. As
a result, the cross bridge cycle is slow which leads to a slow velocity of contraction.
Within the last 25 to 30 years, it has been shown that there are three myosin
isoforms found in Type II fibers: MHC-IIA, MHC-IIB, and MHC-IIX or -IID.
Traditionally, it was thought that there were only two fast twitch fiber types (IIA and
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IIB), and the IIX fibers were being mistakenly categorized as IIB. The mistaken identity
of the IIX fiber was a result of the experimental methods of the time. The use of methods
such as ATPase histochemical reactions resulted in the distinction between slow and fast
twitch fibers in the middle gluteus muscle of horses (411). On the basis of oxidative
capacity, a reflection of NADH-diaphorase staining (427) equine skeletal muscle fibers
have been classified as slow twitch (comparable to Type I), fast twitch with high
oxidative capacity (comparable to Type IIA), and fast twitch with low oxidative capacity
(comparable to Type IIB) (411). This disconnect in nomenclature between and among
species continued until modern day techniques, such as gel electrophoresis and
immunoblotting became regularly available, which provided a greater distinction in these
fiber types (428-430). Definitive evidence that MHC-IIX was a separate protein and not
a product of post-translational modification of MHC-IIB was realized when the cDNA of
MHC-IIX mRNA was isolated. All three Type II MHC isoform cDNAs display different
restriction endonuclease maps, indicating their derivation from three separate genes. In
addition, each isoform contains a unique 3’ untranslated sequence which has been used to
develop specific probes for the use in in situ hybridization studies (424).
1.6.2.1.4.

Classical methods of equine fiber typing

Traditional methods of fiber typing that have been used in rodents and humans
have been utilized in horses for nearly 50 years (411). Generally, the study of equine
skeletal muscle requires muscle biopsies in order to obtain muscle samples, and these are
most commonly collected from the gluteus medius muscle using the percutaneous needle
biopsy technique (411). The gluteus medius muscle is commonly used due to the role of
this muscle in both locomotion and posture (411). The use of myofibrillar ATPase,
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NADH-diaphorase, and periodic acid-Schiff (PAS) as a marker of contraction speed
correlation, oxidative capacity, and glycogen distribution, respectively, provided a basis
for the determination of slow twitch, fast twitch high oxidative, and fast twitch slow
oxidative. Other traditional determinates are the use of biochemical analyses of
metabolites in the muscle: glycogen, pyruvate, lactate, ATP, creatine phosphate, glucose
and glucose-6-phosphate. Lastly, the use of enzyme activities as a marker of glycolytic
and oxidative capacities can aid in the determination of fiber type. These techniques
have provided the evidence for delineation of equine skeletal muscle into three major
fiber types (I, IIA, and IIB (431)).
1.6.2.1.5.

Electrophoretic and immunohistochemical methods for equine fiber typing

After the identification of the myosin heavy chain isoforms (I, IIA, IIB, and IIX)
in rodents and humans, gel electrophoresis was then used to examine equine skeletal
muscle (413). The rat costal diaphragm was used as a control because it contains all four
of the myosin heavy chain isoforms (432). Gel electrophoresis revealed three MHC
isoforms; two of which co-migrated with the Type I and IIA isoforms of the rat. The
third equine isoform migrated between the IIX and IIB rat isoforms; but showed a
mobility closer to that of the IIX. These results provided a new question to be solved:
were the fast oxidative fibers previously classified as Type IIB in horses actually Type
IIB or IIX fibers containing MHC-IIB or -IIX with a different molecular weight due to
post-translational modifications or were they some newly discovered fiber type
containing a unique MHC isoform? Further examination of the MHC isoform at the
protein level revealed that the rat and equine MHC-IIX isoform has identical antigenic
and mATPase determinants (412). This evidence suggests that the MHC-IIB protein is
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not functional at the protein level in horses. Additional evidence of the absence of the
MHC-IIB isoform in equine skeletal muscle was provided with the use of PCR and in situ
hybridization techniques, which allowed researchers to isolate both mRNA and cDNA for
MHC-I, -IIA, and -IIX isoforms (433). The mRNA isolation was performed based on the
conserved sequences of exon 40 in both fast and slow isoforms (424).
Additional proof for the absence of the Type IIB fiber Type In horses came with
nucleotide sequencing of the equine diaphragm, semitendinosus and longissimus thoracis
muscles (409). It could be speculated that if there was an expression of a IIB fiber in the
horse it would be seen in the diaphragm because it has been shown that in rat and mice all
four MHC isoforms are expressed in the diaphragm (432). cDNA synthesis and
sequencing and PCR analysis was done on all of the MHC genes. The equine MHC
isoforms were found to contain 5980, 5982, and 5984 base pairs for IIA, IIX, and I,
respectively. These identified sequences coded for MHC isoforms that contain 1937,
1938, and 1935 amino acids for the IIA, IIX, and I proteins, respectively. The MHC-IIA
and -IIX isoforms are similar both in the number of amino acids and in the overall
structure; however, there are differences in the functional regions of the two proteins.
Within the functional region of the MHC-IIA protein there are two amino acid deletions
compared to the functional region of the MHC-IIX protein. Overall, this study
demonstrated that there are three functional MHC proteins, -I, -IIA, and –IIX.
During the examination of the equine diaphragm, semitendinosus and longissimus
thoracis muscles, Chikuni and his colleagues (409) amplified a 596 base pair fragment of
the MHC 3’ region using MHC-IIB amplification primers. This fragment contained a
similar sequence to the other MHC isoforms, but differed in an additional adenine
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nucleotide. This additional nucleotide resulted in a frame shift, and thus, a shortened
translation. Chikuni and his colleagues (409) referred to this MHC-IIB fragment as the
equine MHC-IIB pseudogene because the gene exists, but cannot be translated into a
functional protein.
1.6.2.1.6.

The large animal theory and the implications of an absent functional MHCIIB isoform

The absence of the MHC-IIB isoform in horses is thought to be due to the large
animal theory, which explains the absence of a functional MHC-IIB isoform because of
differences in velocity of shortening, metabolic energy consumption, and the ability of
bones to resist force in large animals compared to small on the basis of body size. For
example, smaller animals must take a larger number of steps in order to cover the same
distance as larger animals due to their shorter stride length. An animal’s force-velocity
curve must be appropriate for the speed at which they move: larger animals having a
slower velocity of shortening than their smaller counterparts (434). In addition, with the
decreased stride length of smaller animals, more energy must be consumed in order to
meet their increased velocity of shortening in comparison to the large animal (435).
The final component of the large animal theory is that with increases in body size,
there are added stresses on bone due to increased muscle size. The ability of bones to
resist force depends on the ratio of bone to muscle cross sectional area, which decreases
in proportion to animal weight. In an effort to adjust for this, the limbs of large animals
vary in size, and are more closely aligned with the ground reaction force in a sizedependent manner (436).
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The lack of the MHC-IIB isoform in horses may indicate an evolutionary
elimination due to components of the large animal theory. The entire sequence of the
MHC-I, -IIA, and -IIX isoforms are highly conserved in mammals; therefore, the equine
MHC isoform sequences showed high identities to the porcine, bovine and human MHC
isoforms (409). The fact that horses contain a “gene” for MHC-IIB isoform that lacks
expression due to an early termination as a result of a frame shift from the additional
adenine may further indicate the evolution of the species.
During the course of history, the modern horse has evolved from a small (0.4m)
4-toed Hyracotherium to the large (1.6m) hooved animal seen today. This small equine
ancestor and its progeny (3-toed, 0.6m Mesohippus and 3-toed, 1m Merychippus) may
have contained the functional MHC-IIB isoform. These ancestral precursors to the
modern horse are related to the pig and other ungulates who express the MHC-IIB
isoform (409). This would indicate that ancestral animals of the orders Perissodactyla
and Artiodactyla may have kept all four MHC isoforms, and the horse and cattle (others
are still to be determined) lost the functionality of the MHC-IIB isoform. The absence of
the MHC-IIB isoform in horses may be a result of an evolutionary need to decrease bone
stress due to velocity of contraction as the animal evolved to have an increased body size.
1.6.2.2. Implications of breed and sampling depth on equine skeletal muscle fiber type
Fiber type distribution in an individual muscle within a horse is extremely
variable, and is greatly influenced by breed of horse. The percentage of Type I fibers in
the middle gluteus muscle is the highest in Warmblood type horses, and decreases in
ponies, Arabians, Thoroughbreds, and Quarter Horses (414). Alternatively,
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Thoroughbreds express the greatest percentage of Type II fibers, followed by Quarter
Horses, Arabians, ponies, and Warmbood type horses (414). Of the Type II fibers,
Thoroughbreds have the greatest percentage of IIA type fibers, followed by Arabians,
Quarter Horses, ponies and Warmblood type horses (414). The Quarter Horse possesses
the greatest percentage of IIX type fibers and the proportion is lower in Arabians,
Thoroughbreds, ponies and Warmblood type horses. Although variation exists, these
differences are narrow with the range of Type I fibers in the above breeds from 7 - 31%,
Type IIA from 37 - 51%, and Type IIX from 32 - 45% (414). Additionally, breed related
differences are detectable as early as the first day of life (437, 438). It is also important
to note, that these studies did not use modern methodologies of immunohistochemistry or
MHC isoform separation through electrophoresis.
Regardless of fiber typing method, age and breed of the horse, variation exists
within a single skeletal muscle. Because the gluteal muscle is the most commonly
sampled, the majority of data is from this muscle and has shown to vary with depth. The
proportion of Type IIX fibers decreases and Type I fibers increases with depth in mature
horses (413, 439-442) and foals (439) in the gluteal muscle. This is merely a function of
the muscle; the gluteus muscle is used in both locomotion and posture. The deeper
portion of the muscle is used more for posture than the shallower portion of the muscle.
1.6.2.3. Changes in skeletal muscle physiology during development and aging
The proportion of muscle fiber type shifts during development. During neonatal
growth in humans and rodents, there are shifts in the relative proportions of MHCneonate, MHC-I, MHC-IIA and MHC-IIX in skeletal muscle, with increases in all forms,
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except MHC-neonate which vanishes with time. However, the appearance of MHC-II
isoforms is delayed in comparison to MHC-I (432, 443-445). Similar shifts occur in
MHC protein concentration and mRNA expression during the first year of life in Dutch
Warmbloods (410, 446-448) and Thoroughbreds (449). The proportions of MHC-I and
MHC-IIA are increased and MHC-IIX is decreased at 24 months of age, compared to 12
months of age in Dutch Warmblood horses (448, 450). Correlation coefficient analysis
was performed on MHC isoforms throughout the equine lifespan (from birth to 30 years
of age), where it was determined that MHC-I dramatically decreases, MHC-IIA slightly
increases, and MHC-IIX remains unchanged (451). However, further research is
warranted to determine the specific time course for these shifts in MHC fiber type
expression.
Because fiber type is associated with glycolytic and oxidative capacity, alterations
in fiber type during development and aging also lead to alterations in glycolytic and
oxidative capacity. Glycolytic and oxidative capacity are measured through the
expression and activity of enzymes involved in the anaerobic (glycolysis) and aerobic
(Kreb’s cycle and oxidative phosphorylation) production of ATP, respectively (448).
Markers of oxidative capacity are the enzymes succinate dehydrogenase (SDH) and
citrate synthase (CS) and the mitochondrial complexes involved in oxidative
phosphorylation. The enzymes phosphofructokinase (PFK) and lactate dehydrogenase
(LDH) are involved in the glycolytic production of ATP, which may also result in the
production of lactic acid. There is an increase in the activities of several of the oxidative
enzymes during growth (452-454), with subsequent declines in oxidative capacity with
old age in humans and rodents (455, 456). In horses, SDH activity does increase during
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the first 2 years of life (446, 448, 449); however, the effects of maturation on CS activity
appears to be dependent on breed (438, 448). CS activity in Standardbreds and Quarter
horses ceases to decrease earlier in development (~14 weeks) (438) than Dutch
Warmbloods (~22 weeks) (448). Correlation coefficient analysis has been performed on
the enzymes involved in oxidative capacity throughout the equine lifespan (birth to 30
years of age), where it was determined that CS decreases (451), while LDH increases
(438, 451). This data indicates that shifts in MHC throughout the lifespan coincide with
shifts in oxidative capacity.
The gluteal muscle amino acid profile has been examined during the first year of
life in horses, where it was demonstrated that glutamine was the most abundant free αamino acid in the muscle up to 3 months of age (457). As foals grow from 3 to 12
months of age, the concentrations of alanine, glutamate and glycine were greater than that
of glutamine in the skeletal muscle of mature Standardbreds (457). Additionally, the βamino acid, taurine is extremely abundant in equine skeletal muscle (2, 458) and has been
shown to decrease with from 6 to 12 months of foal development (457). However,
mature equine skeletal muscle has taurine concentrations that compare to 6 month old
foal (2, 458). In rodents, taurine protects skeletal muscle from reactive oxygen species
post-exercise (459), and has been demonstrated to increase skeletal muscle force when
taurine is supplemented to the diet (460). Glutamate is the most abundant free α amino
acid in mature skeletal muscle, followed by alanine, glutamine and glycine (2, 458).
Carnosine, the di-peptide of histidine and β-alanine, is present in extremely high
quantities in adult equine skeletal muscle (458, 461), where it buffers lactic acid buildup;
however, it has not been examined in developing equine skeletal muscle. The amino acid
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composition of aged equine skeletal muscle is also limited; therefore, further examination
of the amino acid profile throughout the lifespan is necessary. The elevated abundance of
free α-amino acids in the rapidly growing skeletal muscle of the foal compared to the
mature horse indicates the increased amino acid availability for protein synthesis in order
to accrete muscle during this rapidly growing life stage.
1.6.2.4. Changes in skeletal muscle physiology following exercise
Because of the athletic ability of the horse, there is a considerable amount of
literature regarding the physiological changes to skeletal muscle following a bout of
exercise (415, 462-464) and exercise training (416-419, 465, 466). However, these
studies vary in the age of horses used, and the intensity of exercise and duration of
training. This subsection of the literature review will focus on the alterations in MHC
content, oxidative and glycolytic capacity, and free amino acid content.
The recruitment pattern of muscle fiber types in mammals has been well
characterized, with prolonged exercise there is a shift in the fibers used from Type I to
Type IIX fibers; however this recruitment does not hold true during short high intensity
exercise bouts common in racehorses. Following an 800 and 1200 m race, the
recruitment of Type IIA and IIX fibers were reduced in the equine gluteal muscle based
on myosin ATPase activity, and glycogen depletion did not occur in Type I fibers (464).
An exercise bout, regardless of intensity (462, 463) or track slope (462) will recruit all
MHC fibers to a similar extent if the exercise bout is a minimum of 8 minutes long.
However, during shorter bouts of exercise (4 minutes), there is a higher recruitment of all
MHC fibers in moderate (60% VO2max) to high (80% VO2max) intensity workouts than
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extremely high intensity (100% VO2max) workouts (463). Glycogen can be stored in all
fiber types (Section 1.6.2.1.2), and is typically not depleted in Type I fibers during short
duration high intensity exercise (464). Glycogen depletion following a bout of exercise is
affected by intensity (462, 463), but not track slope (462), where the intensity of the
exercise coincides with the degree of glycogen depletion. Overall, these results indicate
that during short duration high intensity workouts similar to that seen in horse racing
there is a similar recruitment of fiber type which is not what is characteristic of prolonged
exercise.
Duration and intensity alters fiber type recruitment during an exercise bout, but
also alters the MHC protein content following prolonged training. Duration of exercise,
regardless of intensity, there is altered MHC protein composition following exercise,
where MHC-I, -IIA, and –IIX were greatest with 15, 25, and 5 minute exercise bouts,
respectively, after 22 days of training (418). Additionally, following 22 days of training
at moderate (velocity at which blood lactate concentration is 2.5 mmol/L (V2.5)), and high
(V4) intensities, regardless of the duration of each training bout, MHC-I, -IIA, and –IIX
content was higher following the V4, V4, and V2.5 intensity bout, respectively (418).
Overall, 22 days of training, regardless of bout duration or intensity caused MHC-I, -IIA,
and –IIX content to remain unchanged, increase, and decrease, respectively (418). Short
duration high intensity training for 8 months has been reported to have no effect on MHC
content, which the authors’ attributed to the superficial sampling site of 2 cm within the
gluteal muscle (417), which was confirmed when the authors’ performed another short
duration high intensity training for 22 days and alterations in MHC content were detected
at a sampling depth of 6 cm within the gluteal muscle (418). Incline training does not
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appear to alter MHC content or oxidative capacity: 16 weeks of sloped track training
increased SDH activity and MHC-IIA content to a similar extent as 16 weeks of flat track
training (415). Ultimately, with moderate to high intensity short term training protocols,
there is a shift in the proportion of fast twitch fibers mainly towards MHC-IIA and an
increase in glycolytic and oxidative capacities compared to pre-training.
Endurance type racing is another sport that horses commonly participate in. As a
result, this type of exercise training has been examined, where following 90 days of
endurance type training there was a shift in MHC content towards a greater percentage of
MHC-I fibers at the expense of –IIX fibers (466). Similar results were seen following
endurance training by Rivero and colleagues (416) and Serrano and colleagues (419).
Additionally, capillarity associated with Type I and IIA fibers has been demonstrated to
increase following endurance type training (416, 419). Following endurance type
training, oxidative capacity is increased (CS activity and glycogen storage as markers),
and glycolytic capacity is decreased (LDH and PFK activities as markers) (419).
Endurance type training results in increased MHC content of Type I fibers and oxidative
capacity.
Breed has been determined to greatly affect MHC content and also plays a role in
the susceptibility of MHC recruitment to training. For example, the Arabian, who were
breed for endurance type exercise, are more predisposed to MHC conversion toward
MHC-I following endurance type training (416). However, additional research is needed
to examine the susceptibility of MHC recruitment of a breed like the Thoroughbred,
which was bred for high intensity short duration exercise, following endurance type
exercise training.
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Intramuscular amino acid concentrations are altered by exercise. When muscle
biopsies were collected 30 minutes following a maximal exercise test, alanine, leucine
and lysine concentrations increased from pre-exercise values; however, glutamate and
taurine concentrations decreased (458). Following a submaximal exercise test, alanine
concentrations increased immediately and returned to pre-exercise levels 18 hours later
(467). The authors did not detect differences in any other amino acid due to the high
degree of variability, which they attributed to the wide age range of 2.5 to 6 years (467).
The younger horses may have been growing at a slow rate, whereas the older horses were
probably not still developing. Additionally, the increases in alanine post-exercise is most
likely due to the involvement in the Cori cycle (339), and the decrease in taurine indicates
that the exercise protocol used in this study created reactive oxygen species, which
through the indirect measurement of taurine concentration implies that taurine was used
to suppress these reactive oxygen species (459). Additional research is necessary to
determine if alterations in intramuscular amino acids following exercise are influenced by
duration and intensity.
1.6.2.5. Changes in skeletal muscle physiology following exercise during development
and aging
The desire to prepare young prospects for show or race has led horse owners to
place yearlings in training in order to prepare them for the 2 year old races and in hand
futurity events for show horses. As previously discussed (Section 1.6.2.3), there are
many physiological alterations occurring in skeletal muscle of horses during this stage of
rapid growth and development. These normal physiological changes can also be
influenced by exercise. Developmental alterations during the first year of life (increase in
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Type I and IIA and decrease in Type IIX) are less substantial in foals that were housed in
the pasture (receiving ad libitum exercise) compared to those housed in a stall (receiving
no exercise) (448). However, there was no effect of the differences in housing induced
exercise on capillarity CS or SDH activity (448). Dingboom and colleagues (446) found
that the developmental change in fiber type was not altered throughout the first year of
life in foals that were housed in a stall (receiving no exercise), or those housed in a stall
but forced to exercise. The differences in these studies may be a factor of the intensity
and duration of exercise involved. However, growing horses in a moderate exercise
training program that included 6 trips over a 3 fence combination 2 days/week from
weaning to 3 years of age, had a higher percentage of MHC-I and –IIA at 2 and 3 years of
age compared to non-exercising 2 and 3 year old horses (450). This coincided with a
greater developmental increase in CS activity in the training group compared to the nonexercising control group (450). However, short duration high intensity exercise training
for 16 weeks in 2 year old Thoroughbreds did not alter MHC content, SDH or PFK
activities (468). These studies indicate that there is an effect of exercise duration,
intensity and training period on the developmental changes in muscle biology; however,
further research is needed to examine the effects of exercise training on the alterations in
MHC content that occur during development.
The beneficial effects of exercise in the aged have been demonstrated in humans;
however, there is limited data on the effects of exercise in the aging horse. Exercise
training over a period of 10 weeks in aged horses improved VO2max and plasma lactate
concentrations (469). This training period also increased MHC-IIA and –IIX content in
the semimembranosus and triceps muscles, respectively (469). Additionally, CS activity
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was increased in the triceps muscle (469). Implementation of an exercise protocol during
aging appears to improve oxidative capacity, and potentially strengthen muscles which
may prevent injury; however additional research is needed.
1.6.2.6. mTOR related signaling in equine skeletal muscle
Currently there are only two studies in horses to examine mTOR signaling (2) or
other signaling pathways that may directly influence mTOR signaling (470). The first
study examined the effect of exercise on the mitogen activated protein kinase (MAPK)
family, which has three subdivisions: the ERK1/2, MAPK, and c-Jun NH2 terminal kinase
(JNK). The effects of ERK1/2 and MAPK on mTOR signaling have been discussed in
detail above (Section 1.2.2.4). JNK is also a stress-activated MAPK cascade that is
activated during oxidative stress, and by inflammatory cytokines and growth factors. Ten
minutes following a submaximal exercise test, the phosphorylation of p38 MAPK was
elevated in both the vastus lateralis and pectoralis descendens muscles (470). The
authors of that study (470) chose the vastus lateralis because of the involvement of this
hind limb muscle in forward movement and the pectoralis descendens because of the role
in posture (470). The phosphorylation of MAP3K, MAPK activated protein kinase 2 (an
intermediate signaling factor in the MAPK signaling cascade), and JNK were elevated 10
minutes following a submaximal exercise test in the vastus lateralis (470). However, the
phosphorylation of ERK was not affected by exercise in either muscle examined (470).
Activation of these signaling factors following exercise could potentially lead to
increased protein synthesis through inhibiting TSC1/2 complex (Section 1.2.2.4).
Following the consumption 4g/kg of a high protein pelleted feed (90 minutes), there was
a greater abundance of the phosphorylated forms of both 4EBP1 and rpS6 in the gluteal
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muscle of mature horses than during the post-absorptive state (2). However, feeding
status did not alter the phosphorylation of Akt (2). This data indicates that following the
anabolic stimulus of meal consumption muscle protein synthesis may increase.
1.6.2.7. Muscle protein turnover
To date, only a single study has examined skeletal muscle protein synthesis in the
horse using isotopes. Skeletal muscle protein synthesis was examined after a single bout
of high intensity exercise in long 2 year old Thoroughbreds that had been in short
duration high intensity training once a week for 3 months (3). Matsui and colleagues (3)
found that muscle protein synthesis across the hind leg increased to the greatest extent
following exercise when an amino acid-glucose mixture was infused in the jugular vein
during the recovery period compared to the recovery period of the individual infusion of
saline, amino acids, and glucose. Infusion of amino acids alone also increased muscle
protein synthesis (3). However, infusion of glucose alone or saline did not increase
protein synthesis during the 120 minutes recovery period. Skeletal muscle protein
degradation across the hind leg was also measured in this study, were there was an initial
decrease in muscle degradation rates during the first hour following exercise in the amino
acid and amino acid-glucose mixture infused horses (3). During the second hour of
recovery there was no difference in rates of muscle protein degradation in any of the
infused groups; however, during hours 3 and 4 of recovery the rate of muscle protein
degradation in the amino acid-glucose mixture group was elevated (3). This study was a
great step forward in understanding muscle protein metabolism in the exercising horse.
However, the author’s did not examine the effects of pre- to post-exercise on skeletal
muscle protein synthesis, and the exercise bout that was used during the experimental
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period was less intense than the weekly training exercise protocol, which was not typical
of a competition situation. Further research is necessary to determine the effects of a
more intense exercise protocol, similar to that seen in the industry.
1.6.2.8. Summary of muscle biology and development
Because the horse is a highly athletic animal, there is an extensive amount of
research pertaining to skeletal muscle development and exercise. The developmental
changes in MHC content throughout development are similar to other species; however
the recruitment of fibers during and following exercise differs from other species mainly
due to the duration and intensity of the exercise bout. Additional factors that influence
fiber type recruitment and content include duration and intensity of exercise training and
breed and age of the horse. To date a single study has examined the anabolic stimulus of
exercise on skeletal muscle protein synthesis, and another study that characterized mTOR
signaling in response to feeding. This area of research requires further examination,
which will be addressed in subsequent chapters of this dissertation.
1.6.3.

Acute and chronic inflammation in the horse
Inflammatory signaling in response to diseases and laminitis has been the focus of

much of the equine work in this area. Although the studies are limited, this subsection of
the literature review will focus in the areas of exercise induced inflammation and
inflamm-aging in the horse.
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1.6.3.1. Characterization of the acute inflammatory response to exercise in the horse
Exercise induced inflammation was briefly discussed in (Section 1.5.3), but the
focus of this section will be on the literature in the horse. There have been reports
detailing the increased susceptibility of viral infection following exercise (471, 472);
however, the reports detailing the inflammatory response following a bout of exercise or
exercise training will be discussed here.
Reports of exercise induced inflammation in horses vary due to sampling methods
and times, exercise protocols and assay methods. Following prolonged acute exercise,
leukocyte expression of TNF−α and IL−1β are elevated at 23 and 30 days of-high
intensity exercise training, but IL-2, -4, -6, or -10 mRNA expression was not affected
(473). However, immediately following a maximal exercise test, serum concentrations of
TNF−α and PGF2α were elevated and returned to pre-exercise levels at 2 hours (474). In
circulating leukocytes, IL-6 and TNF−α expression was greatest 2 hours following
maximal exercise test with no alterations in leukocyte IL−1β expression (474).
Neutrophil counts have also been demonstrated to be elevated in the blood immediately
following maximal exercise and remain elevated for 6 hours following exercise (475).
However, 24 hours post-maximal exercise test, the mononuclear cells obtained from
circulation did not have differences in the mRNA expression of IL-12, -4, and
IFN−γ (476). Although sampling times and exercise protocols differ, it is certain that
there is an acute increase in circulating inflammatory cytokines following exercise.
This led to a valuable study to determine the 24 hour time course response of
inflammatory cytokines in circulation to a maximal exercise test in horses. This study
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reported increased mRNA expression of IL-1 from 2 to 6 hours, TNF−α at 6 hours, and
IFN−γ immediately following the maximal exercise test (244). However, there were no
alterations in the circulating mRNA expression of IL-6 over the 24 hour period (244).
Because samples were only collected prior to, immediately following, 30 minutes, 1, 2, 6,
and 24 hours following exercise, any alterations in circulating mRNA expression of IL-6
may have been missed.
There has been minimal investigation in the inflammatory response to exercise in
equine skeletal muscle. The 24 hour time course inflammatory response has been
examined following a maximal exercise test, demonstrated an increase in the mRNA
expression of IFN−γ at 1 hour, IL-6 at 30 minutes, and TNF−α immediately following
the maximal exercise test (244). However, the authors did not report any alterations in
the skeletal muscle mRNA expression of IL-1 during the 24 hour period following the
maximal exercise test (244). One implication of this study is that the overall increases in
skeletal muscle mRNA expression of inflammatory cytokines to maximal exercise test
appear to occur more rapidly than increases in circulating inflammatory cytokines.
1.6.3.2. Characterization of chronic inflammation in the aging horse
Throughout the lifespan, horses exhibit changes in circulating inflammatory
cytokines as a result of growth, obesity and aging. Serum C-reactive protein, an acute
inflammatory phase protein, increases from birth to 12 months of age, but then decreases
when the horses reach maturity, around 4 to 5 years of age (477). However, research
examining inflammatory cytokines in circulation of growing horses is limited. Similar to
humans (478-480), obesity in horses is characterized by a mild state of chronic
96

inflammation, and elevations in mRNA expression of TNF−α, IL-1, and IL-6 may play a
role in the development of insulin resistance (481). Additionally, aging in horses is
characterized as inflamm-aging, where there is an increase in circulating inflammatory
cytokines. The relative expression of IL-6 to IL-10 and TNF−α to IL-10 is elevated in
peripheral blood mononuclear cells of aged horses compared to adult horses (482). Not
only is there an increase in circulating inflammatory cytokines in aging horses (IL−1β,
IL-15, IL-18, and TNF−α), the number of actively secreting IFN−γ labeled lymphocytes
and TNF−α labeled lymphocytes are also elevated (483). There is also an increase in the
number of circulating CD5 and CD4 T cell subsets in the aged horse (483). Obesity in
the aged horse further alters circulating cytokines; however, diet restriction which led to a
decrease in bodyweight did lower circulating inflammatory cytokines (484). Overall, it
appears that there may be an increase in inflammation or inflammatory mediators in
circulation during development which decreases during the adult phase of life and then
increases with post-maturity aging. However, there has not been a specific study aimed
at examining inflammatory changes throughout the life span in equine skeletal muscle.
1.6.3.3. Exercise induced inflammation in aged horses
The response of circulating inflammatory cytokines to an acute inflammatory
stimuli, exercise, during a state of chronic inflammation, aging, has been examined in
circulation in the horse. Horohov and colleagues (485) demonstrated that IL-2 stimulated
peripheral blood mononuclear cells cultured from pre- and post- exercise samples
collected in young (~8 years old) and aged (~25 years old) horses (485). However, the
post-exercise response to IL-2 in the cultured peripheral blood mononuclear cells was
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greater in the young horses compared to the aged horses (485). This study indicates that
following exercise, older horses are less responsive to an infection than young horses,
which may be due to the increased production of inflammatory cytokines; therefore the
response is already saturated. However, the acute inflammatory response during low
grade chronic inflammation in the aged horse requires additional research.
1.6.3.4. Summary of inflammation in the horse
Horses respond similarly to other mammals to acute and chronic inflammation.
Although there is still much work to be done, following exercise there is an increase in
circulating and muscle inflammatory cytokines, which differs if the horses have been in a
training program or if untrained horses perform a single bout of high intensity exercise.
Additionally, horses exhibit inflamm-aging which can be exacerbated by obesity. The
effects that these inflammatory states may have on skeletal muscle have not been
examined and will be partially addressed in subsequent chapters of this dissertation.
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1.7. TABLES
Table 1.1. Requirements of various physiological classes of an estimated mature
weight 600 kg mare according to the NRC1
Physiological
State

ADG or Milk
produced in
kg/d

Crude Protein
Requirement
g

Maintenance

Lysine Requirement

756

g/kg
BW/d
1.26

g
32.5

g/kg
BW/d
0.05

Weanling
Growth
(4-6 months old)
Yearling Growth
(12-18 months
old)

0.94

807

1.35

34.7

0.06

0.44

987

1.65

42.4

0.07

Early Pregnancy
(≤ 5 months)
Mid-Pregnancy
(6-8 months)
Late Pregnancy
(9-10 months)

0.09

789

1.32

33.9

0.06

0.30

877

1.46

37.7

0.06

0.63

1012

1.69

43.5

0.07

19.6

1842

3.07

101.7

0.17

18.7

1799

3.00

98.9

0.16

14.7

1597

3.66

85.5

0.14

839
921

1.40
1.54

36.1
39.6

0.06
0.07

1034

1.72

44.5

0.07

1023

1.71

44

0.07

Early Lactation
(1 month)
Mid Lactation
(2-3months)
Late Lactation
(4-6 months)
Light Exercise
Moderate
Exercise
Heavy Exercise

Growth and
0.34
Exercise
(18 month old in
light exercise)
1
Adapted from the NRC 2007 (342)
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1.8. FIGURES

100

Figure 1.1. Schematic drawing of the mTOR signaling pathway.
Abbreviations: P; phosphorylated; IRS1, insulin receptor substrate 1; PTP1β, protein
tyrosine phosphatase 1β; PI3K, phosphoinositide 3-kinase; PtdIns(3,4)P2/PtdIns(3,4,5)P3
PDK1, PtdIns(3,4)P2 / PtdIns(3,4,5)P3-dependent kinase 1; PTEN, phosphatase and
tensin homolog deleted on chromosome 10; SGK, serine/threonine protein kinase; Akt,
protein kinase B; PP2A, protein phosphatase 2A; GLUT4, glucose transporter 4; AMPK,
adenosine monophosphate kinase; p53, protein 53; GDP, guanosine diphosphate; GTP,
guanosine triphosphate; MAP3K, mitogen activated protein kinase kinase kinase; MEK,
mitogen extracellular kinase (sometimes referred to as MAPK); ERK1,2, extracellular
regulated kinase 1,2; Wnt, Wingless-Type MMTV Integration; GSK3β, glycogen
synthase kinase 3β; REDD1,2, Regulated in development and DNA damage response
1,2; TSC1,2, tuberous sclerosis 1,2; 14-3-3, scaffolding protein 14-3-3; VPS34, PI3K
catalytic subunit type 3; MAP4K3, mitogen activated protein 4 kinase kinase kinase;
Rheb, Ras homologue enriched in brain; Ras, RAt Sarcoma protein subfamily;
mTORC1,2, mammalian target of rapamycin complexes 1 and 2; S6K1, 70kDa S6 kinase
1; rpS6, ribosomal protein S6; eIF, eukaryotic initiation factors (2, 3, 4A, 4B, 4E, 4G, 5);
SKAR, Aly/REF-like target; CBP80, 80 kDa RNA splicing export factor nuclear capbinding protein; 4EBP1, eukaryotic initiation factor 4 eukaryotic binding protein 1; 40S,
40S ribosomal subunit; 60S, 60S ribosomal subunit; m7GpppN, Cap structure; an arrow
indicates an activation; and a perpendicular line indicates inhibition.
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Figure 1.3. Schematic drawing of an abridged version of the mTOR pathway.
Abbreviations: IRS1, insulin receptor substrate 1; PI3K, phosphoinositide 3-kinase;
PDK1, PtdIns(3,4)P2 / PtdIns(3,4,5)P3-dependent kinase 1; Akt, protein kinase B;
TSC1/2, tuberous sclerosis 1,2; Rheb, Ras homologue enriched in brain; mTORC1,2,
mammalian target of rapamycin complexes (1,2); S6K1, 70kDa S6 Kinase 1; rpS6,
ribosomal protein S6; 4EBP1, eukaryotic initiation factor 4 eukaryotic binding
protein 1; eIF4, eukaryotic initiation factor 4 (E, G).
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Figure 1.4. Schematic drawing of whole-body phenylalanine kinetics.
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Figure 1.5. Schematic drawing of the inflammatory signaling in circulation and
skeletal muscle.
Abbreviations: TGF−β, transforming growth factor−β; IFN−γ, interferon γ; TNF−α,
tumor necrosis factor−α; IL, interleukins (-1,-6,-8, -10, -12,-18), IκKB, IκB kinase
complex; NF-κB, Nuclear factor κ B.
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Chapter II
Rationale and Objectives
2.1. SCOPE OF DISSERTATION
The aims of the research presented in this dissertation were to examine the
regulation of protein synthesis through the mTOR signaling pathway in the horse during
various physiological states. The horses used in this dissertation varied in age from
growing adolescents to aging horses and were studied in the post-absorptive and
postprandial states and in states of acute and chronic inflammation. Muscle biopsies
were collected in all the studies to examine mTOR signaling responses to growth, aging,
acute and chronic inflammation, as well as in the postprandial and post-absorptive states.
Additionally, stable isotopes were infused intravenously to study whole-body protein
metabolism.
2.2. RATIONALE
As athletic animals, horses’ body mass is nearly 50% skeletal muscle (1). Horses
rely on skeletal muscle for mechanical and metabolic functions during exercise and as a
source of stored protein and amino acids during periods of long term fasting. Although
measurements have not been made in the horse, in other mammals skeletal muscle
accounts for ~25% of whole body protein synthesis (198, 199), indicating that it is a
major site of protein synthesis. In horses, there is an increase in skeletal muscle mass
during growth and development, followed by a decrease during post-adulthood aging
(486). In other species, these age-related shifts in muscle mass are accompanied by
alterations in the response of muscle protein fractional synthesis rates (125-127, 149, 151,
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154) and whole body protein metabolism (185, 202, 487) to anabolic stimuli.
Furthermore, age-related changes are present in the activity of the cell signaling pathway
referred to as the mammalian target of rapamycin (mTOR) pathway, which is responsible
for regulating protein synthesis in response to anabolic stimuli (23, 50, 129, 139, 155157). Despite the age-related examination of whole body and muscle protein synthesis
and the mTOR signaling pathway in other species, there has not been a single study in the
horse to quantify these aging-related changes.
There have been three studies (2, 3, 470) in horses to examine muscle protein
synthesis, mTOR signaling and another cell signaling pathway that can affect
downstream mTOR signaling. However, all of these studies have been performed in the
mature horse under various physiological states including postprandial, post-absorptive
and post-exercise. Because of the limited number of studies in this area, the optimum
methods for muscle biopsy collection, for example the muscle and depth from which the
biopsy is collected, and the lag time between biopsies, have not been determined.
Currently, there is no standardized method, nor do we know how measurements may be
influenced by differences in any of these parameters. Despite the fact that mTOR
signaling in various muscles respond differently to anabolic stimuli, there are currently
no studies to determine the best sample collection methodology to study mTOR signaling
in the horse.
By determining the optimum methods to study mTOR signaling in the horse, and
the age-related changes that occur, insight into protein requirements during these life
stages may be provided, and allow for the development of better dietary and management
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strategies for these animals in the future. This will be extremely important in trying to
optimize growth and delay the loss of muscle mass accompanied with aging.
2.3. SPECIFIC HYPOTHESES AND OBJECTIVES
2.3.1. Hypothesis 1.
Hypothesis 1a: mTOR signaling will not be altered by gluteal muscle biopsy
collection depth in mature horses in response to feeding. Hypothesis 1b: The percentage
of myosin heavy chain isoforms will be altered by gluteal muscle biopsy collection depth
in mature horses. Hypothesis 1c: There will be no variation in the amino acid
concentrations due to gluteal muscle biopsy collection depth in mature horses in response
to feeding.
The objective of the first study in this dissertation was to determine whether
biopsy depth related changes in MHC isoforms were associated with differences in the
feeding-induced activation of mTOR signaling in the gluteal muscle of mature horses.
Gluteal muscle biopsies were collected 60 minutes following the consumption of 3g/kg of
a high protein pellet at 6, 8, and 10 cm below the surface of the skin in mature horses.
The gluteal muscle biopsies were then prepared and analyzed for the following: Western
blot analysis for mTOR signaling factors (Hypothesis 1a), myosin heavy chain separation
analysis (Hypothesis 1b), and reverse phase HPLC for muscle free amino acid
concentrations (Hypothesis 1c).
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2.3.2. Hypothesis 2.
Hypothesis 2a: The collection of gluteal muscle biopsy samples every 24 hours
for 5 consecutive days will reduce mTOR signaling in response to feeding. Hypothesis
2b: Administration of a non steroidal anti-inflammatory drug (NSAID) will blunt the
effects of gluteal muscle biopsies repeated every 24 hours over the course of 5 days on
mTOR signaling. Hypothesis 2c: The collection of gluteal muscle biopsy samples every
24 hours for 5 consecutive days will increase mRNA expression of inflammatory
cytokines (IL−1β, IL-6, IL-10, TNF−α, IFN−γ) in skeletal muscle. Hypothesis 2d:
Administration of a NSAID will reduce mRNA expression of inflammatory cytokines in
skeletal muscle during consecutive gluteal muscle biopsies repeated every 24 hours over
the course of 5 days.
The objective of the second study of this dissertation was to determine the effects
of collecting gluteal muscle biopsies every 24 hours for 5 consecutive days on muscle
inflammatory cytokine expression and the activation of mTOR signaling in response to a
high protein meal. Gluteal muscle biopsies were collected 60 minutes following
consumption of 3g/kg of high protein pellet from 12 mature horses. This process was
repeated every 24 hours for the following 4 days. After the initial biopsy was collected 6
of the mature horses were randomly assigned to begin receiving the NSAID drug
treatment (1 g of phenylbutazone every 12 hours), and the other 6 horses did not receive
any NSAID treatment until the end of the day 5 biopsy. Muscle tissue samples were
prepared and analyzed using Western blotting analysis for mTOR signaling (Hypothesis
2a, 2b) and real time PCR analysis to determine the mRNA expression of the
inflammatory cytokines (Hypothesis 2c, 2d).
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2.3.3. Hypothesis 3.
Hypothesis 3a: There will be an increase in mTOR signaling in the postprandial
state of compared to the post-absorptive state in yearlings, two year olds and mature
horses. Hypothesis 3b: The responsiveness of mTOR signaling to feeding will be
greatest in the muscle of yearlings, followed by 2 year olds and will be lowest in mature
horses. Hypothesis 3c: There will be no differences in mTOR signaling in the postabsorptive state between yearlings, two year olds and mature horses.
The objective of the third study in this dissertation was to determine the effects of
feeding following an 18 hour period of feed withholding on the activation of mTOR
signaling factors in yearling, two year old and mature horses. Following an 18 hour
period feed withholding in yearlings, two year olds, and mature horses, gluteal muscle
biopsies were collected 90 minutes following either the consumption of 4g/kg (2g/kg at
t=0 min and 2g/kg at t=30 min) of a high protein pellet or after 90 minutes of continued
feed withholding (Hypotheses 3a, 3b and 3c). All muscle biopsies were prepared and
analyzed for the activation of mTOR signaling using Western blotting procedures.
2.3.4. Hypothesis 4.
Hypothesis 4a: Aged horses (23.5 ± 2.6 y old) will have lower rates of wholebody protein synthesis compared to mature horses (11 ± 2.6 y old). Hypothesis 4b:
Aged horses will have decreased gluteal muscle mTOR signaling compared to mature
horses. Hypothesis 4c: Aged horses will have increased gluteal muscle mRNA
expression of inflammatory cytokines compared to mature horses. Hypothesis 4d: Aged
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horses will have higher mRNA expression of inflammatory cytokines in circulation than
mature horses.
The objective of the fourth study in this dissertation was to determine the effects
of old age on mTOR signaling and whole-body protein synthesis in mature and aged
horses, and to further characterize the inflammatory state of the aged horses. Mature and
aged horses were studied using a 2 hour primed (14.4 μmol/kg), constant (12 μmol/kg/h)
intravenous infusion of [13C] sodium bicarbonate solution to measure total CO2
production. Horses then received a 4 hour primed (8.4 μmol/kg), constant (6 μmol/kg/h)
intravenous infusion of [1-13C]phenylalanine, with blood and breath sampled every 30
minutes, to measure whole-body phenylalanine kinetics (Hypothesis 4a). A gluteal
muscle biopsy was collected at the end of the infusion period to determine mTOR
signaling (Hypothesis 4b) and the mRNA expression of inflammatory cytokines
(Hypothesis 4c) in skeletal muscle. The day before the infusion procedures, a blood
sample was collected into a PAXgene tube via venopuncture for the determination of
circulating inflammatory cytokine mRNA expression (Hypothesis 4d). mTOR signaling
and mRNA expression of inflammatory cytokines were determined using Western
blotting and real time PCR techniques, respectively.
2.3.5. Hypothesis 5.
Hypothesis 5a: Whole-body protein synthesis will increase in aged (23.5 ± 2.6 y
old) horses following 4 weeks of NSAID administration. Hypothesis 5b: Gluteal
muscle mTOR signaling will increase following 4 weeks of NSAID administration.
Hypothesis 5c: Gluteal muscle mRNA expression of inflammatory cytokines will be
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reduced in aged horses following 4 weeks of NSAID administration. Hypothesis 5d:
Circulating inflammatory cytokine mRNA expression will be reduced in aged horses
following 4 weeks of NSAID administration.
The objective of the final study in this dissertation was to determine the effects of
NSAID (phenylbutazone at 2 g/d) administration over 4 weeks on the activation of
mTOR signaling and whole-body protein synthesis and skeletal muscle and circulating
inflammatory cytokines in aged horses. Aged horses were studied prior to and following
2 and 4 weeks of NSAID administration. Horses were studied using a 2 hour primed
(14.4 μmol/kg), constant (12 μmol/kg/h) intravenous infusion of [13C]sodium bicarbonate
solution in order to determine total CO2 production, followed by a 4 hour primed (8.4
μmol/kg), constant (6 μmol/kg/h) intravenous infusion of [1-13C]phenylalanine, with
blood and breath sampled every 30 minutes, to measure whole-body phenylalanine
kinetics (Hypothesis 5a). A gluteal muscle biopsy was collected at the end of the
infusion period to determine the mTOR signaling (Hypothesis 5b) and the mRNA
expression of inflammatory cytokines (Hypothesis 5c) in skeletal muscle. On the day
before infusion procedures, prior to and following 4 weeks of NSAID administration, a
blood sample was collected via venopunctiure into a PAXgene tube for the determination
of circulating inflammatory cytokine mRNA expression (Hypothesis 5d). mTOR
signaling and mRNA expression of inflammatory cytokines were determined using
Western blotting and real time PCR techniques, respectively.
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Chapter III1
Gluteal muscle sampling depth does not affect mTOR signaling in response to feeding
in mature Thoroughbred mares.
1

At the time of the defense (November 21, 2011), a version of this chapter is currently
under review for publication in the Equine Veterinary Journal.
3.1. INTRODUCTION
The collection of percutaneous muscle biopsy samples from the gluteal muscle is
commonly used to investigate equine skeletal muscle physiology and metabolism (411);
however, there is no standardized depth from which samples are collected. Studies have
demonstrated variation in MHC isoform expression across depth in the gluteal muscle of
horses (413) and MHC content reflects the metabolic properties of the muscle fiber (425).
Protein synthesis is regulated through the mammalian target of rapamycin
(mTOR/mTORC1) signaling pathway. The regulation of mTOR signaling has been the
topic of recent review (488). Our laboratory has examined the activation of factors along
the mTOR pathway, Akt, rpS6 and 4EBP1, in response to meal consumption in mature
horses (2), where it was demonstrated that the anabolic stimulus of meal consumption
activates mTOR signaling in the mature horse. In rodents, muscle groups with a greater
proportion of type II versus I fibers have a greater abundance of the phosphorylated form
of S6K1 in response to resistance exercise (110). However, the effects of MHC
proportion on the activation of mTOR signaling factors in response to feeding have not
yet been determined.
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The objective of this study was to determine whether biopsy depth related
changes in MHC isoforms were associated with differences in the feeding-induced
activation of mTOR signaling in the gluteal muscle of mature horses.
3.2. MATERIALS AND METHODS
3.2.1. Animals and housing
All procedures used in this study were approved by the University of Kentucky
Institutional Animal Care and Use Committee (2009-0442). Six Thoroughbred mares
(13.4 ± 3.4yrs; 536 ± 45 kg BW) of moderate body condition (5-7 on a 1-9 scale (489))
and clinically healthy were used in this study. Mares were housed in 3×15 m partially
covered dry lot pens with crushed limestone footing, with ad libitum access to both water
and salt. Horses were adapted to diet and housing procedures for 1 week prior to
sampling.
3.2.2. Experimental procedures
Individual meals were provided twice daily (at 800 and 1500). Diets consisted of
alfalfa hay cubes [mean ±SD; 0.48 ±0.01Mcal/kg DE, 17.0 ±0.2% CP, 35.2 ±0.8% ADF,
44.9 ±1.3% NDF, 2.3 ±0.1% crude fat, and 9.5 ±0.2% ash] and a ration balancer (mean
±SD; 0.49 ±0.01Mcal/kg DE, 14.9 ±0.2% CP, 22.5 ±0.8% ADF, 43.2 ±0.4% NDF, 3.6
±0.1% crude fat, and 12.9 ±0.1% ash), provided at a rate of 1.75% and 0.2% of BW/d,
respectively.
On the morning of the muscle biopsy, horses were weighed on an electronic scale
(TI-500, Transcell Technology Inc., Buffalo Grove, IL) and then fed 3 g/kg BW of a high
protein pellet (mean ±SD; 0.57 ±0.01Mcal/kg DE, 36.3 ±0.7% CP, 6.8 ±0.3% ADF, 13.8
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±0.8% NDF, 3.9 ±0.1% crude fat, and 17.2 ±0.3% ash) at t = 0 min. This high protein
pellet is a commercially available feed that was used in a previous study examining
mTOR signaling in the horse where the amino acid concentrations of the feed were
provided (2). At t = 60 min, horses were lightly sedated with xylazine hydrochloride
(0.3mg/kg, intravenous [100 mg/mL]), the biopsy site was aseptically scrubbed and and
anesthetized with a local anesthetic (12mL of 2% lidocaine). Muscle biopsies (~500 mg)
were collected from a single incision in the middle gluteal muscle at depths of 6, 8 and 10
cm below the surface of the skin, using the percutaneous needle biopsy technique (411).
Samples were immediately processed for Western blot analysis (~100 mg) and the
remaining muscle was frozen in liquid nitrogen, and stored at -80ºC until analysis for
amino acid concentration determination and myofibrillar protein preparation.
3.2.3. Sample analysis.
3.2.3.1. Amino acids: Muscle free amino acid concentrations were measured using
reverse-phase HPLC (3.9 × 300 mm PICO-TAG reverse phase column; Waters, Milford,
MA) of phenylisothiocyanate derivatives as previously described (2).
3.2.3.2. Muscle homogenate preparation for Western blot analysis: Muscle homogenates
were prepared as previously described (2). Briefly, freshly collected muscle (~ 100 mg)
was weighed and homogenized over ice in 7 µL/mg tissue wet weight of a buffer solution
(20 mM HEPES, 2 mM EGTA, 50 mM sodium fluoride, 100 mM potassium chloride, 0.2
mM EDTA and 50 mM β-glycerophosphate; pH 7.4) that contained 20 µL/mL of a
protease inhibitor (Sigma P8340; Sigma Aldrich, Saint Louis, MO). Homogenized
samples were centrifuged at 10,000 x g for 10 min at 4 ºC and the supernatant was
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aliquoted then stored at -80 ºC until further analysis. After protein concentrations were
determined using a Bradford assay kit (Thermo Scientific, Rockford, IL) modified for a
96 well plate, 50 µL of supernant was added to 25 µL of a 3X Laemmli buffer (125 mM
Trizma® hydrochloride pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol, 100 mM
dithiothreitol, 0.01% (w/v) bromophenol blue). Then, varying amounts of 1X Laemmli
buffer were added to each sample/Laemmli buffer mixture to reach a final protein
concentration of 2 µg/µL. The sample/Laemmli buffer mixture was boiled for 5 min, and
immediately placed on ice prior to gel electrophoresis.
3.2.3.3. Western blot analysis of muscle: The abundance and phosphorylation of 4EBP1, Akt, S6K1, and rpS6 in the gluteal muscle were determined using Western blot
analysis similar to those previously described (2). Proteins in the muscle samples
processed and stored in Laemmli buffer were separated in polyacylamide gels using
electrophoresis and then transferred to 0.45 µm PVDF membranes (BioRad, Hercules,
CA). Samples were standardized by the amount of protein loaded per well for
electrophoresis (20 µg protein was loaded for Akt, rpS6, and 4E-BP1; 30 µg protein was
loaded for S6K1). The membranes were blocked in a 5% fat-free milk solution and were
then incubated with the appropriate primary antibodies for either 16 h at 4 ºC
(phosphorylated and total forms of Akt, S6K1, and rpS6, and phosphorylated form of 4EBP1) or 1 h at room temperature (total form of 4E-BP1).
Individual rabbit polyclonal antibodies (Cell Signaling Technology®, Inc.,
Boston, MA) were used that recognized total, Ser473, and Thr308 Akt (1:2000 dilution for
each); total and Thr389 S6K1 (1:1000 and 1:500 dilutions, respectively); and Ser235/236, and
Ser240/244 rpS6 (1:2000 dilutions for each). Rabbit monoclonal antibodies (Cell Signaling
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Technology®, Inc., Boston, MA) specific to total and Thr37/46 4E-BP1 (1:1000 dilution);
and total rpS6 (1:10,000 dilution) were also used. Following washing, membranes were
incubated with a goat anti-rabbit IgG (H+L) with conjugated horseradish peroxidase
(1:10,000 dilution) (BioRad, Hercules, CA) for 1 h at room temperature. Membranes
were developed using a chemiluminescence kit (Amersham ECL Plus Western Blotting
Detection Reagents; GE healthcare, Piscataway, NJ) and visualized on x-ray film using a
film processor (Kodak X-OMAT film processor, Kodak Health Imaging Division,
Rochester, NY). Band densities were quantified as the mean*pixels in a photo editing
computer software program (Adobe Photoshop Elements™ Version 8.0; Alpha Innotech,
San Leandro, CA).
Gels were run in duplicate, and the average band densities were used to calculate
the ratio of phosphorylated to total abundance (Section 3.4.4). In order, to probe for the
total versus phosphorylated forms using different primary antibodies, the PVDF
membranes were first blotted for the phosphorylated protein abundance and were then
stripped for 10 minutes (62.5 mM Trizma® hydrochloride, 2% (w/v) SDS, 0.1 M βmercaptoethanol, boiling), re-blocked with 5% fat-free milk solution and re-probed for
the total protein abundance. Membrane stripping and re-probing served to minimize the
inter-assay error that would have resulted if the total and phosphorylated protein
abundances had been quantified from different membranes.
Although total Akt and Akt-Ser473, and total and Ser235/236 and Ser240/244 rpS6 have
been previously evaluated in equine skeletal muscle using the rabbit antibodies (2), to the
best of the authors’ knowledge, the other antibodies used in this study had not been
previously validated for horse samples. Therefore, positive control samples (Cell
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Signaling Technology®, Inc., Boston, MA) with known reactivity to the antibodies, were
loaded and run with all gels (Appendix 2). In addition, prior to performing the western
blot analysis for the samples in this study, we confirmed that all antibodies were crossspecies specific to these proteins in horses through the use of blocking peptides (Cell
Signaling Technology®, Inc., Boston, MA). Primary antibody was mixed with blocking
peptide in decreasing ratios of 1:4, 1:1, 1:1/4, and 1:1/16 (antibody volume to blocking
peptide volume) to determine the competition of blocking peptide to equine protein for
the given antibody. In all cases, we were able to verify that the primary antibodies were
reacting with the equine forms of the proteins of interest, because there was a reduced
chemiluminescent signal for the protein of interest as increased amounts of the blocking
peptide were added to the reaction mixture.
3.2.3.4. Myofibrillar protein preparation: Flash frozen muscle was removed from the 80ºC freezer, and allowed to thaw on dry ice. Tissue was then divided into (~50 mg)
portions and homogenized with a manual dounce homogenizer over dry ice in 9 µL/mg
tissue wet weight of a buffer solution (250mM Sucrose, 25mM NaCl, 20mM Tris; pH
7.4). Homogenized samples were centrifuged at 20,000 x g for 30 min at 4 ºC and the
supernatant was removed. The pellet was then resuspended in homogenizing buffer (250
µL). After protein concentrations were determined using a Bradford assay kit (Thermo
Scientific, Rockford, IL) modified for a 96 well plate, 40 µL of sample was added to 20
µL of a 3X Laemmli buffer (0.15 M Tris, pH 6.8, 6% (w/v) SDS, 75 mM dithiothreitol,
0.06% (w/v) bromophenol blue, 40% (w/v) glycerol). Then, varying amounts of 1X
Laemmli buffer were added to each sample/Laemmli buffer mixture to reach a final
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protein concentration of 0.2 µg/µL. The sample/Laemmli buffer mixture was boiled for 2
min, and immediately placed on ice prior to gel electrophoresis.
3.2.3.5. Separation of MHC Isoforms via electrophoresis: The percentage of MHC
isoform in the gluteal muscle was determined using electrophoresis followed by silver
staining similar to the methods previously described (490). In short, myofibrillar proteins
in the muscle samples processed and stored in Laemmli buffer were separated in
polyacrylamide gels using electrophoresis. Samples were standardized by the amount of
protein loaded per well for electrophoresis (2 µg of myofibrillar proteins was loaded),
and mouse gastrocnemius muscle served as a control on each gel. The electrophoresis
ran at 4ºC for 40 hours with constant voltage of 70 V using a BioRad Power PAC3000
power supply (Hercules, CA). Membranes were stained using a silver staining kit (Silver
Stain Plus Kit; BioRad, Hercules, CA) following manufacturer’s directions (Appendix 3).
Band densities were quantified as the mean*pixels using a photo editing computer
software program (Adobe Photoshop Elements™ Version 8.0; Alpha Innotech, San
Leandro, CA).
3.2.4. Calculations and statistics.
Individual band densities were corrected for the band density of the positive
control (Akt Control Cell Extracts treated with Calyculin A, Cell Signaling Technology
®, Inc., Boston, MA) run on each gel. The averages of the corrected band densities from
duplicate gels were averaged, and then expressed as a ratio of the phosphorylated to total
forms for each protein. Protein abundance of the mTOR signaling factors was expressed
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in arbitrary units, with the ratio of the phosphorylated to total forms of each protein at the
6 cm depth set to 1. MHC isoforms are expressed as a percentage of total MHC.
All data were analyzed using the MIXED procedure of SAS Version 9.2 (SAS
Institute Inc., Cary, NC), with statistical significance at P < 0.05. When the fixed effects
were significant, pre-planned comparisons of least squares means were made using the
pdiff test. The dependent variables were analyzed using repeated measures analysis, with
depth and block as the fixed effects and horse nested in block as the subject. The
variance-covariance matrix was chosen for each analysis based on the lowest value for
Schwarz’s Bayesian Criterion. Data are presented as means ± pooled standard error.
3.3. RESULTS
There was a significant effect (P < 0.05; Table 3.1) of sampling depth on the
muscle concentrations of free alanine, aspartate, glutamate, isoleucine, leucine,
methionine, proline and valine.
The phosphorylation of Akt at Ser473 (P = 0.06; Figure 3.1), S6K1 at Thr389 (P =
0.66; Figure 3.1), rpS6 at Ser235/236 & 240/244 (P = 0.21; Figure 3.1), and 4EBP1 at Thr37/46
(P = 0.62; Figure 3.1) was not affected by sampling depth within the gluteal muscle of
mature mares 60 min following the consumption of a high protein pellet.
There was a significant effect of sampling depth on the percentage of MHC IIA (P
= 0.03; Figure 3.2) and IIX (P = 0.02; Figure 3.2) in the gluteal muscle of mature mares;
however there was no effect (P = 0.42; Figure 3.2) of sampling depth on the percentage
of MHC I. The percentage of MHC IIA and IIX increased by 27% and decreased by
15%, respectively, from 6 to 10 cm.
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3.4. DISCUSSION
This is the first study to examine the effects of gluteal muscle biopsy sampling
depth on the activation of mTOR signaling in response to feeding. The results showed no
effect of sampling depth on the activation of mTOR signaling, despite changes in the
proportion of MHC isoforms. Thus, it appears that if percutaneous muscle biopsy
sampling occurs within a 6 to 10 cm range then mTOR signaling in response to feeding
can be compared between mature horses.
The collection of gluteal muscle biopsies at 6, 8, and 10 cm below the surface of
the skin showed that the proportion of MHC IIA, IIX and I isoforms increased, decreased
and remained unchanged, respectively. The changes seen in the proportion of MHC IIA
and IIX are consistent with previous reports (413), where the percentage of MHC IIA and
IIX isoforms increase and decrease, respectively, from 2 cm to 8 cm in the gluteus
muscle (413). However, in the present study we did not see a change in the percentage of
MHC I isoforms which has been previously demonstrated to increase with depth (413),
and may be due to the sampling protocol in the present study: we collected biopsies at 6,
8 and 10 cm below the surface of the skin rather than a more shallow collection
beginning at 2 cm (413). We also did not account for the variation in subcutaneous fat
which we have demonstrated to be up to 2 cm in some mature horses (Section 8.1).
Additionally, it is has been previously demonstrated that extensive variation in fiber type
exists between breeds (414), and the present results in Thoroughbreds are consistent with
what has been previously measurements of 10-15% of Type I fibers in this breed (414).
The activation of the mTOR signaling in response to feeding was not affected by
sampling depth. Although this is the first study to examine biopsy sampling depth in
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horses, it is not the first study to look at the association between of MHC isoform content
of muscle with mTOR signaling response to anabolic stimuli. In rodents,
phosphorylation of mTOR (491) and S6K1 (110) was shown to vary across different
muscles in response to contractile activity and the authors suggested that different fiber
types (Type II vs. Type I) maybe exhibiting a greater mTOR signaling response.
However, the variation in the activation of mTOR signaling factors due to MHC isoforms
remains unclear (104), and fiber type is not associated with different rates of protein
synthesis in humans (492). Horses, like humans, possess a single MHC I and 2 MHC II
isoforms (409), and do not possess a MHC IIB isoform which is present in rodent skeletal
muscle (409). It may be that the increased responsiveness to anabolic stimuli is a
property that is specific to Type IIB fibers seen in rodents; however, this requires
additional research. Additionally, the minimal change in MHC isoforms with depth may
explain the lack of an effect of depth on mTOR signaling in response to feeding.
Although sampling depth did not affect the activation of mTOR signaling, the
gluteal muscle concentrations of branched chain amino acids (BCAA), alanine, aspartate,
glutamate, methionine, and proline were greatest at the 8 cm sampling depth. With
elevated concentrations of BCAA, we expected to see greater mTOR signaling (48) at the
8 cm depth, but this was not the case, and these depth-related differences remain unclear.
However, from a methodological perspective, these results indicate that when comparing
gluteal muscle amino acids of mature horses, researchers need to standardize their biopsy
collection procedures by depth.
Conducting muscle biopsies at a depth range of 6 to 10 cm below the surface of
the skin did not affect the activation of mTOR signaling in response to consumption of a
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high protein pelleted meal, despite differences in the distribution of the MHC isoforms
present. Therefore, the activation of mTOR signaling can be compared across this range
of depths in mature horses.
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3.5. TABLES
Table 3.1: Muscle amino acid concentrations of the gluteus muscle at 6, 8 and 10 cm
below the skin in mature mares.
Amino Acid

6 cm

8 cm

10 cm

p-Value

744a

Pooled
SEM
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Alanine1

697a

944b

Asparagine

60

60

59

6

0.97

Aspartate

70a

94b

68a

9

0.02

Citrulline

41

50

46

6

0.48

Glutamate

305a

442b

390b

49

0.03

Glutamine

246

303

257

35

0.46

Glycine

664

471

664

133

0.50

Histidine

58

68

53

8

0.24

Isoleucine

55a

69b

56a

4

0.004

Leucine

105a

135b

111a

10

0.007

Lysine

296

189

267

128

0.67

Methionine

36a

50b

39a

4

0.004

Ornithine

15

26

17

9

0.59

Phenylalanine

48

64

104

29

0.39

Proline

94a

122b

100a

9

0.004

Serine

144

150

137

12

0.45

Threonine

170

207

173

34

0.69

Tryptophan

18

20

18

2

0.56

Tyrosine

61

104

62

24

0.36

124

0.05

Table 3.1 continued: Muscle amino acid concentrations of the gluteus muscle at 6, 8
and 10 cm below the skin in mature mares.
Valine

111a

148b

119a

9

0.005

1

Plasma amino acids concentrations are reported as least square means in μmol/g of wet
muscle.
abc

Differing letters indicate that values are significantly (P < 0.05) different from each
other.
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3.6. FIGURES
Phosphorylated
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Figure 3.1. Gluteal muscle phosphorylation of Akt at Ser473, S6K1 at Thr389, rpS6 at
Ser235/236 & 240/244, and 4EBP1 at Thr 37/46 at 6, 8, and 10 cm below the surface of the
skin within the gluteus medius muscle of mature mares 60 min after consuming
3g/kg of a high protein pelleted feed. The phosphorylated forms of the translation
initiation factors was corrected by the respective total form abundance, with the value for
mature horses set at 1.0 AU. Values are least square means ± pooled SE, n=6 per depth.
Representative images of the immunoblots are shown above.
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Figure 3.2. Percentage of MHC isoforms at 6, 8, and 10 cm below the surface of the
skin within the gluteus medius muscle of mature mares 60 min after consuming
3g/kg of a high protein pelleted feed. Values are least square means ± pooled SE, n=6
per depth.
ab

Different letters indicate a significant depth effect (P < 0.05).
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Chapter IV
Repeated muscle biopsies over a 5 day period increases mTOR signaling in equine
skeletal muscle
4.1. INTRODUCTION
Repeated percutaneous needle muscle biopsies, over the span of hours or days, are
a common practice in human and equine studies examining various factors affecting
muscle metabolism and physiology. However, the literature examining the effects of
repeated biopsies on muscle metabolism and physiology is limited. Inflammatory
changes in the muscle are induced by aging (493-495), exercise (244, 245, 255), and
muscle biopsy collection (248). In many studies, the effects of repeated biopsies on
muscle inflammation has been confounded by the inclusion of a simultaneous exercise
treatment (244, 245, 255, 332). Multiple biopsies have been reported to increase both
systemic and muscle inflammatory cytokines 30 (245) and 126 minutes (248) following
an initial biopsy. However, repeated biopsies over a 24 hour period in equine skeletal
muscle did not affect systemic or muscle inflammatory cytokines. This disconnect
between human and equine skeletal muscle, in addition to the absence of non-exercise
related studies, necessitated further investigation.
Protein synthesis is regulated through the mammalian target of rapamycin
(mTOR) signaling pathway. There are numerous reviews (21, 488, 496) examining the
regulation of this pathway by anabolic stimuli. Briefly, insulin stimulates the mTOR
signaling pathway through the phosphorylation of Akt (18, 19, 21), which inhibits the
activation of several mTOR inhibitors (18, 19, 21). Amino acids also stimulate the
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mTOR signaling pathway through the activation of a series of signaling proteins which
subsequently activate mTOR (45, 46, 497). mTOR activation results in the
phosphorylation of two downstream signaling proteins, ribosomal S6 Kinase 1 (S6K1)
and eukaryotic initiation factor 4E-binding protein-1 (4EBP1) (146, 496).
Phosphorylation of S6K1 activates ribosomal protein S6 (rpS6) (498), a component of the
40S ribosomal subunit (498). Phosphorylation of rpS6 and 4EBP1 result in the activation
of the translational equipment, allowing for protein synthesis to occur (146, 496).
Numerous studies have shown that the activation of these key proteins in the mTOR
signaling pathway in rodents (499-501), humans (99, 502, 503), and pigs (504-506)
correlate with an increase in the fractional muscle protein synthesis rates.
The use of multiple biopsies to examine protein synthesis rates and the mTOR
signaling pathway typically coincide with an exercise treatment, making it impossible to
separate the effects of exercise from repeated biopsy. These studies typically occurred
during approximately a 24 hour period where the initial biopsy was collected and then
subsequent biopsies are obtained following an exercise regimen or during isotope
infusion techniques over a several hour period. Protein synthesis rates do not change
with multiple muscle biopsies collected between 60, 210 and 240 minutes of a 4 hour
period (507) and during hourly biopsies over a 6 hour period (508). However, no study
has examined the effects of repeated muscle biopsies on muscle protein synthesis rates
after 6 hour, and there has been no study to examine the effects of repeated biopsies on
the activation of mTOR signaling factors. It is crucial to study protein synthesis and
mTOR signaling during a longer period following inflammatory stimuli because in
humans inflammation has shown to remain elevated up to 72 hours following exercise
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(509). Inflammation may impact the responsiveness of the mTOR signaling pathway and
subsequently protein synthesis rates in response to anabolic stimuli. In aged rodents with
systemic inflammation, the administration of a NSAID was able to increase muscle
protein synthesis (335). Therefore, it may be possible to mitigate changes in
inflammation and mTOR signaling due to repeated biopsies using NSAID administration.
The objective of this study was to determine the effects of multiple biopsies over the
course of 5 consecutive days on muscle inflammatory cytokine expression and the
activation of mTOR signaling in response to a high protein meal.
4.2. MATERIALS AND METHODS
4.2.1. Animals and housing.
All procedures used in this study were approved by the University of Kentucky
Institutional Animal Care and Use Committee (2009-0442). Twelve Thoroughbred
mares were obtained from the University of Kentucky Animal and Food Sciences’ Maine
Chance Farm. All mares were classified as mature (average age 13.4 ± 3.4; range 10-19
y old), of a moderate body condition (body condition score 5-7, scale 1-9 (489)), and
clinically healthy. Mares were on a regular vaccination, anthelmintic, and farrier
schedule prior to inclusion on this study. For the duration of the study mares were
housed in 3×15 m partially covered dry lot pens with crushed limestone footing. Ad
libitum access to both water and salt was provided throughout the study. Horses were
adapted to diet and housing procedures for 1 week prior to the initiation of study
procedures.
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4.4.2. Feeding procedures.
Individual meals were provided twice daily (at 800 and 1500). Diets consisted of
alfalfa hay cubes and a ration balancer; and were designed to meet the NRC (336)
requirements for mature horses with an approximate body weight (BW) of 600 kg and
average maintenance needs. The alfalfa hay cubes [mean ±SD; 0.48 ±0.01Mcal/kg DE,
17.0 ±0.2% crude protein (CP), 35.2 ±0.8% acid detergent fiber (ADF), 44.9 ±1.3%
neutral detergent fiber (NDF), 2.3 ±0.1% crude fat, and 9.5 ±0.2% ash] and ration
balancer (mean ±SD; 0.49 ±0.01Mcal/kg DE, 14.9 ±0.2% CP, 22.5 ±0.8% ADF, 43.2
±0.4% NDF, 3.6 ±0.1% crude fat, and 12.9 ±0.1% ash) were provided at a rate of 1.75%
and 0.2% of BW/d, respectively, for the duration of the study. Samples of the alfalfa hay
cubes, ration balancer, and high protein pellet, which was offered on sampling days, were
collected and sent to Dairy One Forage Laboratory (Ithaca, NY) for nutrient analysis.
4.2.3. Experimental design and procedures.
The current study was executed as a 2-way factorial design with day (1-5) and
NSAID administration (+NSAID or -NSAID) as the fixed effects. The twelve mares
were divided into two blocks of 6 horses, with 3 horses on each treatment in each block
to ease sampling procedures.
On the morning of day 1, following the adaptation period, horses were weighed
on an electronic scale (TI-500, Transcell Technology Inc., Buffalo Grove, IL) and fed a
high protein pellet (mean ±SD; 0.57 ±0.01Mcal/kg DE, 36.3 ±0.7% CP, 6.8 ±0.3% ADF,
13.8 ±0.8% NDF, 3.9 ±0.1% crude fat, and 17.2 ±0.3% ash) at 3g/kg. This high protein
pellet is a commercially available feed that was used in a previous study examining
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mTOR signaling in the horse where the amino acid concentrations of the feed were
provided (2). Pre-feeding (t = -15 min) and post-feeding (t = 60 minute after feed was
offered) jugular vein blood samples were collected via venapuncture into evacuated glass
tubes (Vacutainer; Becton-Dickinson, Franklin Lakes NJ) containing sodium heparin.
Blood samples were immediately centrifuged at 1,500 x g for 10 minutes at 4ºC.
Aliquots of plasma samples were frozen at -20ºC until the time of analysis. At t = 60
min, horses were placed in equine stocks (Priefert® Rodeo & Ranch Equipment, Mount
Pleasant TX), and were lightly sedated with xylazine hydrochloride (0.3mg/kg,
intravenous [100mg/mL]). Muscle biopsies (~500 mg) were collected from both the right
and left gluteal muscles, at a standardized site from a depth of 8cm (Chapter III) in the
middle gluteal muscle by use of the percutaneous needle biopsy technique (411).
Biopsies on day 2 – 5 were collected using separate incisions at least 1 cm apart from all
previous biopsy sites. Samples were immediately processed for Western blot analysis
(~100 mg) and quantitative real time (qRT)-PCR (~80 mg), as described below, and the
remaining muscle was frozen in liquid nitrogen, and stored at -80ºC until analysis.
Phenylbutazone (NSAID) was administered orally after the initial biopsy at 1 g every 12
hours for the next consecutive 5 day in the +NSAID group, and was not administered in
the -NSAID group. This procedure was repeated every 24 hr for the next 4 d. At the end
of the sampling period on day 5, all horses received phenylbutazone (2g/day) for the next
3 days to alleviate any discomfort or inflammation that may have been associated with
the procedures. All mares were then returned to the Department of Animal and Food
Sciences Maine Chance Farm Research herd at the end of the study procedures.
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4.2.4. Sample analysis.
4.2.4.1. Plasma glucose and insulin: Plasma glucose concentrations were determined
enzymatically using a YSI 2300 STAT Plus™ Glucose and Lactate Analyzer (YSI Inc.,
Life Sciences, Yellow Springs OH) (Appendix 4.1). A Coat-A-Coat RIA® kit (Siemens
Healthcare Diagnostics Inc., Deerfield IL) was used to determine plasma insulin
concentrations (Appendix 4.2).
4.2.4.2. Amino acids: Both plasma free amino acid concentrations (Appendix 1.1 – 1.2)
and total feed amino acid (Appendix 1.4 – 1.5) content were measured using reversephase HPLC (3.9 × 300 mm PICO-TAG reverse phase column; Waters, Milford MA) of
phenylisothiocyanate derivatives as previously described (2).
4.2.4.3. Western blot analysis of muscle samples: The abundance of the total and
phosphorylated forms of Akt, S6K1, rpS6, and 4E-BP1 in the gluteal muscle
homogenates were determined using electrophoresis followed by Western blotting
techniques (Chapter III)
4.2.4.4. RNA isolation and qRT-PCR. Freshly collected muscle (~ 80 mg) was weighed,
submerged in RNAlater (Qiagen Inc., Valencia, CA), and stored at -20oC until further
analysis. At time of analysis, muscle was homogenized into the RNA-Stat60 solution
(Tel- Test, Friendswood, TX) using the bead beating technique (510). Total RNA was
then isolated and quantified using phenol-chloroform extraction and quantified using
spectrophotometer (BioPhotometer, Eppendorf, Hamburg, Germany). Finally, reverse
transcription reactions were performed as previously described (244, 484), using 0.5 μg
of each RNA sample and reverse transcription master mix (Promega, Madison, WI).
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These reactions were incubated at 42oC for 15 minutes and 95oC for 5 minutes. cDNA
samples were stored at -20oC until analyzed by qRT-PCR.
The mRNA expression of pro -inflammatory cytokines, IFN−γ, IL−1β, IL-6 and
TNF−α, and the anti-inflammatory cytokine IL-10 were measured in cDNA samples
using equine specific intron-spanning primer/probe sets (244). A gene expression master
mix solution containing: 6.25 μL nuclease-free water (Qiagen), 1.25 μL 20 × assay mix
for primer/probe set of interest (Applied Biosystems, Foster City, CA), and 12.5 μL
Taqman™ (Applied Biosystems, Foster City, CA) reacted in 384 well plates with 5 μL of
cDNA. All reactions were run in duplicate under the following PCR conditions: 95oC for
10 minute followed by 45 cycles of 95oC for 15s and 60oC for 60s in an Applied
Biosystems 7500 sequence detection system (Appendix 5). Differences in RNA isolation
and cDNA construction between samples were corrected with the use of an internal
control, β-glucorindase, for each sample (244, 484).
4.2.5. Calculations and statistical analysis.
Protein abundance of the mTOR signaling factors is expressed in arbitrary units,
which is the ratio of the phosphorylated to total forms for each protein (Chapter III). The
ΔΔCT method (484) was used to calculate relative changes in mRNA expression from the
initial biopsy. The calibrator for individual cytokines was set as the mean ΔCT averaged
for all horses at day 1. These results are expressed as the relative quantity (RQ), which is
calculated as 2-ΔΔCT.
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All data were analyzed using the mixed procedure of SAS Version 9.2 (SAS
Institute Inc., Cary, NC), with statistical significance and trends considered if P < 0.05
and 0.05 < P < 0.10, respectively. When the fixed effects were significant, pre-planned
comparisons of least squares means were made using the pdiff test.
The dependent variables plasma glucose, insulin, and amino acid concentrations
were analyzed using repeated measures analysis, with day, NSAID treatment,
day*NSAID treatment interaction, and block as the fixed effects and horse nested within
treatment*block as the random subject. Baseline concentration was also included in the
model as a covariate because it significantly (P < 0.05) influenced the post-meal sample.
Biopsy side (left or right) was initially included in the model for each of the mTOR
signaling proteins, but was not significant (P > 0.05) and was removed from the model.
Each of the mTOR signaling proteins and the expression of individual inflammatory
cytokines were analyzed using repeated measures analysis, with day, NSAID treatment,
day*NSAID treatment interaction, and block as the fixed effects with horse nested within
treatment*block set as the random subject. For all repeated measures analysis, the
variance-covariance matrix was chosen for each analysis based on the lowest value for
Schwarz’s Bayesian Criterion. Data are presented as means ± pooled standard error
unless otherwise noted.
4.3. RESULTS
4.3.1. Plasma glucose, insulin, and amino acid concentrations
Plasma glucose concentrations were significantly affected by the interaction of
NSAID treatment*day (P = 0.05; Table 4.1), where at 60 minutes following the
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consumption of a high protein pelleted meal the plasma glucose concentrations decreased
over the course of the 5 day sampling period in the +NSAID treatment group (P < 0.05),
and did not change in the -NSAID group (P > 0.10). Plasma insulin concentrations were
not affected (P > 0.10; Table 4.1) by day, NSAID treatment, or day*NSAID treatment
interaction.
There was a significant effect (P < 0.05; Table 4.1) of treatment on plasma
concentrations of isoleucine, and proline. There was a statistical trend for an effect of
treatment on the plasma concentrations of leucine (P = 0.10), and valine (P = 0.10; Table
4.1). Day of sampling significantly affected (P < 0.05; Table 4.1) plasma concentrations
of alanine, and threonine. There was a significant (P = 0.04; Table 4.1) day*NSAID
treatment interaction on the plasma concentrations of asparagine.
4.3.2. Muscle mTOR signaling factors
The phosphorylation of Akt at Ser473 decreased significantly with day of biopsy (P
< 0.0001; Figure 4.1), regardless of treatment; however, the +NSAID group decreased
from day 1 to 2, and the –NSAID group decreased from day 1 to 3. Akt P-Ser473 was not
affected by treatment or treatment*day interaction (P > 0.10). There was a significant
treatment*day interaction on the phosphorylation of S6K1 at Thr389 (P = 0.003; Figure
4.2), where the +NSAID group had a transient increase from day1 during days 2 and 3
and returned to baseline by day 4, and the –NSAID group had a greater Thr389 S6K1 on
day 5 than on day 1. The phosphorylation of S6K1 at Thr389 was significantly affected by
day of sampling (P = 0.02), but not treatment (P > 0.10). There was a significant
interaction of treatment*day on the phosphorylation of rpS6 at Ser235/236 & 240/244 (P <
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0.001; Figure 4.3) with a transient decrease from day 1 in the +NSAID group on days 4
and 5, and an increase from day 1 with collection of each subsequent biopsy in the –
NSAID group. The phosphorylation of rpS6 at Ser235/236 & 240/244 was significantly
affected by both day of sampling (P = 0.005) and treatment (P = 0.05). There was a
time*treatment interaction on 4EBP1 at Thr37/46 (P = 0.02; Figure 4.4) with no change
due to day in the +NSAID group and a gradual increase at day 5 from day 1 in the –
NSAID group. There was a trend (P = 0.06) for an effect of sampling day on the
phosphorylation of 4EBP1 at Thr37/46 by sampling day, and no effect of treatment (P >
0.10).
4.3.3. Muscle inflammatory cytokines
IL-1β mRNA expression was significantly affected by sampling day (P = 0.01)
and there was a trend (P = 0.05) for an effect of the treatment*day of sampling interaction
(Table 4.2). IL-1β mRNA expression did not change (P > 0.10) in the +NSAID group
with day, but dramatically increased (P = 0.001) in the –NSAID group on day 5. IFN−γ
mRNA expression was significantly affected (P = 0.003; Table 4.2) by day, with no
change (P > 0.10) in the +NSAID group, and a decrease (P = 0.006) with day in the –
NSAID group. However, there was no effect of the treatment*day of sampling
interaction (P > 0.10) on the expression of IFN−γ mRNA, indicating the main effect of
sampling day was primarily due to changes in the –NSAID group. There was a trend for
an effect of day on IL-10 mRNA with a transient increase in the +NSAID group;
however, there was no effect of treatment, or the interaction of treatment*day of
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sampling (P > 0.10). There was no effect (P > 0.05) of day, treatment, or treatment*day
of sampling interaction for IL-6 (Table 4.2) and TNF−α (Table 4.2).
4.4. DISCUSSION
To the best of our knowledge, this is the first study to examine the effects of
multiple gluteal muscle biopsies over 5 consecutive days on local inflammation and on
the activation of mTOR signaling in response to a high protein meal. The primary
finding of this research was that repeated biopsies over 5 consecutive days may be
obtained without eliciting changes in downstream mTOR signaling response to feeding
due to increases in inflammation when NSAID are administered. However, when
NSAID are not administered, 5 days of consecutive biopsies altered muscle IL−1β and
IFN−γ and elevated the activation of the downstream mTOR signaling proteins in
response to feeding. Thus, the administration of NSAID appeared to reduce the local
inflammation induced by the collection of repeated biopsies and prevented changes in the
downstream mTOR signaling response to feeding.
Reports are varied on the effects of repeated biopsies on local inflammation due
to the frequency and number of biopsies collected, the method of biopsy collection, and
the site of biopsy. In the current study, IFN−γ and IL−1β skeletal muscle mRNA
expression decreased and increased, respectively, from the initial to the fifth biopsy in the
–NSAID group. However, a previous study in horses found no change in the mRNA
expression of IFN−γ or IL−1β with repeated biopsies over a 24 hour period (244),
consistent with our results. In human, there was an initial elevation in the protein
expression of IL−1β 30 minute following the first biopsy, but this increase did not persist
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over the next 7 days (245). The biopsy sites in the present study were more closely
spaced (1 cm) than the previous study (2 cm) (245); therefore, our finding of elevated
IL−1β by day 5 may have been due to the closer spatial arrangement to the previous
biopsy sites. Although IFNγ mRNA expression was elevated on days 1 and 2, it then
decreased on day 3, remaining constant until day 5 in the –NSAID group. IFN−γ
functions as a key regulator of other pro-inflammatory parameters, causing an up
regulation of TNF−α (511) and NF−κB (512), and inhibiting IL−1β (513). Therefore, the
increase in IL−1β seen on day 5 in the -NSAID group may be regulated by the decrease
in IFN−γ expression observed in the current study. The mechanisms surrounding the
decrease in IFN−γ expression in the –NSAID group requires further elucidation.
In the current study, TNF−α mRNA expression was not altered with the
collection of biopsies over 5 consecutive days in the –NSAID group, which is in
agreement with previous work in horses over a 24 hour period (244) and humans over a 7
day period (245). IL-6 mRNA expression has been shown to increase during 7 days of
repeated biopsies (245) and with acute repeated biopsies through separate incision sites
(248) in humans, but this was not seen in the present study or in previous studies in
horses (244). IL-6 production may be more responsive in human skeletal muscle than
equine skeletal muscle; however, this requires further investigation. In the present study,
the absence of an effect of repeated biopsies on the mRNA expression of IL-6 and
TNF−α may have been due to the decline in IFN−γ mRNA expression by day 5 because
IFN−γ plays a crucial role in the stimulation of the production of IL-6 and TNF−α from
monocytes and macrophages (511, 513).
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Although other studies have looked at the effectiveness of NSAID at reducing the
inflammatory response caused by exercise, this is the first study to determine the effects
of NSAID administration on inflammatory cytokines using repeated biopsies to elicit
inflammation. Oral administration of a herbal supplement with NSAID properties in
rodents reduced muscle IL−1β, IL-6, and TNF−α mRNA expression following exercise
(332), although in humans only TNF−α mRNA expression is reduced following postexercise NSAID infusion (333). Intravenous NSAID infusion in horses appeared to
reduce the systemic inflammatory response of lipopolysaccharide (LPS) infusion;
however, TNF−α was the only inflammatory cytokine examined (514). Although the
methods of NSAID administration, cause of inflammatory response, site of inflammation,
and inflammatory cytokine examined were different between the three studies, the current
study also showed that NSAID administration ameliorates the effects of repeated biopsies
over 5 consecutive days on inflammatory cytokines in the gluteal muscle of mature
horses through the absence of a change in mRNA expression of the interleukins (-6, -1β,
and -10), TNF−α, and IFN−γ in the skeletal muscle of the +NSAID group during 5 days
of biopsies.
All animals studied were mature, sedentary and consuming the same meal for 5
consecutive days; therefore, we did not expect a change in the activation of downstream
effectors or protein synthesis, as long as the repeated biopsies and/or NSAID
administration were not influencing muscle metabolism. There were no differences in
the downstream mTOR signaling factors in the +NSAID group showing that any changes
in muscle inflammation or metabolism caused by the repeated biopsies were mitigated by
the NSAID. However, in the absence of NSAID administration, the daily collection of
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muscle biopsies for 5 days increased the activation of the downstream mTOR signaling
proteins, S6K1, rpS6, and 4EBP1, by 22, 73, and 117%, respectively. The increase in
mTOR signaling is suggestive of an increase in rates of muscle protein synthesis in the –
NSAID group (500, 502, 505), although isotopic confirmation is necessary.
Following a bout of exercise there is an increase in muscle inflammatory cytokine
gene expression (244, 255, 509) and the activation of mTOR signaling proteins (515) for
up to 72 hours. It is thought that the increase in inflammatory cytokines following
exercise is necessary for muscle repair post-exercise (334) because inflammatory
cytokines are regulators of satellite cell proliferation (312, 313). A similar phenomenon
may have occurred during the current study, where there was an increase in the activation
of 4EBP1, S6K1, and rpS6 and the pro-inflammatory cytokine, IL−1β, in the –NSAID
group after 5 days of biopsy collection. Additionally, when a NSAID was administered
locally following eccentric exercise there was a reduction in satellite cell proliferation
(316), but protein synthesis was unaltered (333). However, when NSAID are
administered orally there is a reduction in post-exercise protein synthesis (516).
Therefore, the increase in IL−1β mRNA expression in the –NSAID group in the current
study which coincided with an increase in all of the downstream mTOR signaling factors
may be necessary for muscle to repair; however, further research is needed to confirm
this. Overall the findings from the –NSAID group may indicate that future experiments
using repeated biopsies over the course of several days to examine the activation of
mTOR signaling proteins in response to anabolic stimuli may require a control group or
NSAID treatment to account for changes in mTOR signaling not related to the
experimental treatments.
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Regardless of treatment, the activation of Akt over the course of 5 days of
repeated biopsies was reduced. Akt is activated through insulin signaling (18, 19), and
circulating insulin levels were variable in the present study regardless of treatment group,
which may indicate that the phenylbutazone dose (1g every 12 hours) was not sufficient
to elicit treatment differences. Hepatic activation of NF−κB, an inhibitor of Akt
phosphorylation (517), has been associated with systemic insulin resistance in mice
(518). Although we did not examine NF−κB in the present study, Akt activation may
have been inhibited through NF−κB due to insufficient inhibition by phenylbutazone
(519), or through NF−κB altered insulin sensitivity. Additionally, the reduction in Akt
activation could indicate a reduction in insulin sensitivity associated with the repeated
biopsies that could not be mediated by the administration of an NSAID.
Although there was a reduction in the activation of Akt with repeated biopsies,
there was an increase in the activation of all of the downstream mTOR signaling factors
in the –NSAID group. This may indicate that although Akt was inhibited and perhaps
insulin signaling, other factors such as amino acids were sufficiently stimulating the
activation of mTOR and subsequently S6K1, rpS6 and 4EBP1, which is consistent with
the results of a previous study (2) performed by our lab.
The reduced activation of NF−κB by phenylbutazone (519) may allow for an
increase in the activation of downstream effectors. Administration of ibuprofen during
low grade chronic inflammation in aging rodents ameliorated the reduction in muscle
protein synthesis normally associated with the aging population (335), however, there
was no affect on mTOR signaling factors. During an acute inflammatory response
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following exercise, the administration of local (333) and oral (516) NSAID following
exercise did not alter and reduced protein synthesis, respectively. In the present study,
there was no difference in the activation of the downstream signaling factors between day
1 and day 5 in the +NSAID group and an elevation in the –NSAID group indicating that
NSAID ameliorated the effect of repeated biopsies. This is consistent with the response
following exercise. Overall, our results indicate that the administration of a NSAID
during an acute inflammatory response due to the collection of multiple biopsies
maintained protein synthesis at levels equal to rates prior to the collection of the initial
biopsy.
Conducting muscle biopsy procedures every 24 hours for up to 5 days increases
muscle inflammatory cytokine gene expression, specifically IL−1β, and increases the
activation of S6K1, rpS6, and 4EBP1 in response to a meal when NSAID are not
administered. However, if repeated biopsies are collected over 5 days with oral
administration of a NSAID, then the increase in inflammatory cytokines is ameliorated
and the activation of the downstream effectors of the mTOR signaling factors are not
different over the 5 day period. Additionally, repeated biopsy collection every 24 hours
over the course of 5 days resulted in a reduction in the activation of Akt regardless of
NSAID. Therefore, a control group may be a useful tool when studying animals using
repeated percutaneous needle muscle biopsies.
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Table 4.1 continued: Plasma metabolite concentrations 60 minutes after consuming
a high protein pelleted meal during 5 days of consecutive NSAID administration in
mature Thoroughbred horses.
*Within a day, values are significantly (P < 0.05) different from the –NSAID group.
1

Glucose values are reported as least square means in mmol/L.

2

Insulin values are reported as least square means in μIU/mL

3

Amino acids values are reported as least square means in μmol/L
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4.6. FIGURES
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Figure 4.1. Gluteal muscle phosphorylation of Akt at Ser473 in mature
Thoroughbred horses either receiving NSAID administration (1g/12 hours;
+NSAID) or not receiving NSAID administration (-NSAID) for 5 days 60 minutes
following consumption of a 3g/kg of a high protein pelleted meal. Muscle biopsies
were taken at 60 min after t = 0 min. Akt phosphorylation at Ser473 was corrected by total
Akt abundance, with the value for the left side at day 1set at 1.0 AU. Values are pooled
least square means ± pooled SE of both gluteal muscle sides because side was not
significant (P > 0.05), n=6 per treatment group. Representative images of the
immunoblots are shown above.
abcd
Different letters indicate a significant day effect (P < 0.05) within a treatment group.
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Figure 4.2. Gluteal muscle phosphorylation of S6K1 at Thr389 Ser473 in mature
Thoroughbred horses either receiving NSAID administration (1g/12 hours;
+NSAID) or not receiving NSAID administration (-NSAID) for 5 days 60 minutes
following consumption of a 3g/kg of a high protein pelleted meal. Muscle biopsies
were taken at 60 min after t = 0 min. S6K1 phosphorylation at Thr389 was corrected by
total S6K1 abundance, with the value for the left side at day 1set at 1.0 AU. Values are
pooled least square means ± pooled SE of both gluteal muscle sides because side was not
significant (P > 0.05), n=6 per treatment group. Representative images of the
immunoblots are shown above.
*Indicates that, within a day, the value is significantly different (P < 0.05) from the –
NSAID group value.
ab
Different letters indicate a significant day effect (P < 0.05) within a treatment group.
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Figure 4.3. Gluteal muscle phosphorylation of rpS6 at Ser235/236 & 240/244 in mature
Thoroughbred horses either receiving NSAID administration (1g/12 hours;
+NSAID) or not receiving NSAID administration (-NSAID) for 5 days 60 minutes
following consumption of a 3g/kg of a high protein pelleted meal. Muscle biopsies
were taken at 60 min after t = 0 min. rpS6 phosphorylation at Ser235/236 & 240/244 was
corrected by total rpS6 abundance, with the value for the left side at day 1set at 1.0 AU.
Values are pooled least square means ± pooled SE of both gluteal muscle sides because
side was not significant (P > 0.05), n=6 per treatment group. Representative images of
the immunoblots are shown above.
*Indicates that, within a day, the value is significantly different (P < 0.05) from the –
NSAID group value.
abc
Different letters indicate a significant day effect (P < 0.05) within a treatment group.
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Figure 4.4. Gluteal muscle phosphorylation of 4EBP1 at Thr36/47 in mature
Thoroughbred horses either receiving NSAID administration (1g/12 hours;
+NSAID) or not receiving NSAID administration (-NSAID) for 5 days 60 minutes
following consumption of a 3g/kg of a high protein pelleted meal. Muscle biopsies
were taken at 60 min after t = 0 min. 4EBP1 phosphorylation at Thr36/47 was corrected by
total rpS6 abundance, with the value for the left side at day 1set at 1.0 AU. Values are
pooled least square means ± pooled SE of both gluteal muscle sides because side was not
significant (P > 0.05), n=6 per treatment group. Representative images of the
immunoblots are shown above.
*Indicates that, within a day, the value is significantly different (P < 0.05) from the –
NSAID group value.
abc
Different letters indicate a significant day effect (P < 0.05) within a treatment group.
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Chapter V1
Developmental regulation of the activation of translation initiation factors in response
to feeding in the skeletal muscle of horses
1

A version of this chapter has been accepted for publication in the American Journal of
Veterinary Research at the time of the defense (November 21, 2011).
5.1. INTRODUCTION
The neonatal period is characterized by the highest growth rate during the lifespan
with skeletal muscle showing the largest increase in mass (125). Elevated growth rate in
the neonate is a result of protein synthesis rates being higher than protein degradation
rates. However, with post-natal maturation, protein synthesis rates gradually decrease
(125-127) until both synthesis and degradation are equal in non-growing adult muscle.
To date, the life stage following the neonatal period, but before maturity, which is often
characterized by slow growth and is often referred to as the adolescent phase in human
development, has not been investigated with regards to protein synthesis.
Protein synthesis is limited by both the abundance and efficiency of ribosomes to
translate mRNA into protein and the availability of amino acids to form a protein (128).
The skeletal muscle of neonates has been reported to have a higher concentration of
ribosomes which decreases with age (127, 147); this may also contribute to the elevated
protein synthetic rates. The efficiency of ribosomes to translate mRNA into a protein is
modulated by a series of intracellular signaling cascades that are associated with the
mammalian target of rapamycin (mTOR) pathway. The mTOR pathway regulates
translation initiation and has been the subject of numerous recent reviews (21, 146, 488,
496). Briefly, insulin and insulin like growth factor 1 bind to their respective receptors
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activating protein kinase B (PKB or Akt) through the activation of several intermediate
signaling proteins (16, 18, 19, 21). Akt activation occurs when both the Thr308 and Ser473
sites are phosphorylated, and both sites are activated in association with insulin receptor
signaling (18, 19, 21). Activation of Akt inactivates the mTOR inhibitor tuberous
sclerosis complex 2 through phosphorylation (19, 21); thus, allowing activation of mTOR
through phosphorylation. Amino acids, specifically Leu, have also been demonstrated to
phosphorylate mTOR through the activation of several signaling proteins (45, 46, 497).
mTOR is recognized in skeletal muscle as the key regulator of translation initiation and
subsequent protein synthesis through the phosphorylation of two downstream signaling
proteins: ribosomal S6 Kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding
protein-1 (4EBP1). Phosphorylation of S6K1 results in the activation of ribosomal
protein S6 (rpS6), a component of the 40S ribosomal subunit (498). Phosphorylation of
rpS6 and 4EBP1 result in the activation of the translational equipment; thus, allowing the
synthesis of a protein (146, 496).
Examination of protein synthesis in response to anabolic stimuli during the
neonatal period has been demonstrated using both translation initiation factor activation
and isotope infusion techniques to measure protein synthesis (125, 126, 520). Anabolic
stimuli such as feeding a meal (521), amino acid administration (520, 522), or insulin
infusion (522) increases the activation of translation initiation factors in the mTOR
signaling pathway and fractional muscle protein synthesis rates (133, 140). As with
protein synthesis, the responsiveness of the activation of translation initiation factors to
anabolic stimuli is blunted with post-natal age (133, 140), and is lowered in the adult
(149); however, the adolescent period of slowed growth has yet to be examined.
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Furthermore, the activation of translation initiation factors and subsequent protein
synthesis in response to an anabolic stimuli has been demonstrated to decline from the
mature to aged individual in rodents (133, 140) and humans (149, 155). The activation of
translation initiation factors has been examined in equine skeletal muscle tissue in only a
single study (2), where the response to meal feeding increased the activation of
translation initiation factors in the mature horse, but age-related effects have not been
studied.
The objective of this study was to determine the effects of feeding following an
18 hour period of feed withholding on the activation of translation initiation factors,
specifically Akt, S6K1, rpS6, and 4EBP1 in yearling, two year old and mature horses.
We chose an adolescent age group, consisting of yearlings and two year olds, because to
the best of our knowledge, there has not yet been a single study in any species to examine
the activation of translation initiation factors in response to an anabolic stimulus in
adolescents. The translation initiation factors studied were chosen as a representation of
both up- and down-stream factors in the mTOR signaling pathway.
5.2. MATERIALS AND METHODS
5.2.1. Animals and housing.
The University of Kentucky Institutional Animal Care and Use Committee
approved all procedures used in this study (2009-0442). Fifteen Thoroughbred mares,
two Thoroughbred/Quarter Horse cross mares, and one Quarter Horse mare were
obtained from the University of Kentucky Animal and Food Sciences’ Maine Chance
Farm. Of these 18 mares, 6 were yearlings (15.8±0.8 mo old; 395±12 kg BW), 6 were 2
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years olds (27.4±1.0 mo old; 484±28 kg BW), 6 were mature (13.8±2.9 years old;
549±59 kg BW) mares. All horses were of moderate body condition for their age group
(body condition score: yearlings: 4-5, two year olds and mature horses: 5-7; scale 1-9
(489)), and clinically healthy. The group of mature mares were selected from a candidate
pool of mares which were no longer growing, but had not yet been defined as
chronologically old (ie. greater than 20 years) (523). For the duration of the study, horses
were housed in 3.7×3.7 m stalls bedded with pine shavings overnight, with daily turn out
into drylots, and ad libitum access to water and salt at all times. Horses were adapted to
diet and housing procedures for 2 weeks prior to any experimental or sampling
procedures. During the 18 hour period of feed withholding, and during the sampling
procedures, horses remained in the stalls bedded with pine shavings.
5.2.2. Feeding procedures.
All animals were individually fed in stalls two meals daily (at 0800 and 1500).
Diets were designed to meet the National Research Council (336) requirements for
mature horses with average maintenance needs and a BW of 600 kg, two year old horses
with a targeted average daily gain (ADG) of 0.22 kg/d, and yearling horses with a
targeted ADG of 0.54 kg/d. The meals consisted of alfalfa cubes, a ration balancer, and a
protein/mineral supplement. The alfalfa cubes [mean ±SD; 0.49 ±0.01Mcal/kg digestible
energy (DE), 16.95 ±0.24% crude protein (CP), 35.2 ±0.82% acid detergent fiber (ADF),
44.88 ±1.31% neutral detergent fiber (NDF), 2.28 ±0.05% crude fat, and 9.5 ±0.22% ash]
were fed at a rate of 1.75% of body weight per day to all age groups. The ration balancer
pellet (mean ±SD; 0.48 ±0.01Mcal/kg DE, 14.93 ±0.15% CP, 22.53 ±0.81% ADF, 43.2
±0.36% NDF, 3.57 ±0.06% crude fat, and 12.9 ±0.1% ash) was fed at a rate of 0.15, 0.25,
155

and 0.40% of body weight per day to mature, 2 years old, and yearlings, respectively.
The protein/mineral supplement (mean ±SD; 0.57 ±0.01Mcal/kg DE, 36.3 ±0.72% CP,
6.77 ±0.25% ADF, 13.8 ±0.8% NDF, 3.87 ±0.06% crude fat, and 17.2 ±0.3% ash) was
fed at a rate of 0, 0.15, and 0.20% of body weight per day to mature, 2 year olds, and
yearlings, respectively. Samples of the alfalfa cubes, ration balancer pellet, and
protein/mineral supplement were collected throughout the experimental period and sent
to Dairy One Forage Laboratory (Ithaca, NY) for nutrient analysis.
5.2.3. Experimental design and procedures.
This study was conducted as a 3×2-factorial crossover design with age and
feeding state (post-absorptive versus postprandial) as the fixed effects, with each horse
being studied in both feeding states. To facilitate sampling procedures, the eighteen
horses were divided into three blocks, with 2 horses from each age group in each block.
Each horse was studied under both feeding states in a randomly determined order, such
that within each block there were an equal number of horses (n = 3) receiving each
treatment during each period. There was a minimum of 1week between the sampling
periods for each horse.
The experimental procedures used in this study were similar to those previously
reported (2). Briefly, on the day prior to sampling procedures, horses were weighed and
a jugular vein catheter (14 gauge X 14.0 cm, Abbocath; Abbott Laboratories, North
Chicago, IL) was placed. The gluteus medius muscle was ultrasounded to determine
subcutaneous fat and gluteal muscle depth (524). This allowed for the accurate
determination of 50% of gluteal muscle depth, in order to standardize biopsy collection
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depth between the different ages of horses; which was determined to be 6.0±0.4, 7.4±0.3,
and 8.1±0.3 cm for yearlings, two year olds, and mature horses, respectively (Appendix
6). Horses were then placed into individual stalls and provided a high crude protein
pelleted feed meal (Table 5.1), at 2 g/kg BW on an as-fed basis. The purpose of this meal
was to standardize the duration of feed withholding prior to the sampling procedures for
all horses. Horses were kept in stalls overnight (18 hour), with ad libitum access to
water, but feed and hay were withheld.
At t = 0 minute, 18 hours following the previous meal, horses either remained in
the post-absorptive state for an additional 90 minutes (post-absorptive treatment) or
received a 2 g/kg BW meal of the aforementioned pelleted feed at t = 0 minute and again
at t = 30 minutes, for a total targeted intake of 4 g/kg BW of pelleted feed during the
postprandial period (postprandial treatment). This feeding regimen has been previously
shown to result in differences in plasma glucose, insulin and amino acid concentration
and in the activation of mTOR-related signaling factors in the gluteal muscle in mature
horses (2). Feed intake was monitored and any feed refusals were removed at the end of
the postprandial period and weighed.
Two baseline blood samples (10 mL), separated by a minimum of 15 minutes,
were collected prior to t = 0 minute. Subsequent blood samples were taken every 10
minutes until t = 80 minutes. All samples were collected into evacuated tubes containing
sodium heparin (Vacutainer; Becton-Dickinson, Franklin Lakes, NJ) and were
immediately centrifuged at 3,000 x g for 10 minutes at 4ºC. Aliquots of the plasma
samples were frozen at -20ºC until the time of analysis.
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At t = 80 minutes, horses were placed in equine stocks (HS Equine Stocks;
Priefert® Rodeo & Ranch Equipment, Mount Pleasant, TX), and lightly sedated with
xylazine hydrochloride (0.3 mg/kg, intravenous [100 mg/mL]). The area over the middle
gluteal muscle (~100 cm2) was shaved, aseptically prepared, and desensitized with a local
anesthetic (12 mL of 2% lidocaine). At t = 90 minutes, approximately 500 mg of muscle
biopsy specimen was obtained at a standardized site and depth (50% of gluteal muscle
depth) in the middle gluteal muscle by use of the percutaneous needle biopsy technique
(411). Approximately 400 mg of the sample was flash frozen in liquid nitrogen, and
stored at -80ºC until analysis. The remaining 100 mg was processed in preparation for
Western blot analysis, as described below. Phenylbutazone was administered after the
biopsy (1g every 12 hours for 48 hours post-biopsy) to alleviate any potential discomfort
associated with the procedure.
During the second treatment period, horses underwent the same experimental
procedures as during the first period, but received the alternate treatment. In the second
treatment period, the jugular vein catheter was inserted into the vein not used for the
previous period and the muscle biopsy specimen was taken from the contralateral side.
Following the second muscle biopsy, horses returned to drylots during the day and were
stalled overnight and were then returned to the Department of Animal and Food
Sciences’ Maine Chance Farm Research herd.
5.2.4. Sample analysis procedures.
5.2.4.1. Plasma Glucose and Insulin: Plasma glucose concentrations were assayed
enzymatically using a glucose analyzer (YSI 2300 STAT Plus™ Glucose and Lactate
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Analyzer, YSI Inc., Life Sciences, Yellow Springs, OH). Plasma insulin concentrations
were determined using a commercially available kit (Coat-A-Coat RIA®kitSiemens,
Healthcare Diagnostics Inc., Deerfield, IL).
5.2.4.2. Amino Acids: The plasma free amino acid concentrations and feed amino acid
content were measured using reverse-phase HPLC (3.9 x 300 mm PICO-TAG reverse
phase column; Waters, Milford, MA) of phenylisothiocyanate derivatives as previously
described (2).
5.2.4.3. Western blot analysis of muscle samples: Electrophoresis of the gluteal muscle
homogenates was followed by Western blotting techniques to determine the abundance of
the total and phosphorylated forms of Akt, S6K1, rpS6, and 4E-BP1 (Chapter III).
5.2.5. Statistical analysis.
All data were analyzed using the mixed procedure of SAS Version 9.1 (SAS
Institute Inc., Cary NC), and data were considered statistically significant if P < 0.05, and
considered a statistical trend if 0.05 < P < 0.10. When the fixed effects were significant,
pre-planned comparisons of least squares means were made using the pdiff test.
The dependent variables plasma glucose, insulin, and amino acid concentrations
were analyzed using a repeated measures analysis, with age, treatment, time,
age*treatment, time*treatment, age*time, age*time*treatment interaction as the fixed
effects and horse nested in treatment and block as the random effects. The two baseline
sample values were averaged for each of the dependent variables, and the resulting
baseline concentration was included in the model as a covariate if its effect was
determined to be significant (P < 0.05). Baseline was significant (P < 0.05) for plasma
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glucose, insulin, and each amino acid and was therefore included in each of the respective
models. Each of the translation initiation factors were analyzed using a repeated
measures analysis, with treatment, age, treatment*age interaction, treatment period, and
block as the fixed effects and horse nested with in age*block as the subject. For all
repeated measures analysis, the variance-covariance matrix was chosen for each analysis
based on the lowest value for Schwarz’s Bayesian Criterion. Data are presented as means
± pooled standard error unless otherwise noted.
5.3. RESULTS
All horses remained healthy and maintained normal growth rates according to the
recommendations of the NRC (336) throughout the course of the experimental period.
The yearlings and two year olds maintained an ADG of 0.94±0.67 and 0.18±0.38 kg/d,
respectively. The mature mares did not gain weight over the course of the experimental
period with an ADG of 0.00±0.25 kg/d.
5.3.1. Plasma Glucose
There was a significant effect of treatment (P = 0.0002), time (P < 0.0001), and
treatment*time interaction (P < 0.0001) on plasma glucose concentration (Figure 5.1);
where, the yearlings had higher (P < 0.05) plasma glucose concentrations at 30 minutes
following the meal stimulus than the two year old and mature horses. Regardless of age,
the horses in the postprandial state had higher glucose concentrations at 60 and 80
minutes than those in the post-absorptive state. During the postprandial phase, plasma
glucose concentration increased from baseline with time in all age groups. There was
also a trend for decreased glucose concentrations with age (P = 0.08). However, there
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was no effect of treatment*age interaction (P = 0.53), age*time interaction (P = 0.26), or
treatment*age*time interaction (P = 0.36) on plasma glucose concentration.
5.3.2. Plasma Insulin
Plasma insulin was significantly affected by treatment (P < 0.0001), time (P <
0.0001), treatment*time (P < 0.0001), treatment*age (P = 0.003), and
treatment*age*time interaction (P = 0.032; Figure 5.2). Circulating insulin was higher in
the postprandial phase (P < 0.05) compared to the post-absorptive phase beginning at 30
minutes in the mature horses. However, the yearlings and the two year olds did not show
differences between the postprandial and post-absorptive phase until 80 minutes when
insulin was greater in the postprandial phase. During the postprandial phase, insulin
concentrations increased with time across all age groups. At both 0 and 30 minutes
following a meal stimulus there was no difference (P > 0.05) between the age groups for
circulating insulin in the postprandial group. However, at both 60 and 80 minutes post
consumption of a high protein pelleted meal the mature horses had significantly greater
(P < 0.05) circulating insulin than either the yearlings or two year olds. There was no
effect of age (P = 0.53), but there was an age*time interaction (P = 0.07) on plasma
insulin concentration.
5.3.3. Plasma Amino Acids
There was a significant effect of treatment, time, and treatment*time interaction
(P < 0.05; Table 5.2) on all plasma amino acids examined, except glycine, where its
concentration was only affected by time (P < 0.05). For the essential amino acids, plasma
concentrations were increased at t = 80 minutes by an average of 48% in the postprandial
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phase, while the plasma amino acid concentrations in the post-absorptive phase remained
unchanged (P < 0.05) compared to the baseline values. With the exception of glutamate
and aspartate, there was no effect of age on any plasma amino acid concentrations (P >
0.05; Table 5.2). There was no interaction of treatment*time*age (P > 0.05) for any of
the plasma amino acids examined.
5.3.4. Muscle Translation Initiation Factors
The phosphorylation of Akt at Ser473 was significantly greater in the postprandial
period (P < 0.0001; Figure 5.3) in all ages of horses; however, there was no effect of age
(P = 0.24) or the treatment*age interaction (P = 0.51). The abundance of Akt
phosphorylation at Thr308 trended to increase in the postprandial period compared to the
post-absorptive period. However, there was no effect of age (P = 0.90) or treatment*age
interaction (P = 0.48) on Akt phosphorylation at Thr308. There was a significantly greater
phosphorylation of S6K1 at Thr389 from the post-absorptive to postprandial period (P =
0.0001; Figure 5). There was also a significantly higher phosphorylation of S6K1 at
Thr389 with age (P = 0.0079), and a significant treatment*age interaction (P = 0.0027).
Postprandial phosphorylation of S6K1 at Thr389 was greater (P < 0.05) in the mature
horses than the yearlings or two year olds, and the yearlings had a higher (P = 0.008)
abundance than the two year olds. The phosphorylation of rpS6 at Ser235/236 was
significantly greater in the postprandial period compared to the post-absorptive period (P
< 0.0001; Figure 6), and a significant treatment*age interaction (P= 0.03) was present;
where, the yearlings (P = 0.009; 3.3±0.3 arbitrary units) and mature horses (P = 0.002;
3.6±0.3 arbitrary units) were greater in the postprandial phase compared to the two year
olds (2.0±0.3 arbitrary units). There was no difference in the postprandial phase between
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the yearlings and mature horses (P = 0.42). However, there was a trend for the main
effect of age (P = 0.07). There was a significantly higher phosphorylation of rpS6 at
Ser240/244 rpS6 in the postprandial period (P < 0.0001; Figure 7); however, there was no
effect of age (P = 0.35) or treatment*age interaction (P = 0.27). The phosphorylation of
4EBP1 at Thr37/46 was significantly greater in the postprandial period (P = 0.003; Figure
8), and a significant treatment*age interaction (P = 0.04) was present. The yearlings had
an increase (P = 0.0007) in the postprandial phase compared to the post-absorptive, with
no effects of feeding seen in the other ages of horses. There was no effect of age (P =
0.68) on the phosphorylation of 4EBP1 at Thr36/47.
5.4. DISCUSSION
To the best of our knowledge, this is the first study to examine S6K1 in the
skeletal muscle of horses of any age, and the first study to examine the activation of
translation initiation factors in response to anabolic stimuli in the skeletal muscle of
adolescent animals of any species. There was a marked increase in the phosphorylation
of both up and downstream mTOR signaling factors during the postprandial state
compared to the post-absorptive state in the gluteal muscle of yearling, two year old and
mature horses, with the higher degree of sensitivity to anabolic stimuli exhibited by the
yearlings.
Following mTOR activation, S6K1 and subsequently rpS6 are phosphorylated
(21). Previous work in our lab (2) has shown that the protein abundance of the
phosphorylated form of rpS6 was higher in the postprandial state in mature horses. This
is in agreement with the current study, where protein abundance of the phosphorylated
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forms of S6K1 and rpS6 were elevated in the postprandial state. There is an absence of
comparable literature on the adolescent, therefore, we examined previous work in the
swine neonate (521, 525) to determine if similar developmental trends continued during
adolescence. In the present study, we have demonstrated that there is a decrease in the
activation of translation initiation factors to a meal stimulus with adolescent development
which is a trend that appears to continue from neonatal development (521, 525). There
was a 158, -7, and 109% percent change in the phosphorylation of S6K1 from the postabsorptive to postprandial states in yearlings, two year olds and mature horses,
respectively. Not only was there a difference in the abundance of S6K1 P-Thr389 in the
postprandial state between the age groups, but there were also differences in the postabsorptive state where the yearling had a lower expression than either the mature or two
year olds, allowing for a more pronounced postprandial response in the younger horses.
Research in developmental changes of skeletal muscle protein abundance of S6K1-Thr389
during the post-absorptive state in the neonatal pig vary with reports of no difference
(521, 525) and increases (526) from 7 to 26d of age, respectively. Although we
examined adolescent horses, we demonstrated a similar phenomenon as previously
described in the swine neonate (526), indicating the horse is not unique in the activation
of translation initiation in skeletal muscle during development. Additionally, there were
increases in the protein abundance of rpS6 phosphorylation at Ser235/236 and Ser240/244.
rpS6 P-Ser235/236 increased 147, 73, and 228% in yearlings, two year olds, and mature
horses, respectively, from the post-absorptive to postprandial periods. Increases of 144,
76, and 167% in the protein abundance of rpS6 P-Ser240/244 from the post-absorptive to
postprandial state were exhibited in yearlings, two year olds and mature horses,
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respectively. Thus, the S6K1 portion of the signaling pathway following mTOR
phosphorylation was activated in all age groups in the postprandial period indicating a
potential increase in translation initiation. Our results of the downstream effectors
indicate that there is a decrease in the response to a meal-feeding stimuli in the adolescent
horse from year one to year two of life, which may be continuation of the development
decline demonstrated in the neonate (521, 522, 525). However, further research is
warranted to elucidate this in the equine neonate.
The other side of the downstream pathway following mTOR activation is the
phosphorylation of 4EBP1 at Thr37/46. Our laboratory has previously shown (2) that
protein abundance of the phosphorylated form of 4EBP1 was higher in the postprandial
state in mature horses; however, in the current study, the yearlings were the only age
group that responded to the anabolic stimuli with a higher protein abundance of the
phosphorylated form of 4EBP1 in the postprandial state. This discrepancy may be at
least partially attributable to the differences in the antibodies used during the Western
blotting procedure. In the previous study (2), the 4EBP1 antibody was specific for all
forms of 4EBP1 (α, β and γ) and then expressed as the percentage of γ; however, in this
study two antibodies were used: one specific for phosphorylated Thr37/46 4EBP1 and the
other recognized total 4EBP1. Activation of 4EBP1 during the postprandial state was 50,
4, and 15% greater in yearlings, two year olds, and mature horses, respectively, than the
post-absorptive state; with only a significant activation over post-absorptive abundance in
the yearlings. This may indicate that the yearlings were more sensitive to the anabolic
stimuli of a meal than the two year olds or mature horses, which is in agreement with the
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previous work in the swine neonate (521, 525) demonstrating a decrease in the activation
of translation initiation factors to a meal stimulus with development.
Based on previous research we hypothesized that the anabolic stimuli of
consuming a meal would cause a greater activation of translation initiation factors in the
yearlings than the two year olds, who we expected to be more responsive than the mature
horses; however, this was not observed. In the adolescent age groups examined in the
current study the downstream effectors were more responsive to a meal stimulus in the
yearling group of horses in comparison to the two year olds. This is comparable to the
results of previous studies performed in the swine neonate which show a decrease in the
responsiveness of downstream effectors in the 26 compared to the 7 days old pig to a
meal stimulus (521, 525, 526), amino acid supplementation (520, 522) or insulin infusion
(522). However, postprandial protein abundance of the phosphorylated forms of rpS6
and 4EBP1 were not different between the yearlings and the mature horses, with the
lowest abundance seen in the two year old horses. This may be partially attributed to the
feeding protocol utilized. In the current study we fed all age groups a total of 4 g/kg of
feed in the postprandial treatment in an effort to standardize the protein intake between
the age groups. This standardization was intended to meet the protein requirements of a
mature sedentary horse with an average body weight of 600 kg; as a result, this meal did
not meet the requirements of the adolescent horses. This meal only supplied 54 and 80%
of the daily requirements of the yearlings and two year olds, respectively. The increased
responsiveness seen in the yearlings, who were consuming only 54% of their daily
protein intake, indicates that if this study were repeated standardizing the meal by
meeting 100% of daily protein requirements, would likely be sufficient anabolic stimuli
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to elucidate a potential step wise decrease in the activation of translation initiation factors
with age.
Although we saw increases in the downstream effectors following a meal stimulus
across the age groups, future research is needed to examine if this indeed lead to
increased protein synthesis using isotopic techniques. It is also necessary to determine if
there are age related differences in the adolescent equine in whole body and muscle
fractional protein synthetic rates following a meal stimulus. Accretion of skeletal muscle
occurs when protein synthesis is greater than protein degradation. In mature sedentary
animals, there should be a balance between protein synthesis and degradation resulting in
maintenance of skeletal muscle, but no accretion. Similar to the mTOR signaling
pathway for protein synthesis, there are signaling pathways in skeletal muscle that are
associated with protein degradation which include the ubiquitin and proteosomal
pathways. In the present study, we did not measure any molecular indicators of protein
breakdown such as muscle-RING-finger protein 1 or forkhead box proteins. Previous
research has demonstrated that there is an increase in the abundance of the factors
associated with protein degradation with aging in other mammals (179, 180, 296) and in
the post-absorptive versus postprandial state (180). Although we saw lower activation of
the downstream mTOR signaling effectors following a meal stimulus in the two year old
horses in comparison to the mature horses, we expect that the mature horses would also
have elevated rates of muscle protein breakdown, as is seen in other mature species (179,
180, 296); therefore, it is likely that the 2 year old horses were accreting more muscle
protein than the mature horses, despite having a lower activation of the mTOR related
signaling factors.
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Exercise, amino acid, and insulin dependent mechanisms can all stimulate mTOR
phosphorylation (21, 521, 522). In the current study, mTOR may have been
phosphorylated in an insulin- and amino acid-dependent manner because both up- and
down- stream effectors were activated. Although Akt phosphorylation at Thr308 only
showed a trend to increase between the post-absorptive and postprandial states, Akt
phosphorylation at Ser473 was elevated approximately 86% across the age groups with no
difference seen between the age groups. It has been shown that although Akt activation
requires both sites to be phosphorylated, the contribution of each site is not equal (18,
19). Akt P-Thr308 can sufficiently stimulate Akt activation without the phosphorylation
of Ser473; however, the reverse is not true (18, 19). Our results may indicate that Akt may
have already been sufficiently phosphorylated at Thr308 in the post-absorptive state
resulting in a lack of difference at the postprandial state. In agreement with the present
study, Akt P-Ser473 in human skeletal muscle is more responsive to postprandial insulin
concentrations than phosphorylation at the Thr308 site (527); however, further research is
needed to confirm this in horses using a hyperinsulinemic-euglycemic isoaminoacidemic
clamp technique. The use of the hyperinsulinemic-euglycemic isoaminoacidemic clamp
technique would allow for the determination of the responsiveness of skeletal muscle Akt
to administered insulin concentrations independent of other changes that occur in
response to a meal. The phosphorylation of Ser473 Akt results in the mature horses during
the postprandial period are in disagreement with previous results from our lab (2), where
there was no difference from the post-absorptive to postprandial state in the gluteal
muscle of mature horses. The same feed and feeding practices were used in mares of a
similar age in both studies; however, a different population of horses was used. Despite
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the similar postprandial insulin concentrations at the time of biopsy in both groups, the
horses in the previous study (2) may have been more insulin resistant; explaining the
absent change in Akt P-Ser473 with feeding. In future studies, all horses should be
screened for insulin sensitivity prior to being included in the study population.
The absence of an age effect on Akt may be attributed to differences in insulin
sensitivity between the three ages of horses studied. Postprandial insulin concentrations
were higher in the mature horses than the yearlings or two year olds at the time of biopsy;
therefore, we expected the phosphorylation of Akt to be greater in the mature horses than
the yearlings or two year olds, but this was not the case. This may indicate that the
younger age groups had higher insulin sensitivity than the mature horses, which
corresponds with epidemiological studies on the prevalence of obesity and
hyperinsulinemia (528). Furthermore, the majority of obese and hyperinsulinemic horses
are between the ages of 5 and 15 years (528), which is substantially older than a yearling
or a two year old, and similar to the mature horses used in the current study whose
average age was 13.8±2.9 years old. The response of Akt phosphorylation may have also
been maximized at the lower insulin concentrations in the yearlings and two year olds;
however, this requires further investigation.
Insulin alone cannot sufficiently simulate protein synthesis in adults (529, 530);
and because the downstream effectors were significantly elevated in the postprandial
state, it is more likely that the increase in translation initiation was the result of a
combination of increased amino acids and insulin following the high crude protein pellet.
There was no difference in the majority of the circulating plasma indispensable amino
acids at the time of biopsy across the ages; however, the mature horses had an elevated
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S6K1 response compared to the yearlings or two year olds. This may indicate an increase
in amino acid sensitivity with age. However, amino acid sensitivity decreases with
neonatal development in pigs (531), and has been shown to decline from maturity to old
age in humans (155). Therefore, further research is needed using amino acid clamp
techniques, which would allow for a controlled dosage of amino acids, in the horse to
determine if the mature horse truly has increased amino acid sensitivity.
The current study revealed that feeding a high protein diet after an 18 hours
period of feed withholding resulted in an increase in the activation of translation initiation
factors, Akt, S6K1, rpS6 and 4EBP1 in mature, two year old, and yearling horses. This
would suggest that regardless of age there is a postprandial increase in rates of muscle
protein synthesis. The effect of age on the activation of the downstream effectors with a
greater postprandial increase in the yearlings compared to the two year olds may indicate
developmental differences in the responsiveness of muscle protein synthesis to insulin
and amino acids. The mature horses appeared to have a greater postprandial
responsiveness to amino acids and were less sensitive to insulin than the yearlings or two
year old in the activation of translation initiation factors. This finding warrants further
investigation, and it may have implications for designing feeding and management
strategies specific to young adolescent versus mature horses.
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5.5. TABLES
Table 5.1: As-fed nutrient composition of a high crude protein pelleted diet and
nutrient intake from the pelleted diet during the postprandial period in horses that
had feed withheld for 18 hours (mean ± SD values).

Nutrient

Pellet composition*

Nutrient intake†
(mg/kg of bodyweight)

Moisture

9.07 ± 0.31%

Crude protein

33.0 ± 0.53%

1,320 ± 21

Alanine

1.05 ± 0.01%

42 ± 1

Arginine

1.79 ± 0.06%

71 ± 2

Aspartate+asparagine

1.76 ± 0.08%

71 ± 3

Glutamate+glutamine

4.32 ± 0.07%

173 ± 3

Glycine

0.91 ± 0.01%

37 ± 1

Histidine

0.58 ± 0.02%

23 ± 1

Isoleucine

0.90 ± 0.03%

36 ± 2

Leucine

1.96 ± 0.15%

78 ± 6

Lysine

1.36 ± 0.01%

54 ± 1

Methionine

0.32 ± 0.01%

13 ± 1

Proline

1.93 ± 0.09%

77 ± 4

Phenylalanine

1.22 ± 0.01%

49 ± 1

Serine

1.28 ± 0.02%

51 ± 1
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Table 5.1 continued: As-fed nutrient composition of a high crude protein pelleted
diet and nutrient intake from the pelleted diet during the postprandial period in
horses that had feed withheld for 18 hours (mean ± SD values).
Threonine

0.93 ± 0.04%

37 ± 2

Tyrosine

0.85 ± 0.10%

34 ± 1

Valine

0.92 ± 0.01%

37 ± 2

Acid detergent fiber

6.17 ± 0.25%

247 ± 10

Neutral detergent fiber

12.56 ± 0.75%

503 ± 30

Non-fiber carbohydrates

26.2 ± 0.36%

1048 ± 14

Starch

4.67 ± 0.06%

191 ± 2

Water-soluble carbohydrates

8.43 ± 0.15%

337 ± 6

Crude fat

3.47 ± 0.07%

139 ± 2

Ash

15.6 ± 0.26%

624 ± 11

Calcium

3.34 ± 0.13%

134 ± 5

Phosphorus

2.05 ± 0.09%

82 ± 4

Potassium

1.44 ± 0.01%

58 ± 0.2

Sodium

0.682 ± 0.01%

27 ± 0.4

Iron

1263 ± 32 mg/kg

5.05 ± 0.13

Zinc

548 ± 40 mg/kg

2.19 ± 0.16
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Table 5.1 continued: As-fed nutrient composition of a high crude protein pelleted
diet and nutrient intake from the pelleted diet during the postprandial period in
horses that had feed withheld for 18 hours (mean ± SD values).
*

Values represent the amount of the nutrient present as a portion of the total diet on an as-

fed basis. †During the postprandial period, following an 18-hour feed withholding period,
horses were given 2 equal meals of the pelleted feed (targeted total intake of 4 g of
feed/kg of bodyweight), separated by 30 minutes .
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Table 5.2: The effect of an 18 hour feed withholding period followed by either
continued feed withholding (post-absorptive) or subsequent re-feeding of a high
protein pellet (postprandial) on plasma amino acid concentrations at time of biopsy
(80 minutes) in yearling, two year old and mature horses1
Amino Acids

Two
Year
Old
259*

Mature Pooled
SE

Alanine

Post-absorptive
Postprandial
Yearling
Two Mature Yearling
Year
Old
157
163 163
245*

236*

12.3

Arginine

73

70

71

156*

143*

153*

8.3

Asparagine

47

43

43

80*

70*

73*

5.4

Aspartate

4.2a

3.8ab 3.6b

5.7a*

5.7a*

4.8b

0.2

Citrulline

70

65

66

83*

89*

94*

3.8

Glutamate

22ab

24a

19b

26ab*

28a*

23b*

1.5

Glutamine

442

443

420

580*

540*

531*

26

Glycine

579

569

562

610

629

555

23

Histidine

60

57

56

72*

68*

68*

3.2

Isoleucine

67

69

61

97*

102*

88*

4.3

Leucine

120

124

117

161*

170*

152*

6.7

Lysine

107

108

102

197*

200*

196*

11

Methionine

27

28

29

34*

40*

37*

2.5

Ornithine

35

35

33

56*

56*

57*

2.7

Phenylalanine 56

56

52

71*

72*

62*

2.8

Proline

74

70

61

121*

112*

102*

5.2

Serine

186

184

171

245*

234*

231*

11
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Table 5.2 continued: The effect of an 18 hour feed withholding period followed by
either continued feed withholding (post-absorptive) or subsequent re-feeding of a
high protein pellet (postprandial) on plasma amino acid concentrations at time of
biopsy (80 minutes) in yearling, two year old and mature horses1
Taurine

34

35

34

48*

46*

39*

2.1

Threonine

102

102

94

140*

139*

132*

6.7

Tryptophan

10

9.3

9.1

14*

12

11

1.3

Tyrosine

56

49

51

90*

78*

77*

4.4

Valine

205

204

196

258*

259*

251*

8.3

1

Plasma amino acid concentrations are presented as least squares mean values in μmol/L.

a,b

Within a treatment, values with different superscript letters are significantly (P < 0.05)

different.
*Within an age, value is significantly (P < 0.05) different from the value post-absorptive
value.
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5.6. FIGURES

Figure 5.1. Plasma glucose concentrations (mmol/L) in yearling, two year old, and
mature horses that were fed 2g/kg of a high protein pellet at t = 0 and t = 30 minutes
following an 18 hour period of feed withholding. Values are least square means ±
pooled SE, n=6 per age group.
*Indicates that, within an age group, the value is significantly different (P < 0.05) from
the baseline value.
ab

Different letters indicate a significant age effect (P < 0.05) within a time period.

176

Figure 5.2. Plasma insulin concentrations (mIU/L) in yearling, two year old, and
mature horses that were fed 2g/kg of a high protein pellet at t = 0 and t = 30 minutes
following an 18 hour period of feed withholding. Values are least square means ±
pooled SE, n=6 per age group.
*Indicates that, within an age group, the value is significantly different (P < 0.05) from
the baseline value.
ab

Different letters indicate a significant age effect (P < 0.05) within a time period.
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Figure 5.3. Gluteal muscle phosphorylation of Akt at Ser473 in yearling, two year
old, and mature horses that were either fed 2g/kg of a high protein pellet at t = 0 and
t = 30 minutes (postprandial) or had feed withheld for an additional 90 minutes
(post-absorptive) following an 18 hour period of feed withholding. Muscle biopsies
were taken at 90 minutes after t = 0 minutes. Akt phosphorylation at Ser473 was corrected
by total Akt abundance, with the value for the post-absorptive mature horse set at 1.0 AU.
Values are least square means ± pooled SE, n=6 per age group. Representative images of
the immunoblots are shown above.
*Indicates that, within an age group, the value is significantly different (P < 0.05) from
the postprandial value.
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Figure 5.4. Gluteal muscle phosphorylation of Akt at Thr308 in yearling, two year
old, and mature horses that were either fed 2g/kg of a high protein pellet at t = 0 and
t = 30 minutes (postprandial) or had feed withheld for an additional 90 minutes
(post-absorptive) following an 18 hour period of feed withholding. Muscle biopsies
were taken at 90 minutes after t = 0 minutes. Akt phosphorylation at Thr308 was
corrected by total Akt abundance, with the value for the post-absorptive mature horse set
at 1.0 AU. Values are least square means ± pooled SE, n=6 per age group.
Representative images of the immunoblots are shown above.
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Figure 5.5. Gluteal muscle phosphorylation of S6K1 at Thr389 in yearling, two year
old, and mature horses that were either fed 2g/kg of a high protein pellet at t = 0 and
t = 30 minutes (postprandial) or had feed withheld for an additional 90 minutes
(post-absorptive) following an 18 hour period of feed withholding. Muscle biopsies
were taken at 90 minutes after t = 0 minutes. S6K1 phosphorylation at Thr389 was
corrected by total S6K1 abundance, with the value for the post-absorptive mature horse
set at 1.0 AU. Values are least square means ± pooled SE, n=6 per age group.
Representative images of the immunoblots are shown above.
*Indicates that, within an age group, the value is significantly different (P < 0.05) from
the postprandial value.
abc

Different letters indicate a significant age effect (P < 0.05) within a treatment group.
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Figure 5.6. Gluteal muscle phosphorylation of rpS6 at Ser235/236 in yearling, two year
old, and mature horses that were either fed 2g/kg of a high protein pellet at t = 0 and
t = 30 minutes (postprandial) or had feed withheld for an additional 90 minutes
(post-absorptive) following an 18 hour period of feed withholding. Muscle biopsies
were taken at 90 minutes after t = 0 minutes. rpS6 phosphorylation at Ser235/236 was
corrected by total rpS6 abundance, with the value for the post-absorptive mature horse set
at 1.0 AU. Values are least square means ± pooled SE, n=6 per age group.
Representative images of the immunoblots are shown above.
*Indicates that, within an age group, the value is significantly different (P < 0.05) from
the postprandial value.
abc

Different letters indicate a significant age effect (P < 0.05) within a treatment group.
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Figure 5.7. Gluteal muscle phosphorylation of rpS6 at Ser240/244 in yearling, two
year old, and mature horses that were either fed 2g/kg of a high protein pellet at t =
0 and t = 30 minutes (postprandial) or had feed withheld for an additional 90
minutes (post-absorptive) following an 18 hour period of feed withholding. Muscle
biopsies were taken at 90 minutes after t = 0 minutes. rpS6 phosphorylation at Ser240/244
was corrected by total rpS6 abundance, with the value for the post-absorptive mature
horse set at 1.0 AU. Values are least square means ± pooled SE, n=6 per age group.
Representative images of the immunoblots are shown above.
*Indicates that, within an age group, the value is significantly different (P < 0.05) from
the postprandial value.
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Figure 5.8. Gluteal muscle phosphorylation of 4EBP1 at Thr36/47 in yearling, two
year old, and mature horses that were either fed 2g/kg of a high protein pellet at t =
0 and t = 30 minutes (postprandial) or had feed withheld for an additional 90
minutes (post-absorptive) following an 18 hour period of feed withholding. Muscle
biopsies were taken at 90 minutes after t = 0 minutes. 4EBP1 phosphorylation at Thr36/47
was corrected by total rpS6 abundance, with the value for the post-absorptive mature
horse set at 1.0 AU. Values are least square means ± pooled SE, n=6 per age group.
Representative images of the immunoblots are shown above.
*Indicates that, within an age group, the value is significantly different (P < 0.05) from
the postprandial value.
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Chapter VI
Whole body protein metabolism is not different between healthy aging and older
mature horses
6.1. INTRODUCTION
Sarcopenia is the involuntary loss of muscle mass and strength, and has been
partially attributed to a multitude of factors which include a decline in physical activity
and a less than optimal diet in the aging human population (148-150). Similar to aging
humans, horses have also shown a decrease in muscle mass (532). Furthermore, the
number of horses over the age of 20 years old is approximately 7.6% of the equine
population and approaches 20% in some areas (523, 533). Horses over the age of 20
years old typically exhibit visible signs of aging (533). Although there is anecdotal
evidence to suggest that the aging equine population exhibits a decline in physical
activity similar to what is seen in aging humans, there has been limited research
regarding protein requirements. From the few studies that have examined protein
nutrition in the aging equine population, it appears that old horses may have lower
protein digestibility than their mature counterparts (534); however, when studies were
repeated with a different cohort of old horses the results were conflicting (535). As a
result, it is necessary to determine if protein metabolism of the aging horse varies from
the mature counterparts which would be the first step in determining if protein
requirements differ between these groups of horses.
Sarcopenia is a result of an imbalance of protein synthesis and breakdown. The
increase in muscle protein fractional synthesis rates in response to anabolic stimuli such
as exercise (149, 151, 152), amino acids (149, 153), insulin (154), or meal consumption
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(152, 153) is decreased in the aged compared to the younger adult. Additionally,
differences in whole-body protein metabolism suggest that a greater protein requirement
is necessary for the aging human population (487). Systemic inflammation associated
with aging has been associated with lowered rates of muscle protein synthesis (493).
Although the effects of aging on whole-body or muscle protein metabolism have not been
elucidated in the horse, there has been a single study to determine whole-body protein
synthesis rates using stable isotope infusion techniques in the mature horses (Urschel et
al., University of Kentucky, submitted). The most effective way to measure whole-body
protein synthesis is through the use of isotope infusion and stochastic analysis to
calculate parameters of whole-body protein synthesis and breakdown and these methods
have been extensively used in a variety of physiological states in humans (151, 487, 536).
The use of these methodologies may be the first step in determining if the aging equine
has different protein requirements than their mature counterparts.
Protein synthesis is modulated by a series of intracellular signaling cascades that
are associated with the mammalian target of rapamycin (mTOR) pathway. The mTOR
pathway regulates translation initiation and has been the subject of numerous recent
reviews (21, 488, 537). In short, insulin activates Akt (also referred to as PKB) through
the activation of several intermediate signaling proteins (16, 18, 19, 21). Akt activation
occurs when both the Thr308 and Ser473 sites are phosphorylated, and both sites are
activated in association with insulin receptor signaling (18, 19, 21). Activation of Akt
inactivates the mTOR inhibitor tuberous sclerosis complex 2 through phosphorylation
(19, 21); thus, allowing activation of mTOR through phosphorylation. Amino acids (45,
46, 497) and exercise (149, 488, 538) also phosphorylate mTOR through Akt185

independent mechanisms. The activation of mTOR allows for the phosphorylation of
two downstream signaling proteins: ribosomal S6 Kinase 1 (S6K1) and eukaryotic
initiation factor 4E-binding protein-1 (4EBP1). Phosphorylation of S6K1 results in the
activation of ribosomal protein S6 (rpS6) (498), a component of the 40S ribosomal
subunit (498). The phosphorylation of rpS6 and 4EBP1 result in the activation of the
translational equipment and subsequently protein synthesis (21, 537). The activation of
translation initiation factors in the mTOR signaling pathway in response to anabolic
stimuli is reduced with aging (155-157). Although the activation of translation initiation
factors in response to a meal have been examined in adolescent (Chapter V) and mature
(2) equine skeletal muscle, this has not been studied in the aging equine population. The
objective of this study was to determine the effects of aging on the activation of
translation initiation factors, specifically Akt, S6K1, rpS6, and 4EBP1, and whole-body
protein synthesis in mature and aged horses.
6.2. MATERIALS AND METHODS
6.2.1. Animals and housing
The University of Kentucky Institutional Animal Care and Use Committee (20090562) approved all procedures used in this study. Twelve mixed breed horses were
obtained from the University of Kentucky Veterinary Sciences’ Farm: 6 aged (23.5 ± 2.6
y old; 3 geldings and 3 mares) and 6 mature (11 ± 2.6 y old; 3 geldings and 3 mares)
horses. To facilitate sampling procedures, the twelve horses were divided into three
blocks, with 2 horses from each age group (1 mare and 1 gelding) in each block. All
horses were of a moderate body condition (body condition score 5-7, scale 1-9 (489)),
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were clinically healthy with all of their teeth and were able to live outdoors in a group
housing environment, and on a regular farrier, anthelmintic, dental, and vaccination
regimen. Additionally, the pool of candidate horses were screened for plasma αmelanocyte stimulating hormone (α-MSH) concentration, a marker of pituitary pars
intermedia dysfunction (PPID; Equine Cushing’s Disease) (539). Selected horses were
well below the normal cut-off value of < 35 pmol/L (539). Horses were group housed on
dry lots with ad libitum acess to salt and water, and grass hay (mean ± SD; 0.91 ± 0.02
Mcal/kg DE, 8.2 ± 0.8% CP; 48.3 ± 0.3% ADF; 76.5 ± 1.4% NDF; 2.0 ± 0.5% crude
fat;and 7.0 ± 0.5% ash) was provided to the group at 2% of body weight per day. Horses
were brought into 3.7×3.7 m stalls and individually fed the concentrate ration twice daily
at 0800 and 1500. The concentrate ration consisted of a 50:50 mixture of a ration
balancer pelleted feed (Table 6.1) and oats (Table 6.1) at 0.2% of body weight per day.
Horses were adapted to diet and housing protocols for 2 weeks prior to the initiation of
experimental procedures. During the isotope infusion procedures horses were housed in
3.7×3.7 m stalls bedded with pine shavings with ad libitum access to water and salt.
6.2.2. Experimental design and procedures
Following the 2 week adaptation period, horses were removed from the group
housed dry lot at 0800 on day 0, weighed on a portable electronic scale (model 700, Tru
Test Inc., Mineral Wells, TX), put into individual stalls and fed the morning concentrate
meal of 0.1% of body weight and their individual portion of hay at 2% of body weight
per day. Following consumption of the morning concentrate meal, a blood sample was
collected into PAXgene™ Blood RNA tubes (Quiagen, Inc., Santa Clarita, CA) via
jugular vein venipuncture to measure circulating inflammatory cytokines gene
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expression. At 1500, horses were fed their afternoon concentrate meal. Horses remained
in their individual stall during day 1 and were fed in the same manner as on day 0.
On day 2, following consumption of the morning concentrate meal which was
given as previously described, and 2 indwelling jugular vein catheters (14 gauge X 14.0
cm, Abbocath; Abbott Laboratories, North Chicago IL) were placed using aseptic
techniques as previously described (2): one for isotope infusion and one for blood
sampling. Fat thickness on the croup near the site of biopsy was ultrasounded in order to
calculate percent body fat (481). After these procedures were completed, horses were
returned to their stalls and fed their afternoon meal as previously described.
On day 3, the whole-body phenylalanine kinetics were measured using primed,
constant stable isotope infusions. During the course of the whole-body phenylalanine
kinetic measurements, horses were fed the morning concentrate divided into 24 equal
portions, with 1 portion fed every 30 minutes for 7.5 h, with the initial portion was
provided 1.5 h prior to the start of isotope administration. This feeding regimen was used
in order to bring all of the horses to a steady state, which is necessary when using steadystate isotope kinetics. In order to accurately quantify feed intake during the isotope
infusions, hay was removed from the stall during these procedures. Each horse received
a 14.4 μmol/kg priming dose of [13C] sodium bicarbonate solution (Isotec™,
Miamisburg, OH), followed by a 2-h constant infusion at 12 μmol/kg/h in order to
determine total CO2 production(540). This was followed by a 4-h primed (8.4 μmol/kg),
constant (6 μmol/kg/h) infusion of [1-13C]phenylalanine solution (Isotec™, Miamisburg,
OH) to measure whole-body phenylalanine oxidation and flux(541). The primed to
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constant ratio for both [13C] sodium bicarbonate (542) and [1-13C]phenylalanine were
previously determined (Urschel et al., Univerity of Kentucky, submitted). The [13C]
sodium bicarbonate and [1-13C]phenylalanine solutions were individually prepared by
dissolving the isotope into 0.9% sterile saline (Butler Animal Health Supply, Dublin,
OH) and filtering the solution through 0.22 μm sterile filters (Millipore, Billerica, MA)
into empty sterile ethylene vinyl acetate bags (Baxter Healthcare Corporation, Deerfield,
IL). The isotope filled ethylene vinyl acetate bags were attached to a surcingle and
connected to the catheter using a primary IV set (Baxter Healthcare Corporation,
Deerfield, IL). Isotope was delivered into the catheter using pressure sensitive, cordless
intravenous infusion pumps (J-1097 VetPro Infusion Pump, Jorgensen Laboratories Inc.,
Loveland, CO) which was also attached to the surcingle on each horse. This cordless
pump-surcingle system permitted the horses to remain in individual stalls during the
infusion period without restraint.
Two baseline breath samples were collected prior to the [13C] sodium bicarbonate
infusion (-30 min and 0 min), and subsequent breath samples were collected every 30
min throughout the infusion procedures of both [13C] sodium bicarbonate and [113

C]phenylalanine. Breath samples were collected using a modified Equine Aeromask®

(Trudell Medical International, London ON, Canada) enabling the collection of air
through a 1-way valve into impermeable gas bags (Wagner Analysen Technik Vetriebs
GmbH, Bremen, Germany). During breath collection, horses wore the Aeromask® for
approximately 1 minute to allow time for the air in the mask to equilibrate, and then bags
were attached to the 1-way valve and remained there until full (approximately 1 min).
Immediately following each sample collection, another 1/24 meal was provided. Blood
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sampling commenced at t = 90 min into the [13C] sodium bicarbonate infusion, and
continued every 30 min until the end of the [1-13C]phenylalanine infusion. All blood
samples were collected into evacuated vacutainers (Vacutainer; Becton-Dickinson,
Franklin Lakes NJ) containing sodium heparin. The 90 min [13C] sodium bicarbonate
and 0 min [1-13C]phenylalanine blood samples provided 2 baseline samples to measure
the background enrichments of [1-13C] phenylalanine in the blood prior to isotope
infusion.
At the end of the [1-13C]phenylalanine infusion, the infusion pumps were turned
off and the horses were led to a set of equine stocks. Horses were lightly sedated with
xylazine hydrochloride (0.3mg/kg, IV [100mg/mL]; Butler Animal Health Supply,
Dublin, OH), and a gluteal muscle biopsy was collected as previously described (2).
Briefly, the area over the middle gluteal muscle (~100-cm2) was shaved, aseptically
prepared, and desensitized with a local anesthetic (12 mL of 2% lidocaine; Butler Animal
Health Supply, Dublin, OH). Approximately 500 mg of muscle biopsy specimen was
collected at approximately 50% (~8 cm; Chapter III; ChapterV) depth of the middle
gluteal muscle using the percutaneous needle biopsy technique(411). Of this, ~100 mg
was processed in preparation for Western blot analysis, as described below, and ~ 80 mg
was stored in RNAlater (Quiagen, Inc., Santa Clarita, CA) for qRT-PCR analysis of
inflammatory cytokines as described below. The remainder was flash frozen in liquid
nitrogen, and stored at -80ºC until analysis. Catheters were removed following muscle
biopsy collection.
At the end of the sampling period, horses were given the remaining portions of
concentrate and their daily allotment of hay as a single meal, and then returned to the
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drylot. Samples of the grass hay, ration balancer pellet, and oats were collected
throughout the experimental period and sent to Dairy One Forage Laboratory (Ithaca,
NY) for nutrient analysis. For the next 3 days, 2g/d of phenylbutazone was administered
to alleviate any discomfort associated with the sampling procedures.
6.2.3. Sample analysis procedures
6.2.3.1. Blood sample collection and storage: Blood samples collected for qRT-PCR in
PAXgene™ Blood RNA tubes (Quiagen, Inc., Santa Clarita, CA) were gradually frozen
to -80oC per manufacturer instructions and remained at -80oC until analysis. The
remaining blood samples were immediately centrifuged at 1,500 x g for 10 minutes at
4ºC, and aliquots of plasma samples were frozen at -20ºC until the time of analysis.
6.2.3.2. Plasma glucose and insulin: Plasma glucose concentrations were assayed
enzymatically using a YSI 2700 SELECT™ Biochemistry Analyzer (YSI Inc., Life
Sciences, Yellow Springs, Ohio). Plasma insulin concentrations were determined using
Coat-A-Coat RIA®kit (Siemens Healthcare Diagnostics Inc., Deerfield, IL).
6.2.3.3. Amino acids: The plasma free amino acid concentrations were measured using
reverse-phase HPLC (3.9 x 300 mm PICO-TAG reverse phase column; Waters, Milford
MA) of phenylisothiocyanate derivatives as previously described (2). Total amino acid
concentrations of the concentrate, oats, and grass hay were also measured using reversephase HPLC (3.9 x 300 mm PICO-TAG reverse phase column; Waters, Milford MA) of
phenylisothiocyanate derivatives as previously described (2), following 24 hour acid
hydrolysis in 6N HCl at 110oC.
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6.2.3.4. Plasma phenylalanine enrichment: The isotopic enrichment of phenylalanine
(the amount of [1-13C]phenylalanine relative to unlabeled phenylalanine) in the plasma
samples collected on day 3 was determined by Metabolic Solutions, Inc. (Nashua, NH)
using a previously described method (543) which was modified by Matthews, Persola
and Campbell (544). Briefly, the isotopic enrichment of plasma samples were
determined by negative chemical ionization GC-MS analysis of a heptafluorobutyric, npropyl derivative. 1-13C-phenylalanine enrichment was measured using methane negative
chemical ionization GC-MS (Agilent 5973 EI/CI MSD with a Agilent 6890 GC). A
Phenomenex ZB-1MS capillary column was used to separate the derivative of
phenylalanine. Selected ion chromatograms were obtained by monitoring ions m/z 383
and 384 for L-phenylalanine and L-[1-13C]phenylalanine, respectively.
6.2.3.5. Muscle phenylalanine enrichment: Approximately 25-30 mg of flash frozen
muscle tissue was sent to Metabolic Solutions, Inc. (Nashua, NH) for the determination
of mixed-muscle protein and intracellular 1-13C-phenylalanine enrichment (545). Muscle
was homogenized twice in 10% trichloroacetic acid. The protein-free solution was
treated as described above for plasma 1-13C-phenylalanine. The muscle proteins were
hydrolyzed in 6N HCl for 24 h at 110°C. Amino acids were isolated using cationexchange chromatography (50W-x8 resin, Sigma-Aldrich®, St. Louis, MO). Amino
acids were eluted from the resin using 2 ml of 4N NH4OH. Eluates were evaporated to
dryness with nitrogen gas. The heptafluorobutyric, n-propyl derivative of phenylalanine
was prepared as described above.
6.2.3.6. Breath sample analysis: The ratio of 13CO2:12CO2 in the breath samples
(Appendix 7) was determined using an isotope selective non-dispersive infrared
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absorption (NDIR) analyzer (IRIS-2; Wagner Analysen Technik Vetriebs GmbH,
Bremen, Germany).
6.2.3.7. Western blot analysis of muscle samples: The abundance of the total and
phosphorylated forms of Akt, S6K1, rpS6, and 4E-BP1 in the gluteal muscle
homogenates were determined using electrophoresis followed by Western blotting
techniques (Chapter III)
6.2.3.8. RNA isolation: Total RNA was isolated from PAXgene™ tubes using the
PAXgene™ RNA Blood Kit (Quiagen, Inc., Santa Clarita, CA). Muscle samples that had
been stored in RNAlater (Quiagen, Inc., Santa Clarita, CA) were homogenized using the
bead beating technique (510) into the RNA-Stat60 solution (Tel- Test, Friendswood, TX).
Total RNA was then isolated and quantified from both types of samples as previously
described (Chapter IV). Reverse transcription reactions were performed as previously
described (Chapter IV).
6.2.3.9. Real time polymerase chain reaction: The mRNA expressions of pro inflammatory cytokines, IFN-γ, IL-1β, IL-6 and TNFα, and the anti-inflammatory
cytokine IL-10 were measured in cDNA samples using equine specific intron-spanning
primer/probe sets (Chapter IV). Differences in RNA isolation and cDNA construction
between samples were corrected with the use of an internal control β-glucorindase for
each sample ((244, 484); ChapterIV).
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6.2.4. Calculations and statistical analysis
6.2.4.1. Fat free mass: Body fat percentage was determined using the following
equation:
Fat (%) = [5.4 × ultrasonic fat depth in cm) + 2.47] (546).
Once determined, body fat percentage was used to calculate fat mass from total body
mass:
Fat mass (kg) = Fat (%) × body mass (kg).
Fat-free mass was determined by difference of body mass and fat mass.
6.2.4.2. Plasma phenylalanine enrichment: Isotope enrichment in mol percent excess
was calculated from peak area ratios at isotopic steady state and baseline. The final value
for all determinations was corrected using an enrichment calibration curve (Appendix 7).
6.2.4.3. Breath CO2 enrichment: The δ enrichment value obtained from the NDIR
analyzer for each sample was converted to a % enrichment:
Enrichment (%) = [0.0112372δ/(0.0112372δ + 1000)] × 100% ((547); Urschel et al.,
University of Kentucky, submitted).
Then, total CO2 production (FCO2) was calculated based on breath CO2 enrichment using
the following equation:
FCO2 = i × [(Ei/Eb) – 1] (Appendix 7).
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Where, i was the rate of isotope administration in μmol/kg/min, Ei was the enrichment of
the isotope in the solution and Eb was the enrichment of the breath samples at plateau,
corrected for baseline enrichment ((540, 542, 547); Urschel et al., University of
Kentucky, submitted)
6.2.4.4. Whole-body phenylalanine kinetics: The average plasma enrichment at isotopic
steady state (plateau) was used to calculate whole-body phenylalanine kinetics. This
plateau in phenylalanine enrichment included at least 3 values and was defined as not
having a slope statistically different from 0 (P > 0.05), determined single linear
regression analysis (GraphPad Prism 4; GraphPad Software, La Jolla CA). These plateau
enrichment values were then used to calculate the whole-body phenylalanine flux:
Flux (Q; μmol/kg/h) = i × [(Ei/Ep) – 1 (Appendix 7),
where I was the rate of isotope infusion (in μmol/kg/h), Ei was the enrichment of infused
isotope, and Ep was the plateau plasma enrichment. Flux includes the amount of amino
acids entering the pool through dietary intake (I), de novo synthesis (N), and protein
breakdown (B), or leaving the pool through protein synthesis (Z), oxidation (E), or the
conversion to other metabolites:
Q = I + N B = Z + E + M.
In order to account for the ~50% of dietary phenylalanine that is extracted during firstpass splanchnic metabolism in other monogastric species ((548, 549); Urschel et al.,
Univeristy of Kentucky, submitted), the amount of phenylalanine entering the plasma free
amino acid pool from dietary intake was estimated by multiplying dietary intake by 0.5.
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De novo synthesis of phenylalanine does not occur in horses because it is a dietary
indespensible amino acid; therefore, phenylalanine released into the free amino acid pool
as a result of protein breakdown can be estimated using the following equation:
B = Q – I,
where I is phenylalanine intake corrected for first-pass splanchnic extraction.
The rate of [1-13C]phenylalanine oxidation to 13CO2 (F13CO2) was calculated:
F13CO2 = FCO2 × ECO2 ((550); Urschel et al., University of Kentucky, submitted)
(Appendix 7),
where ECO2 was the average enrichment of the breath samples at isotopic steady state
(minimum of 3 points, with a slope not different from zero), corrected for baseline
enrichment, during the [1-13C]phenylalanine infusion. Then, whole-body phenylalanine
oxidation was calculated using the following equation:
O = F13CO2 × (1/Ep – 1/Ei) × 100 ((550); Urschel et al., University of Kentucky,
submitted) (Appendix 7).
Non-oxidative phenylalanine metabolism can be calculated through the difference
between phenylalanine flux and oxidation, and this can be used as an indicator of wholebody phenylalanine use for protein synthesis. The major non-CO2 product of
phenylalanine is tyrosine, and since all horses were consuming the same diet, and
tyrosine is not generally considered to be a limiting amino acid in any other monogastric
species, it was assumed that phenylalanine conversion to tyrosine was minimal.
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Therefore, any change in non-oxidative phenylalanine disposal was assumed to signify
changes in phenylalanine use for whole-body protein synthesis.
6.2.4.5. Relative quantity of inflammatory cytokines: Changes in mRNA expression
were calculated using the ΔΔCT method (484), with the mean ΔCT averaged for mature
horses set as the calibrator for each individual cytokine. Results are expressed as relative
quantity (RQ) calculated as 2-ΔΔCT (Chapter IV).
6.2.4.6. Statistics: All data were analyzed using the mixed procedure of SAS Version
9.2 (SAS Institute Inc., Cary, NC), with statistical significance and trends considered if P
< 0.05 and 0.05 < P < 0.10, respectively. When the fixed effects were significant, preplanned comparisons of least squares means were made using the pdiff test. All of the
dependent variables were analyzed using an ANOVA with the fixed effect of age and
horse nested in age and block as the random subject. Data are presented as means ±
pooled standard error, unless otherwise noted.
6.3. RESULTS
6.3.1. Equine demographics
The two age groups were only statistically different in age. There was no effect
of age (P > 0.05) on body weight (mature: 469±30 kg; aged 499±30 kg) or fat free mass
(mature: 421±26 kg; aged 448±26 kg). The measurement of fat free mass indicates that
the mature and aged animals used in this study were moderately lean. α-MSH
concentrations were well below (mature:10.1± 1.8 pmol/L; aged: 9.5 ± 1.8 pmol/L) the <
35 pmol/L cut-off value to exclude potentially PPID horses(539).
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6.3.2. Plasma insulin, glucose, and amino acids
Plasma insulin, glucose, and amino acid concentrations were measured in the final
blood sample of the [1-13C] phenylalanine infusion, immediately prior to biopsy. Plasma
insulin (P = 0.53; Table 6.2) and glucose (P = 0.43; Table 6.2) concentrations at the time
of biopsy were not affected by age. However, there was a significant effect of age on the
plasma concentrations of isoleucine (P = 0.05; Table 6.2) and lysine (P = 0.04; Table
6.2), where both were elevated in the aged compared to the mature group. Additionally,
there was a trend for elevated plasma concentrations of asparagine (P = 0.08; Table 6.2)
and phenylalanine (P = 0.08; Table 6.2) in the aged horses. The remainder of the amino
acids were not affected by age (P > 0.05; Table 6.2).
6.3.3. Inflammatory cytokines
Age did not affect mRNA expression of the circulating inflammatory cytokines
IL-1β (P = 0.92; Table 6.3), IL-6 (P = 0.90; Table 6.3), IL-10 (P = 0.20; Table 6.3), IFNγ
(P = 0.30; Table 6.3), and TNFα (P = 0.38; Table 6.3). Additionally, there was no effect
of age on the mRNA expression of muscle IL-1β (P = 0.53; Table 6.3), IL-10 (P = 0.23;
Table 6.3), IFNγ (P = 0.49; Table 6.3), and TNFα (P = 0.58; Table 6.3). There was
limited detection of muscle IL-6 mRNA expression where expression was detected in
only 3 mature horses and a single aged animal.
6.3.4. Activation of translation initiation factors
There was no effect of age on the activation of Akt at Ser473 (P = 0.33; Figure 6.1)
and Thr308 (P = 0.83; Figure 6.1), rpS6 at Ser235/236 & 240/244 (P = 0.48; Figure 6.1), or
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4EBP1 at Thr37/46 (P = 0.13; Figure 6.1). However, the activation of S6K1 at Thr389 was
significantly lower (P = 0.03; Figure 6.1) in the aged compared to the mature horses.
6.3.5. Whole-body protein synthesis
There was no effect of age on whole-body CO2 production (P = 0.51; Table 6.4),
phenylalanine flux (P = 0.84; Table 6.4), phenylalanine oxidation (P = 0.15; Table 6.4),
phenylalanine release from protein breakdown (P = 0.99; Table 6.4) or non-oxidative
phenylalanine disposal (P = 0.48; Table 6.4).

6.3.6. Muscle phenylalanine enrichments
There was no effect of age on the free (P = 0.53; mature: 11.1±0.8%; aged:
10.3±0.8%) or protein bound (P = 0.62; mature: 0.3±0.1%; aged: 0.4±0.1%) enrichment
of [1-13C] phenylalanine in the gluteal muscle. Because we only collected a single biopsy
at the end of the isotope infusion period, we could not calculate the change in the protein
bound phenylalanine enrichment, which is necessary to calculate muscle protein
fractional synthesis rates. However, if we assume that there were no initial differences in
muscle bound enrichments of [1-13C] phenylalanine between the age groups, the lack of a
difference between the ages in both free and protein bound muscle enrichment of [1-13C]
phenylalanine indicates no difference in muscle protein fractional synthesis rates between
the age groups.
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6.4. DISCUSSION
To the best of the authors’ knowledge this is the first time that whole-body protein
kinetics and mTOR signaling have been examined in the aging horse. There were no
differences in the whole-body protein kinetics of the mature and aged horses; however
the phosphorylation of the downstream mTOR signaling factor, S6K1, was lower in the
gluteal muscle of the aged compared to the mature horses following 7.5 hours of steady
state feeding.
Numerous studies of the effects of aging in humans have studied aging
populations with different demographics than the mature population. Body fat mass and
weight were elevated in the aging populations of these previous studies (156, 185, 204);
however, in the present study there were no differences in the aged compared to the
mature group for any measurement of body mass. Additionally, all of the aged horses in
the current study were clinically normal with no signs of PPID, as plasma α-MSH
concentrations were within the clinically normal reference range (539). Although aging
is typically characterized by low grade chronic inflammation, specifically elevations in
the mRNA expression of circulating IL-1, IL-6, and TNFα (483, 493, 495), there were no
differences in the mRNA expression of circulating or muscle inflammatory cytokines
between the mature and aged horses in the current study. Previous studies (483) in horses
have demonstrated age related differences in circulating inflammatory cytokine
expression; however the mature population in the previous study (483) was younger (4.5
years old) than the mature group in the current study (11 years old). Furthermore, the
aged horses were mobile, had all of their teeth, and were thriving in an outdoor group
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housing environment, indicating that the aging population in the current study was in a
healthy aging state.
The similar demographics and health status of the mature and aged groups used in
the present study may explain the unexpected result of no significant difference in any of
the markers of whole-body protein kinetics. It has been previously demonstrated that up
to 87% of the variance seen in whole-body protein kinetics can be attributed to fat free
mass(151). Further, muscle protein fractional synthesis rates in lean young adult (20
years old) and aged lean men (75 years old) following the co-ingestion of a protein and
leucine supplement are not different (209). Leucine oxidation and fractional synthesis
rates of sarcoplasmic proteins do not differ between middle aged (52 years old) and aged
(77 years old) humans (200). The results from previous studies (200, 201) support the
present findings that the narrow age range, and similar physical characteristics of the
subjects were likely a cause of no significant difference in phenylalanine kinetics.
Of all of the translation initiation factors studied, S6K1 appears to be the most
influenced by aging. The phosphorylation of S6K1 at Thr389 was reduced by 42% in the
aged horses compared to the mature horses, which has also been demonstrated in aged
(30 mo) and very aged (36 mo) male rodent soleus muscle (551). Additionally, the
phosphorylation of S6K1 in response to amino acids and insulin does not increase from
the basal state in aging humans (156), or following a meal in aged rats with and without
low grade chronic inflammation (493). The significant reduction in the abundance of
S6K1 P-Thr389 without an increase in inflammatory cytokines in the aged horse may
indicate that the effect of aging on S6K1 occurs through some other mechanism;
however, this requires further elucidation.
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The effect of aging on S6K1 phosphorylation in the absence of an effect on
whole-body protein synthesis may indicate that examining protein synthesis at the whole
body level masked the possible changes occurring in skeletal muscle. Although skeletal
muscle comprises approximately 50% of body weight, there is only about a 25%
contribution to whole-body protein synthesis (198, 199); therefore, without drastic
changes at the skeletal muscle level there will not be alterations at the whole-body level
or if another tissue decreases its rate of protein synthesis and the muscle increases its rate
of protein synthesis then there would be no net effect at the whole-body level. The
significant reduction in the abundance of S6K1 P-Thr389, without similar indications of
change in muscle fractional synthesis rates or whole-body protein synthesis, requires
further elucidation.
No age differences were detected in the activation of Akt, rpS6, and 4EBP1. The
lack of an effect of age on Akt, rpS6, and 4EBP1 may be attributed to the narrow age
range between the mature and aged horses in the current study, which has also been
demonstrated in middle aged and aged rodents (551). Additionally, the lack of elevated
circulating and muscle inflammatory cytokines in the aged group compared to the mature
group may also explain the absence of an age effect on the activation of Akt, rpS6, and
4EBP1 because inflammatory cytokines stimulate NF-κB activation which inhibits the
phosphorylation of Akt (517). Although NF-κB was not examined in this study, the lack
of an age effect on inflammatory cytokines may explain the absence of an age effect on
Akt, rpS6, and 4EBP1 activation.
The experimental protocol used in the current study may have concealed any
differences in the activation of translation initiation factors and whole-body protein
202

synthesis that were possibly present. For 7.5 hours prior to biopsy collection, horses
received half of their daily concentrate allocation (0.1% BW) divided into 1/24 portions
every 30 minutes. Because the whole diet was primarily hay based (2% BW), each of
these small concentrate meals only met 0.5% and 0.37% of the daily CP and digestible
energy requirement, respectively. Feeding small meals throughout the isotope infusion
procedures may at least partially explain the lack of an age effect on the phosphorylation
of Akt, rpS6, and 4EBP1, or whole-body protein synthesis rates as it may not have been a
strong enough anabolic stimulus. In mature horses, the consumption of a larger high
protein meal (4g/kg) did result in the activation of translation initiation factors in the
skeletal muscle of mature horses (2) and it is unknown whether the magnitude of this
activation may have been lower in the old horses of the present study. This phenomenon
is seen during development when yearlings and two year olds consumed 4 g/kg of a high
protein meal the activation of translation initiation factors was greater in the yearling
horses compared to two year olds (Chapter V). The plasma glucose (mature: 5.5 ± 0.28
mmol/L, aged: 5.3 ± 0.28 mmol/L), insulin (mature: 5.8 ± 0.8 μIU/mL; aged: 6.1 ± 0.8
μIU/mL), and total indispensable amino acid (mature: 543 ± 40 μmol/L; aged: 670 ± 40
μmol/L) concentrations at the time of biopsy more closely resembled concentrations of
mature horses in the post-absorptive state (glucose: 5.5 mmol/L; insulin: 5 mU/L; total
indispensable amino acids: 898 μmol/L) (2) rather than the postprandial state (glucose:
6.5 mmol/L; insulin: 36 mU/L; total indispensable amino acids: 1245 μmol/L) (2).
Additionally, non-oxidative disposal, the indirect measure of protein synthesis, was less
than phenylalanine release from protein breakdown which is characteristic of the postabsorptive state (185). Because the horses were in a physiological state more similar to
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the post-absorptive state, then our results are consistent with previous findings that there
are no age-related differences in the activation of translation initiation factors or protein
synthesis during the post-absorptive state (156, 157, 204). Further research is necessary
to determine if age related changes in the activation of translation initiation factors or
whole-body protein synthesis exist in horses during a true postprandial state.
Although we did not see differences in whole-body protein synthesis or
breakdown, there may have been differences in the molecular markers of muscle protein
degradation, which we did not measure. Muscle loss traditionally associated with aging
occurs when there is an imbalance in muscle protein synthesis and breakdown, and
because there was no difference in the activation of translation initiation factors with the
exception of S6K1, which may be enough to reduce skeletal muscle protein synthesis,
differences in the molecular markers of muscle protein degradation (muscle-RING-finger
protein 1 or forkhead box proteins) may also contribute for the loss of muscle seen with
aging. Aging rodents have elevated proteasome content and activity and free ubiquitin
and ubiquitylated protein concentrations in skeletal muscle than mature rodents (179).
The aged also have higher abundance of forkhead box proteins than the mature
counterparts (35). Additionally, ubiquitination rate is greater in the post-absorptive state
than the postprandial state in the aged rodent whereas the mature rodents are not affected
by physiological state (180). Because our horses were in a state more similar to the postabsorptive state is possible that our aging may have had elevated molecular markers of
muscle protein breakdown. The lack of a difference in body composition between the
mature and aging horses in the current study may indicate that over the course of an
entire day protein synthesis is equal to protein degradation because our horses were
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clinically healthy; however, this requires further investigation. Additionally, further
investigation is warranted to determine if aging horses have increased skeletal muscle
proteolysis which may account for reduced muscle mass traditionally seen in this
population.
The implications of the current findings are that clinically healthy aging horses
may not require different management practices than their mature counterparts. Previous
research (534) has indicated that aged horses have lowered protein digestibility than
mature horses. However, when the same research group repeated the study 12 years
later, there was no difference in protein digestibility between the two age groups (535).
The authors attributed the differences in the results to the fact that the aged horses in the
initial study may have endured intestinal damage during their youth, growing up prior to
the use of regular anthelmintics. As a result, the most recent edition of the NRC (336)
does not indicate differing requirements between mature and aged horses. Our results
show that there are no differences in whole-body protein metabolism, which may imply
that the protein requirements do not differ between healthy aging and mature horses;
however, further research is needed to specifically determine individual amino acid
requirements during aging.
The clinically healthy aging horses in the current study were similar to their
mature counterparts; however, the growing aging equine population contains horses with
PPID at a rate of 15 to 30% (552). PPID horses are typically insulin resistant,
hyperglycemic, have abnormal fat deposits, are susceptible to laminitis, and have
elevated cortisol levels and muscle atrophy (552). To the best of the authors’ knowledge,
there is currently no literature pertaining to the activation of translation initiation factors
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or protein synthesis in this population. Although clinically healthy aging horses did not
differ from mature horses and thus may not require different management practices,
symptoms of the aging horse with PPID may affect Akt and mTOR signaling and wholebody protein metabolism. Protein metabolism in the less healthy aged horse is an area
where additional research is warranted.
Aging appears to affect equine skeletal muscle similar to both humans and rodents
in that S6K1 activation is lowered, which could impair muscle protein synthesis, although
there was not evidence of this in the present study. Additionally, healthy aging horses do
not have differences in circulating or muscle inflammatory cytokine mRNA expression
compared to older mature counterparts (~13 years old) which may have resulted in
similar whole-body protein synthesis rates. Although additional research is needed to
determine age-related differences in muscle protein metabolism in response to a larger
anabolic stimuli, these findings indicate that healthy older horses have similar wholebody protein metabolism and requirements to the mature horse.
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6.5. TABLES
Table 6.1: As-fed nutrient composition of ration balancer pellet and oat diet fed to
the horses during the 7.5 hours of steady state feeding prior to muscle biopsy
collection

Nutrient

Ration balancer pellet

Oat composition,1

composition,1

(mean ± SD values)

(mean ± SD)
Moisturea

9.5 ± 0.2%

11.2 ± 0.3%

Digestible energya

2.76 ± 0.01 Mcal/kg

3.15 ± 0.06 Mcal/kg

Crude proteina

17.0 ± 0.3%

13.4 ± 1.9%

Alanineb

0.51 ± 0.03%

0.35 ± 0.04%

Arginineb

0.56 ± 0.03%

0.49 ± 0.07%

Aspartate+asparagineb

0.81 ± 0.04%

0.58 ± 0.04%

Glutamate+glutamineb

1.50 ± 0.06%

1.43 ± 0.14%

Glycineb

0.44 ± 0.02%

0.35 ± 0.05%

Histidineb

0.24 ± 0.01%

0.16 ± 0.03%

Isoleucineb

0.37 ± 0.02%

0.25 ± 0.04%

Leucineb

0.75 ± 0.02%

0.54 ± 0.08%

Lysineb

0.41 ± 0.02%

0.27 ± 0.04%

Methionineb

0.09 ± 0.01%

0.09 ± 0.01%
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Table 6.1 continued: As-fed nutrient composition of ration balancer pellet and oat
diet fed to the horses during the 7.5 hours of steady state feeding prior to muscle
biopsy collection
Prolineb

0.71 ± 0.04%

0.40 ± 0.06%

Phenylalanineb

0.47 ± 0.02%

0.37 ± 0.06%

Serineb

0.47 ± 0.01%

0.37 ± 0.05%

Threonineb

0.35 ± 0.02%

0.23 ± 0.05%

Tyrosineb

0.29 ± 0.02%

0.21 ± 0.04%

Valineb

0.47 ± 0.03%

0.32 ± 0.05%

Acid detergent fibera

18.4 ± 1.1%

11.0 ± 0.9%

Neutral detergent fibera

32.5 ± 2.8%

23.3 ± 2.2%

Non-fiber carbohydratesa

45.1 ± 2.4%

63.8 ± 2.7%

Starcha

29.7 ± 3.0%

56.0 ± 3.8%

Water-soluble carbohydratesa

7.1 ± 0.5%

4.2 ± 0.8%

Crude fata

6.2 ± 0.2%

8.4 ± 0.7%

Asha

9.6 ± 0.1%

3.6 ± 0.9%

Calciuma

1.15 ± 0.03%

0.24 ± 0.20%

Phosphorusa

0.64 ± 0.04%

0.32 ± 0.06%

Potassiuma

1.81 ± 0.01%

0.62 ± 0.06%

Sodiuma

0.33 ± 0.04%

0.12 ± 0.15%

208

Table 6.1 continued: As-fed nutrient composition of ration balancer pellet and oat
diet fed to the horses during the 7.5 hours of steady state feeding prior to muscle
biopsy collection
Irona

509 ± 13 mg/kg

157 ± 47 mg/kg

Zinca

62 ± 5 mg/kg

35 ± 5 mg/kg

1

Values represent the amount of the nutrient present as a portion of the total diet on an as-

fed basis. Horses received 0.1% of body weight/day of the ration balancer pellet and the
oats, individually, which resulted in a total of 0.2% of body weight/day.
a

Proximate analysis of the feed was conducted by Dairy One Forage Laboratory (Ithaca,

NY).
b

Amino acid content of the feed was determined using high performance liquid

chromatography analysis following an acid hydrolysis of the feed sample, as described in
Materials and Methods.

209

Table 6.2: Plasma metabolite concentration at the time of biopsy in mature and aged
horses
Metabolite

Mature

Aged

Insulin1

5.8

6.1

Pooled
SEM
0.8

Glucose2

5.5

5.3

0.28

Alanine3
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218

24

Arginine

69

74

5.8

Asparagine

38

52†

4.9

Aspartate

19

14

2.4

Citrulline

83

91

8.3

Glutamate

54

49

6.3

Glutamine

273

306

27

Glycine

352

441

39

Histidine

58

64

2.8

Isoleucine

33

46*

3.9

Leucine

68

87

7.4

Lysine

69

92*

6.9

Methionine

26

32

2.8

Ornithine

34

44

4.8

Phenylalanine 68

83†

5.4

Proline

90

97

7.6

Serine

232

288

23

Taurine

21

28

3.4
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Table 6.2 continued: Plasma metabolite concentration at the time of biopsy in
mature and aged horses
Threonine

94

112

11

Tryptophan

4.7

5.3

0.4

Tyrosine

50

55

5.0

Valine

121

148

12

1

Plasma insulin concentrations are reported as least square means in μIU/mL.

2

Plasma glucose concentrations are reported as least square means in mmol/L.

3

Plasma amino acids concentrations are reported as least square means in μmol/L.

*Indicates the aged horse value is significantly (P < 0.05) different from the mature horse
value.
†

Indicates the values in the aged horses showed a trend (P < 0.10) to be different from the
mature horse values.
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Table 6.3: Relative quantities of circulating and gluteal muscle inflammatory
cytokines of mature and aged horses1
Inflammatory Cytokine

Mature

Aged

Pooled SEM

IFNγ

1.23

1.58

0.22

TNFα

1.11

1.35

0.18

IL-6

1.63

1.71

0.77

IL-1β

1.16

1.14

0.13

IL-10

1.21

0.72

0.22

IFNγ

1.02

1.5

0.43

TNFα

0.43

0.64

0.23

IL-1β

2.61

5.06

2.53

IL-10

0.24

0.52

0.17

Circulation

Muscle

1

Values are least squares means ± SEM.

212

Table 6.4: Whole-body phenylalanine kinetics in mature and aged horses1.
Mature

Aged

Pooled SEM

41.5

42.2

2.3

15080

1410

Phenylalanine flux [μmol/(kg·h)]

Carbon dioxide production [μmol/(kg·h)]
16977

Phenylalanine entering the free phenylalanine pool [μmol/(kg·h)]2
Phenylalanine from dietary intake 4.0

3.9

0.08

Phenylalanine from protein

37.5

2.2

37.5

breakdown
Phenylalanine leaving the free phenylalanine pool [μmol/(kg·h)]2
Phenylalanine oxidation

13.2

16.7

1.6

Non-oxidative phenylalanine

28.3

25.5

2.7

disposal
1

Values are least squares means ± SEM.

2

The following stochastic model of phenylalanine kinetics was used: flux = rate of

phenylalanine entry = rate of phenylalanine leaving; rate of phenylalanine entry =
phenylalanine intake + phenylalanine release from protein breakdown; rate of
phenylalanine leaving = phenylalanine oxidation + non-oxidative phenylalanine disposal.
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6.6. FIGURES
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Figure 6.1. Gluteal muscle phosphorylation of Akt at Ser473, Akt at Thr308, S6K1 at
Thr389, rpS6 at Ser235/236 & 240/244, and 4EBP1 at Thr 37/46 in mature and aged horses
following 7.5-hours of steady state feeding. The phosphorylated forms of the
translation initiation factors was corrected by the respective total form abundance, with
the value for mature horses set at 1.0 AU. Values are least square means ± pooled SE,
n=6 per age group. Representative images of the immunoblots are shown above.
*Indicates that, within a translation initiation factor, the value is significantly different (P
< 0.05) from the mature horse value.
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Chapter VII
Whole body protein synthesis is improved following non-steroidal anti-inflammatory
drug administration to aging horses
7.1. INTRODUCTION
Aging has been associated with low grade chronic inflammation in humans (495),
rodents (493), and horses (483) and is referred to as “inflamm-aging”. Chronic
inflammation is characterized by elevated levels of circulating inflammatory cytokines,
which have been linked with decreased physical performance and increased incidence of
injury (553, 554), as well as with the development of sarcopenia in the elderly (553) and
in aged horses (532). Additionally, the population of aging horses has been estimated at
7.6% and in some regions over 20% of all horses (523, 533). Older horses may
demonstrate visible signs of aging such as loss of muscle mass and are usually horses
over the age of 20 years old (523). Sarcopenia is the involuntary loss of muscle mass and
strength, and has been partially attributed to a multitude of factors which include a
decline in physical activity and a less than optimal diet (149, 150, 553), and results from
a shift in the balance between protein synthesis and breakdown. Sarcopenia has been
partly attributed to reduced protein synthesis and activation of translation initiation
factors in response to anabolic stimuli such as amino acid administration (149, 155),
insulin (165), or exercise (149, 538). Further, systemic inflammation in the aged has also
been associated with decreased activation of translation initiation factors in response to
various anabolic stimuli (155) and with lower rates of muscle protein synthesis (493);

215

however, the effects of aging on muscle protein metabolism have not been fully
elucidated in the horse.
Protein synthesis is limited by both the abundance and efficiency of ribosomes to
translate mRNA into protein and the availability of amino acids to form a protein (128),
which is regulated by a series of intracellular signaling cascades associated with the
mammalian target of rapamycin (mTOR) pathway. Insulin and insulin like growth factor
phosphorylate Akt through the activation of several intermediate signaling proteins (16,
18, 19, 21). Activation of Akt inactivates the mTOR inhibitor tuberous sclerosis complex
2 through phosphorylation (19, 21), allowing for the phosphorylation of mTOR. The
phosphorylation of mTOR can also be stimulated by amino acids (45, 46, 497) and
exercise (149, 488, 538), through separate Akt-independent mechanisms. Phosphorylated
mTOR phosphorylates and activates two downstream signaling proteins: ribosomal S6
Kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein-1 (4EBP1).
Phosphorylation of S6K1 results in the activation of ribosomal protein S6 (rpS6) (498), a
component of the 40S ribosomal subunit (498). Therefore, the phosphorylation of rpS6
and 4EBP1 result in the activation of the translational equipment, allowing protein
synthesis (21, 537).
The decline in the responsiveness of translation initiation factors and subsequent
protein synthesis to various anabolic stimuli with aging in rodents (538) and humans
(149, 155) has been associated with elevated systemic inflammation (155, 493). In aged
rodents with systemic inflammation, the administration of a NSAID was able to increase
muscle protein synthesis (335), but to the best of our knowledge, this has not been
studied at the whole-body level in any species. We hypothesized that daily NSAID
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administration would reduce systemic and muscle inflammation in aged horses and
increase whole-body and muscle protein synthesis. The objective of this study was to
determine the effects of NSAID administration over 4 weeks on the activation of mTOR
signaling and whole-body protein synthesis in aged horses.
7.2. MATERIALS AND METHODS
7.2.1. Animals, housing, and feeding
The University of Kentucky Institutional Animal Care and Use Committee (20090562) approved all procedures used in this study. Six mixed breed aged (23.5 ± 2.6 y
old; 3 geldings and 3 mares) horses were obtained from the University of Kentucky
Veterinary Sciences’ Maine Chance Farm. Prior to selection, the pool of candidate
horses were screened for plasma α-melanocyte stimulating hormone concentration, a
marker of pituitary pars intermedia dysfunction (PPID; Equine Cushing’s Disease) (539,
555), and horses below the normal cut-off value of < 35 pmol/L were selected (539,
555). Selected horses were of a moderate body condition (body condition score 5-7,
scale 1-9 (489)), were clinically healthy with all of their teeth and the ability to live
outdoors in a group housing environment, and on a regular farrier, anthelmintic, dental,
and vaccination regiment. Horses were group housed on dry lots with ad libitum acess to
salt and water. Grass hay (mean ± SD; 0.91 ± 0.02 Mcal/kg DE, 8.2 ± 0.8% CP; 48.3 ±
0.3% ADF; 76.5 ± 1.4% NDF; 2.0 ± 0.5% crude fat; and 7.0 ± 0.5% ash) was provided to
the group at 2% of body weight per day and omeprazole (Gastroguard® Merial Limited,
Duluth, GA) was administered at preventative dose rate of 1.2 mg/horse/d. Horses were
brought into 3.7×3.7 m stalls and individually fed the concentrate ration twice daily at
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0800 and 1500. The concentrate ration consisted of a 50:50 mixture of a ration balancer
pelleted feed (Chapter VI) and oats (Chapter VI) at 0.2% of body weight per day. Horses
were adapted to diet, omeprazole administration and housing protocols for 2 weeks prior
to the initiation of experimental procedures. During the isotope infusion procedures
horses were housed in 3.7×3.7 m stalls bedded with pine shavings with ad libitum access
to water and salt.
7.2.2. Experimental procedures
There were 3 sampling periods before NSAID administration commenced (0
week of NSAID administration), and then following 2 and 4 weeks of NSAID
administration. The following sampling procedures which were described in detail
(Chapter VI) were repeated during each of the sampling periods. Briefly, at 0800 on day
0, following the two week adaptation, horses were weighed fed the morning concentrate
meal at 0.1% of body weight and their individual portion of hay at 2% of body weight per
day in individual stalls. Horses remained in stalls throughout the sampling period. At
this time a blood sample was collected into PAXgene™ Blood RNA tubes (Quiagen,
Inc., Santa Clarita, CA) via jugular vein venipuncture to measure circulating
inflammatory cytokines via qRT-PCR analysis, described below. Horses were fed their
afternoon concentrate meal at 1500. On d1, horses remained in the individual stalls and
received feed as described above.
On day 2, horses were individually fed the morning concentrate meal as described
above. Following morning meal consumption, two indwelling jugular vein catheters (14
gauge X 14.0 cm, Abbocath; Abbott Laboratories, North Chicago IL) were placed using
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aseptic techniques as previously described (2): one for isotope infusion and one for blood
sampling. At this time, fat thickness on the croup near the site of biopsy was
ultrasounded in order to calculate percent body fat (481). At 1100 all forage, water and
salt were removed, and 2 hours later a baseline blood sample (10 mL) was collected into
an evacuated vacutainer (Vacutainer; Becton-Dickinson, Franklin Lakes NJ) containing
sodium heparin prior to the bolus intravenous administration of deuterium oxide (SigmaAldrich, St. Louis, MO) at 0.15 g/kg BW. Three hours following deuterium oxide
infusion a second blood sample was collected, in order to determine changes in total body
water, as an indicator of body composition alterations, during the 4 weeks of NSAID
administration. Deuterium oxide infusion measurements were performed during the 0
and 4 week sampling period. Salt, water and forage were returned at 1630 with the
addition of the evening concentrate meal. The removal of all feed and water was
necessary for the measurement of body water using deuterium oxide isotope techniques.
On day 3, whole-body phenylalanine kinetics were measured using primed,
constant stable isotope infusions as previously described (Chapter VI). During the
whole-body phenylalanine kinetic measurements, horses were fed half of the daily
concentrate allocation divided into 24 equal portions, with 1 portion fed every 30 minutes
for 7.5 h, with the initial portion provided 1.5 h prior to the start of isotope
administration. Each horse received a 14.4 μmol/kg primed dose of [13C] sodium
bicarbonate solution (Isotec™, Miamisburg, OH), followed by a 2-h constant infusion at
12 μmol/kg/h in order to measure total CO2 production (540). This was followed by a 4h primed (8.4 μmol/kg), constant (6 μmol/kg/h) infusion of [1-13C]phenylalanine solution
(Isotec™, Miamisburg, OH) in order to measure whole-body phenylalanine oxidation and
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flux (541). The isotope filled ethylene vinyl acetate bags were attached to a surcingle and
connected to the catheter using a primary IV set (Baxter Healthcare Corporation,
Deerfield, IL). Isotope was delivered into the catheter using a pressure sensitive, cordless
intravenous infusion pump (J-1097 VetPro Infusion Pump, Jorgensen Laboratories Inc.,
Loveland, CO) which was also attached to the surcingle on each horse.
Two baseline breath samples were collected prior to the [13C] sodium bicarbonate
infusion (-30 min and 0 min), and subsequent breath samples were collected every 30
min throughout the infusion procedures of both [13C] sodium bicarbonate and [113

C]phenylalanine for a total of 6.5 h. Breath samples were collected using a modified

Equine Aeromask® (Trudell Medical International, London ON, Canada) enabling the
collection of air through a 1-way valve into gas impermeable bags (Wagner Analysen
Technik Vetriebs GmbH, Bremen, Germany). Immediately following each sample
collection, another 1/24 meal was provided. Blood sampling commenced at 90 min into
the [13C]sodium bicarbonate infusion, and continued every 30 min until the end of the [113

C]phenylalanine infusion. All blood samples were collected into evacuated vacutainers

(Vacutainer; Becton-Dickinson, Franklin Lakes NJ) containing sodium heparin. The t=
90 min [13C]sodium bicarbonate and t= 0 min [1-13C]phenylalanine blood samples were
used to measure the background amounts of [1-13C] phenylalanine in the blood, prior to
isotope infusion.
At the end of the [1-13C]phenylalanine infusion, the infusion pumps were turned
off and the horses were led to a set of equine stocks. Horses were lightly sedated with
xylazine hydrochloride (0.3mg/kg, IV [100mg/mL]; Butler Animal Health Supply,
Dublin, OH), and a gluteal muscle biopsy was collected as previously described (2).
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Briefly, the area over the middle gluteal muscle (~100-cm2) was shaved, aseptically
prepared, and desensitized with a local anesthetic (12 mL of 2% lidocaine; Butler Animal
Health Supply, Dublin, OH). Approximately 500 mg of muscle biopsy specimen was
obtained at a depth of approximately 50% (~8 cm; Chapter III; Chapter V) of the depth of
the middle gluteal muscle, by use of the percutaneous needle biopsy technique (411). Of
this, ~100 mg was processed in preparation for Western blot analysis, as described below,
and ~ 80 mg was stored in RNAlater (Quiagen, Inc., Santa Clarita, CA) for qRT-PCR
analysis of inflammatory cytokines as described below. The remainder was flash frozen
in liquid nitrogen, and stored at -80ºC until analysis. Catheters were removed and 1 g of
phenylbutazone was administered following muscle biopsy collection. At this time,
horses were given the remaining portions of concentrate and their daily allotment of hay
as a single meal. Following consumption of the evening meal, horses were returned to
the drylot. For the next 4 weeks, 2g/d of phenylbutazone paste (Butler Animal Health
Supply, Dublin, OH) was administered to the horses; 1g was given orally prior to each
meal. The experimental procedures were repeated following 2 weeks and 4 weeks of
phenylbutazone administration. Samples of the grass hay, ration balancer pellet, and oats
were collected throughout the experimental period and sent to Dairy One Forage
Laboratory (Ithaca, NY) for nutrient analysis.
7.2.3. Sample analysis procedures
7.2.3.1. Blood sample collection and storage: Blood samples collected for qRT-PCR in
PAXgene™ Blood RNA tubes (Quiagen, Inc., Santa Clarita, CA) were gradually frozen
to -80oC per manufacturer instructions and remained at -80oC until analysis. The
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remaining blood samples were immediately centrifuged at 1,500 x g for 10 minutes at
4ºC, and aliquots of plasma samples were frozen at -20ºC until the time of analysis.
7.2.3.2. Plasma glucose and insulin: Plasma glucose concentrations were assayed
enzymatically using a YSI 2700 SELECT™ Biochemistry Analyzer (YSI Inc., Life
Sciences, Yellow Springs, Ohio). Plasma insulin concentrations were determined using
Coat-A-Coat RIA®kit (Siemens Healthcare Diagnostics Inc., Deerfield, IL).
7.2.3.3. Amino acids: Samples of grass hay, pelleted concentrate, and oats were
hydrolyzed for 24 hours at 110oC in 6N HCl. Total amino acid concentrations of the
hydrolysates were then measured using reverse-phase HPLC (3.9 x 300 mm PICO-TAG
reverse phase column; Waters, Milford MA) of phenylisothiocyanate derivatives as
previously described (2). The plasma free amino acid concentrations were also measured
using reverse-phase HPLC (3.9 x 300 mm PICO-TAG reverse phase column; Waters,
Milford MA) of phenylisothiocyanate derivatives as previously described (2).
7.2.3.4. Plasma phenylalanine enrichment: The isotopic enrichment of phenylalanine
(the amount of [1-13C]phenylalanine relative to unlabeled phenylalanine) in the plasma
samples collected on day 3 was determined by Metabolic Solutions, Inc. (Nashua, NH)
using a previously described method (543) which was modified by Matthews, Persola
and Campbell (544) (Chapter VI).
7.2.3.5. Muscle phenylalanine enrichment: Approximately 25-30 mg of flash frozen
muscle tissue was sent to Metabolic Solutions, Inc. (Nashua, NH) for the determination
of mixed-muscle protein and intracellular 1-13C-phenylalanine enrichment ((545);
Chapter VI).
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7.2.3.6. Breath sample analysis: The ratio of 13CO2:12CO2 in the breath samples was
determined using an isotope selective non-dispersive infrared absorption (NDIR)
analyzer (IRIS-2; Wagner Analysen Technik Vetriebs GmbH, Bremen, Germany)
(Chapter VI).
7.2.3.7. Western blot analysis of muscle samples: The abundance of the total and
phosphorylated forms of Akt, S6K1, rpS6, and 4E-BP1 in the gluteal muscle
homogenates were determined using electrophoresis followed by Western blotting
techniques (Chapter III).
7.2.3.8. Real time polymerase chain reaction. Pro -inflammatory cytokines, IFN-γ, IL1β, IL-6 and TNFα, and the anti-inflammatory cytokine IL-10 mRNA expressions were
measured in cDNA samples using equine specific intron-spanning primer/probe sets
((244, 484); Chapter IV).
7.2.4. Calculations and statistical analysis
7.2.4.1. Fat free mass. Fat free mass was calculated from ultrasonic fat depth as
previously described (Chapter VI).
7.2.4.2. Plasma phenylalanine enrichment. Isotope enrichment in mol % excess was
calculated from peak area ratios at isotopic steady state and baseline (Chapter VI). The
final value for all determinations was corrected using an enrichment calibration curve
(Chapter VI).
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7.2.4.3. Breath CO2 enrichment. The equation used to convert the δ enrichment value
obtained from the NDIR analyzer for each sample to a % enrichment was described in
Chapter VI.
7.2.4.4. Whole-body phenylalanine kinetics. The average plasma enrichment at isotopic
steady state (plateau) was used to calculate whole-body phenylalanine kinetics, and was
described in Chapter VI.
7.2.4.5. Relative quantity of inflammatory cytokines. Changes in mRNA expression
were calculated using the ΔΔCT method ((244, 484); Chapter IV), with the mean ΔCT
averaged for all horses during the week 0 sampling period set as the calibrator for each
individual cytokine. Results are expressed as relative quantity (RQ) calculated as 2-ΔΔCT
(Chapter IV).
7.2.4.6. Statistics. All data were analyzed using in the PROC MIXED procedure of SAS
Version 9.2 (SAS Institute Inc., Cary, NC), with statistical significance and trends
considered if P < 0.05 and 0.05 < P < 0.10, respectively. When the fixed effect was
significant, pre-planned comparisons of least squares means were made using the pdiff
test. All of the dependent variables were analyzed using repeated measures with the
fixed effect of time on NSAID and horse nested in block as the random subject. For all
repeated measures analysis, the variance-covariance matrix was chosen for each analysis
based on the lowest value for Schwarz’s Bayesian Criterion. Data are presented as means
± pooled standard error unless otherwise noted.
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7.3. RESULTS
7.3.1. Equine demographics
All horses remained healthy and maintained their body weight (P = 0.87; 0 weeks
on NSAID: 499±35 kg; 4 weeks on NSAID: 500±35 kg) throughout the experimental
period. Additionally, there was no change in fat free mass calculated from ultrasounded
rump fat thickness (481) (P = 0.75; 0 weeks on NSAID: 448±30 kg; 4 weeks on NSAID:
451±30 kg). The measurements of fat free mass that these horses maintained
approximately 10% body fat throughout the study procedures.
7.3.2. Plasma metabolites
There was no effect of time on NSAID on the plasma insulin (P = 0.37; Table 7.1)
or glucose (P = 0.12; Table 7.1) concentrations at the time of biopsy. Plasma
concentrations of Ala, Asp, Glu, Ile, Leu, Lys, and Thr decreased with time on NSAID (P
< 0.05; Table 7.1) at the time of biopsy. Arg, Gln, and Gly plasma concentrations at the
time of biopsy increased with time on NSAID (P < 0.05; Table 7.1). Plasma
concentrations of Phe and Trp at the time of biopsy decreased at week 2 of NSAID
administration, and then returned to baseline concentrations by week 4 of NSAID
administration (P < 0.05; Table 7.1). There was no effect of time on NSAID (P > 0.05) at
the time of biopsy on plasma concentrations of Asn, His, Met, Pro, Ser, Tyr, and Val.
7.3.3. Inflammatory cytokines
Time on NSAID did not affect mRNA expression of the circulating inflammatory
cytokines: IL-1β (P = 0.22; Figure 7.1), IL-6 (P = 0.20; Figure 7.1); IL-10 (P = 0.42;
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Figure 7.1); IFNγ (P = 0.40; Figure 7.1), and TNFα (P = 0.72; Figure 7.1). The muscle
mRNA expression of IL-1β decreased with time on NSAID (P = 0.02; Figure 7.2).
However, there was no effect of time on NSAID on the mRNA expression of muscle IL10 (P = 0.86; Figure 7.2), IFNγ (P = 0.15; Figure 7.2), or TNFα (P = 0.15; Figure 7.2).
There was limited detection of muscle IL-6 mRNA expression; where expression was
only detected in 1 horse prior to NSAID administration, 2 horses following 2 weeks of
NSAID administration, and 1 horse following 4 weeks of NSAID administration.
7.3.4. Activation of translation initiation factors
There was no effect of time on NSAID on the activation of Akt at Ser473 (P =
0.14; Figure 7.3) and Thr308 (P = 0.52; Figure 7.3), rpS6 at Ser235/236 & 240/244 (P = 0.14;
Figure 7.3), or 4EBP1 at Thr37/46 (P = 0.53; Figure 7.3). However, the activation of S6K1
at Thr389 showed a trend to increase following 2 weeks of NSAID administration and then
returned to baseline following 4 weeks of NSAID administration (P =0.09; Figure 7.3).
7.3.5. Whole-body protein synthesis
Although there was no effect of time on NSAID on whole-body CO2 production
(P = 0.41; Table 7.2), phenylalanine flux (P = 0.55; Table 7.2), phenylalanine oxidation
(P = 0.28; Table 7.2), or phenylalanine release from protein breakdown (P = 0.53; Table
7.2), there was an increase in non-oxidative phenylalanine disposal (P = 0.02; Table 7.2).
An increase in non-oxidative phenylalanine disposal with time on NSAID is indicative of
an increase in phenylalanine used for whole-body protein synthesis with time on NSAID.
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7.3.6. Muscle phenylalanine enrichment
There was no effect of time on NSAID on free (P = 0.64; Table 7.3) or protein
bound (P = 0.18; Table 7.3) enrichment of [1-13C] phenylalanine in the gluteal muscle.
Because we only collected a single biopsy at the end of the isotope infusion period, we
could not measure the changes in [1-13C] phenylalanine incorporation into protein over
time and could not calculate muscle fractional synthesis rates. However, if the
assumption is made that there were no initial differences in muscle bound enrichments of
[1-13C] phenylalanine on each sampling day, then no change with time on NSAID at the
end of the isotope infusion periods in both free and protein bound fractional muscle
enrichment of [1-13C] phenylalanine implies no effect of NSAID administration on
muscle protein fractional synthesis rates.
7.4. DISCUSSION
This is the first time whole-body protein kinetics and mTOR signaling have been
examined in the aging horse during NSAID administration. The oral administration of a
NSAID, phenylbutazone, at a rate of 2g/day reduced the mRNA expression of IL-1β in
skeletal muscle, increased whole-body protein synthesis, and tended to increase the
phosphorylation of S6K1 following 7.5 hours of steady state feeding. The results of the
present study indicate that NSAID administration in aged horses may ameliorate the
blunted response of protein synthesis to anabolic stimuli that is seen in aging mammals.
The horses used in this study were also used in the companion study (Chapter VI),
and were characterized as healthy aging horses. We previously (Chapter VI) determined
this group of aging horses to be similar to mature horses in body fat mass and weight,
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circulating and muscle inflammatory cytokines, and to be clinically normal with no signs
of PPID, as plasma α-MSH concentrations were within the clinically normal reference
range (539, 555).
The reduction in the muscle mRNA expression of IL−1β indicates the
effectiveness of the phenylbutazone administration of 2 g per day at reducing
inflammation in the current study. We have previously (Chapter IV) demonstrated that
this dose of phenylbutazone was effective at preventing the increase in the mRNA
expression of IL−1β in skeletal muscle following the collection of 5 days of repeated
biopsies. Collectively, these studies may indicate that IL−1β mRNA expression in
skeletal muscle is responsive to phenylbutazone treatment. However, there was no effect
of phenylbutazone administration on the mRNA expression of IFNγ, IL-6, TNFα, and IL10 in skeletal muscle or IL−1β, IFNγ, IL-6, TNFα, and IL-10 in circulation in the present
study. The lack of an effect of NSAID administration on circulating inflammatory
cytokines may be due to the fact that the aged horses (23.5 ± 2.6 y old) used in the
present study did not have elevated levels of circulating inflammatory cytokines
compared to older (11 ± 2.6 y old) mature horses (Chapter VI). Additionally, this study
was designed to determine differences in protein metabolism, where a sample size of 6 is
large enough to detect statistical differences (Urschel et al., University of Kentucky,
submitted; Chapter VI); however, previous studies used a minimum of 8 horses (484)
when studying changes in circulating inflammatory cytokines in response to experimental
treatments. As a result, there may not have been enough statistical power to detect
differences in inflammatory cytokine production in response to NSAID treatment. The
extended use (5 months) of oral NSAID administration has been shown to reduce
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circulating inflammatory cytokines (IL−1β, and IL-6),in the aged rodent (335). The
reduction in circulating inflammatory cytokines may occur after prolonged NSAID
administration, which would explain the lack of an effect of a short term (4 weeks) of
oral NSAID administration on circulating inflammatory cytokines in the present study.
The studies examining the effect of NSAID administration on muscle inflammatory
cytokines in the aged are limited; however, there is an abundance of literature examining
the reduction of post-exercise skeletal muscle inflammation by NSAID, where NSAID
administration reduced post-exercise inflammatory cytokines (332, 333). It is important
to recognize that post-exercise inflammation is an acute inflammatory response, whereas
aging is characterized as low grade chronic inflammation; therefore, further research is
needed to examine the effects of oral NSAID administration on skeletal muscle
inflammatory cytokine production during chronic inflammation. Although
phenylbutazone administration has been implicated with the development of gastric
ulcers in horses (323, 556) we do not believe there were any adverse effects in the horses
in the present study. All horses maintained an appetite, body weight and lean mass
throughout the four week study period, which may be partly attributed to the
administration of omeprazole for the prevention of gastric ulcers (557). Ultimately, we
believe the dose of phenylbutazone in the present study was effective at reducing some of
the chronic inflammation associated with aging, because of the reduction of muscle
IL−1β.
Variations in whole-body protein metabolism between mature and aged humans,
suggest that the aged population may have a higher protein requirement (202). Within
the aged population, presence of low grade inflammation in circulation may be partially
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responsible for to the reduced muscle protein fractional synthesis rates in the postprandial
state (493). However, both whole-body protein synthesis and muscle protein fractional
synthesis do not vary between these age groups during the post-absorptive state (186,
493). In the present study, there was a 77% increase in whole-body non-oxidative
phenylalanine disposal, which is an indirect measure of protein synthesis, with the
administration of oral NSAID for 4 weeks. This is consistent with the results of a
previous study (335), where oral administration of ibuprofen reduced in circulating levels
of inflammatory cytokines and increased muscle fractional synthesis rates in aged
rodents. Additionally, the present study demonstrated a reduction in the plasma
concentrations of the indispensable amino acids, Ile, Leu, Lys, Phe, Thr, and Trp with
time on NSAID, which is suggestive of an increase in the incorporation of these amino
acids to support the synthesis of new proteins. Together the decreased plasma amino
acids and increased whole-body protein synthesis indicates that oral administration of a
NSAID may reduce inflammation and increase whole-body protein synthesis. Studying
whole-body protein metabolism is a useful tool to examine the subject in its entirety;
however, it does not allow researchers to isolate the tissues that are responsible for the
alterations seen at the whole-body level. Because skeletal muscle comprises
approximately 25% of whole-body protein synthesis (198, 199), it is possible that
alterations seen at the whole-body level are due to changes in protein metabolism in
skeletal muscle, although additional research is necessary to identify the specific tissues
most affected by NSAID administration.
Our original hypothesis was that protein synthesis in the skeletal muscle would
increase following NSAID treatment; however, there was only limited evidence that
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muscle protein metabolism was altered by NSAID treatment. Of the translation initiation
factors studied, S6K1 appears to be the most affected by aging (Chapter VI) and NSAID
administration. The phosphorylation of S6K1 at Thr389 tended to be elevated 118%
following 2 weeks of NSAID administration and then returned to baseline following 4
weeks of NSAID administration. The increase in the phosphorylation of S6K1 following
2 weeks of NSAID administration coincided with a 59% reduction in skeletal muscle
IL−1β mRNA expression which remained reduced by week 4, and no change in wholebody protein synthesis or breakdown. Oral administration of ibuprofen for 5 months to
rodents resulted in a postprandial elevation in muscle protein fractional synthesis rates
and reduced circulating inflammatory cytokines, but there were no differences in the
activation of any of the mTOR signaling factors studied (335), which is in agreement
with the results from the present study. However, there were no differences in muscle
protein fractional synthesis rates or mTOR signaling with 5 months of oral administration
of ibuprofen to aging rodents in the post-absorptive state (335).
One of the aims of the experimental protocol was to measure whole-body protein
kinetics, which necessitated keeping all of the horses in a steady state during the infusion
procedures. This was achieved through the consumption of small meals every 30 minutes
which consisted of half of their daily concentrate allocation (0.1% BW) divided into 1/24
portions. This feeding protocol placed plasma glucose (0 week: 5.3 ± 0.2 mmol/L; 2
weeks: 5.5 ± 0.2 mmol/L; 4 weeks: 5.1 ± 0.2 mmol/L), insulin (0 week: 6.1 ± 0.8
μIU/mL; 2 weeks: 10.1 ± 0.8 μIU/mL; 4 weeks: 7.9 ± 0.8 μIU/mL), and total
indispensable amino acid (0 week: 670 ± 40 μmol/L; 2 weeks: 607 ± 40 μmol/L; 4
weeks: 571 ± 40 μmol/L) concentrations of these horses at the time of biopsy in a
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physiological state that more closely resembled a post-absorptive state (glucose: 5.5
mmol/L; insulin: 5 mU/L; total indispensable amino acids: 898 μmol/L) (2) rather than
the postprandial state (glucose: 6.5 mmol/L; insulin: 36 mU/L; total indispensable amino
acids: 1245 μmol/L) (2). In addition, the whole-body protein metabolism data indicated
that these horses were in a post-absorptive state, because the indirect measure of protein
synthesis, non-oxidative disposal, was less than phenylalanine from protein breakdown
(185). Since our horses were in a post-absorptive state, the lack of an effect of NSAID
administration on mTOR signaling factors is consistent with previous findings (335).
Because this is the first study to examine the effects of oral administration of a
NSAID with the aim of reducing inflammation and examining whole-body protein
metabolism, there is ample room for additional research. In the present study, horses
received a short course (4 weeks) of oral NSAID, which proved to reduce muscle
inflammation and increase whole-body protein synthesis; however, administration of oral
NSAID over a longer course may be necessary to examine mechanistic changes in
skeletal muscle. Additionally, in the present study horses were examined in a postabsorptive state, and although we saw an increase in whole-body protein synthesis,
examining horses in the postprandial state during oral NSAID administration will be
useful in determining if these alterations seen at the whole-body level will translate to
skeletal muscle.
The use of daily administration of a NSAID for 4 weeks to horses in the present
study was a tool to aid in the elucidation of the mechanism behind reductions in protein
synthesis with aging. Although the results of the present study show promise, that with
reduced inflammation there was an increase in whole-body protein synthesis, it would not
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be practical or acceptable to horse owner to advocate the daily administration of an
NSAID for an extended period of time to aging horses. Rather, the objectives of the
present study were to examine from a mechanistic standpoint whether the reduction in
chronic inflammation would have beneficial effects on whole-body and muscle protein
metabolism. We chose to use phenylbutuzane as our anti-inflammatory agent because of
its known anti-inflammatory properties (321) and because it is structurally related to
ibuprofen, which has previously been shown to increase rates of muscle protein synthesis
in aged rodents (335). This study provides initial insight the potential impact of chronic
inflammation on protein metabolism in the aged horse and is the first step towards
investigating other means of reducing inflammation in the aged population through
alterations in the diet or by other strategies. For example, resveratrol supplemented to the
diet has showed promise in reducing inflammation in horses through inhibiting the
formation of reactive oxygen species (558). Ultimately, there is a need to examine the
diet of the aging equine population and discover practical methods of reducing
inflammation which will allow for an increase in whole-body, and hopefully muscle,
protein synthesis.
NSAID administration affects aging equine skeletal muscle by tending to elevate
S6K1 activation after 2 weeks, which coincided with a reduction in mRNA expression of
IL−1β, and was followed by an increase in whole-body protein synthesis. Although
additional research is needed to further elucidate the mechanistic effect that inflammation
has on both whole-body and muscle protein fractional synthesis, these findings indicate
that management strategies targeted at reducing inflammation result in elevations in
whole-body protein synthesis.
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7.5. TABLES
Table 7.1: Plasma metabolite concentrations at the time of biopsy before NSAID
administration and following 2 and 4 weeks of NSAID administration in aging
horses.
Metabolite

2 weeks
on
NSAID
10.1

4 weeks
on
NSAID
7.9

Poole
d
SEM
2.0

p-Value

Insulin1

0 weeks
on
NSAID
6.1

Glucose2

5.3

5.5

5.1

0.2

0.12

Alanine3

218a

170b

185b

12

0.05

Arginine

74b

90a

88a

4.9

0.007

Asparagine

52

54

52

5.8

0.83

Aspartate

15a

11b

6.7c

1.2

0.002

Glutamate

49a

35b

28c

2.4

0.0001

Glutamine

306b

358a

349a

9.3

0.004

Glycine

441b

467b

520a

54

0.02

Histidine

64

63

65

3.1

0.75

Isoleucine

46a

45a

39b

2.6

0.05

Leucine

87a

79ab

70b

4.3

0.01

Lysine

92a

86a

69b

5.3

0.01

Methionine

32

30

29

1.8

0.63

Phenylalanine

83a

75b

80ab

2.2

0.05

Proline

97

91

86

5.7

0.24

Serine

288

277

281

8.3

0.66
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0.37

Table 7.1 continued: Plasma metabolite concentration at the time of biopsy before
NSAID administration and following 2 and 4 weeks of NSAID administration in
aging horses.
Threonine

112a

87b

75c

5.3

0.0001

Tryptophan

5.3ab

4.3b

6.2a

0.4

0.03

Tyrosine

55

53

53

2.1

0.63

Valine

148

138

138

7.1

0.16

1

Plasma insulin concentrations are reported as least square means in μIU/mL.

2

Plasma glucose concentrations are reported as least square means in mmol/L.

3

Plasma amino acids concentrations are reported as least square means in μmol/L.

abc

Differing letters indicate that values are significantly (P < 0.05) different from each
other.
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Table 7.2: Whole-body phenylalanine kinetics in aged horses over 4 weeks of NSAID
administration1.
0 weeks of
2 weeks of
4 weeks of
NSAID
NSAID
NSAID
administration administration administration
Phenylalanine flux [μmol/(kg·h)]
42.1
47.7
44.0
Carbon dioxide production [μmol/(kg·h)]
15080
16658
14164
Phenylalanine entering the free phenylalanine pool [μmol/(kg·h)]2
Phenylalanine 3.9
3.9
3.8
from dietary
intake
Phenylalanine 37.5
43.2
39.4
from protein
breakdown
Phenylalanine leaving the free phenylalanine pool [μmol/(kg·h)]2
Phenylalanine 16.7
17.3
9.4
oxidation
19.6a
34.6b
Non-oxidative 25.5a
phenylalanine
disposal
1
Values are least squares means ± SEM.

Pooled
SEM

pvalue

3.5

0.55

1387

0.41

0.06

0.53

3.5

0.53

3.9

0.28

3.0

0.02

2

The following stochastic model of phenylalanine kinetics was used: flux = rate of
phenylalanine entry = rate of phenylalanine leaving; rate of phenylalanine entry =
phenylalanine intake + phenylalanine release from protein breakdown; rate of
phenylalanine leaving = phenylalanine oxidation + non-oxidative phenylalanine disposal

ab

Values with different superscript letters are significantly (P < 0.05) different.
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Table 7.3: Muscle phenylalanine enrichments in aged horses over 4 weeks of NSAID
administration1.
0 weeks of
2 weeks of
NSAID
NSAID
administration administration
Muscle free enrichments (%)
10.1
10.4
Muscle protein bound enrichments (%)
0.41
0.56
1
Values are least squares means ± SEM.
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4 weeks of
NSAID
administration

Pooled
SEM

p-value

11.2

0.8

0.64

0.50

0.08

0.18

0 weeks on NSAID
4 weeks on NSAID

2.5
2.0
1.5
1.0
0.5

IF
Nγ

TN
Fα

IL
-1
0

IL
-6

0.0

IL
-1
β

Circulating Inflammatory
Cytokine RQ Values

7.6. FIGURES

Figure 7.1. Circulating inflammatory cytokines (RQ) in aged horses following 0
weeks, 2 weeks, and 4 weeks of NSAID administration. Values are least square means
± pooled SE, n=6 per treatment group.
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2.0
1.5

a

1.0
0.5

b

b
IF
Nγ
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Fα

IL
-1
0

0.0
IL
-1
β

Muscle Inflammatory
Cytokine RQ Values

0 weeks on NSAID
2 weeks on NSAID
4 weeks on NSAID

2.5

Figure 7.2. Muscle inflammatory cytokines (RQ) in aged horses following 0 weeks, 2
weeks, and 4 weeks of NSAID administration. Values are least square means ± pooled
SE, n=6 per treatment group.
ab

Differing letters indicate, within an inflammatory cytokine, the values are significantly

different (P < 0.05).
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Phosphorylated
Form
Total Form

60
kDa
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kDa

70
kDa

20
kDa

32
kDa

Arbitrary Units

5
4

0 weeks on NSAID
2 weeks on NSAID
4 weeks on NSAID
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1
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Figure 7.3. Gluteal muscle phosphorylation of Akt at Ser473, Akt at Thr308, S6K1 at
Thr389, rpS6 at Ser235/236 & 240/244, and 4EBP1 at Thr 37/46 in aged horses following 0
weeks, 2 weeks, and 4 weeks of NSAID administration after 7.5-hour of steady state
feeding. The phosphorylated forms of the translation initiation factors was corrected by
the respective total form abundance, with the value for mature horses set at 1.0 AU.
Values are least square means ± pooled SE, n=6 per treatment group. Representative
images of the immunoblots are shown above.
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Chapter VIII
Summary, General Discussion and Future Directions
8.1. OPTIMIZING METHODOLOGICAL PROCEDURES FOR ASSESSING
mTOR SIGNALING IN THE HORSE
One of the primary objectives of this dissertation was to determine the optimum
methodological procedures for assessing mTOR signaling in the horse. Because there
has only been a single previous study examining mTOR signaling in horses (2), the
optimum methodological procedures have not been assessed. The first study in this
dissertation (Chapter III) examined the effect of sampling depth in the gluteus medius
muscle on the activation of mTOR signaling in response to feeding and showed that there
was no effect of sampling depth (6, 8 or 10 cm below the surface of the skin) on the
activation of any of the mTOR signaling factors in response to feeding in mature horses.
The focus of the second study in this dissertation (Chapter IV) was to determine the
effects of conducting percutaneous gluteal muscle biopsy procedures every 24 hours for 5
days on mTOR signaling in response to feeding in mature horses, both with and without
NSAID administration. These results showed that in the absence of NSAID
administration, obtaining gluteal muscle biopsies every 24 hours for 5 days resulted in the
decreased activation of Akt and increased the activation of the downstream signaling
factors (S6K1, rpS6, and 4EBP1) in response to feeding. On the other hand, there was no
effect of sampling day on the activation of the downstream mTOR signaling factors in the
presence of NSAID administration. A secondary objective this study (Chapter IV) was to
determine whether there would be differences in mTOR signaling in response to feeding
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in samples collected from the right and left gluteal muscles at the same time. The results
showed that there was no difference in mTOR signaling based on the side of gluteal
muscle sample. These initial studies in this dissertation were designed to determine
optimum sampling methods for assessing mTOR signaling in the horse.
The results of the first two studies in this dissertation suggest that:
1. The activation of mTOR signaling in response to feeding in mature horses is
not affected by biopsy sampling depth as long as samples are collected from 6
to10 cm below the surface of the skin (Chapter III).
2. NSAID administration was able to prevent changes in the activation of
downstream mTOR signaling in response to feeding during 5 days of repeated
biopsy collection. Therefore, if study design requires repeated biopsy
procedures over the course of 24 hours to up to 5 days, NSAID administration
is recommended to prevent sampling-related changes in mTOR activation
(Chapter IV).
3. mTOR signaling in response to feeding from biopsies collected at the same
time from the same site in the right and left side of the gluteal muscle can be
compared (Chapter IV).
These studies were only an initial attempt to determine the optimum
methodological procedures for assessing mTOR signaling in horses and led to
several further directions for method development. Although there was no
alteration in mTOR signaling in response to feeding in mature horses when
biopsies were collected at depths ranging from 6 to 10 cm below the surface of
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the skin (Chapter III), there may have been alterations in mTOR signaling if a
wider range of depths had been examined, for example, if gluteal muscle depth
ranged from 2 to 12 cm. The rodent data has shown that the phosphorylation of
mTOR (491) and S6K1 (559) in response to contractile activity appears greater in
Type II than Type I fibers. The proportion of the different fiber types in the
gluteal muscle in horses changes with muscle depth, and there is an increase in
Type I fibers with gluteal muscle depth in the horse (560). However, the greatest
changes in fiber type proportions seem to occur between 2 and 6 cm depth, with a
140% increase in Type I fibers, whereas, changes from 6 to 10 cm in depth
resulted in no change in Type I fibers (Chapter III). Therefore, there may be a
greater activation of downstream mTOR signaling in response to anabolic stimuli
at a shallower depth of 2 cm than at a deeper depth of 12 cm. Not only does
mTOR signaling need to be examined at a wider range of depths, but the different
types of anabolic stimulus used to activate mTOR signaling must also be
examined. Because the anabolic stimuli used in the rodent studies (491, 559) was
contraction as opposed to feeding, there may have been differences in the
activation of downstream signaling in response to sampling depth if exercise had
been used as the anabolic stimuli. Although contraction and feeding both
stimulate mTOR signaling, these stimuli act through different upstream factors
(Section 1.2). Additionally, in all of the studies in this dissertation muscle
biopsies were collected from the gluteus medius muscle due to the role of this
muscle in both locomotion and posture and because external landmarks for
identifying this muscle have been well described (411). However, differences in
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the mitogen activated protein kinase (MAPK) family, a pathway upstream of
mTOR signaling (Section 1.2), in response to exercise in mature horses were
determined when biopsies were obtained from the vastus lateralis and pectoralis
descendens muscles (470). The authors chose the vastus lateralis because of the
involvement of this hind limb muscle in forward movement and the pectoralis
descendens because of the role in posture, and the MAPK family signaling in
response to exercise was greater in the vastus lateralis then the pectoralic
descendens (470). Additionally, the response of mTOR signaling to contraction
has been reported to vary due to muscle group in rodents, with greatest activity in
the tibialis anterior followed by the plantaris and then the soleus (491). The fiber
type composition of these muscles in the rodent is tibialis anterior: 3% Type I,
61% Type IIA, 36% Type IIB; plantaris: 7% Type I, 52% Type IIA, 41% Type
IIB; and soleus:83% Type I, 17% Type IIA, 0% Type IIB (561). Therefore, it is
necessary to determine the response of mTOR signaling in various muscle groups
to both feeding and exercise because the effect of exercise will likely be greater in
muscle groups used primarily for locomotion rather than for posture.
Another important factor to consider in optimizing procedures to study mTOR
signaling is determining the best time following the anabolic stimuli to obtain the muscle
biopsy samples. Previous research (562) has demonstrated that in the gastrocnemius and
soleus of neonatal piglets 60 and 90 minutes following feeding, there was no difference
in the abundance of the phosphorylated forms of mTOR, 4EBP1, and S6K1. As a result,
in the first study to examine mTOR signaling in horses, Urschel and collegues (2) chose
to collect gluteal muscle biopsies 90 minutes following feeding in horses. Their study (2)
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determined that there was no change in plasma amino acids, insulin and glucose
concentrations from 60 to 80 minutes post-feeding, indicating that any feed induced
changes in mTOR signaling due to increased plasma metabolites should not differ
between 60 and 80 minutes. Thus, muscle biopsy samples were obtained 60 – 90 minutes
following the consumption of a high protein meal in the research described in this
dissertation (Chapters III, IV and V). However, in order to confirm that the muscle
samples were obtained at the peak of post-stimuli mTOR signaling, it is necessary to
determine the time course changes in mTOR signaling in response to feeding in horses.
The second study of this dissertation (Chapter IV) looked at the effects of
repeated gluteal muscle biopsies, with biopsies collected every 24 hours for 5 days. This
study did not characterize the acute time course changes in mTOR signaling for the first
24 hours following the initial biopsy. Although muscle protein fractional synthesis rates
do not change with multiple muscle biopsies collected between 60, 210 and 240 minutes
of a 4 hour period (507) or during hourly biopsies over a 6 hour period (508), there has
not been a single study to examine the effects of repeated multiple biopsy collection
within a 24 hour period on mTOR signaling. However, others (248, 563) have examined
the activation of stress related signaling factors including ERK1/2 and MAPK, which
influence mTOR signaling (Section 1.2), in response to multiple biopsies. There is an
increase in ERK1/2 and MAPK with repeated biopsies collected 30 and 60 minutes
following the initial biopsy from the same incision site (564). However, there were no
alterations in MAPK signaling when repeated biopsies were collected within 126 minute
period from separate incision sites (248). Unfortunately, there has not been a study to
examine the time course changes in MAPK signaling following the collection of a muscle
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biopsy; however the previous studies (248, 565) have demonstrated that repeated biopsies
if collected within 2 hours of the initial biopsy from separate incision sites do not alter
stress related MAPK signaling. Thus, mTOR signaling should not be altered through this
mechanism; however, additional research is necessary to elucidate this. Additional
research is also necessary to examine the collection of repeated biopsies over a 24-72
hour period, because the results of the Chapter IV show a greater increase in the
activation of mTOR signaling in response to feeding 24 hours after the collection of the
initial biopsy. The first two studies of this dissertation led to many other areas where the
knowledge base is lacking and the methods may be improved.
Although the goal of the last three studies (Chapters V – VII) in this dissertation
was not to further methodological development, there are methodological lessons that are
learned from every study. The goal of the third study in this dissertation (Chapter V) was
to determine to activation of mTOR signaling in response to feeding in yearlings, two
year olds and mature horses. Although the first study in this dissertation (Chapter III)
showed that sampling depth (6 to 10 cm below the surface of the skin) did not alter
mTOR signaling in response to feeding in mature horses, there was no way to be sure this
would hold true in yearlings and two years olds. Therefore, the decision was made to
ultrasound the rump fat and gluteal muscle to determine their depths, so that muscle
biopsy collection could be standardized to 50% of the gluteal muscle depth (Chapter V).
In this study, we determined that there was considerable variation in subcutaneous fat
within and across the age groups (mature horses: 2.07 ± 0.30 cm, 1.7-2.7 cm range; two
year olds: 1.29 ± 0.49 cm, 0.9-2.1 cm range; yearlings: 1.05 ± 0.18 cm, 0.9 – 1.4 cm
range), which led to 2 additional considerations. First, in the initial study (Chapter III)
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biopsies were collected 6, 8, and 10 cm below the surface of the skin; however, if
subcutaneous fat in mature horses can vary by a cm, then biopsies were actually being
collected 4-5 cm, 6-7 cm, and 8-9 cm within the gluteal muscle for the 6, 8 and 10 cm
depths below the surface of the skin, respectively. So this variation in collection sites
may have led to the absence of alterations in mTOR related signaling because there is a
170% increase in Type I fibers from 4 to 8 cm (560). The second consideration was that
because there are alterations in fiber type with development in horses (410, 446-450), it is
unknown whether 50% of the gluteal muscle is optimum depth for collecting muscle
biopsies for assessment of differences in mTOR signaling across different ages of horses.
Therefore, it is also necessary to study mTOR signaling in response to various anabolic
stimuli at a wide range of gluteal muscle biopsy depths throughout development.
Another methodological consideration in this study (Chapter V), is that regardless
of age group, all horses were fed 4g/kg of body weight of high protein pelleted feed
following an 18 hour period of feed withholding in order to standardize protein intake.
This standardization met the protein requirement of a mature sedentary horse; however,
the protein requirements of the yearlings and two year olds differ greatly from that of a
mature sedentary horse (336). As a result, this meal only supplied 50 and 72% of the
daily requirements of the yearlings and two year olds, respectively, and so there was a
different magnitude of anabolic stimuli used in each of the three ages of horses studied.
This difference in anabolic stimuli may partly explain why we did not see the
hypothesized decrease in responsiveness to anabolic stimuli between the adolescent and
mature horses (Chapter V). Perhaps rather than examining the response of mTOR
signaling to a particular protein intake, it may be more valuable for comparison purposes
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to focus on the response of mTOR signaling to a percentage of protein requirements.
Because the effects of amino acid concentration on the activation of mTOR signaling is
dose dependent (101), a potentially graded response of mTOR signaling may exist with
graded protein requirements (50, 75, 100, 150% of protein requirements) and this should
be examined in the horse. Overall, from a methodological perspective Chapter V
suggests that:
1. When examining mTOR signaling response to feeding across various age
groups to standardize feeding by a percentage of protein requirements may be
more appropriate than standardizing by absolute protein intake.
Because the samples from the studies described in Chapters VI and VII were
analyzed at the same time, the methodological lessons for the assessment of mTOR
signaling in the horse are the same for both studies. In these studies mTOR signaling was
examined from gluteal muscle biopsies collected following whole-body protein kinetics
measurements. In order to maintain study horses at steady state for the measurement of
whole-body protein metabolism, horses received half of the daily allocation of
concentrate divided into 1/24 portions served every 30 minutes for 7.5 hours. Because
the whole diet was primarily hay based (2% body weight), each of these small
concentrate meals only met 0.5% and 0.37% of the daily CP and digestible energy
requirement, respectively. The feeding protocol used in this study did not result in
differences between mature and aged horses in the activation of Akt, rpS6, and 4EBP1,
and it is unknown whether this was because there were no differences in mTOR signaling
between these ages of horses or because the small meals did not provide sufficient
anabolic stimuli to elicit a postprandial mTOR signaling response. This raises an
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additional question: at what level of intake (or percent of protein requirements) does
mTOR signaling increase from the post-absorptive level? Additionally, it is necessary to
determine if mTOR signaling is altered by the consumption of a large meal to a similar
extent as same percent of protein requirements offered as small over a period of time in
the horse, because feeding a large meal activates mTOR signaling to a greater extent than
the consumption of the same amount of nutrients through small meals over a period of
time in neonatal pigs (566). Therefore, if feeding is to be used as the anabolic stimulus
for activating mTOR signaling then it may be necessary to administer it as a large meal in
order for it to be a large enough anabolic stimulus to elicit alterations in mTOR signaling.
Overall, from a methodological perspective Chapters VI and VII suggest that:
1. When examining mTOR signaling response to feeding, the feeding stimuli
must be strong enough to elicit changes in mTOR signaling.
The focus of the studies of this dissertation were to examine mTOR signaling;
however, in Chapters VI and VII isotopes were infused with the intention of
characterizing whole-body protein synthesis and the end point of mTOR signaling,
muscle protein synthesis. Although muscle samples were collected following the isotope
infusion procedures in the studies described in Chapter VI and VII, because only a single
muscle biopsy was obtained, it was not possible to measure how the amount of isotope
incorporated in the muscle protein changed over time and so we could not calculate the
fractional synthesis rates of muscle protein in the horses studied. Future studies will need
to collect muscle biopsies during and following isotope infusions in order to calculate
muscle protein fractional synthesis rates.
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8.1.1. Summary of the optimum methodological procedures for assessing mTOR
signaling in the horse
The studies in this dissertation have 5 lessons that should be considered by future
researchers intending to study mTOR signaling in the horse. In mature horses, mTOR
signaling in response to feeding from the right or left side of the gluteal muscle biopsies
from a depth of 6 to 10 cm below the surface of the skin can be compared; however if
these biopsies are repeated then a NSAID should be administered in order to avoid the
confounding effect of biopsy. Additionally, when examining mTOR signaling in
response to feeding, the meal should be standardized by a percentage of the animal’s
protein or amino acid requirement and the researcher must ensure that the level of feeding
provides a strong enough anabolic stimuli to elicit alterations in mTOR signaling
compared to the post-absorptive state.
8.2. ALTERATIONS IN mTOR SIGNALING THROUGHOUT THE LIFESPAN
IN HORSES
The second major objective of this dissertation was to examine the alterations in
the activation of mTOR signaling throughout the lifespan in the horse. mTOR signaling
in response to feeding in various life stages, including the neonatal period, adulthood, and
post-adulthood aging, has been characterized in other species. However, there are no
studies in any species examining mTOR signaling in the slower growing pre- and postpubertal adolescent and relatively few studies examining mTOR signaling and protein
synthesis in healthy aging animals or humans. Furthermore, the only studies to examine
mTOR signaling (2) and protein synthesis (3) in response to anabolic stimuli in the horse
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have been in mature horses. As a result, the third study in this dissertation (Chapter V)
examined developmental changes in the activation of mTOR signaling in response to
feeding, and the fourth and fifth studies (Chapter VI and VII) examined mTOR signaling
during post-adulthood aging. The research described in Chapter V showed that there was
an increase in mTOR signaling during the postprandial state, compared to the postabsorptive state, in the gluteal muscle of yearling, two year old and mature horses, and
the yearlings exhibited a higher degree of sensitivity to anabolic stimuli than the other
two ages of horses studied. Specifically, the activation of mTOR signaling factors in
yearlings appeared to be more sensitive to insulin than for the two year olds and mature
horses, because there was no difference in the activation of Akt between the age groups
even though there was an increase in insulin in circulation with development. The results
of Chapter VI demonstrated that whole-body protein synthesis and the activation of Akt,
rpS6 and 4EBP1 did not differ between mature (11 ± 2.6 year old) and healthy aging
(23.5 ± 2.6 year old) horses. If taken together, the results of Chapters V and VI may
suggest that post-natal development alters mTOR signaling to a greater extent than aging;
however, the magnitude of anabolic stimulus was different in the two studies and
therefore an additional study examining all of these age groups in response to the same
anabolic stimuli is necessary.
The previous literature examining mTOR signaling throughout the lifespan of
other mammalian species has focused on alterations in mTOR signaling during the
postprandial state; however, as discussed earlier (Section 8.1), a true postprandial state
was not obtained in the horses used for Chapter VI, and therefore, comments on the
postprandial changes in mTOR signaling throughout lifespan cannot be made.
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Alternatively, the changes in mTOR signaling during the post-absorptive period
throughout the lifespan can be commented on. From the results in the post-absorptive
state, it appears that mTOR signaling is altered to a greater extent by aging than during
development. The evidence of this was shown by the lowered abundance of the
phosphorylated form of S6K1 in the aging horses compared to the mature horses in
Chapter VI and no difference in the abundance of the phosphorylated form of S6K1
during the post-absorptive state between yearlings, two year olds and mature horses in
Chapter V. Examination of mTOR signaling during the post-absorptive period in the
neonatal piglet demonstrated no change in mTOR signaling with neonatal development in
skeletal muscle (129). Additionally, in humans there is no change in mTOR signaling
during the post-absorptive period during post-adulthood aging (157). Muscle protein
fractional synthesis rates are also not altered by development (157) or aging (157) during
the post-absorptive state. Thus, the results of our studies uniquely indicate that aging in
horses may have a greater influence on mTOR signaling during the post-absorptive
period than it does during adolescent development. This requires further examination
during the post-absorptive state in the equine neonate to determine if mTOR signaling is
regulated more during aging than during any other life stage in the horse. Although the
results of these studies Chapter V and VI indicate the post-absorptive alteration in mTOR
signaling throughout the lifespan, even more valuable information could be obtained by
studying the equine neonate, mature and aging horse using similar methodologies to that
used in Chapter V in order to study all horses in a postprandial state. Not only is there
more available literature to compare postprandial results to, but in the literature the
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postprandial state shows differences in the increase in mTOR signaling and subsequently
protein synthesis across different ages of research subjects.
As mentioned in the (Section 8.1), in order to accurately compare mTOR
signaling in skeletal muscle in response to feeding in different age groups, the meal
should meet an equal percentage of protein requirements for these animals (i.e. 100% for
each animal). However, during the research described in Chapter V, horses consumed an
equal protein intake which met 100, 72, and 50% of the daily requirements of the mature
horses, two year olds and yearlings, respectively. Regardless of the varied requirements,
the yearlings, who were consuming only 50% of their daily protein intake, had an
increase in mTOR signaling. This indicates that if this study were repeated standardizing
the meal by meeting 100% of daily protein requirements, the anabolic stimuli may likely
be strong enough to elucidate a potential step wise decrease in mTOR signaling with age,
with mTOR signaling being the greatest in the yearlings, followed by the two year olds,
then the mature horses, and possibly the aged horse. This pattern has been described in
neonatal piglets and mature and aging humans (129, 157).
The possible mechanisms of amino acids on mTOR signaling were discussed in
detail in Section 1.2.2.3. Briefly, amino acids cause the phosphorylation of S6K1
through mechanisms that are both dependent and independent on mTOR activation,
although in both cases amino acids phosphorylate S6K1 independently of Akt. Of all of
the amino acids, leucine has the greatest influence of mTOR signaling. Because the
greatest postprandial rise in the phosphorylated form of S6K1 occurred in the yearlings
compared to the two year olds or the mature horses (Chapter V), the yearlings may have a
greater sensitivity to amino acids than the two year olds or mature horses. Therefore, the
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results of this study may indicate that younger horses are more sensitive to amino acids,
which could be confirmed through examining the responsiveness of mTOR signaling in
growing, mature and aging horses to different levels of amino acid, or specifically
leucine, intake.
The research described in Chapters V and VI found no developmental (during the
postprandial and post-absorptive states) or aging (during the post-absorptive state) effects
on the activation of Akt, regardless of the fact that postprandial circulating insulin
concentrations increased with age in Chapter V. As previously mentioned, the mature
and aging horses in studied in Chapter VI were in a post-absorptive state, and there were
no alterations in circulating insulin concentrations due to age during this physiological
state. However, insulin sensitivity in regards to carbohydrate metabolism has been
demonstrated to decrease with the age of the horse (481). The effects of insulin
sensitivity on protein metabolism has been examined in humans, where young humans
had a greater increase in muscle protein fractional synthesis rates at the same dose of
insulin than older humans (161), and only supraphysiological doses of insulin were able
to improve muscle protein fractional synthesis rates and the activation of Akt and mTOR
signaling in the aged (159). Thus, the lack of an increase in Akt activation with increased
concentration of insulin in the mature horse in Chapter V may be a result of a greater
degree of insulin resistance in the mature horses. Therefore, the equal activation of Akt
in adolescent horses and mature horses (regardless of physiological state; Chapter V) and
mature horses and aging horses (in the post-absorptive state; Chapter VI) indicates that
Akt activation is more responsive to insulin in the adolescent horses, or that the Akt
activation response is maximized at the lowest plasma concentrations of insulin (yearling
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horses). However, the latter is unlikely, because unpublished data by Urschel and
colleagues found that mature horses subjected to a wide range of insulin infusion rates (0,
1.2, 3, 6 mU/kg/min), resulting in plasma insulin concentrations ranging from 10 – 1000
mU/L, had a dose dependent increase in Akt activation. This requires further
examination across the lifespan with controlled levels of insulin using a
hyperinsulinemic-euglycemic isoaminoacidemic clamp technique, which would allow for
the determination of the responsiveness of skeletal muscle Akt to administered insulin
concentrations, independent of other changes that occur in response to a meal.
In addition to advancing the physiological understanding of how stage of
development and aging alter mTOR signaling in response to feeding, the research
described Chapters V and VI of this dissertation also have several implications specific to
the horse. Based on the results discussed in Chapter V, the mTOR signaling in the
muscle of young growing horses was more sensitive to feeding stimuli than 2 year old
horses, which coincides with the fact that the greatest rate of average daily gain occurs in
the yearlings compared to the 2 year olds (336). This also indicates that the muscle of
this age of horse may be more sensitive to other anabolic stimuli such as exercise,
although this requires confirmation. A related implication is that if the skeletal muscle of
younger growing horses is more responsive than that of older growing horses to anabolic
stimuli, then if some factor, such as illness or poor nutrition, impairs growth and muscle
accretion during the more responsive younger stages of development, could have lasting
effects on muscle mass throughout the rest of the lifespan. Additionally, prolonged
periods of inactivity or stall rest may be more deleterious in the mature horse compared
to the growing horse, because the muscle lost during this period would be more difficult
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to recover due to decreased responsiveness to anabolic stimuli. In order to slow the loss
of muscle mass associated with post-adulthood aging, it may be necessary to gain a better
understanding of the factors regulating muscle protein metabolism the mature horse first,
especially in response to exercise. Reducing both insulin resistance and inflammation
will improve protein synthesis in response to feeding; this may reduce the loss of muscle
mass associated with post-adulthood aging. A related implication is that if the skeletal
muscle of aging horses is less responsive than that of mature horses to anabolic stimuli,
then if some factor, such as illness or poor nutrition, increases age associated muscle loss,
then muscle recovery will be extremely difficult. Ultimately, more research is needed but
the results of the studies in this dissertation provide insight to alternatives in management
practices that may improve skeletal muscle accretion and maintenance throughout the
lifespan.
8.2.1. Summary of the alterations in mTOR signaling throughout the lifespan in horses
A substantial amount of work is still required to examine the effects of aging
throughout the lifespan on mTOR signaling in the skeletal muscle of horses; however, it
is also imperative to examine the physiological endpoint of the mTOR signaling pathway
which is protein synthesis in the muscle. The studies in this dissertation have provided
the initial insight to the alterations in mTOR signaling throughout the lifespan in horses
and are the first to examine changes in mTOR signaling during the adolescent phase in
any species. These works indicate that in the post-absorptive state, in post-adulthood
aging may cause the reduction in mTOR signaling, where there were no differences in
post-absorptive mTOR signaling during growth. However, during the postprandial state,
it appears that mTOR signaling is more responsive in the faster growing young animals.
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These studies open up many possible future directions for additional research, and imply
that muscle accretion is more responsive to feeding in growing compared to mature
horses.
8.3. THE INFLUENCE OF INFLAMMATION ON mTOR SIGNALING IN
HORSES
The final key objective of this dissertation was to examine the influence of
inflammation on mTOR signaling horses. Models of acute (Chapter IV) and chronic
(Chapter VI and VII) inflammation were studied through the collection of repeated
muscle biopsies and aging, respectively. In both series of studies, the administration of a
NSAID, phenylbutazone, was administered to determine whether the reduction in
inflammation would result in changes in the responsiveness of mTOR signaling. Acute
inflammation reduced the activation of upstream mTOR signaling and increased the
activation of downstream mTOR signaling in response to meal consumption. However,
when a NSAID was administered, inflammation was reduced and the increase in mTOR
signaling due to acute inflammation was mediated. However, during chronic
inflammation in a relatively post-absorptive state, only the activation of S6K1 was
reduced. Because both states of inflammation were studied under different physiological
states they cannot be compared in the sense of which type of inflammation alters mTOR
signaling to a greater extent, although they can be discussed from a mechanistic
perspective. However, future research is warranted to examine the effects of both types
of inflammation (acute and chronic) on mTOR signaling under equal physiological states
(both postprandial and post-absorptive). For example, aging horses with confirmed low
grade chronic inflammation could be studied in an experimental design similar to that of
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Chapter IV: this would allow for the examination of the effect of acute inflammatory
stimuli in a state of chronic inflammation during the postprandial state on mTOR
signaling.
The activation of NF−κΒ by inflammatory cytokines was discussed in the
inflammatory signaling Section 1.5.1. Briefly, inflammatory cytokines activate IκKB
which phosphorylates NF−κΒ. Once activated, NF−κΒ inhibits the activation of Akt
(Section 1.3). Therefore the reduction in the activation of Akt in response to a meal
during acute inflammation may be a result of the increase in inflammatory cytokines
stimulating NF−κΒ activation. However, the administration of NSAID did not
ameliorate this reduction in Akt activation, even though there was a decrease in the
mRNA expression of IL−1β. Because the mRNA expression of TNF−α was not altered
in skeletal muscle due to NSAID administration and TNF−α has been demonstrated to
influence IκKB activation to a greater extent than any other inflammatory cytokine, then
it is possible that NSAID administration did not alter NF−κB activity which would
explain the absence of an effect of NSAID on Akt activation. Either the NSAID used
(phenylbutazone) did not target TNF−α expression or was not a large enough dose (1g
every 12 hours) to reduce TNF−α mRNA expression in skeletal muscle. Therefore, the
activation of IκKB may not have been altered and subsequently neither was NF−κΒ
phosphorylation. Unfortunately, the activation of IκKB and NF−κΒ were not examined,
which is needed in order to have a clearer perspective of this pathway. However, acute
inflammation increased the activation of downstream signaling factors in response to
meal consumption. In horses, MAPK signaling in skeletal muscle (470) and
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inflammatory cytokines in circulation and skeletal muscle (244) are increased following
exercise. MAPK signaling reduces the phosphorylation of the TSC1/2 complex
independent of Akt (Section 1.2), and would be expected to increase mTOR signaling in
cases of acute inflammation. The MAPK pathways may be an additional mechanism in
which inflammatory cytokines alter mTOR signaling.
During the post-absorptive state, low grade chronic inflammation has not been
shown to alter mTOR signaling in humans. However, Chapter VII showed that reducing
low grade chronic inflammation by administering 2g/day of phenylbutazone increased the
activation of S6K1. This may be due to an increase in MAPK signaling as mentioned
above; however, further research is warranted to fully elucidate this mechanism during
both the post-absorptive and postprandial states, and during both acute and chronic
inflammation.
The effect of NSAID administration on whole-body protein synthesis during low
grade chronic inflammation was also examined in Chapter VII. The results demonstrated
an increase in non-oxidative phenylalanine disposal, which is an indicator of protein
synthesis (Section 1.4.1), following 4 weeks of NSAID administration (2g/day of
phenylbutazone). The increase in protein synthesis coincided with a decrease in skeletal
muscle mRNA expression of IL−1β. The examination of the effects of NSAID in
reducing low grade chronic inflammation on protein synthesis are limited; however, it
has been demonstrated that 5 months of ibuprofen administration to aged rodents reduced
IL-6 and −1β and increased muscle protein fractional synthesis rates during the
postprandial state, with no change in muscle protein fractional synthesis rates during the
post-absorptive state (567). Thus, if age-related sarcopenia is to be controlled, a
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reduction in low grade chronic inflammation may be necessary. It is not practical or
healthy to recommend the daily administration of an NSAID, such as phenylbutazone, to
horses because of the possible damage to the gastrointestinal tract (323). Therefore,
investigations in reducing low grade chronic inflammation through dietary alterations are
necessary. Resveratrol may be a possible alternative because supplementation has
showed promise in reducing inflammation in horses through inhibiting the formation of
reactive oxygen species (558). Ultimately, there is a need to examine the diet of horses
with low grade chronic inflammation, most commonly the aged, in order to discover
practical methods of reducing inflammation which may allow for increased whole-body
and muscle protein synthesis and support the maintenance of muscle mass with
advancing age.
The studies in this dissertation did not examine the effects of altered mTOR
signaling on satellite cell proliferation during acute and chronic inflammation. This is an
area that requires examination because acute inflammation may be beneficial during postexercise or biopsy recovery. In humans, the reports of the effects of NSAID
administration during post-exercise recovery on protein synthesis are mixed due to the
NSAID drug administered, the dose of the drug administered, the method of
administration, the intensity of the exercise and the time post-exercise that muscle protein
fractional synthesis rates were examined. Reports indicate that oral NSAID
administration inhibits (568) the increase in muscle protein fractional synthesis rates from
pre- to post exercise, and localized NSAID administration does not alter (333) postexercise increase in the NSAID leg compared to the opposite leg. The increase in
inflammatory cytokines following exercise may be necessary for muscle repair post260

exercise (334) because inflammatory cytokines are regulators of satellite cell proliferation
(312, 313). However, local NSAID administration reduces satellite cell proliferation
(316) without altering muscle protein fractional synthesis rates (333) following exercise.
Therefore, it remains to be determined if a connection between mTOR signaling and
subsequent protein synthesis and satellite cell proliferation following exercise exists.
Additionally, low grade chronic inflammation has been demonstrated to increase
apoptosis of satellite cells (174, 281) which may influence the loss of muscle mass seen
with aging; however, further research is required to examine this.
In addition to advancing the physiological understanding of how acute and
chronic inflammation alter mTOR signaling in response to feeding, the research
described in Chapters IV and VII of this dissertation also have several implications
specific to the horse. First, the use of NSAID following acute inflammation in the
muscle may impair tissue regeneration and protein synthesis, and should be avoided in
cases where muscle growth or regeneration is desired. For example, horses in active
training, where the goal is to develop muscle needed for a particular discipline, the
beneficial effects of the exercise on muscle growth may be counteracted by NSAID
administration. The use of NSAID in reducing low grade chronic inflammation in the
aged showed that from mechanistic standpoint, the reduction of inflammation may have
beneficial effects on whole-body and muscle protein metabolism in horses. However,
daily NSAID administration would not likely be a practical part of a management plan
for the older horses, rather alternative strategies should be studied in an attempt to
mitigate the chronic inflammation that occurs in old horses (483, 484) and control muscle
loss in the aged.
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8.3.1. Summary of the influence of inflammation on mTOR signaling in horses
Although a substantial amount of work is required to elucidate the mechanisms
through which inflammatory cytokines alter mTOR signaling, the studies in this
dissertation provide insight into the effects of both acute and chronic inflammation on
mTOR signaling. Acute and chronic inflammation increased and decreased downstream
mTOR signaling, respectively, under the experimental conditions used in this research.
The use of phenylbutazone provided a mechanistic tool to reduce acute and chronic
inflammation and indicated that inflammatory cytokines may alter mTOR signaling
through Akt dependent and independent mechanisms. Ultimately, acute inflammation
may be beneficial for tissue repair, whereas chronic inflammation reduces mTOR
signaling and subsequent protein synthesis, likely resulting in a loss of skeletal muscle
mass over time.
8.4. CONCLUSION
In conclusion, the series of studies described in this dissertation have provided
initial knowledge in mTOR signaling in the adolescent and during acute inflammation
resulting from repeated biopsies. These studies were also the first examination of mTOR
signaling and whole-body protein synthesis in the aged horse. Methodologically, the
examination of mTOR signaling in mature horses can be compared from right and left
gluteal muscles at a depth of 6 to 10 cm below the surface of the skin, but if biopsies are
repeated administration of a NSAID is suggested in order to avoid the confounding effect
of biopsy. When examining mTOR signaling in response to feeding stimuli in different
ages of horses, the protein intake should be standardized by a percentage of the animal’s
protein requirement and the researcher must ensure that this is a strong enough anabolic
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stimuli to elicit alterations in mTOR signaling. Aging appeared to have a greater
influence on mTOR signaling during the post-absorptive state compared to any other life
stage; however, mTOR signaling during development appeared to be more responsive to
anabolic stimuli than any other life stage. Acute and chronic inflammation altered mTOR
signaling differently, where acute inflammation may be increase to mTOR signaling and
aid with muscle recovery from the inflammatory challenge. The results from this
dissertation are an important contribution to our knowledge of mTOR signaling,
regardless of the species studied, but particularly in the horse where the current
knowledge about muscle protein metabolism is extremely limited. This dissertation also
revealed the many potential areas for future research with regards to mTOR signaling in
horses.
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Appendix
A.1. HPLC CHROMATOGRAM EXAMPLES

A.1.1. An example of a physiological free amino acid standard chromatogram. The
free amino acid standard was used in the calculations of free plasma amino acid samples
and free muscle amino acid samples. The injected standard had a concentration of 0.5
nmol/μL of each amino acid and 500 pmol of each amino acid was injected onto the
column. Since all of the amino acids had the same concentration, the purpose of running
the standard was to determine amino acid differences in peak area relative to Norleucine
(the internal standard run with every sample and standard) to correct peak area to correct
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sample amino acid peak areas. The interassay C.V. expressed as standard AA relative to
Norleucine ranged from as low as 0.07 ± 0.08% for Asp and as high as 1.42 ± 0.10% for
Lys.
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A.1.2. An example of a plasma free amino acid chromatogram. This is an example
of a horse from Chapter V at the 15 minute sampling period of the post-absorptive state.
The calculation used for determining free plasma amino acid concentrations is as follows:
pmol = [(sample AA peak area)/(standard AA peak area/standard internal standard peak
area)]*(pmol of internal standard injected with sample/peak area of internal standard in
sample)
Then pmol must be converted to μmol/L plasma using the following equation:
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μmol/L plasma = (pmol of AA/ μL of reconstituted sample injected)*( μL of diluents
used to reconstitute derivatized sample/ μL of ultrafiltrate that was derivatized)*dilution
of plasma prior to ultrafiltration*((106 μL/L)/(109 pmol/μmol)).
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A.1.3. An example of a muscle free amino acid chromatogram. This is an example of
a horse from Chapter III at a sampling depth of 6 cm below the surface of the skin. The
calculation used for determining free muscle amino acid concentrations is as follows:
pmol = [(sample AA peak area)/(standard AA peak area/standard internal standard peak
area)]*(pmol of internal standard injected with sample/peak area of internal standard in
sample)
Then pmol must be converted to μmol/g of wet weight muscle using the following
equation:
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nmol/g of wet weight muscle = (pmol of AA/ μL of reconstituted sample injected)*( μL
of diluents used to reconstitute derivatized sample/ μL of ultrafiltrate that was
derivatized)* (extraction volume/tissue extracted)*(10-9 μmol/pmol).
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A.1.4. An example of a total hydralysate amino acid standard chromatogram. The
total hydralysate amino acid standard was used in the calculations of total hydralysate
amino acid samples for example feed samples. The injected standard had a concentration
of 6.25 nmol/μL, and 6250 pmol of each amino acid was injected onto the column. Since
all of the amino acids had the same concentration, the purpose of running the standard
was to determine amino acid differences in peak area relative to Norleucine (the internal
standard run with every sample and standard) to correct peak area to correct sample
amino acid peak areas. The interassay C.V. expressed as standard AA relative to
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Norleucine ranged from as low as 0.86 ± 0.05% for Thr and as high as 1.76 ± 0.08% for
Lys.
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A.1.5. An example of a total hydralysate amino acid chromatogram from a feed
sample. This is an example of the total hydralysate amino acid chromatogram from the
high protein pellet fed in Chapters III – V. The calculation used for determining total
hydralysate amino acid concentrations is as follows:
pmol = pmol of AA in injected from the standard *[AA peak area in sample/(internal
standard pear area in the sample/internal standard peak area in the standarad)]/AA peak
area in the standard.
Then pmol must be converted to pmol/g of feed using the following equation:
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pmol/g of feed = (pmol of AA in the injected sample/injection volume, μL)*(volume of
diluent to reconstitute sample, μL/amount of HCl filtrate derivatized, μL) * (amount of
HCl used, mL/feed sample weight, g) * (10-3).
Then to convert pmol of AA/g of feed to g of AA/100g of feed:
g of AA/100g of feed = (pmol of AA/g feed)* (1 mol/1012 pmol) * (MW of AA residue
in g/mol) *100.
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contained 0.002 μg of antigen; the “1:1 antibody to antigen mixture” contained 0.2 μg of
antigen; and the “1:4 antibody to antigen mixture contained 2 μg of antigen. These
mixtures were allowed to incubate at room temperature for 30 minutes, which was the
manufacturer’s suggested time allotment for the reaction between the antibody and
antigen to occur. The mixtures were then placed on the membrane and allowed to react
with the proteins bound to the membrane for 18 hours at 4oC. Then, all sections of the
membrane were washed and treated with secondary antibody which was a goat anti-rabbit
IgG (H+L) with conjugated horseradish peroxidase (1:10,000 dilution in 5% fat-free milk
solution; BioRad, Hercules, CA) for 1 hour at room temperature. Membranes were
developed using a chemiluminescence kit (Amersham ECL Plus Western Blotting
Detection Reagents; GE Healthcare, Piscataway, NJ) and visualized on x-ray film using a
film processor (Kodak X-OMAT film processor, Kodak Health Imaging Division,
Rochester, NY). In the wells of the above figure: (1) a molecular marker (MagicMark™,
Invitrogen, Carlsbad, CA) (2) a positive control (Akt Control Cell Extracts from Jurkat
cells treated with Calyculin A, Cell Signaling Technology ®, Inc., Boston, MA), (3) a
negative control (Akt Control Cell Extracts from Jurkat cells treated with LY294002,
Cell Signaling Technology ®, Inc., Boston, MA), (4) mature equine gluteal muscle in the
postprandial state, (5) mature equine gluteal muscle in the postprandial state, (6) mature
equine gluteal muscle in the postprandial state, (7) a positive control (Akt Control Cell
Extracts from Jurkat cells treated with Calyculin A, Cell Signaling Technology ®, Inc.,
Boston, MA), (8) a negative control (Akt Control Cell Extracts from Jurkat cells treated
with LY294002, Cell Signaling Technology ®, Inc., Boston, MA), (9) mature equine
gluteal muscle in the postprandial state, (10) mature equine gluteal muscle in the
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postprandial state, and (11) mature equine gluteal muscle in the postprandial state. Wells
1-4 were treated with 100% primary antibody. Well 5 was treated with 0% primary
antibody. Well 6 was treated with a primary antibody to antigen (P-Akt Ser473 Blocking
Peptide, Cell Signaling Technology ®, Inc., Boston, MA) at a ratio of 1:1/16. Wells 7-9
were treated with a primary antibody to antigen ratio of 1:1/4. Well 10 was treated with a
primary antibody to antigen ratio of 1:1, and well 11 was treated with a primary antibody
to antigen ratio of 1:4. This validated the use of this primary antibody in the horse,
because when an antigen was applied there was inhibition of the antibody to bind with
the mature equine gluteal muscle in the postprandial state. Additionally, the “0% primary
antibody” validated the use of this secondary antibody, because in the absence of a
primary antibody there was total inhibition of binding.
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the manufacturer’s suggested time allotment for the reaction between the antibody and
antigen to occur. The mixtures were then placed on the membrane and allowed to react
with the proteins bound to the membrane for 18 hours at 4oC. Then, all sections of the
membrane were washed and treated with secondary antibody which was a goat anti-rabbit
IgG (H+L) with conjugated horseradish peroxidase (1:10,000 dilution in 5% fat-free milk
solution; BioRad, Hercules, CA) for 1 hour at room temperature. Membranes were
developed using a chemiluminescence kit (Amersham ECL Plus Western Blotting
Detection Reagents; GE Healthcare, Piscataway, NJ) and visualized on x-ray film using a
film processor (Kodak X-OMAT film processor, Kodak Health Imaging Division,
Rochester, NY). In the wells of the above figure: (1) a molecular marker (MagicMark™,
Invitrogen, Carlsbad, CA) (2) a positive control (Akt Control Cell Extracts from Jurkat
cells treated with Calyculin A, Cell Signaling Technology ®, Inc., Boston, MA), (3) a
negative control (Akt Control Cell Extracts from Jurkat cells treated with LY294002,
Cell Signaling Technology ®, Inc., Boston, MA), (4) mature equine gluteal muscle in the
postprandial state, (5) a positive control (Akt Control Cell Extracts from Jurkat cells
treated with Calyculin A, Cell Signaling Technology ®, Inc., Boston, MA), (6) a negative
control (Akt Control Cell Extracts from Jurkat cells treated with LY294002, Cell
Signaling Technology ®, Inc., Boston, MA), (7) mature equine gluteal muscle in the
postprandial state, (8) mature equine gluteal muscle in the postprandial state, (9) mature
equine gluteal muscle in the postprandial state, (10) a positive control (Akt Control Cell
Extracts from Jurkat cells treated with Calyculin A, Cell Signaling Technology ®, Inc.,
Boston, MA), (11) a negative control (Akt Control Cell Extracts from Jurkat cells treated
with LY294002, Cell Signaling Technology ®, Inc., Boston, MA), and (12) mature
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equine gluteal muscle in the postprandial state. Wells 1-4 were treated with 100%
primary antibody. Well 5-7 were treated with a primary antibody to antigen (P-Akt
Thr308 Blocking Peptide, Cell Signaling Technology ®, Inc., Boston, MA) at a ratio of
1:4. Well 8 was treated with a primary antibody to antigen ratio of 1:1. Well 9 was
treated with a primary antibody to antigen ratio of 1:1/4, and wells 10-12 were treated
with a primary antibody to antigen ratio of 1:1/16. This validated the use of this primary
antibody in the horse, because when an antigen was applied there was inhibition of the
antibody to bind with the mature equine gluteal muscle in the postprandial state.
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in the post-absorpt
p
tive state, (100) a gluteal muscle
m
biopsy
coollected from
m a mature horse
h
in the postprandial
p
l state, (11) a gluteal musscle biopsy
coollected from
m a mature horse
h
in the post-absorpt
p
tive state, (122) a gluteal muscle
m
biopsy
coollected from
m a yearling horse in thee postprandiaal state, (13) ) a gluteal muscle
m
biopssy
coollected from
m a yearling horse in thee post-absorpptive state, (14) a molecuular marker
(M
MagicMark™
™, Invitrogeen, Carlsbad,, CA).
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A
A.2.3a.
An example
e
of the
t Akt Tottal Antibodyy Validation
n. In order to determine
crross-species reactivity of the primaryy and seconddary antiboddies used forr the
determination
n of the abunndance of thee 60 kDa Akkt Total, poooled equine gluteal
g
musccle
m horses in thhe postpranddial state undderwent electtrophoresis on
o
saamples from
polyacrylamide gels and then
t
were transferred to a PVDF meembrane (addditional detaail
T membraane
reegarding elecctrophoresiss and transferr can be founnd in Sectionn 3.4.1.3). The
w then stain
was
ned with Fasst Green Staiin (1% fast green,
g
50% methanol,
m
1%
% glacial aceetic
accid), which stains
s
the prootein bound to the membbrane. Nextt the membraane was cut
between wells 3 and 4, 4 and 5, 7 andd 8, 8 and 9 and
a 9 and 100, and placedd in individuual
coontainers. The
T Fast Green Stain wass removed with
w Destain (50% methaanol, 1% glaacial
accetic acid), and
a the mem
mbranes weree washed andd blocked with
w 5% fat-frree milk soluution
foor 1 hour at room
r
temperrature. Meaanwhile, the primary
p
antiibody and prrimary antibody
annd antigen mixtures
m
werre prepared as
a follows: thhe “100% prrimary antibody” was a
raabbit polyclo
onal antibodyy that recognnized Akt Tootal (Cell Siignaling Technology®, Inc.,
I
B
Boston,
MA) and prepareed as a 1:20000 dilution inn 5% fat-freee milk solutiion; the “0%
%
prrimary antib
body” was a 5% fat-free milk solutioon; the “1:1/116 antibody to antigen
m
mixture”
conttained 0.00000000004 μgg antigen; thee “1:1/4 antiibody to antiigen mixturee”
coontained 0.0
000001 μg anntigen; the “1:1 antibodyy to antigen mixture”
m
conntained 0.0005 μg
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antigen; and the “1:4 antibody to antigen mixture” contained 5 μg of antigen. These
mixtures were allowed to incubate at room temperature for 30 minutes, which was the
manufacturer’s suggested time allotment for the reaction between the antibody and
antigen to occur. The mixtures were then placed on the membrane and allowed to react
with the proteins bound to the membrane for 18 hours at 4oC. Then, all sections of the
membrane were washed and treated with secondary antibody which was a goat anti-rabbit
IgG (H+L) with conjugated horseradish peroxidase (1:10,000 dilution in 5% fat-free milk
solution; BioRad, Hercules, CA) for 1 hour at room temperature. Membranes were
developed using a chemiluminescence kit (Amersham ECL Plus Western Blotting
Detection Reagents; GE Healthcare, Piscataway, NJ) and visualized on x-ray film using a
film processor (Kodak X-OMAT film processor, Kodak Health Imaging Division,
Rochester, NY). In the wells of the above figure: (1) a negative control (Akt Control Cell
Extracts from Jurkat cells treated with LY294002, Cell Signaling Technology ®, Inc.,
Boston, MA), (2) a positive control (Akt Control Cell Extracts from Jurkat cells treated
with Calyculin ,A Cell Signaling Technology ®, Inc., Boston, MA), (3) mature equine
gluteal muscle in the postprandial state, (4) mature equine gluteal muscle in the
postprandial state, (5) mature equine gluteal muscle in the postprandial state, (6) a
positive control (Akt Control Cell Extracts from Jurkat cells treated with Calyculin A,
Cell Signaling Technology ®, Inc., Boston, MA), (7) a negative control (Akt Control Cell
Extracts from Jurkat cells treated with LY294002, Cell Signaling Technology ®, Inc.,
Boston, MA), (8) mature equine gluteal muscle in the postprandial state, (9) mature
equine gluteal muscle in the postprandial state, and (10) mature equine gluteal muscle in
the postprandial state. Wells 1-3 were treated with 100% primary antibody. Well 4 was
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treated with 0% primary antibody. Wells 5-7 were treated with a primary antibody to
antigen (Akt pan Blocking Peptide, Cell Signaling Technology ®, Inc., Boston, MA) at a
ratio of 1:4. Well 8 was treated with a primary antibody to antigen ratio of 1:1. Well 9
was treated with a primary antibody to antigen ratio of 1:1/4, and well 10 was treated
with a primary antibody to antigen ratio of 1:1/16. This validated the use of this primary
antibody in the horse, because when an antigen was applied there was inhibition of the
antibody to bind with the mature equine gluteal muscle in the postprandial state.
However, it is important to note that the presence of Akt total in the negative control was
expected. Because this protein is ubiquitous, the negative controls serve a greater
purpose in the validation of the phosphorylated forms. Additionally, the “0% primary
antibody” validated the use of this secondary antibody, because in the absence of a
primary antibody there was total inhibition of binding.
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A
A.2.3b.
An example
e
of an
a Akt Totaal x-ray film
m from Chap
pter IV. Thhis is an x-raay of
thhe same mem
mbrane that is
i shown in A.2.1b.
A
afterr it has beenn stripped an re-probed with
w
A Total prim
Akt
mary antiboddy. In the wells
w
of the above
a
figure: (1) a moleccular markerr
(M
MagicMark™
™, Invitrogeen, Carlsbad,, CA), (2) a positive
p
conntrol (Akt Coontrol Cell
E
Extracts
from
m Jurkat cellss treated withh Calyculin A, Cell Signnaling Technnology ®, Innc.,
B
Boston,
MA), (3) a gluteaal muscle bioopsy collecteed 60 minutees followingg consuming a
high protein pellet
p
on Dayy 1 from thee left side, (44) a gluteal muscle
m
biopssy collected 60
6
m
minutes
following consum
ming a high protein pelleet on Day 1 from the rigght side, (5) a
gluteal musclle biopsy colllected 60 minutes
m
follow
wing consum
ming a high protein
p
pelleet on
D 2 from th
Day
he left side, (6) a gluteall muscle bioppsy collectedd 60 minutess following
coonsuming a high proteinn pellet on Day
D 2 from thhe right side,, (7) a gluteaal muscle bioopsy
coollected 60 minutes
m
folloowing consuuming a highh protein pellet on Day 3 from the left
siide, (8) a glu
uteal muscle biopsy colleected 60 minnutes following consumiing a high
prrotein pellett on Day 3 frrom the rightt side, (9) a gluteal
g
musccle biopsy coollected 60
m
minutes
following consum
ming a high protein pelleet on Day 4 from the left
ft side, (10) a
gluteal musclle biopsy colllected 60 minutes
m
follow
wing consum
ming a high protein
p
pelleet on
D 4 from th
Day
he right side, (11) a gluteeal muscle biopsy
b
colleccted 60 minuutes followinng
coonsuming a high proteinn pellet on Day
D 5 from thhe left side, (12)
(
a gluteaal muscle bioopsy
coollected 60 minutes
m
folloowing consuuming a highh protein pellet on Day 5 from the rigght
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side. The abundance of this protein is reported as a ratio of the phosphorylated to total
form. The positive control was used to account for interassay variability. The C.V. of
the phosphorylated to total ratio of the positive control for P-Akt Ser473 and P-Akt Thr308
are 0.22 ± 0.13 and 0.12 ± 0.12, respectively. The right to left side phosphorylated to
total ratio of for P-Akt Ser473 was 0.16 ± 0.12. P-Akt Thr308 was not examined in
Chapter IV. These were from Chapter IV for P-Akt Ser473 and Chapter V for P-Akt
Thr308. In Chapter IV side was tested in the statistical model and found to not be
significant (P < 0.05).
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A
A.2.4a.
An example
e
of the
t P-S6K1 Thr389 Antiibody Valid
dation. In orrder to deterrmine
crross-species reactivity of the primaryy and seconddary antiboddies used forr the
determination
n of the abunndance of thee P-p70 kDaa S6K1 Thr3889, pooled eqquine gluteall
m
muscle
samplles from horrses in the poostprandial state
s
underwent electrophhoresis on
polyacrylamide gels and then
t
were transferred to a PVDF meembrane (addditional detaail
T membraane
reegarding elecctrophoresiss and transferr can be founnd in Sectionn 3.4.1.3). The
w then stain
was
ned with Fasst Green Staiin (1% fast green,
g
50% methanol,
m
1%
% glacial aceetic
accid), which stains
s
the prootein bound to the membbrane. Nextt the membraane was cut
between wells 4 and 5, 7 and 8, 8 andd 9 and 9 andd 10, and plaaced in indivvidual contaiiners.
T Fast Greeen Stain wass removed with
The
w Destain (50% methaanol, 1% glaccial acetic accid),
annd the memb
branes were washed andd blocked witth 5% fat-freee milk soluution for 1 hoour at
rooom temperaature. Meannwhile, the primary antibbody and prim
mary antibody and antiggen
m
mixtures
weree prepared as
a follows: thhe “100% prrimary antiboody” was a rabbit
r
polycllonal
anntibody that recognized P-S6K1 Thrr389, which iss present in two
t forms thhe 85 kDa annd 70
kD
Da our interrest is in the 70 kDa S6K
K1 (Cell Signnaling Technnology®, Incc., Boston, MA),
M
annd prepared as a 1:500 dilution
d
in 5%
% fat-free milk
m solution;; the “1:1/322 antibody too
anntigen mixtu
ure” containeed 9.77*10-222 μg antigenn; the “1:1/166 antibody too antigen
m
mixture”
conttained 3.9*110-18 μg antiggen; the “1:11/4 antibody to antigen mixture”
m
coontained 1.5
56*10-14 μg antigen;
a
and the “1:1 anttibody to anttigen mixture” containedd
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0.002 μg of antigen. These mixtures were allowed to incubate at room temperature for
30 minutes, which was the manufacturer’s suggested time allotment for the reaction
between the antibody and antigen to occur. The mixtures were then placed on the
membrane and allowed to react with the proteins bound to the membrane for 18 hours at
4oC. Then, all sections of the membrane were washed and treated with secondary
antibody which was a goat anti-rabbit IgG (H+L) with conjugated horseradish peroxidase
(1:10,000 dilution in 5% fat-free milk solution; BioRad, Hercules, CA) for 1 hour at
room temperature. Membranes were developed using a chemiluminescence kit
(Amersham ECL Plus Western Blotting Detection Reagents; GE Healthcare, Piscataway,
NJ) and visualized on x-ray film using a film processor (Kodak X-OMAT film processor,
Kodak Health Imaging Division, Rochester, NY). In the wells of the above figure: (1) a
molecular marker (MagicMark™, Invitrogen, Carlsbad, CA), (2) a positive control (p70
S6 Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling
Technology ®, Inc., Boston, MA), (3) a negative control (p70 S6 Kinase Control Cell
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA),
(4) mature equine gluteal muscle in the postprandial state, (5) a positive control (p70 S6
Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling
Technology ®, Inc., Boston, MA), (6) a negative control (p70 S6 Kinase Control Cell
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA),
(7) mature equine gluteal muscle in the postprandial state, (8) mature equine gluteal
muscle in the postprandial state, (9) mature equine gluteal muscle in the postprandial
state, (10) a positive control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells
treated with insulin, Cell Signaling Technology ®, Inc., Boston, MA), (11) a negative
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control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells untreated, Cell Signaling
Technology ®, Inc., Boston, MA), and (12) mature equine gluteal muscle in the
postprandial state. Wells 1-4 were treated with 100% primary antibody. Wells 5-7 were
treated with a primary antibody to antigen (P-S6K1 Thr389 Blocking Peptide, Cell
Signaling Technology ®, Inc., Boston, MA) at a ratio of 1:1. Well 8 was treated with a
primary antibody to antigen ratio of 1:1/4. Well 9 was treated with a primary antibody to
antigen ratio of 1:1/16, and wells 10-12 were treated with a primary antibody to antigen
ratio of 1:1/32. This validated the use of this primary antibody in the horse, because
when an antigen was applied there was inhibition of the antibody to bind with the mature
equine gluteal muscle in the postprandial state. However, it is important to note that the
presence of both the 85 kDa and 70 kDa S6K1 total in the negative and positive controls
was expected. The use of the molecular weight marker allowed us to determine the 70
kDa from the 85 kDa S6K1 bands, our interest was in the 70 kDa S6K1. Because S6K1
is phosphorylated following mTORC1 activation, which can be activated by both insulin
and amino acids, the negative controls were untreated with insulin but remained in a
media that contained amino acids resulting in a diminished response than the positive
controls.
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A
A.2.4b.
An example
e
of a P-S6K1 Thr
T 389 x-ray film from Chapter
C
IV.. This is an
exxample of a horse on –N
NSAID treatm
ment. In thee wells of thee above figuure: (1) a possitive
coontrol (p70 S6
S Kinase Control
C
Cell Extracts
E
from
m MCF-7 ceells treated with
w insulin, Cell
Signaling Tecchnology ®,, Inc., Bostonn, MA), (2) a gluteal muuscle biopsy collected 600
m
minutes
following consum
ming a high protein pelleet on Day 1 from the left
ft side, (3) a
gluteal musclle biopsy colllected 60 minutes
m
follow
wing consum
ming a high protein
p
pelleet on
D 1 from th
Day
he right side, (4) a gluteaal muscle bioopsy collected 60 minutes followingg
coonsuming a high proteinn pellet on Day
D 2 from thhe left side, (5)
( a gluteal muscle bioppsy
coollected 60 minutes
m
folloowing consuuming a highh protein pellet on Day 2 from the rigght
siide, (6) a glu
uteal muscle biopsy colleected 60 minnutes following consumiing a high
prrotein pellett on Day 3 frrom the left side,
s
(7) a glluteal musclee biopsy collected 60
m
minutes
following consum
ming a high protein pelleet on Day 3 from the rigght side, (8) a
gluteal musclle biopsy colllected 60 minutes
m
follow
wing consum
ming a high protein
p
pelleet on
D 4 from th
Day
he left side, (9) a gluteall muscle bioppsy collectedd 60 minutess following
coonsuming a high proteinn pellet on Day
D 4 from thhe right side,, (10) a gluteeal muscle
biopsy collected 60 minuutes following consumingg a high prottein pellet onn Day 5 from
m the
leeft side, (11)) a gluteal muuscle biopsyy collected 60
6 minutes foollowing connsuming a hiigh
prrotein pellett on Day 5 frrom the rightt side.
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A
A.2.5a.
An example
e
of the
t S6K1 Tootal Antibod
dy Validatioon. In orderr to determinne
crross-species reactivity of the primaryy and seconddary antiboddies used forr the
determination
n of the abunndance of thee 70 kDa S66K1 Total, poooled equinee gluteal muscle
m horses in thhe postpranddial state undderwent electtrophoresis on
o
saamples from
polyacrylamide gels and then
t
were transferred to a PVDF meembrane (addditional detaail
T membraane
reegarding elecctrophoresiss and transferr can be founnd in Sectionn 3.4.1.3). The
w then stain
was
ned with Fasst Green Staiin (1% fast green,
g
50% methanol,
m
1%
% glacial aceetic
accid), which stains
s
the prootein bound to the membbrane. Nextt the membraane was cut
between wells 4 and 5, 7 and 8, 8 andd 9 and 9 andd 10, and plaaced in indivvidual contaiiners.
T Fast Greeen Stain wass removed with
The
w Destain (50% methaanol, 1% glaccial acetic accid),
annd the memb
branes were washed andd blocked witth 5% fat-freee milk soluution for 1 hoour at
rooom temperaature. Meannwhile, the primary antibbody and prim
mary antibody and antiggen
m
mixtures
weree prepared as
a follows: thhe “100% prrimary antiboody” was a rabbit
r
polycllonal
anntibody that recognized S6K1 Total, which is prresent in twoo forms the 85
8 kDa and 70
7
kD
Da our interrest is in the 70 kDa S6K
K1 (Cell Signnaling Technnology®, Incc., Boston, MA),
M
annd prepared as a 1:1,0000 dilution in 5% fat-free milk solutioon; the “1:1/332 antibody to
anntigen mixtu
ure” containeed 9.77*10-222 μg antigenn; the “1:1/166 antibody too antigen
m
mixture”
conttained 3.9*110-18 μg antiggen; the “1:11/4 antibody to antigen mixture”
m
coontained 1.5
56*10-14 μg antigen;
a
and the “1:1 anttibody to anttigen mixture” containedd
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0.002 μg of antigen. These mixtures were allowed to incubate at room temperature for
30 minutes, which was the manufacturer’s suggested time allotment for the reaction
between the antibody and antigen to occur. The mixtures were then placed on the
membrane and allowed to react with the proteins bound to the membrane for 18 hours at
4oC. Then, all sections of the membrane were washed and treated with secondary
antibody which was a goat anti-rabbit IgG (H+L) with conjugated horseradish peroxidase
(1:10,000 dilution in 5% fat-free milk solution; BioRad, Hercules, CA) for 1 hour at
room temperature. Membranes were developed using a chemiluminescence kit
(Amersham ECL Plus Western Blotting Detection Reagents; GE Healthcare, Piscataway,
NJ) and visualized on x-ray film using a film processor (Kodak X-OMAT film processor,
Kodak Health Imaging Division, Rochester, NY). In the wells of the above figure: (1) a
molecular marker (MagicMark™, Invitrogen, Carlsbad, CA), (2) a positive control (p70
S6 Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling
Technology ®, Inc., Boston, MA), (3) a negative control (p70 S6 Kinase Control Cell
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA),
(4) mature equine gluteal muscle in the postprandial state, (5) a positive control (p70 S6
Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling
Technology ®, Inc., Boston, MA), (6) a negative control (p70 S6 Kinase Control Cell
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA),
(7) mature equine gluteal muscle in the postprandial state, (8) mature equine gluteal
muscle in the postprandial state, (9) mature equine gluteal muscle in the postprandial
state, (10) a positive control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells
treated with insulin, Cell Signaling Technology ®, Inc., Boston, MA), (11) a negative
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control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells untreated, Cell Signaling
Technology ®, Inc., Boston, MA), and (12) mature equine gluteal muscle in the
postprandial state. Wells 1-4 were treated with 100% primary antibody. Wells 5-7 were
treated with a primary antibody to antigen (S6K1 Blocking Peptide, Cell Signaling
Technology ®, Inc., Boston, MA) at a ratio of 1:1. Well 8 was treated with a primary
antibody to antigen ratio of 1:1/4. Well 9 was treated with a primary antibody to antigen
ratio of 1:1/16, and wells 10-12 were treated with a primary antibody to antigen ratio of
1:1/32. This validated the use of this primary antibody in the horse, because when an
antigen was applied there was inhibition of the antibody to bind with the mature equine
gluteal muscle in the postprandial state. However, it is important to note that the
presence of both the 85 kDa and 70 kDa S6K1 total in the negative and positive controls
swas expected. The use of the molecular weight marker allowed us to determine the 70
kDa from the 85 kDa S6K1 bands, our interest was in the 70 kDa S6K1. Because this
protein is ubiquitous, the negative controls serve a greater purpose in the validation of the
phosphorylated forms.
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A
A.2.5b.
An example
e
of an
a S6K1 Tootal x-ray fillm from Ch
hapter IV. This
T is an x-rray
of the same membrane
m
thhat is shown in A.2.4b. after it has beeen stripped an re-probedd
w S6K1 To
with
otal primaryy antibody. In
I the wells of
o the abovee figure: (1) a positive coontrol
(pp70 S6 Kinaase Control Cell
C Extractss from MCF--7 cells treatted with insuulin, Cell
Signaling Tecchnology ®,, Inc., Bostonn, MA), (2) a gluteal muuscle biopsy collected 600
m
minutes
following consum
ming a high protein pelleet on Day 1 from the left
ft side, (3) a
gluteal musclle biopsy colllected 60 minutes
m
follow
wing consum
ming a high protein
p
pelleet on
D 1 from th
Day
he right side, (4) a gluteaal muscle bioopsy collected 60 minutes followingg
coonsuming a high proteinn pellet on Day
D 2 from thhe left side, (5)
( a gluteal muscle bioppsy
coollected 60 minutes
m
folloowing consuuming a highh protein pellet on Day 2 from the rigght
siide, (6) a glu
uteal muscle biopsy colleected 60 minnutes following consumiing a high
prrotein pellett on Day 3 frrom the left side,
s
(7) a glluteal musclee biopsy collected 60
m
minutes
following consum
ming a high protein pelleet on Day 3 from the rigght side, (8) a
gluteal musclle biopsy colllected 60 minutes
m
follow
wing consum
ming a high protein
p
pelleet on
D 4 from th
Day
he left side, (9) a gluteall muscle bioppsy collectedd 60 minutess following
coonsuming a high proteinn pellet on Day
D 4 from thhe right side,, (10) a gluteeal muscle
biopsy collected 60 minuutes following consumingg a high prottein pellet onn Day 5 from
m the
leeft side, (11)) a gluteal muuscle biopsyy collected 60
6 minutes foollowing connsuming a hiigh
prrotein pellett on Day 5 frrom the rightt side. The abundance
a
o this proteinn is reportedd as a
of
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ratio of the phosphorylated to total form. The positive control was used to account for
interassay variability. The C.V. of the phosphorylated to total ratio of the positive control
for P-S6K1 Thr389 was 0.14 ± 0.13. The right to left side phosphorylated to total ratio of
for P-S6K1 Thr389 was 0.18 ± 0.16. These were obtained from Chapter IV. In Chapter
IV side was tested in the statistical model and found to not be significant (P < 0.05).
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A
A.2.6a.
An example
e
of the
t P-rpS6 Ser
S 235/236 An
ntibody Validation. In order to
determine cro
oss-species reactivity
r
of the primary and secondaary antibodiees used for the
t
2
determination
n of the abunndance of theeP-rpS6 Ser235/236
, pooleed equine gluuteal musclee

saamples from
m horses in thhe postpranddial state undderwent electtrophoresis on
o
polyacrylamide gels and then
t
were transferred to a PVDF meembrane (addditional detaail
T membraane
reegarding elecctrophoresiss and transferr can be founnd in Sectionn 3.4.1.3). The
w then stain
was
ned with Fasst Green Staiin (1% fast green,
g
50% methanol,
m
1%
% glacial aceetic
accid), which stains
s
the prootein bound to the membbrane. Nextt the membraane was cut
between wells 4 and 5, 7 and 8, 8 andd 9 and 9 andd 10, and plaaced in indivvidual contaiiners.
T Fast Greeen Stain wass removed with
The
w Destain (50% methaanol, 1% glaccial acetic accid),
annd the memb
branes were washed andd blocked witth 5% fat-freee milk soluution for 1 hoour at
rooom temperaature. Meannwhile, the primary antibbody and prim
mary antibody and antiggen
m
mixtures
weree prepared as
a follows: thhe “100% prrimary antiboody” was a rabbit
r
polycllonal
anntibody that recognized P-rpS6 Ser235/236 (Cell Signaling
S
Tecchnology®, Inc., Bostonn,
M
MA),
and preepared as a 1:2,000 dilutiion in 5% faat-free milk solution;
s
thee “1:1/32
anntibody to an
ntigen mixtuure” containeed 4.88*10-222 μg antigenn; the “1:1/166 antibody too
anntigen mixtu
ure” containeed 1.95*10-118 μg antigenn; the “1:1/4 antibody to antigen
m
mixture”
conttained 7.8*110-15 μg antiggen; and the “1:1 antiboddy to antigenn mixture”
coontained 0.0
001 μg of anttigen. Thesee mixtures were
w allowedd to incubatee at room
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temperature for 30 minutes, which was the manufacturer’s suggested time allotment for
the reaction between the antibody and antigen to occur. The mixtures were then placed
on the membrane and allowed to react with the proteins bound to the membrane for 18
hours at 4oC. Then, all sections of the membrane were washed and treated with
secondary antibody which was a goat anti-rabbit IgG (H+L) with conjugated horseradish
peroxidase (1:10,000 dilution in 5% fat-free milk solution; BioRad, Hercules, CA) for 1
hour at room temperature. Membranes were developed using a chemiluminescence kit
(Amersham ECL Plus Western Blotting Detection Reagents; GE Healthcare, Piscataway,
NJ) and visualized on x-ray film using a film processor (Kodak X-OMAT film processor,
Kodak Health Imaging Division, Rochester, NY). In the wells of the above figure: (1) a
molecular marker (MagicMark™, Invitrogen, Carlsbad, CA), (2) a positive control (p70
S6 Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling
Technology ®, Inc., Boston, MA), (3) a negative control (p70 S6 Kinase Control Cell
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA),
(4) mature equine gluteal muscle in the postprandial state, (5) a positive control (p70 S6
Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling
Technology ®, Inc., Boston, MA), (6) a negative control (p70 S6 Kinase Control Cell
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA),
(7) mature equine gluteal muscle in the postprandial state, (8) mature equine gluteal
muscle in the postprandial state, (9) mature equine gluteal muscle in the postprandial
state, (10) a positive control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells
treated with insulin, Cell Signaling Technology ®, Inc., Boston, MA), (11) a negative
control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells untreated, Cell Signaling
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Technology ®, Inc., Boston, MA), and (12) mature equine gluteal muscle in the
postprandial state. Wells 1-4 were treated with 100% primary antibody. Wells 5-7 were
treated with a primary antibody to antigen (P-rpS6 Ser235/236 Blocking Peptide, Cell
Signaling Technology ®, Inc., Boston, MA) at a ratio of 1:1. Well 8 was treated with a
primary antibody to antigen ratio of 1:1/4. Well 9 was treated with a primary antibody to
antigen ratio of 1:1/16, and wells 10-12 were treated with a primary antibody to antigen
ratio of 1:1/32. This validated the use of this primary antibody in the horse, because
when an antigen was applied there was inhibition of the antibody to bind with the mature
equine gluteal muscle in the postprandial state. However, it is important to note that the
presence P-rpS6-Ser235/236 in the negative and positive controls was expected, because
rpS6 is phosphorylated following S6K1 phosphorylation which is activated by the active
from of mTORC1. mTORC1 is activated due to both insulin and amino acids, the
negative controls were untreated with insulin and the positive controls were treated with
insulin, but both were in media containing amino acids. As a result, P-rpS6 Ser235/236 is
present in the negative control, but diminished in comparison to the positive control.
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A
A.2.6b.
An example
e
of the
t P-rpS6 Ser240/244 An
ntibody Vallidation. In order to
determine cro
oss-species reactivity
r
of the primary and secondaary antibodiees used for the
t
2
determination
n of the abunndance of theeP-rpS6 Ser240/244
, pooleed equine gluuteal musclee

saamples from
m horses in thhe postpranddial state undderwent electtrophoresis on
o
polyacrylamide gels and then
t
were transferred to a PVDF meembrane (addditional detaail
reegarding elecctrophoresiss and transferr can be founnd in Sectionn 3.4.1.3). The
T membraane
w then stain
was
ned with Fasst Green Staiin (1% fast green,
g
50% methanol,
m
1%
% glacial aceetic
accid), which stains
s
the prootein bound to the membbrane. Nextt the membraane was cut
between wells 4 and 5, 7 and 8, 8 andd 9 and 9 andd 10, and plaaced in indivvidual contaiiners.
T Fast Greeen Stain wass removed with
The
w Destain (50% methaanol, 1% glaccial acetic accid),
annd the memb
branes were washed andd blocked witth 5% fat-freee milk soluution for 1 hoour at
rooom temperaature. Meannwhile, the primary antibbody and prim
mary antibody and antiggen
m
mixtures
weree prepared as
a follows: thhe “100% prrimary antiboody” was a rabbit
r
polycllonal
anntibody that recognized P-rpS6 Ser244/240 (Cell Signaling
S
Tecchnology®, Inc., Bostonn,
M
MA),
and preepared as a 1:2,000 dilutiion in 5% faat-free milk solution;
s
thee “1:1/32
anntibody to an
ntigen mixtuure” containeed 4.88*10-222 μg antigenn; the “1:1/166 antibody too
anntigen mixtu
ure” containeed 1.95*10-118 μg antigenn; the “1:1/4 antibody to antigen
m
mixture”
conttained 7.8*110-15 μg antiggen; and the “1:1 antiboddy to antigenn mixture”
coontained 0.0
001 μg of anttigen. Thesee mixtures were
w allowedd to incubatee at room
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temperature for 30 minutes, which was the manufacturer’s suggested time allotment for
the reaction between the antibody and antigen to occur. The mixtures were then placed
on the membrane and allowed to react with the proteins bound to the membrane for 18
hours at 4oC. Then, all sections of the membrane were washed and treated with
secondary antibody which was a goat anti-rabbit IgG (H+L) with conjugated horseradish
peroxidase (1:10,000 dilution in 5% fat-free milk solution; BioRad, Hercules, CA) for 1
hour at room temperature. Membranes were developed using a chemiluminescence kit
(Amersham ECL Plus Western Blotting Detection Reagents; GE Healthcare, Piscataway,
NJ) and visualized on x-ray film using a film processor (Kodak X-OMAT film processor,
Kodak Health Imaging Division, Rochester, NY). In the wells of the above figure: (1) a
molecular marker (MagicMark™, Invitrogen, Carlsbad, CA), (2) a positive control (p70
S6 Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling
Technology ®, Inc., Boston, MA), (3) a negative control (p70 S6 Kinase Control Cell
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA),
(4) mature equine gluteal muscle in the postprandial state, (5) a positive control (p70 S6
Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling
Technology ®, Inc., Boston, MA), (6) a negative control (p70 S6 Kinase Control Cell
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA),
(7) mature equine gluteal muscle in the postprandial state, (8) mature equine gluteal
muscle in the postprandial state, (9) mature equine gluteal muscle in the postprandial
state, (10) a positive control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells
treated with insulin, Cell Signaling Technology ®, Inc., Boston, MA), (11) a negative
control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells untreated, Cell Signaling
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Technology ®, Inc., Boston, MA), and (12) mature equine gluteal muscle in the
postprandial state. Wells 1-4 were treated with 100% primary antibody. Wells 5-7 were
treated with a primary antibody to antigen (P-rpS6 Ser240/244 Blocking Peptide, Cell
Signaling Technology ®, Inc., Boston, MA) at a ratio of 1:1. Well 8 was treated with a
primary antibody to antigen ratio of 1:1/4. Well 9 was treated with a primary antibody to
antigen ratio of 1:1/16, and wells 10-12 were treated with a primary antibody to antigen
ratio of 1:1/32. This validated the use of this primary antibody in the horse, because
when an antigen was applied there was inhibition of the antibody to bind with the mature
equine gluteal muscle in the postprandial state. However, it is important to note that the
presence P-rpS6-Ser240/244 in the negative and positive controls was expected, because
rpS6 is phosphorylated following S6K1 phosphorylation which is activated by the active
from of mTORC1. mTORC1 is activated due to both insulin and amino acids, the
negative controls were untreated with insulin and the positive controls were treated with
insulin, but both were in media containing amino acids. As a result, P-rpS6 Ser240/244 is
present in the negative control, but diminished in comparison to the positive control.
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A
A.2.6c.
An example
e
of a P-rpS6 Ser235/236 & 240/2244 x-ray film
m from Chaapter IV. This
T
iss an examplee of a horse on
o +NSAID treatment. In the wells of the abovee figure: (1) a
m
molecular
maarker (MagiccMark™, Invvitrogen, Caarlsbad, CA), (2) a positive control (pp70
S6 Kinase Co
ontrol Cell Extracts
E
from
m MCF-7 cellls treated wiith insulin, Cell
C Signalinng
T
Technology
®,
® Inc., Bostton, MA), (33) a gluteal muscle
m
biopssy collected 60
6 minutes
foollowing con
nsuming a hiigh protein pellet
p
on Dayy 1 from the left side, (44) a gluteal
m
muscle
biopsy
y collected 60
6 minutes following
f
consuming a high
h
protein pellet
p
on Daay 1
frrom the rightt side, (5) a gluteal
g
musccle biopsy coollected 60 minutes
m
folloowing
coonsuming a high proteinn pellet on Day
D 2 from thhe left side, (6)
( a gluteal muscle bioppsy
coollected 60 minutes
m
folloowing consuuming a highh protein pellet on Day 2 from the rigght
siide, (7) a glu
uteal muscle biopsy colleected 60 minnutes following consumiing a high
prrotein pellett on Day 3 frrom the left side,
s
(8) a glluteal musclee biopsy collected 60
m
minutes
following consum
ming a high protein pelleet on Day 3 from the rigght side, (9) a
gluteal musclle biopsy colllected 60 minutes
m
follow
wing consum
ming a high protein
p
pelleet on
D 4 from th
Day
he left side, (10) a gluteaal muscle bioopsy collecteed 60 minutees followingg
coonsuming a high proteinn pellet on Day
D 4 from thhe right side,, (11) a gluteeal muscle
biopsy collected 60 minuutes following consumingg a high prottein pellet onn Day 5 from
m the
leeft side, (12)) a gluteal muuscle biopsyy collected 60
6 minutes foollowing connsuming a hiigh
prrotein pellett on Day 5 frrom the rightt side.
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A
A.2.7a.
An example
e
of the
t rpS6 Tootal Antibod
dy Validatioon. In order to determinee
crross-species reactivity of the primaryy and seconddary antiboddies used forr the
determination
n of the abunndance of rpS6 Total, poooled equine gluteal musscle samples
frrom horses in
n the postpraandial state underwent
u
e
electrophores
sis on polyaccrylamide geels
annd then weree transferredd to a PVDF membrane (additional
(
d
detail
regardiing
ellectrophoressis and transffer can be foound in Sectiion 3.4.1.3). The membrane was theen
sttained with Fast
F Green Stain
S
(1% fasst green, 50%
% methanol,, 1% glacial acetic acid),,
w
which
stains the
t protein bound
b
to the membrane. Next the membrane
m
waas cut betweeen
w
wells
4 and 5, 7 and 8, 8 and
a 9 and 9 and 10, and placed in inndividual conntainers. Thhe
Fast Green Sttain was rem
moved with Destain
D
(50%
% methanol, 1% glacial acetic
a
acid), and
thhe membranees were washed and bloccked with 5%
% fat-free milk
m solution for 1 hour at
a
rooom temperaature. Meannwhile, the primary antibbody and prim
mary antibody and antiggen
m
mixtures
weree prepared as
a follows: thhe “100% prrimary antiboody” was a rabbit
r
m
monoclonal
antibody
a
thatt recognizedd rpS6 Total (Cell Signalling Technollogy®, Inc.,
B
Boston,
MA), and prepared as a 1:10,000 dilutionn in 5% fat-ffree milk sollution; the
-26
“1:1/32 antibo
ody to antigen mixture” contained 2.44*10
2
μgg antigen; thhe “1:1/16

anntibody to an
ntigen mixtuure” containeed 3.9*10-19 μg antigen; the “1:1/4 antibody
a
to
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antigen mixture” contained 6.3*10-12 μg antigen; and the “1:1 antibody to antigen
mixture” contained 0.0002 μg of antigen. These mixtures were allowed to incubate at
room temperature for 30 minutes, which was the manufacturer’s suggested time allotment
for the reaction between the antibody and antigen to occur. The mixtures were then
placed on the membrane and allowed to react with the proteins bound to the membrane
for 18 hours at 4oC. Then, all sections of the membrane were washed and treated with
secondary antibody which was a goat anti-rabbit IgG (H+L) with conjugated horseradish
peroxidase (1:10,000 dilution in 5% fat-free milk solution; BioRad, Hercules, CA) for 1
hour at room temperature. Membranes were developed using a chemiluminescence kit
(Amersham ECL Plus Western Blotting Detection Reagents; GE Healthcare, Piscataway,
NJ) and visualized on x-ray film using a film processor (Kodak X-OMAT film processor,
Kodak Health Imaging Division, Rochester, NY). In the wells of the above figure: (1) a
molecular marker (MagicMark™, Invitrogen, Carlsbad, CA), (2) a positive control (p70
S6 Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling
Technology ®, Inc., Boston, MA), (3) a negative control (p70 S6 Kinase Control Cell
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA),
(4) mature equine gluteal muscle in the postprandial state, (5) a positive control (p70 S6
Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling
Technology ®, Inc., Boston, MA), (6) a negative control (p70 S6 Kinase Control Cell
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA),
(7) mature equine gluteal muscle in the postprandial state, (8) mature equine gluteal
muscle in the postprandial state, (9) mature equine gluteal muscle in the postprandial
state, (10) a positive control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells
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treated with insulin, Cell Signaling Technology ®, Inc., Boston, MA), (11) a negative
control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells untreated, Cell Signaling
Technology ®, Inc., Boston, MA), and (12) mature equine gluteal muscle in the
postprandial state. Wells 1-4 were treated with 100% primary antibody. Wells 5-7 were
treated with a primary antibody to antigen (rpS6 Blocking Peptide, Cell Signaling
Technology ®, Inc., Boston, MA) at a ratio of 1:1. Well 8 was treated with a primary
antibody to antigen ratio of 1:1/4. Well 9 was treated with a primary antibody to antigen
ratio of 1:1/16, and wells 10-12 were treated with a primary antibody to antigen ratio of
1:1/32. This validated the use of this primary antibody in the horse, because when an
antigen was applied there was inhibition of the antibody to bind with the mature equine
gluteal muscle in the postprandial state. However, it is important to note that the
presence of rpS6 Total in both positive and negative controls was expected. Because this
protein is ubiquitous, the negative controls serve a greater purpose in the validation of the
phosphorylated forms.

305

A
A.2.7b.
An example
e
of a rpS6 Totaal x-ray film
m from Chap
pter IV. Thhis is an x-rayy of
thhe same mem
mbrane that is
i shown in A.2.6c.
A
afterr it has been stripped an re-probed with
w
rppS6 Total prrimary antiboody. In the wells
w
of the above figuree: (1) a moleecular markeer
(M
MagicMark™
™, Invitrogeen, Carlsbad,, CA), (2) a positive
p
conntrol (p70 S66 Kinase Conntrol
C Extracts from MCF-7 cells treateed with insulin, Cell Siggnaling Techhnology ®, Innc.,
Cell
B
Boston,
MA), (3) a gluteaal muscle bioopsy collecteed 60 minutees followingg consuming a
high protein pellet
p
on Dayy 1 from thee left side, (44) a gluteal muscle
m
biopssy collected 60
6
m
minutes
following consum
ming a high protein pelleet on Day 1 from the rigght side, (5) a
gluteal musclle biopsy colllected 60 minutes
m
follow
wing consum
ming a high protein
p
pelleet on
D 2 from th
Day
he left side, (6) a gluteall muscle bioppsy collectedd 60 minutess following
coonsuming a high proteinn pellet on Day
D 2 from thhe right side,, (7) a gluteaal muscle bioopsy
coollected 60 minutes
m
folloowing consuuming a highh protein pellet on Day 3 from the left
siide, (8) a glu
uteal muscle biopsy colleected 60 minnutes following consumiing a high
prrotein pellett on Day 3 frrom the rightt side, (9) a gluteal
g
musccle biopsy coollected 60
m
minutes
following consum
ming a high protein pelleet on Day 4 from the left
ft side, (10) a
gluteal musclle biopsy colllected 60 minutes
m
follow
wing consum
ming a high protein
p
pelleet on
D 4 from th
Day
he right side, (11) a gluteeal muscle biopsy
b
colleccted 60 minuutes followinng
coonsuming a high proteinn pellet on Day
D 5 from thhe left side, (12)
(
a gluteaal muscle bioopsy
coollected 60 minutes
m
folloowing consuuming a highh protein pellet on Day 5 from the rigght
siide. The abu
undance of thhis protein is reported ass a ratio of thhe phosphorrylated to tottal
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form. The positive control was used to account for interassay variability. The C.V. of
the phosphorylated to total ratio of the positive control for P-rpS6 Ser235/236 & 240/244 was
0.14 ± 0.14. The right to left side phosphorylated to total ratio of for P-rpS6235/236 & 240/244
was 0.19 ± 0.13. These were obtained from Chapter IV. In Chapter IV side was tested in
the statistical model and found to not be significant (P < 0.05).

307

A
A.2.8a.
An ex
xample of th
he P-4EBP11 Thr37/46 An
ntibody Vallidation. Inn order to
determine cro
oss-species reactivity
r
of the primary and secondaary antibodiees used for the
t
determination
n of the abunndance of theeP-4EBP1 Thr
T 37/46, poolled equine glluteal muscle
saamples from
m horses in thhe postpranddial state undderwent electtrophoresis on
o
polyacrylamide gels and then
t
were transferred to a PVDF meembrane (addditional detaail
reegarding elecctrophoresiss and transferr can be founnd in Sectionn 3.4.1.3). The
T membraane
w then stain
was
ned with Fasst Green Staiin (1% fast green,
g
50% methanol,
m
1%
% glacial aceetic
accid), which stains
s
the prootein bound to the membbrane. Nextt the membraane was cut
between wells 4 and 5, 7 and 8, 8 andd 9 and 9 andd 10, and plaaced in indivvidual contaiiners.
T Fast Greeen Stain wass removed with
The
w Destain (50% methaanol, 1% glaccial acetic accid),
annd the memb
branes were washed andd blocked witth 5% fat-freee milk soluution for 1 hoour at
rooom temperaature. Meannwhile, the primary antibbody and prim
mary antibody and antiggen
m
mixtures
weree prepared as
a follows: thhe “100% prrimary antiboody” was a rabbit
r
m
monoclonal
antibody
a
thatt recognizedd P-4EBP1 Thr
T 37/46 (Cell Signaling Technology®
T
®,
Innc., Boston, MA), and prrepared as a 1:1,000 diluution in 5% fat-free
f
milkk solution; thhe
-25
“1:1/32 antibo
ody to antigen mixture” contained 2.44*10
2
μgg antigen; thhe “1:1/16

anntibody to an
ntigen mixtuure” containeed 3.9*10-18 μg antigen; the “1:1/4 antibody
a
to
anntigen mixtu
ure” containeed 6.3*10-11 μg antigen; and the “1:11 antibody too antigen
m
mixture”
conttained 0.0022 μg of antiggen. These mixtures
m
werre allowed too incubate att
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room temperature for 30 minutes, which was the manufacturer’s suggested time allotment
for the reaction between the antibody and antigen to occur. The mixtures were then
placed on the membrane and allowed to react with the proteins bound to the membrane
for 18 hours at 4oC. Then, all sections of the membrane were washed and treated with
secondary antibody which was a goat anti-rabbit IgG (H+L) with conjugated horseradish
peroxidase (1:10,000 dilution in 5% fat-free milk solution; BioRad, Hercules, CA) for 1
hour at room temperature. Membranes were developed using a chemiluminescence kit
(Amersham ECL Plus Western Blotting Detection Reagents; GE Healthcare, Piscataway,
NJ) and visualized on x-ray film using a film processor (Kodak X-OMAT film processor,
Kodak Health Imaging Division, Rochester, NY). In the wells of the above figure: (1) a
molecular marker (MagicMark™, Invitrogen, Carlsbad, CA), (2) a positive control (p70
S6 Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling
Technology ®, Inc., Boston, MA), (3) a negative control (p70 S6 Kinase Control Cell
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA),
(4) mature equine gluteal muscle in the postprandial state, (5) a positive control (p70 S6
Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling
Technology ®, Inc., Boston, MA), (6) a negative control (p70 S6 Kinase Control Cell
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA),
(7) mature equine gluteal muscle in the postprandial state, (8) mature equine gluteal
muscle in the postprandial state, (9) mature equine gluteal muscle in the postprandial
state, (10) a positive control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells
treated with insulin, Cell Signaling Technology ®, Inc., Boston, MA), (11) a negative
control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells untreated, Cell Signaling
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Technology ®, Inc., Boston, MA), and (12) mature equine gluteal muscle in the
postprandial state. Wells 1-4 were treated with 100% primary antibody. Wells 5-7 were
treated with a primary antibody to antigen (P-4EBP1 Thr37/46 Blocking Peptide, Cell
Signaling Technology ®, Inc., Boston, MA) at a ratio of 1:1. Well 8 was treated with a
primary antibody to antigen ratio of 1:1/4. Well 9 was treated with a primary antibody to
antigen ratio of 1:1/16, and wells 10-12 were treated with a primary antibody to antigen
ratio of 1:1/32. This validated the use of this primary antibody in the horse, because
when an antigen was applied there was inhibition of the antibody to bind with the mature
equine gluteal muscle in the postprandial state. However, it is important to note that the
presence P-4EBP1 Thr37/46 in the negative and positive controls was expected, because
4EBP1 is phosphorylated following activation of mTORC1. mTORC1 is activated due to
both insulin and amino acids, the negative controls were untreated with insulin and the
positive controls were treated with insulin, but both were in media containing amino
acids. As a result, P-4EBP1 Thr37/46 is present in the negative control, but diminished in
comparison to the positive control. Also, 4EBP1 has a large band that represents the
three isoforms (α, β, and γ).
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A
A.2.8b.
An example
e
of a P-4EBP1 Thr37/46 x-raay film from
m Chapter IV.
I This is an
a
exxample of a horse on +N
NSAID treatm
ment. In thee wells of thee above figuure: (1) a
m
molecular
maarker (MagiccMark™, Invvitrogen, Caarlsbad, CA), (2) a negatiive control (p70
(
S6 Kinase Co
ontrol Cell Extracts
E
from
m MCF-7 cellls untreated,, Cell Signalling Technollogy
® Inc., Bosto
®,
on, MA), (3)) a positive control
c
(p70 S6 Kinase Control
C
Cell Extracts froom
M
MCF-7
cells treated
t
with insulin, Celll Signaling Technology
T
®, Inc., Bosston, MA), (4)
( a
gluteal musclle biopsy colllected 60 minutes
m
follow
wing consum
ming a high protein
p
pelleet on
D 1 from th
Day
he left side, (5) a gluteall muscle bioppsy collectedd 60 minutess following
coonsuming a high proteinn pellet on Day
D 1 from thhe right side,, (6) a gluteaal muscle bioopsy
coollected 60 minutes
m
folloowing consuuming a highh protein pellet on Day 2 from the left
siide, (7) a glu
uteal muscle biopsy colleected 60 minnutes following consumiing a high
prrotein pellett on Day 2 frrom the rightt side, (8) a gluteal
g
musccle biopsy coollected 60
m
minutes
following consum
ming a high protein pelleet on Day 3 from the left
ft side, (9) a
gluteal musclle biopsy colllected 60 minutes
m
follow
wing consum
ming a high protein
p
pelleet on
D 3 from th
Day
he right side, (10) a gluteeal muscle biopsy
b
colleccted 60 minuutes followinng
coonsuming a high proteinn pellet on Day
D 4 from thhe left side, (11)
(
a gluteaal muscle bioopsy
coollected 60 minutes
m
folloowing consuuming a highh protein pellet on Day 4 from the rigght
siide, (12) a glluteal muscle biopsy colllected 60 minutes follow
wing consum
ming a high
prrotein pellett on Day 5 frrom the left side,
s
(13) a gluteal
g
musccle biopsy coollected 60
m
minutes
following consum
ming a high protein pelleet on Day 5 from the rigght side.
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A
A.2.9a.
An example
e
of the
t 4EBP1 Total
T
Antib
body Validattion. In ordder to determ
mine
crross-species reactivity of the primaryy and seconddary antiboddies used forr the
determination
n of the abunndance of thee 4EBP1 Tootal, pooled equine
e
gluteaal muscle
m horses in thhe postpranddial state undderwent electtrophoresis on
o
saamples from
polyacrylamide gels and then
t
were transferred to a PVDF meembrane (addditional detaail
reegarding elecctrophoresiss and transferr can be founnd in Sectionn 3.4.1.3). The
T membraane
w then stain
was
ned with Fasst Green Staiin (1% fast green,
g
50% methanol,
m
1%
% glacial aceetic
accid), which stains
s
the prootein bound to the membbrane. Nextt the membraane was cut
between wells 4 and 5, 7 and 8, 8 andd 9 and 9 andd 10, and plaaced in indivvidual contaiiners.
T Fast Greeen Stain wass removed with
The
w Destain (50% methaanol, 1% glaccial acetic accid),
annd the memb
branes were washed andd blocked witth 5% fat-freee milk soluution for 1 hoour at
rooom temperaature. Meannwhile, the primary antibbody and prim
mary antibody and antiggen
m
mixtures
weree prepared as
a follows: thhe “100% prrimary antiboody” was a rabbit
r
m
monoclonal
antibody
a
thatt recognizedd 4EBP1 Total (Cell Signnaling Technnology®, Incc.,
B
Boston,
MA), and prepared as a 1:1,0000 dilution in 5% fat-freee milk soluution; the “1:1/32
anntibody to an
ntigen mixtuure” containeed 2.44*10-225 μg antigenn; the “1:1/166 antibody too
anntigen mixtu
ure” containeed 3.9*10-18 μg antigen; the “1:1/4 antibody
a
to antigen
a
mixtuure”
coontained 6.3
3*10-11 μg anntigen; and thhe “1:1 antibbody to antiggen mixture”” contained
0.002 μg of antigen.
a
Theese mixtures were alloweed to incubatte at room teemperature for
f
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30 minutes, which was the manufacturer’s suggested time allotment for the reaction
between the antibody and antigen to occur. The mixtures were then placed on the
membrane and allowed to react with the proteins bound to the membrane for 1 hour at
room temperature. Then, all sections of the membrane were washed and treated with
secondary antibody which was a goat anti-rabbit IgG (H+L) with conjugated horseradish
peroxidase (1:10,000 dilution in 5% fat-free milk solution; BioRad, Hercules, CA) for 1
hour at room temperature. Membranes were developed using a chemiluminescence kit
(Amersham ECL Plus Western Blotting Detection Reagents; GE Healthcare, Piscataway,
NJ) and visualized on x-ray film using a film processor (Kodak X-OMAT film processor,
Kodak Health Imaging Division, Rochester, NY). In the wells of the above figure: (1) a
molecular marker (MagicMark™, Invitrogen, Carlsbad, CA), (2) a positive control (p70
S6 Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling
Technology ®, Inc., Boston, MA), (3) a negative control (p70 S6 Kinase Control Cell
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA),
(4) mature equine gluteal muscle in the postprandial state, (5) a positive control (p70 S6
Kinase Control Cell Extracts from MCF-7 cells treated with insulin, Cell Signaling
Technology ®, Inc., Boston, MA), (6) a negative control (p70 S6 Kinase Control Cell
Extracts from MCF-7 cells untreated, Cell Signaling Technology ®, Inc., Boston, MA),
(7) mature equine gluteal muscle in the postprandial state, (8) mature equine gluteal
muscle in the postprandial state, (9) mature equine gluteal muscle in the postprandial
state, (10) a positive control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells
treated with insulin, Cell Signaling Technology ®, Inc., Boston, MA), (11) a negative
control (p70 S6 Kinase Control Cell Extracts from MCF-7 cells untreated, Cell Signaling
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Technology ®, Inc., Boston, MA), and (12) mature equine gluteal muscle in the
postprandial state. Wells 1-4 were treated with 100% primary antibody. Wells 5-7 were
treated with a primary antibody to antigen (4EBP1 Total Blocking Peptide, Cell
Signaling Technology ®, Inc., Boston, MA) at a ratio of 1:1. Well 8 was treated with a
primary antibody to antigen ratio of 1:1/4. Well 9 was treated with a primary antibody to
antigen ratio of 1:1/16, and wells 10-12 were treated with a primary antibody to antigen
ratio of 1:1/32. This validated the use of this primary antibody in the horse, because
when an antigen was applied there was inhibition of the antibody to bind with the mature
equine gluteal muscle in the postprandial state. However, it is important to note that the
presence P-4EBP1 Thr37/46 in the negative and positive controls was expected, because
4EBP1 is a ubiquitous protein. The negative control has a greater role in phosphorylated
forms. Also, 4EBP1 has a large band that represents the three isoforms (α, β, and γ).
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A
A.2.9b.
An example
e
of a 4EBP1 Tootal x-ray fillm from Ch
hapter IV. This
T is an x-ray
of the same membrane
m
thhat is shown in A.2.8b. after it has beeen stripped an re-probedd
w rpS6 Tottal primary antibody.
with
a
In the wells off the above figure:
f
(1) a molecular
m
m
marker
(MagiicMark™, Innvitrogen, Carlsbad,
C
CA
A), (2) a negaative control (p70 S6 Kinnase
C
Control
Cell Extracts
E
from
m MCF-7 ceells untreatedd, Cell Signaaling Technoology ®, Incc.,
B
Boston,
MA), (3) a positiive control (pp70 S6 Kinaase Control Cell
C Extractss from MCF-7
ceells treated with
w insulin, Cell Signaliing Technology ®, Inc., Boston, MA
A), (4) a glutteal
m
muscle
biopsy
y collected 60
6 minutes following
f
consuming a high
h
protein pellet
p
on Daay 1
frrom the left side, (5) a glluteal muscle biopsy colllected 60 miinutes follow
wing consum
ming
a high protein
n pellet on Day
D 1 from thhe right side, (6) a gluteaal muscle bioopsy collected
60 minutes fo
ollowing connsuming a hiigh protein pellet
p
on Dayy 2 from the left side, (7)) a
gluteal musclle biopsy colllected 60 minutes
m
follow
wing consum
ming a high protein
p
pelleet on
D 2 from th
Day
he right side, (8) a gluteaal muscle bioopsy collected 60 minutes followingg
coonsuming a high proteinn pellet on Day
D 3 from thhe left side, (9)
( a gluteal muscle bioppsy
coollected 60 minutes
m
folloowing consuuming a highh protein pellet on Day 3 from the rigght
siide, (10) a glluteal muscle biopsy colllected 60 minutes follow
wing consum
ming a high
prrotein pellett on Day 4 frrom the left side,
s
(11) a gluteal
g
musccle biopsy coollected 60
m
minutes
following consum
ming a high protein pelleet on Day 4 from the rigght side, (12)) a
gluteal musclle biopsy colllected 60 minutes
m
follow
wing consum
ming a high protein
p
pelleet on
D 5 from th
Day
he left side, (13) a gluteaal muscle bioopsy collecteed 60 minutees followingg
coonsuming a high proteinn pellet on Day
D 5 from thhe right side.. The abunddance of this
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protein is reported as a ratio of the phosphorylated to total form. The positive control
was used to account for interassay variability. The C.V. of the phosphorylated to total
ratio of the positive control for P-4EBP1 Thr37/46 was 0.10 ± 0.07. The right to left side
phosphorylated to total ratio of for P-4EBP1 Thr37/46 was 0.13 ± 0.10. These were
obtained from Chapter IV. In Chapter IV side was tested in the statistical model and
found to not be significant (P < 0.05).
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A
A.3.
MYOSIIN HEAVY
Y CHAIN IS
SOFORM SEPERATIO
ON

A
A.3.1
An exa
ample of the MHC Isofform gel sep
paration. Thhis is an exam
mple of a hoorse
inn Chapter IIII at the varioous samplingg depths and murine gasttrocnemius which
w
servedd as a
coontrol
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A.4. STANDARD CURVES
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A.4.1. An example of a glucose standard curve used in the YSI 2700 SELECT™
Biochemistry Analyzer. The YSI 2700 SELECT™ Biochemistry Analyzer determines
glucose concentration enzymatically. This is an example of the standard curve of glucose
from Chapter VI. The r2 is 0.99 and the standard C.V. is 0.004 ± 0.003.
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A.4.2. An example of the standard curve used in the Coat-A-Count RIA® kit.
Along the y axis is %B: percent of radioactive binding, and along the x axis is the
concentration of insulin in μIU/mL. The linear range of this graph is from 6 μIU/mL to
103 6 μIU/mL with a %B of 80.17 and 31.6%, respectively.
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A.5. qRT-PCR AMPLIFICATION PLOTS

A.5.1. An example of β-glucoronidase amplification plot from a negative control.
This is an example of an amplification plot of the housekeeping gene, β-glucoronidase,
from a negative control (RNA free water) in Chapter IV. As expected, there was a lack
of amplification.
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A.5.2. An example of β-glucoronidase amplification plot from a positive control.
This is an example of an amplification plot of the housekeeping gene, β-glucoronidase,
from a postivie control (pooled equine tissues post infection challenge) in Chapter IV.
The linear portion of the amplification curve begins following 20 cycles and ends at 26
cycles. The linear portion has an r2 of no less than 0.95, and the amplification efficiency
must be between 0.8 and 1.
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A.5.3. An example of an IFN−γ amplification plot from a negative control. This is
an example of an amplification plot of the pro-inflammatory cytokine, IFN−γ, from a
negative control (RNA free water) in Chapter IV. As expected, there was a lack of
amplification.
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A.5.4. An example of an IFN−γ amplification plot from a positive control. This is an
example of an amplification plot of the pro-inflammatory cytokine, IFN−γ, from a
positive control (pooled equine tissues post infection challenge) in Chapter IV. The
linear portion of the amplification curve begins following 27 cycles and ends at 33
cycles. The linear portion has an r2 of no less than 0.95, and the amplification efficiency
must be between 0.8 and 1.
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A.5.5. An example of a TNF−α amplification plot from a negative control. This is
an example of an amplification plot of the pro-inflammatory cytokine, TNF−α, from a
negative control (RNA free water) in Chapter IV. As expected, there was a lack of
amplification.
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A.5.6. An example of a TNF−α amplification plot from a positive control. This is an
example of an amplification plot of the pro-inflammatory cytokine, TNF−α, from a
positive control (pooled equine tissues post infection challenge) in Chapter IV. The
linear portion of the amplification curve begins following 25 cycles and ends at 29
cycles. The linear portion has an r2 of no less than 0.95, and the amplification efficiency
must be between 0.8 and 1.
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A.5.7. An example of an IL−1β amplification plot from a negative control. This is
an example of an amplification plot of the pro-inflammatory cytokine, IL−1β, from a
negative control (RNA free water) in Chapter IV. As expected, there was a lack of
amplification.
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A.5.8. An example of an IL−1β amplification plot from a positive control. This is an
example of an amplification plot of the pro-inflammatory cytokine, IL−1β, from a
positive control (pooled equine tissues post infection challenge) in Chapter IV. The
linear portion of the amplification curve begins following 20 cycles and ends at 26
cycles. The linear portion has an r2 of no less than 0.95, and the amplification efficiency
must be between 0.8 and 1.
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A.5.9. An example of an IL−6 amplification plot from a negative control. This is an
example of an amplification plot of the pro-inflammatory cytokine, IL−6, from a negative
control (RNA free water) in Chapter IV. As expected, there was a lack of amplification.
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A.5.10. An example of an IL−6 amplification plot from a positive control. This is an
example of an amplification plot of the pro-inflammatory cytokine, IL−6, from a positive
control (pooled equine tissues post infection challenge) in Chapter IV. The linear portion
of the amplification curve begins following 24 cycles and ends at 30 cycles. The linear
portion has an r2 of no less than 0.95, and the amplification efficiency must be between
0.8 and 1.
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A.5.11. An example of an IL−10 amplification plot from a negative control. This is
an example of an amplification plot of the anti-inflammatory cytokine, IL−10, from a
negative control (RNA free water) in Chapter IV. As expected, there was a lack of
amplification.
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A.5.12. An example of an IL−10 amplification plot from a positive control. This is
an example of an amplification plot of the anti-inflammatory cytokine, IL−10, from a
positive control (pooled equine tissues post infection challenge) in Chapter IV. The
linear portion of the amplification curve begins following 27 cycles and ends at 32
cycles. The linear portion has an r2 of no less than 0.95, and the amplification efficiency
must be between 0.8 and 1.
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A.5.13. The amplification plots for β-gus, IFN−γ, TNF−α, IL−1β, IL-6, and IL-10 in
various equine gluteal muscle samples collected in Chapter IV.
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10

A.6.2. Gluteal muscle biopsy collection depths from yearlings, two year olds and
mature horses in Chapter V. The gluteal muscle biopsy collection depths were
determined following the performance of ultrasound measurements on gluteal muscle
depth and subcutaneous fat. Gluteal muscle biopsy collection depth was determined as
(50% of the gluteal muscle depth) + subcutaneous fat depth.
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Percent Isotope Enrichment
Over Baseline

A.7. WHOLE-BODY PROTEIN METABOLISM
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A.7.1. An example of the percent isotope enrichment over baseline in the breath
from a mature horse during the [13C] sodium bicarbonate infusion period in
Chapter VI. The ratio of 13CO2:12CO2 in the breath samples was determined using an
isotope selective non-dispersive infrared absorption (NDIR) analyzer (IRIS-2; Wagner
Analysen Technik Vetriebs GmbH, Breman, Germany). This ratio is given in δ units,
which is the ratio in the sample – the average ratio at baseline. This δ enrichment value
can then be converted into a percent enrichment using the following equation:
Enrichment (%) = [0.0112372δ/(0.0112372δ + 1000)] × 100%. The red box indicates a
plateau in the percent enrichment over baseline, which can be used to calculate total CO2
production. The average number of points used to determine plateau were 3.2 ± 0.5. The
average C.V. of the plateau percent enrichment was 2.4 ± 1.8%. Total production of CO2
can be calculated using the following equation:
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FCO2 = i × [(Ei/Eb) – 1]. Where, i is the rate of isotope administration in μmol/kg/min, Ei
is the enrichment of the isotope in the solution and Eb is the enrichment of the breath
samples at plateau, corrected for baseline enrichment (average of the red box points).
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A.7.2. An example of the percent isotope enrichment over baseline in the breath
from an aged horse during the [1-13C] phenylalanine infusion period in Chapter VII.
The ratio of 13CO2:12CO2 in the breath samples was determined using an isotope selective
non-dispersive infrared absorption (NDIR) analyzer (IRIS-2; Wagner Analysen Technik
Vetriebs GmbH, Breman, Germany). This ratio is given in δ units, which is the ratio in
the sample – the average ratio at baseline. This δ enrichment value can then be converted
into a percent enrichment using the following equation:
Enrichment (%) = [0.0112372δ/(0.0112372δ + 1000)] × 100%.
The red box indicates a plateau in the percent enrichment over baseline. This plateau can
be used to calculate the rate of [1-13C]phenylalanine oxidation to 13CO2 (F13CO2): F13CO2
= FCO2 × ECO2, where ECO2 is the average enrichment of the breath samples at isotopic
steady state (average of the 3 points in the red box), corrected for baseline enrichment,
during the [1-13C]phenylalanine infusion. The average number of points used for the
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plateau were 3.1 ± 0.5. The average C.V. for the plateau percent enrichments was 1.1 ±
1.3%.
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A.7.3. An example of the percent isotope enrichment in the plasma from an aged
horse during the [1-13C] phenylalanine infusion period in Chapter VII. This is the
percent enrichment corrected for the baseline enrichment. The red box indicates a
plateau in the percent enrichment over baseline. The average number of points used in
the plateau were 4.8 ± 1, and the average C.V. of the enrichment values used in the
plateau was 3.7 ±1.3%. This plateau can be used to calculate whole-body phenylalanine
flux:
Flux (Q; μmol/kg/h) = i × [(Ei/Ep) – 1, where I is the rate of isotope infusion (in
μmol/kg/h), Ei is the enrichment of infused isotope, and Ep is the plateau plasma
enrichment (average of the red box points). Flux includes the amount of amino acids
entering the pool through dietary intake (I), de novo synthesis (N), and protein
breakdown (B), or leaving the pool through protein synthesis (Z), oxidation (E), or the
conversion to other metabolites: Q = I + N B = Z + E + M. Because phenylalanine is a
dietary indispensable amino acid, N is negligible; thus B = Q – I. Then, whole-body
phenylalanine oxidation can be calculated using the following equation: O = F13CO2 ×
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(1/Ep – 1/Ei) × 100, where Ei is the enrichment of infused isotope, and Ep is the plateau
plasma enrichment (average of 3 points in the red box). If tyrosine is balanced in the diet
and is not generally considered to be a limiting amino acid in nonruminant, the
assumption can be made that phenylalanine conversion to tyrosine is minimal. As a
result, non-oxidative phenylalanine metabolism can be calculated through the difference
of Q – O, which can be used to indicate changes in phenylalanine used for whole-body
protein synthesis.
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A.8. SAS EXAMPLES
A.8.1. Repeated measures input example.

data rpS6_Density;
input horse depth$ block$ PrpS6;
cards;
1 6cm
A
1.027141
1 8cm
A
1.048161
1 10cm
A
1.068832
2 6cm
B
1.034807
2 8cm
B
1.172738
2 10cm
B
0.942196
3 6cm
A
.
3 8cm
A
1.285698
3 10cm
A
1.122919
4 6cm
B
0.938052
4 8cm
B
0.958085
1.121907
4 10cm
B
5 6cm
B
0.520908
5 8cm
B
0.958247
5 10cm
B
0.867442
6 6cm
A
1.479092
6 8cm
A
1.48873
6 10cm
A
1.571769
;
run;
PROC mixed data= rpS6_Density;
class horse depth block;
model PrpS6 = depth block/ddfm=kr;
random horse (block);
repeated depth/type=un r rcorr sub=horse(block);
lsmeans depth/pdiff;
run;
PROC mixed data= rpS6_Density;
class horse depth block;
model PrpS6 = depth block/ddfm=kr;
random horse (block);
repeated depth/type=ante(1) r rcorr
sub=horse(block);
lsmeans depth/pdiff;
run;
PROC mixed data= rpS6_Density;
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class horse depth block;
model PrpS6 = depth block/ddfm=kr;
random horse (block);
repeated depth/type=simple r rcorr
sub=horse(block);
lsmeans depth/pdiff;
run;
PROC mixed data= rpS6_Density;
class horse depth block;
model PrpS6 = depth block/ddfm=kr;
random horse (block);
repeated depth/type=toep r rcorr sub=horse(block);
lsmeans depth/pdiff;
run;
PROC mixed data= rpS6_Density;
class horse depth block;
model PrpS6 = depth block/ddfm=kr;
random horse (block);
repeated depth/type=arh(1) r rcorr
sub=horse(block);
lsmeans depth/pdiff;
run;
PROC mixed data= rpS6_Density;
class horse depth block;
model PrpS6 = depth block/ddfm=kr;
random horse (block);
repeated depth/type=ar(1) r rcorr sub=horse(block);
lsmeans depth/pdiff;
run;
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A.8.2. Repeated measures output example.
The variance-covariance matrix was chosen for each analysis based on the lowest value
for Schwarz’s Bayesian Criterion, which is highlighted in this example.
The Mixed Procedure
Model Information
Data Set
Dependent Variable
Covariance Structures
Subject Effect
Estimation Method
Residual Variance Method
Fixed Effects SE Method
Degrees of Freedom Method

WORK.RPS6_DENSITY
PrpS6
Variance Components,
Unstructured
horse(block)
REML
None
Kenward-Roger
Kenward-Roger

Fit Statistics
-2 Res Log Likelihood
AIC (smaller is better)
AICC (smaller is better)
BIC (smaller is better)

-5.6
8.4
30.8
6.9

Type 3 Tests of Fixed Effects

Effect
depth
block

Num
DF

Den
DF

F Value

Pr > F

2
1

3.65
4.08

1.19
1.45

0.4005
0.2932

The Mixed Procedure
Model Information
Data Set
Dependent Variable
Covariance Structures
Subject Effect
Estimation Method
Residual Variance Method
Fixed Effects SE Method
Degrees of Freedom Method

WORK.RPS6_DENSITY
PrpS6
Variance Components,
Ante-dependence
horse(block)
REML
None
Kenward-Roger
Kenward-Roger

Fit Statistics
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-2 Res Log Likelihood
AIC (smaller is better)
AICC (smaller is better)
BIC (smaller is better)

-5.6
6.4
20.4
5.1

Type 3 Tests of Fixed Effects

Effect
depth
block

Num
DF

Den
DF

F Value

Pr > F

2
1

3.65
4.08

0.83
1.49

0.5035
0.2873

The Mixed Procedure
Model Information
Data Set
Dependent Variable
Covariance Structure
Subject Effect
Estimation Method
Residual Variance Method
Fixed Effects SE Method
Degrees of Freedom Method

WORK.RPS6_DENSITY
PrpS6
Variance Components
horse(block)
REML
Parameter
Kenward-Roger
Kenward-Roger

Fit Statistics
-2 Res Log Likelihood
AIC (smaller is better)
AICC (smaller is better)
BIC (smaller is better)

-4.1
-0.1
1.1
-0.5

Type 3 Tests of Fixed Effects

Effect
depth
block

Num
DF

Den
DF

F Value

Pr > F

2
1

9.13
4.06

1.85
3.29

0.2117
0.1426

The Mixed Procedure
Model Information
Data Set

WORK.RPS6_DENSITY
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Dependent Variable
Covariance Structures
Subject Effect
Estimation Method
Residual Variance Method
Fixed Effects SE Method
Degrees of Freedom Method

PrpS6
Variance Components,
Toeplitz
horse(block)
REML
Profile
Kenward-Roger
Kenward-Roger

Fit Statistics
-2 Res Log Likelihood
AIC (smaller is better)
AICC (smaller is better)
BIC (smaller is better)

-4.1
1.9
4.6
1.3

Type 3 Tests of Fixed Effects

Effect
depth
block

Num
DF

Den
DF

F Value

Pr > F

2
1

4.98
3.93

1.51
3.22

0.3073
0.1485

The Mixed Procedure
Model Information
Data Set
Dependent Variable
Covariance Structures

Subject Effect
Estimation Method
Residual Variance Method
Fixed Effects SE Method
Degrees of Freedom Method

WORK.RPS6_DENSITY
PrpS6
Variance Components,
Heterogeneous
Autoregressive
horse(block)
REML
None
Kenward-Roger
Kenward-Roger

Fit Statistics
-2 Res Log Likelihood
AIC (smaller is better)
AICC (smaller is better)
BIC (smaller is better)

-5.6
4.4
13.0
3.4

Type 3 Tests of Fixed Effects

Effect

Num
DF
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Den
DF

F Value

Pr > F

depth
block

2
1

5.03
4.07

1.09
1.44

0.4034
0.2949

The Mixed Procedure
Model Information
Data Set
Dependent Variable
Covariance Structures
Subject Effect
Estimation Method
Residual Variance Method
Fixed Effects SE Method
Degrees of Freedom Method

WORK.RPS6_DENSITY
PrpS6
Variance Components,
Autoregressive
horse(block)
REML
Profile
Kenward-Roger
Kenward-Roger

Fit Statistics
-2 Res Log Likelihood
AIC (smaller is better)
AICC (smaller is better)
BIC (smaller is better)

-4.1
1.9
4.6
1.3

Type 3 Tests of Fixed Effects

Effect
depth
block

Num
DF

Den
DF

F Value

Pr > F

2
1

4.98
3.93

1.25
3.46

0.3625
0.1377
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A.8.3. One Way ANOVA input example.
data Akt_Density;
input horse age$ block$ PSerAkt;
cards;
2 Mature
A
0.808913
4 Mature
A
1.191087
8 Old
A
0.775572
10 Old
A
0.987907
3 Old
B
0.670911
6 Mature
B
1.082008
11 Old
B
0.271198
12 Mature
B
0.917992
1 Mature
C
1.288538
5 Mature
C
0.711462
7 Old
C
1.165816
9 Old
C
1.15654
;
run;
PROC mixed data=
Akt_Density;
class horse age block;
model PSerAkt = age block/ddfm=kr;
random horse (age block);
lsmeans age/pdiff;
run;
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A.8.4. One Way ANOVA output example.
The Mixed Procedure
Model Information
Data Set
Dependent Variable
Covariance Structure
Estimation Method
Residual Variance Method
Fixed Effects SE Method
Degrees of Freedom Method

WORK.AKT_DENSITY
PSerAkt
Variance Components
REML
Profile
Kenward-Roger
Kenward-Roger

Type 3 Tests of Fixed Effects

Effect

Num
DF

Den
DF

F Value

Pr > F

1
2

8
8

1.06
1.62

0.3342
0.2573

age
block

Least Squares Means

Effect

age

age
age

Mature
Old

Estimate

Standard
Error

DF

t Value

Pr > |t|

1.0000
0.8380

0.1115
0.1115

8
8

8.97
7.52

<.0001
<.0001
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